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State-Mandated	Health	Insurance	Benefits	and	
Health	Insurance	Costs	in	Massachusetts	
	
Executive	Summary	M.G.L.	Chapter	3	§38C	requires	that	the	Massachusetts	Center	for	Health	Information	and	Analysis	(CHIA)	issue	a	comprehensive	report	at	least	once	every	four	years	on	the	cost	and	public	health	impact	of	all	existing	mandated	health	insurance	benefits.		Compass	Health	Analytics,	Inc.	(Compass)	has	been	engaged	to	prepare	the	2016	report.	This	is	the	third	comprehensive	review	of	health	benefit	mandates.		The	first	comprehensive	review	was	published	in	2008	as	required	under	Chapter	58	of	the	Laws	of	2006.1		The	second	comprehensive	review,	published	in	January	2013,	was	the	first	review	prepared	under	M.G.L.	Chapter	3	§38C.2	The	study	provides	a	general	review	of	the	efficacy	of	the	benefits	described	in	the	mandates.		However,	the	cost	estimates	apply	only	to	the	population	with	health	insurance	subject	to	Massachusetts	state	health	benefit	plan	mandate	laws:	individuals	covered	by	fully-insured	commercial	products	regulated	by	the	Massachusetts	Division	of	Insurance.		In	addition,	the	Group	Insurance	Commission	(GIC),	which	provides	benefits	to	public	employees	in	Massachusetts,	voluntarily	complies	with	state	benefit	mandates.i		Costs	associated	with	mandated	benefits	are	a	subset	of	the	total	health	care	costs	for	this	population.		Excluded	from	the	cost	estimates	in	this	study	are	costs	associated	with	self-insured	plans	(other	than	those	offered	through	the	GIC),	which	are	not	regulated	by	The	Division	of	Insurance	and	not	subject	to	the	benefit	mandate	laws.		The	cost	implications	and	clinical	efficacy	of	39	mandates	are	assessed	in	this	report;	the	cost	results	are	displayed	in	Table	E1.	The	first	result	column	in	Table	E1	displays	total	required	direct	costs,	or	RDCs,	which	measure	the	total	2014	claim	costs	for	services	described	in	the	mandate	laws.		RDCs	are	estimated	to	be	$1.9	billion	in	medical	expenses	after	elimination	of	overlaps	in	cost	between	mandates	($2.1	billion	including	administrative	costs).		However,	RDCs	are	not	a	measure	of	the	marginal	impact	of	the	mandates.		RDCs	include	both	costs	for	services	that	would	be	provided	voluntarily	in	the	absence	of	the	mandates	and	marginal	costs	resulting	from	the	imposition	of	the	mandate	laws.		The	second,	third,	and	fourth	results	columns	display	lower	and	upper	bound	estimates	of	mandate	marginal	costs;	marginal	costs	represent	the	estimated	expenses	for	services	provided	in	the	presence	of	the	mandates	that	would	not	have	been	provided	in	their	absence.																																											 																					i	The	majority	of	the	GIC’s	covered	members	are	in	self-insured	plans;	a	subset	of	the	mandates	applies	to	the	GIC’s	members	by	statute	(both	fully-insured	and	self-insured),	in	addition	to	the	overall	fully-insured	population.		Based	on	the	understanding	that	all	self-insured	GIC	plans	voluntarily	offer	all	Massachusetts	state	mandated	benefits,	to	the	extent	possible,	all	GIC	plans	are	treated	as	part	of	the	mandate-covered	group	throughout	this	analysis.	
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The	mandates	at	the	bottom	of	Table	E1	labeled	“Mandates	Judged	to	Have	Zero	Marginal	Cost”	were	deemed	so	by	the	largest	Massachusetts	health	insurance	carriers	participating	in	the	study,	with	the	exceptions	of	the	contraception	and	mental	health	mandates.		The	contraception	and	mental	health	mandates	were	treated	as	potential	marginal	cost	mandates	in	the	previous	comprehensive	reviews.		However,	since	the	2009	analysis	period	covered	by	the	previous	review,	the	benefits	required	by	both	mandates	have	been	superseded	by	federal	statutes,3	thus	erasing	any	incremental	effect	of	these	Massachusetts	state	health	benefit	plan	mandates.		All	zero	marginal	cost	mandates	have	$0	lower	(and	upper)	bound	marginal	cost	estimates	(see	the	second	through	sixth	result	columns).		Many	of	the	mandates	in	the	“potential	marginal	direct	cost”	section	in	Table	E1	were	shown	to	have	costs	at	higher	levels	in	the	self-insured	population	than	in	the	fully-insured	population.		We	assign	these	to	a	zero	cost	lower-bound	rather	than	treating	them	as	having	negative	cost	or	savings	(e.g.,	diabetes	related	services	and	supplies).	The	other	mandates	in	Table	E1	have	non-zero	marginal	costs	relative	to	self-insured	plans	(e.g.,	infertility	treatment).	ii		
																																								 																					ii	As	discussed	in	the	body	of	the	report,	measurement	for	some	zero	marginal	cost	mandates	was	not	feasible.		These	mandates	are	shown	as	having	no	cost	in	the	required	direct	cost	column	of	Table	E1.	
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Table	E1	
Summary	of	Estimated	Costs	for	Massachusetts	Mandated	Benefits	as	of	2014	
Dollars	in	Millions	(000,000s)	
	The	lower	bound	marginal	claims	estimate	of	$46.9	million	in	the	second	column	represents	one	measure	of	the	marginal	impact	of	the	mandates	on	claims	spending,	calculated	from	per-person	spending	differences	on	mandated	benefits	between	the	fully-insured	population	subject	to	the	mandates	and	the	self-insured	population	not	subject	to	mandates.		This	$46.9	million	difference	represents	$1.66	per	member	per	month,	or	0.43	percent	of	premium.		Stated	simply,	the	additional	spending	on	mandated	services	in	plans	subject	to	the	mandates	compared	to	those	plans	not	subject	to	the	mandates	represents	approximately	one	half	of	one	percent	of	premium.	To	measure	the	full	impact,	insurer	administrative	costs	should	be	added.		In	the	next	two	columns	of	Table	E1	the	lower	bound	estimate	of	$46.9	million	becomes	$52.7	million	with	administration,	and	the	$1.9	billion	RDC	becomes	an	upper	bound	estimate	of	$796.8	million	after	removing	zero	marginal	cost	mandates	and	adding	administrative	expense.	
Required	Direct	Cost	
Claims	Estimate
Lower	Bound	
Marginal	Claims	
Estimate
Lower	Bound	
Estimate	with	
Admin	Exp
Upper	Bound		
Estimate	with	
Admin	Exp
Lower	Bound	
Percent	of	
Premium
Upper	Bound	
Percent	of	
Premium
Unduplicated	Total	All	Mandates 1,912.96$																			 46.94$																			 52.74$														 796.81$														 0.43% 6.45%
Mandates	with	Potential	Marginal	Direct	Cost
Service	Mandates
Autism	Spectrum	Disorders	Services 39.54$																								 15.25$																			 17.13$														 44.42$																 0.14% 0.36%
Chiropractic	Services 2.68$																											 0.94$																					 1.06$																 3.01$																		 0.01% 0.02%
Child	Hearing	Aids 6.89$																											 -$																							 -$																		 7.74$																		 0.00% 0.06%
Cleft	Palate	and	Lip 3.30$																											 0.10$																					 0.12$																 3.70$																		 0.00% 0.03%
Diabetes-related	Services	and	Supplies 175.79$																						 -$																							 -$																		 197.52$														 0.00% 1.60%
Early	Intervention	Services 25.72$																								 2.78$																					 3.12$																 28.90$																 0.03% 0.23%
Home	Health	Care 257.25$																						 -$																							 -$																		 289.04$														 0.00% 2.34%
Hormone	Replacement	Therapy	(HRT) 11.56$																								 0.74$																					 0.83$																 12.99$																 0.01% 0.11%
Human	Leukocyte	Antigen	Testing 0.02$																											 -$																							 -$																		 0.02$																		 0.00% 0.00%
Hypodermic	Syringes	or	Needles 1.08$																											 -$																							 -$																		 1.22$																		 0.00% 0.01%
Infertil ity	Treatment 104.73$																						 12.67$																			 14.24$														 117.67$														 0.12% 0.95%
Low	Protein	Food	Products	for	Inherited	Amino	
			Acid	and	Organic	Acid	Diseases	(PKU)
Nonprescription	Enteral	Formulas 0.92$																											 -$																							 -$																		 1.04$																		 0.00% 0.01%
Oral	Cancer	Drugs 1.38$																											 0.49$																					 0.55$																 1.55$																		 0.00% 0.01%
Prosthetic	Limbs	and	Associated	Services 3.87$																											 -$																							 -$																		 4.35$																		 0.00% 0.04%
Scalp	Hair	Prostheses	for	Cancer	Patients 0.41$																											 -$																							 -$																		 0.46$																		 0.00% 0.00%
Speech,	Hearing	and	Language	Disorders 7.12$																											 -$																							 -$																		 8.00$																		 0.00% 0.06%
Provider	Mandates
Certified	Nurse	Midwives 1.62$																											 -$																							 -$																		 1.83$																		 0.00% 0.01%
Certified	Registered	Nurse	Anesthetists 22.09$																								 -$																							 -$																		 24.83$																 0.00% 0.20%
Chiropractors 7.97$																											 0.81$																					 0.91$																 8.96$																		 0.01% 0.07%
Dentists 1.39$																											 -$																							 -$																		 1.56$																		 0.00% 0.01%
Nurse	Practitioners 44.63$																								 9.31$																					 10.46$														 50.15$																 0.08% 0.41%
Optometrists 6.23$																											 -$																							 -$																		 7.00$																		 0.00% 0.06%
Physician	Assistants 41.01$																								 2.01$																					 2.26$																 46.07$																 0.02% 0.37%
Podiatrists 16.38$																								 0.81$																					 0.91$																 18.41$																 0.01% 0.15%
Mandates	Judged	to	Have	Zero	Marginal	Cost
Bone	Marrow	Transplants	for	Treatment	of	Breast	Cancer -$																													 -$																							 -$																		 -$																				 0.00% 0.00%
Cardiac	Rehabilitation 2.28$																											 -$																							 -$																		 -$																				 0.00% 0.00%
Clinical	Trials	(to	treat	cancer) 2.28$																											 -$																							 -$																		 -$																				 0.00% 0.00%
Contraceptive	Services 94.20$																								 -$																							 -$																		 -$																				 0.00% 0.00%
Cytologic	Screening 17.54$																								 -$																							 -$																		 -$																				 0.00% 0.00%
Hearing	Screening	for	Newborns 3.32$																											 -$																							 -$																		 -$																				 0.00% 0.00%
Hospice	Care 16.49$																								 -$																							 -$																		 -$																				 0.00% 0.00%
Lead	Poisoning	Screening 1.20$																											 -$																							 -$																		 -$																				 0.00% 0.00%
Mammography 17.69$																								 -$																							 -$																		 -$																				 0.00% 0.00%
Maternity	Health	Care	(including	minimum	maternity	stay) 471.27$																						 -$																							 -$																		 -$																				 0.00% 0.00%
Mental	Health	Care 455.40$																						 -$																							 -$																		 -$																				 0.00% 0.00%
Preventive	Care	for	Children	Up	to	Age	Six	 122.14$																						 -$																							 -$																		 -$																				 0.00% 0.00%
Off-Label	Uses	of	Prescription	Drugs	to	Treat	Cancer -$																													 -$																							 -$																		 -$																				 0.00% 0.00%
Off-Label	Uses	of	Prescription	Drugs	to	Treat	HIV/AIDS -$																													 -$																							 -$																		 -$																				 0.00% 0.00%
0.01%1.53$																											 0.08$																					 1.71$																		0.09$																 0.00%
Comprehensive	Mandated	Benefit	Review		
compass Health Analytics iv December 2016 
The	initial	range	of	the	marginal	direct	cost	impact	of	all	39	mandate	laws	studied,	including	administrative	costs,	is	therefore	between	$52.7	million	and	$796.8	million.		However,	the	true	value	is	not	likely	to	be	near	either	end	of	this	range.		The	upper	bound	estimate	includes	all	RDCs	except	those	for	mandates	judged	likely	to	have	zero	marginal	costs,	and	so	assumes	that	100	percent	of	the	RDC	for	mandates	with	potential	marginal	direct	cost	is	marginal,	and	that	carriers	would	eliminate	all	mandated	benefits	completely	in	the	absence	of	the	mandate	laws.		This	is	very	unlikely	to	be	true	or	close	to	true	given	that	$469.4	million	of	this	amount	(about	59	percent;	these	figures	are	net	of	mandate	overlaps)	is	composed	of	two	mandates--home	health	services	and	diabetes	services	and	supplies--that	would	likely	be	provided	as	cost-effective	benefits,	even	if	at	somewhat	lower	levels.	The	lower	bound	marginal	cost	estimate	for	each	mandate	judged	to	have	potential	marginal	direct	costs	is	derived	by	comparing	the	allowed	amounts	per	person	approved	by	insurers	for	the	fully-insured	sample	to	the	allowed	amounts	for	the	self-insured	sample	(which	is	not	subject	to	the	mandates).		Cases	in	which	the	self-insured	spending	per	person	is	higher	are	ignored,	and	the	differences,	net	of	mandate	overlaps,	for	the	remaining	cases	in	which	the	fully-insured	costs	per	person	are	higher	are	summed	to	calculate	the	overall	lower	bound	mandate	marginal	cost.		This	lower	bound	estimate	assumes	that	100	percent	of	the	spending	for	the	mandates	in	the	self-insured	market	would	occur	in	the	absence	of	the	mandate	laws,	and	that	none	of	the	spending	is	influenced	by	the	mandated	spending	levels	in	the	fully-insured	market.		This,	too,	is	very	unlikely	to	be	true	or	close	to	true,	owing	to	the	upward	pressure	mandates	in	the	fully-insured	market	place	on	benefits	offered	by	self-insured	plans.			This	reasoning	supports	narrowing	the	range	of	the	mandate	law	impact.		Table	E2	displays	medical	costs	in	the	fully-insured	population	for	each	percent	of	premium	in	the	$60	million	to	$800	million	range.		While	the	scope	of	this	study	does	not	allow	a	direct	empirical	basis	for	narrowing	the	range,	the	actual	direct	cost	impact	is	likely	to	be	somewhere	in	the	middle	part	of	the	range.		As	self-insured	employers	must	compete	in	the	labor	market	with	fully-insured	employers	whose	health	insurance	policies	must	include	the	mandated	benefits,	self-insured	benefits	are	likely	to	be	significantly	influenced	by	the	presence	of	the	mandate	laws	and	the	laws’	effect	on	benefit	structures	at	competing	employers.		While	there	are	potential	effects	that	could	cause	the	lower	bound	to	be	over-estimated,	on	net	it	is	likely	that	the	0.43	percent	of	premium	in	fully-insured	cost	levels	over	and	above	self-insured	cost	levels	significantly	understates	the	true	impact.		At	the	same	time,	federal	benefit	requirements	would	remain	even	if	state	mandates	were	repealed,	and	it	is	unlikely	that	popular	and/or	cost-effective	benefits	like	diabetes	care	would	be	completely	removed	from	policies	if	the	mandate	laws	were	not	in	place,	making	6.45	percent	of	premium	(which	assumes	all	costs	of	the	25	potential	marginal	cost	mandates	are	marginal)	a	certain	overstatement	of	the	impact.		Based	on	the	foregoing	discussion,	mid-range	estimates	in	the	one	to	four	percent	of	premium	(roughly	$125	million	to	$500	million	annually)	range,	while	not	directly	empirically	supported	by	this	analysis,	may	be	a	logically	inferable	estimate	of	the	marginal	impact	on	health	care	costs	directly	associated	with	the	covered	benefits	described	in	the	mandate	laws.	
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Table	E2	
Cost	Implications	of	Impact	Assumptions	
	We	note	that,	owing	in	part	to	general	cost	inflation	but	in	large	part	to	an	expansion	of	the	service	codes	that	carriers	have	provided	as	services	covered	under	the	mandates,	the	RDCs	in	the	current	study	at	$1.9	billion	are	far	higher	than	the	$1.2	billion	in	the	2012	study.		However,	relative	to	the	2012	results	these	additional	RDCs	had	a	minimal	effect	on	the	upper	bound	estimate	because	mental	health	and	contraceptive	services	coverage	are	now	required	by	federal	law.		They	also	had	a	minimal	impact	on	the	lower	bound	estimate	because	self-insured	plans	also	tend	to	cover	both	contraceptive	services	and	mental	health	at	or	near	the	levels	provided	by	fully-insured	plans,	and	also	cover	many	of	the	additional	service	codes	in	the	carriers’	expanded	lists.	In	addition	to	the	direct	cost	impacts,	there	are	indirect	cost	effects,	such	as	avoided	hospitalizations	as	a	result	of	the	diabetes	mandate,	that	we	are	not	able	to	address	in	this	study.		Almost	75	percent	of	the	total	estimated	direct	cost	stems	from	three	service	mandates:	home	health,	infertility,	and	diabetes	services	and	supplies.		The	eight	provider	mandates	represent	nearly	another	20	percent.		Consideration	of	these	mandates	and	their	likely	indirect	cost	effects	would	provide	most	of	the	required	information	on	how	the	direct	costs	might	be	added	to	or	reduced	by	indirect	cost	effects.		It	is	possible	that	after	consideration	of	indirect	cost	effects,	the	net	impact	of	these	five	mandates	is	cost	reducing,	though	we	cannot	estimate	that	impact	in	this	study.		Finally,	there	are	individual	and	socially	beneficial	impacts	aside	from	health	care	spending	that	these	mandates	may,	and	in	many	cases	certainly	do,	provide.		Benefit	mandates	are	often	enacted	when	such	beneficial	effects	are	perceived	but	something	short	of	government	provision	of	the	benefit	is	the	balance	point	of	the	political	process.4			The	results	section	of	the	report	discusses	the	efficacy	and	public	health	benefits	of	services	described	in	the	mandates	in	detail.	
Percent	of	
Premium PMPM
Dollars	
(millions)
0.5% 2.18$																 61.81$													
1.0% 4.36$																 123.62$											
2.0% 8.72$																 247.24$											
3.0% 13.08$													 370.85$											
4.0% 17.44$													 494.47$											
5.0% 21.80$													 618.09$											
6.0% 26.16$													 741.71$											
6.5% 28.34$													 803.52$											
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State-Mandated	Health	Insurance	Benefits	and	
Health	Insurance	Costs	in	Massachusetts	
	
Introduction	and	Background	
Statutory	Basis	and	Scope	M.G.L.	Chapter	3	§38C	requires	the	Center	for	Health	Information	and	Analysis	(CHIA)	to	issue	a	comprehensive	report	at	least	once	every	four	years	on	the	cost	and	public	health	impact	of	all	existing	mandated	benefits.		Compass	Health	Analytics,	Inc.	(Compass)	was	engaged	to	prepare	this	analysis.		This	is	the	third	comprehensive	review	of	health	benefit	mandates,	and	the	second	(following	the	2012	report5)	under	the	statute	cited	above;	the	first	comprehensive	review	was	published	in	2008	as	required	under	Chapter	58	of	the	Laws	of	2006.6	The	statute	defines	a	health	benefit	mandate	as	one	that	“mandates	health	insurance	coverage	for	specific	health	services,	specific	diseases	or	certain	providers	of	health	care	services.”		Appendix	A	lists	the	mandates	addressed	in	this	report,	including	all	mandates	studied	in	the	previous	two	mandate	review	reports,	and	adds	to	that	set	new	mandates	passed	since	the	analysis	period	for	the	2012	report.		This	report	addresses	mandates	in	force	at	the	end	of	2014.		It	does	not	address	Chapter	258	of	the	Acts	of	2014	“An	Act	to	increase	opportunities	for	long-term	substance	abuse	recovery,”	the	relevant	portions	of	which	were	not	effective	until	October	2015,	leaving	insufficient	time	for	the	Act’s	provisions	to	have	an	effect	measurable	under	this	report’s	methodology.	Most	mandates	in	Massachusetts	require	insurers	to	cover	specific	services	or	to	provide	benefits	to	individuals	with	specific	conditions,	for	those	individuals	the	insurers	cover.		Another	smaller	set	of	mandates	requires	insurers	to	cover	the	services	of	specific	types	of	providers.		Most	of	these	provider-centered	mandates	are	similar	in	effect,	essentially	providing	that	payers	must	pay	practitioners	of	the	specified	provider	type	when	the	service	is	covered	and	when	the	practitioner’s	provider	type	is	licensed	to	provide	the	covered	service.		Because	all	mandates	addressed	in	this	review	apply	to	medical	insurance	policies,	as	opposed	to	policies	that	cover	other	sets	of	services,	such	as	dental	care,	these	provider-centered	mandates	do	not	address	non-medical	services.		For	example,	while	they	require	payers	to	pay	dentists	for	a	medical	service	that	either	a	physician	or	dentist	may	perform	under	their	licenses,	they	do	not	mandate	coverage	for	services	typically	covered	by	dental	plans.	Massachusetts	statutes	place	various	other	requirements	on	insurers,	including	ones	addressing	confidentiality,	coverage	practices	(continuity	of	coverage,	dependent	coverage,	coordination	of	benefits,	etc.),	and	limitations	on	insurers’	ability	to	deny	coverage	in	general	to	individuals	with	specified	conditions	(blind	persons,	victims	of	domestic	abuse,	etc.).		The	statute	charging	CHIA	with	this	review	does	not	include	within	the	scope	of	the	review	these	other	types	of	requirements,	and	consequently	this	review	does	not	address	them.	
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As	discussed	in	Appendix	B,	the	most	recent	comprehensive	claim	data	from	the	Massachusetts	All	Payer	Claims	Database	(MA	APCD)	available	during	the	period	Compass	performed	this	analysis	were	from	calendar	year	2014	(as	paid	through	June	30,	2015),	which	sets	the	timeframe	basis	for	the	study.		Results	presented	here	include	those	mandates	in	force	in	2014.	
Approach	to	reviewing	mandate	efficacy	The	goal	of	this	report,	in	its	review	of	evidence	related	to	the	efficacy	of	the	provisions	of	each	benefit	mandate,	is	not	to	judge	their	efficacy,	but	rather	to	summarize	how	each	is	currently	regarded	by	government	or	professional	entities	that	recommend	treatment	or	by	general	medical	literature.		If	the	efficacy	of	a	mandated	service	is	controversial,	this	report	will	describe,	but	not	attempt	to	resolve,	the	controversy.		The	report	includes	appropriate	reference	notes	for	readers	who	wish	to	learn	more.	For	some	mandates,	the	depth	the	report	can	reach	in	analyzing	the	mandate’s	impact	is	limited.		In	particular,	for	the	analysis	of	the	efficacy	of	provider-centered	mandates,	the	report	describes	whether	the	services	are	widely	covered	or	whether	standard-setting	entities,	such	as	Medicare,	pay	for	them.		However,	a	complete	assessment	of	current	thought	about	the	clinical	effectiveness	of	an	entire	profession	is	beyond	the	scope	of	this	review.	For	mandates	with	potentially	significant	public	health	impact,	meaning	an	effect	on	the	health	of	individuals	other	than	those	covered	by	the	mandated	benefit,	the	report	provides	information	describing	the	impact,	but	generally	does	not	attempt	to	quantify	it.i		This	approach	is	consistent	with	the	treatment	of	indirect	costs	in	the	economic	analysis,	and	further	consistent	with	the	treatment	of	indirect	costs	in	the	previous	reviews.	
Approach	to	analyzing	mandate	costs	For	calendar	year	2014,	this	study	estimates	the	cost	of	Massachusetts	health	insurance	benefit	mandates	in	force	during	that	year	to	premium	payers.		This	section	summarizes	the	methodology	for	measuring	those	costs.		Appendix	B	contains	a	more	detailed	description	of	the	methodology.	
Applicable	Population	This	study	estimates	the	effect	of	mandates	on	health	care	costs	only	for	people	in	Massachusetts	with	health	insurance	plans	subject	to	health	benefit	mandate	laws;	those	plans	fall	into	two	main	groups.		First,	all	mandates	in	the	study	apply	to	fully-insured	commercial	plans	regulated	by	the	Massachusetts	Division	of	Insurance.		Second,	a	subset	of	the	mandates	in	this	study	also	applies	to	coverage	for	public	employees	provided	under	the	Group	Insurance	Commission	(GIC).		The	great	majority	of	the	GIC	coverage	is	provided	on	a	self-insured	basis,	with	the	remainder	included																																									 																					i	This	approach	is	consistent	with	the	treatment	of	indirect	costs	in	this	report’s	analysis	of	mandated	benefit	costs,	and	further,	consistent	with	the	treatment	of	indirect	costs	in	the	2012	comprehensive	review	of	mandated	benefits.	
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among	the	fully-insured	plans	subject	to	all	the	mandates.		However,	it	is	Compass’s	understanding	that	the	GIC	voluntarily	follows	all	benefit	mandates	in	its	self-insured	plans.	State	health	insurance	benefit	mandates	do	not	apply	to	individuals	covered	under:	
• Self-insured	policies	(except	the	GIC	population	for	some	mandates),	as	these	policies	are	governed	by	federal	ERISA	statutes	and	not	subject	to	state	mandate	laws	
• Medicare	and	Medicare	Advantage	plans,	the	benefits	of	which	are	qualified	by	Medicare	
• Federally-funded	plans	including	the	Veterans	Administration,	TRICARE	(covering	military	personnel	and	dependents),	and	the	Federal	Employee’s	Health	Benefit	Plan	This	analysis	excludes	members	of	fully-insured	plans	over	64	years	of	age,	and	does	not	address	potential	effects	on	Medicare	supplement	plans	(which	generally	cover	patient	cost	sharing	within	the	Medicare	benefit	structure)	even	to	the	extent	they	are	regulated	by	state	law.		Finally,	some	Massachusetts	mandate	laws	affect	MassHealth,	which	administers	the	Massachusetts	Medicaid	program;	however,	this	analysis	does	not	address	the	potential	effect	of	those	mandates	on	MassHealth	expenditures.	The	total	number	of	persons	estimated	to	be	covered	by	fully-insured	policies	in	Massachusetts	was	estimated	through	a	variety	of	sources.		U.S.	Census	Bureau	data	on	the	Massachusetts	population	and	percent	covered	by	employer-sponsored	plans	and	MA	APCD	eligibility	data7	lead	to	an	estimate	of	3.8	million	Massachusetts	residents	under	age	65	covered	by	employer-sponsored	plans	in	2014,	approximately	1.8	million	of	whom	are	fully-insured.		Compass	used	Massachusetts	Department	of	Insurance	(DOI),8,9	MA	APCD	eligibility,10	and	CHIA	enrollment	trends11	data	to	develop	an	estimate	of	approximately	139,000	additional	individuals	under	age	65	residing	in	other	states	are	covered	by	Massachusetts-issued	fully-insured	employer-sponsored	insurance	subject	to	the	mandates.		Finally,	MA	APCD	eligibility	data12	yielded	an	estimate	of	approximately	170,000	persons	under	age	65	purchased	insurance	in	the	non-group	market	in	2014.		The	sum	of	the	employer-sponsored	state	residents,	non-residents,	and	individually	insured	produces	a	total	estimate	of	2.1	million	fully-insured	members.		Because	self-insured	GIC	plans	follow	the	mandates	voluntarily,	an	additional	261,000	members	are	added	to	the	covered	population	(based	on	GIC	annual	reports)13	for	a	total	of	2.4	million	individuals.		Appendix	C	contains	more	details	about	these	population	calculations.		Unless	otherwise	noted,	throughout	this	report	“fully-insured	population”	will	be	understood	to	include	the	self-insured	GIC	members,	and	“self-insured	population”	will	be	understood	to	not	include	the	self-insured	GIC	members.	Table	1	summarizes	the	license	types	and	populations	to	which	the	mandates	apply.		Most	mandates	apply	to	plans	under	all	types	of	state	insurance	license	(indemnity,	hospital/medical	service	corporation,	HMO);	some,	however,	apply	only	to	subsets	of	licenses.		To	calculate	the	percent	of	premium	the	analysis	uses	as	a	member-months	denominator	the	sum	of	member-months	for	all	license	types,	since	it	estimates	the	per-person	costs	of	the	benefits	with	respect	to	the	overall	average	fully-insured	health	insurance	premium.		However,	for	the	five	mandates	that	apply	to	less	than	the	entire	fully-insured	population,	estimated	claims	were	included	in	the	numerator	only	for	the	sub-groups	indicated	in	Table	1,	as	these	are	the	only	claims	related	to	
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benefits	required	by	those	mandates.		The	resulting	estimates	represent	the	impact	on	the	average	fully-insured	premiums,	not	on	the	premium	for	the	sub-group(s)	to	which	the	mandate	applies.		
Table	1	
2014	Estimates	of	Populations	to	Which	Mandates	Apply	
	
Sample	Population	To	develop	a	cost	estimate	for	each	mandate,	a	sample	per-member	per-month	(PMPM)	cost	estimate	was	developed	from	available	data	sources	and	multiplied	by	the	applicable	population	defined	in	the	preceding	section.ii		The	estimated	PMPM	cost	developed	from	claim	data	drew	upon	calendar	year	2014	data	from	CHIA’s	MA	APCD,14	Release	4.0.		CHIA	collects	and	manages	data	from	commercial	carriers,	third	party	administrators,	and	public	programs.15		CHIA	works	with	each	carrier	to	conduct	a	quality	control	process	on	the	MA	APCD	data,	and	“clears”	data	through	this																																									 																					ii	As	discussed	below	in	the	Results	section,	for	aggregated	cost	estimates,	overlap	between	mandates	is	removed	when	summing	total	dollars.	
Mandate Applicable	Population
Estimated	
Statute	
Membership
Est.	Effective	
Membership	
(incl.	SI	GIC)
Certified	Nurse	Midwives
Chiropractors
Dentists
Optometrists
Chiropractic	Services Blue	Cross	Blue	Shield	fully-
insured	members,	excluding 	HMO	
Blue
												165,174	 												165,174	
Infertil ity	Services All	fully-insured	Massachusetts-
resident	members
									1,962,021	 									2,206,099	
Certified	Registered	Nurse	Anesthetists
Early	Intervention
Home	Health	Care
HRT
Infertil ity
Low	Protein	Foods
Nurse	Practitioner
Podiatrist
Syringe
Cardiac	Rehab
Clinical	Trials	for	Cancer
Contraception
Cytologic	Screening
Lead	Screening
Mammography
Off-label	Uses	of	Prescription	Drugs	-	Cancer
Off-label	Uses	of	Prescription	Drugs	-	HIV/AIDS
Preventive	Care	to	Age	6
Autism	Services
Child	Hearing	Aids
Cleft	Palate	and	Lip
Diabetes
HLA	Testing
Limb	Prosthesis
Mental	Health
Nonprescription.	Enteral	Formulas
Oral	Cancer	Drugs
Physician	Assistants
Scalp	Hair	Prosthesis
Speech	&	Hearing
Bone	Marrow	Transplants	for	Breast	Cancer
Hearing	Screening	for	Newborns
Hospice	Care
Maternity	Care
												730,715	
									2,362,745	
									2,362,745	
Indemnity	and	Blue	Cross	Blue	
Shield	fully-insured	members 												479,865	
All 	fully-insured	members	and	all 	
GIC	members		(fully	and	self-
insured)
									2,362,745	
All 	fully-insured	members 									2,101,336	
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process	on	a	carrier-by-carrier	basis	as	this	process	is	complete.		This	quality-controlled	sample	comprises	approximately	87	percent	of	total	commercial	fully-insured	primary	medical	membership	under	age	65	in	the	Commonwealth.	iii		Compass	relied	upon	this	quality-controlled	data	sample	after	verifying	basic	reasonableness	checks	on	membership	and	expenses.		Compass	then	joined	claims	to	de-duplicated	eligibility	data	to	review	match	rates	and	average	paid	and	allowed	claims	PMPMs	by	carrier.		The	average	fully-insured	and	self-insured	GIC	medical	membership	subject	to	the	mandates	represented	in	the	sample	passing	this	additional	quality-control	step	for	2014	is	1.9	million,	or	79	percent	of	the	estimated	2.4	million	total	average	membership	for	the	fully-insured	and	self-insured	GIC	population	in	Massachusetts.		Cost	estimates	contained	in	this	report	assume	the	PMPM	costs	obtained	from	the	MA	APCD	sample	data	are	representative	of	the	overall	fully-insured	under-65	population.		For	the	mandates	developed	with	secondary	data	sources	(discussed	in	the	next	section),	the	underlying	utilization,	prevalence,	and	other	rates	were	drawn	from	Massachusetts	data	wherever	possible.		The	samples	used	are	discussed	in	detail	in	the	methodology	appendices.	Appendix	B	provides	a	more	detailed	discussion	of	the	cost	estimation	methodology	and	Appendix	C	details	the	development	of	Massachusetts	population	segment	estimates.	
Definition	of	Estimated	Costs	Costs	associated	with	mandated	benefits	are	a	relatively	small	subset	of	total	health	care	costs	for	the	affected	population;	to	begin	to	address	by	how	much	mandate	laws	impact	total	costs	it	will	be	helpful	to	define	terminology	for	the	purpose	of	this	report.		The	general	cost	concepts	defined	below	will	aid	in	interpreting	the	results	of	the	study.		In	practice,	these	cost	sub-categories	are	difficult	to	measure,	and	no	precise	measurement	of	these	cost	breakouts	can	be	achieved	within	the	scope	of	this	project,	although	conceptual	definition	will	aid	in	interpreting	the	results	of	the	analysis.		Two	general	types	of	costs	may	be	associated	with	any	mandate:	
• Required	direct	costs.		These	are	the	costs	of	services	explicitly	described	in	a	mandate	law,	used	by	covered	members,	and	paid	for	by	the	regulated	insurance	plans,	whether	or	not	some	or	all	of	the	costs	would	have	been	incurred	in	the	absence	of	the	mandate	through	voluntary	provision	of	the	benefits.		These	costs	are	the	primary	focus	of	this	study,	and	are	the	most	easily	measurable.	Required	direct	costs	(RDCs)	are	the	sum	of	
base	direct	costs	and	marginal	direct	costs.	
o Base	direct	costs	(BDCs)	are	those	costs	that	would	be	present	even	if	the	mandate	law	were	not	in	force.		Mandate	laws	may	require	benefits	that	would	be	provided,	wholly	or	in	part,	voluntarily	(by	some	or	all	of	the	market)	or	that	are	required	by	another	mandate	law	(state	or	federal).		
																																								 																					iii	Total	average	fully-insured	commercial	primary	medical	insurance	membership	under	age	65	reported	in	the	MA	APCD	is	approximately	2	million,	or	94	percent	of	Compass’s	2014	fully-insured	commercial	membership	estimate	of	2.1	million.		Total	average	under-65	fully-insured	and	self-insured	GIC	primary	medical	insurance	membership	from	the	MA	APCD	is	2.1	million,	or	90	percent	of	Compass’s	2.4	million	population	estimate	(not	all	carriers’	GIC	accounts	can	be	identified	in	the	MA	APCD;	these	accounts	are	excluded	from	the	2.1	million	estimate).	
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o Marginal	direct	costs	(MDCs)	are	those	additional	costs	beyond	the	base	direct	costs	that	the	imposition	of	the	mandate	impels.			
• Indirect	costs.		Indirect	costs	are	costs	that	may	be	added	as	a	result	of	the	related	delivered	services	associated	with	the	mandate	(e.g.,	costs	of	additional	complicated	births	associated	with	infertility	treatment)	or	service	costs	avoided	(these	would	be	“negative	costs”	or	cost	offsets)	as	a	result	of	the	mandate	(e.g.,	fewer	emergency	department	visits	for	diabetics	due	to	coverage	for	diabetes	services	and	supplies).		While	we	can	measure	RDCs	reasonably,	measuring	their	breakdown	into	base	and	marginal	direct	costs	is	far	more	difficult,	and	measuring	indirect	costs	even	more	difficult.		To	measure	the	true	cost	impact	of	a	mandate	law	on	regulated	insurance	product	premiums,	one	would	include	only	marginal	costs,	which	would	consist	of	marginal	direct	costs	and	marginal	indirect	costs	(those	indirect	costs	associated	with	the	marginal	utilization	produced	by	the	mandate	law).		Since	marginal	indirect	costs	may	be	either	positive	or	negative,	the	net	impact	of	any	one	mandated	benefit	on	total	costs	may	be	either	increasing	or	decreasing,	depending	on:	
• How	much	of	the	direct	cost	associated	with	the	mandate	is	marginal	(i.e.,	attributable	to	the	imposition	of	the	mandate)	
• Whether	indirect	costs	are	positive	or	negative	on	net	
• The	size	of	those	indirect	costs	relative	to	the	direct	costs	Though	not	within	the	scope	of	this	study,	a	well-conducted	multivariate	statistical	analysis	using	multi-state	data	would	be	better	able	to	estimate	marginal	costs	that	include	both	direct	and	indirect	components.		Some	multivariate	econometric	studies	comparing	benefit	mandates	and	cost	levels	across	states	have	shown	that	some	specific	mandated	benefits	decrease	costs	on	net,	while	others	increase	costs	on	net.16	This	study	provides	some	information	that	may	be	useful	in	understanding	the	proportion	of	the	required	direct	costs	that	are	likely	to	be	marginal	for	the	mandates.		The	scope	of	this	study	does	not	attempt	to	measure	precisely	the	amount	of	RDC	that	is	marginal	(which	would	require	multi-state	data),	and	the	report	does	not	include	evaluation	of	indirect	costs.		As	a	result,	it	is	not	possible	to	ascertain	from	the	information	in	this	study	the	net	impact	on	health	care	costs	in	the	Commonwealth	associated	with	the	mandate	laws,	but	previous	research	suggests	that	total	RDCs	will	greatly	overstate	the	net	effect	of	the	mandates,	that	offsetting	indirect	cost	savings	can	be	larger	than	direct	cost	effects	(making	the	net	effect	of	such	a	mandate	to	reduce	cost),	and	that	the	impact	of	mandate	laws	on	insurance	premium	levels	will	not	be	directly	inferable	from	the	RDC	estimates	contained	herein.17	This	report	does,	however,	compare	the	fully-insured	population	RDCs	to	the	RDCs	observed	in	the	Massachusetts	self-insured	sector	(not	subject	to	the	mandate	laws)iv;	this	difference	provides	one																																									 																					iv	Note	that	the	Group	Insurance	Commission	(GIC),	which	administers	health	insurance	benefits	for	public	employees	in	the	Commonwealth,	has	both	fully-insured	and	self-insured	members.			The	GIC	is	specifically	included	in	a	number	of	benefit	mandates,	and	is	understood	to	follow	the	others	voluntarily	as	a	matter	of	policy.		As	a	result,	the	GIC	membership	that	can	be	identified	in	the	data	are	treated	as	fully-insured	for	the	purpose	of	measuring	PMPM	costs	relative	to	the	self-insured	market.		See	Appendix	B	for	more	details.	
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estimate	of	the	marginal	cost	introduced	by	the	mandate	legislation.		Previous	research	has	found	that	benefit	levels,	including	for	mandated	services,	are	similar,	if	not	richer,	in	the	self-insured	market.18		Mandate	laws	may	have	small	effects	to	the	extent	these	research	findings	indicate	firms	offer	the	benefits	voluntarily.		However,	considering	that	employers	in	Massachusetts	that	self-insure	must	compete	in	the	labor	market	with	fully-insured	firms	that	must	offer	the	mandated	benefit	package	and	public-sector	employers	offering	GIC	plans	that	voluntarily	include	all	mandated	health	insurance	benefits	(even	when	the	text	of	the	mandate	laws	does	not	reach	the	self-insured	GIC),	the	benefits	in	the	self-insured	firms	are	likely	to	be	at	least	somewhat	richer	than	they	would	be	in	the	absence	of	the	mandate	laws.		This	competitive	labor	market	effect	would	shrink	the	cost	difference	between	fully-insured	and	self-insured	plans	and	understate	(or	provide	a	lower	bound	for)	the	implied	impact	of	benefit	laws	on	health	care	costs	provided	by	the	difference	between	fully-insured	and	self-insured	costs.	In	the	cost	estimates	displayed	in	the	Results	section,	these	lower-bound	estimates	are	derived	from	the	difference	between	insurer	spending	in	the	fully-insured	population	for	the	mandated	benefit	and	the	insurer	spending	in	the	self-insured	population	for	the	same	benefit.		To	reduce	the	impact	that	differences	in	average	patient	cost	sharing	between	these	populations	may	have	on	the	result,	the	calculation	is	performed	by	computing	the	percentage	by	which	the	fully-insured	allowed	(before	cost	sharing)	PMPM	exceeds	the	self-insured	allowed	PMPM,	and	applying	that	percentage	to	the	fully-insured	paid	PMPM.		The	result	is	a	lower-bound	estimate	of	the	impact	of	the	mandate	on	fully-insured	paid	expenditures.		Where	the	self-insured	allowed	PMPM	is	higher	than	the	fully-insured	allowed	PMPM,	we	treat	the	impact	as	zero,	rather	than	negative;	we	assume	that	if	self-insured	firms	on	average	have	a	higher	spending	level	than	fully-insured	products	subject	to	the	mandates,	it	is	not	caused	by	the	existence	of	the	mandate.		That	is:	Lower	Bound	Marginal	Cost	=	[(FIv	Allowed	–	SI	Allowed)/FI	Allowed]*FI	paid	RDC,	if	FI	Allowed	–	SI	Allowed	>	0	Lower	Bound	Marginal	Cost	=	0,	otherwise	An	upper-bound	claim	cost	estimate	is	also	provided	for	each	mandate,	which	includes	the	entire	RDC,	except	for	those	mandates	judged	by	the	carriers	likely	to	have	zero	marginal	costs.		This	upper-bound	estimate	assumes	that	100	percent	of	the	RDC	for	mandates	with	potential	marginal	direct	cost	is	marginal,	and	that	carriers	would	pay	zero	dollars	in	claims	for	the	services	described	by	the	mandates	in	the	absence	of	the	mandate	laws.		For	most	mandates	there	is	good	reason	to	believe	the	actual	marginal	cost	is	far	lower,	though	we	do	not	have	a	direct	method	of	estimating	by	how	much.		For	example,	home	health	care	services	are	widely	considered	to	be	cost-effective	in	many	contexts.		In	all	likelihood	carriers	would	cover	this	benefit,	if	at	a	somewhat	lower	level,	in	the	absence	of	the	mandate.		As	a	result,	the	upper	bound	estimates	are	likely	to	be	well	above	the	actual	marginal	direct	cost.	To	calculate	the	total	cost	of	the	mandates	to	the	Massachusetts	health	care	system,	administrative	loading	(the	additional	costs	over	and	above	health	care	claims	required	to	administer	the	health																																									 																					v	In	this	and	other	equations	and	exhibits	in	this	report,	the	abbreviation	“FI”	refers	to	the	fully-insured	and	self-insured	GIC	population	subject	to	the	mandates,	and	“SI”	refers	to	the	non-GIC	self-insured	comparison	population.	
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plan)	must	be	added	to	the	claims	expense	measures	described	above.		According	to	CHIA’s	September	2016	report	on	the	performance	of	the	Massachusetts	health	care	system,	in	2014,19	average	administrative	loading	(including	profit)	in	the	fully-insured	commercial	market	was	estimated	to	be	11	percent.		Therefore,	to	arrive	at	estimates	of	fully	loaded	healthcare	premium	costs,	claims	costs	were	divided	by	one	minus	the	11	percent	administrative	load	(1	–	0.11),	or	0.89.		Comparing	the	present	study	to	the	2012	reports	shows	that	RDC	results	for	some	mandates		have	changed	significantly;	most	notably,	the	RDC	estimates	for	diabetes	services	and	supplies	and	mental	health	care	show	nearly	three-fold	and	two-fold	increases,	respectively.		The	main	drivers	of	these	and	other	significant	differences,	illustrated	by	selected	examples,	follow.	
• Carrier	Input	
o For	the	mental	health	mandate,	the	carriers	provided	an	extensive	list	of	procedure	and	diagnosis	codes	to	be	added	to	the	cost	model	specification,	including	diagnoses	not	commonly	considered	behavioral	health	diagnoses,	such	as	intellectual	disabilities,	Alzheimer’s	disease,	and	Parkinson’s	disease.vi		
o This	was	also	true	for	the	speech,	hearing,	and	language	and	the	non-prescription	enteral	formulas	mandates,	which	had	many-fold	cost	increases	(but	very	small	absolute	RDCs	even	after	the	large	increases	shown	in	this	study).	
o Significant	additions	were	also	made	to	the	diabetes	services	and	supplies	specification	to	include	new	products,	such	as	the	new	insulin	pumps	discussed	below.	
• Price	and	service	mix	changes	
o A	recent	study	found	that	the	average	price	of	insulin	has	tripled	in	the	past	decade.20	
o New,	more	expensive	insulin	pumps	have	also	become	popular	with	clinicians	and	diabetes	patients	in	recent	years.21	
• Clinical	practice	and	guideline	changes	
o As	discussed	below,	decreased	frequency	guidelines	for	mammographic	and	cytological	screening	(Pap	smear)	have	been	released	by	U.S.	government	agencies	and	medical	societies	since	the	previous	study	period.22,23	These	changes	also	affected	the	self-insured	cost	estimates;	therefore,	changes	in	the	lower	bound	estimates	were	much	more	modest.		Furthermore,	the	new	Federal	requirements	for	mental	health	and	contraceptive	services	coverage	have	mitigated	the	impact	of	these	changes	on	the	aggregate	upper	bound	estimate.	The	mandates	in	the	study	were	reviewed	by	the	major	carriers	in	Massachusetts	to	ascertain	whether,	in	their	opinion,	the	RDCs	of	the	mandates	would	be	affected	if	the	mandate	were	repealed.		Those	for	which	the	law	was	judged	not	to	affect	measurable	cost	were	deemed	“zero	marginal	direct	cost”	mandates.		In	the	present	study,	the	MA	APCD	allowed	estimation	of	the	RDCs	for	four	of	the	original	zero	marginal	direct	cost	mandates	(cardiac	rehabilitation,	cytological	screening,	lead	poisoning	screening,	and	mammography)	with	claim	data.		RDCs	for	the	remaining																																									 																					vi	These	physical	health	diagnosis	codes	combined	account	for	approximately	1	percent	of	sample	paid	claim	expenses	for	plans	subject	to	the	mandate.	
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zero	marginal	direct	cost	mandates	identified	by	the	carriers,	where	measurable,	were	calculated	using	secondary	data	sources.		In	addition,	in	light	of	federal	benefit	requirements	in	the	Mental	Health	Parity	and	Addiction	Equity	Act	of	2008	(MHPAEA)	and	the	Patient	Protection	and	Affordable	Care	Act	of	2010	(ACA),	Compass	has	re-classified	the	mental	health	and	contraceptive	services	mandates	as	zero	marginal	direct	cost	mandates	in	the	present	study.vii		RDC	estimates	for	these	two	mandates	were	prepared	with	MA	APCD	data.	The	remaining	“mandates	with	potential	marginal	direct	cost”	were	estimated	using	the	MA	APCD.		More	details	about	this	distinction	and	the	overall	methodology	can	be	found	in	Appendix	B.		In	the	presentation	of	results	below,	the	mandates	are	organized	into	potential	marginal	direct	cost	and	zero	marginal	cost	categories.	
Effect	of	the	ACA	on	the	Incremental	Cost	of	the	Mandates	As	noted	above,	this	analysis	measures	a	mandate’s	RDC	and	then	uses	it	to	estimate	a	lower	bound	for	how	much	of	the	RDC	is	due	to	the	Massachusetts	benefit	mandate	by	subtracting	from	it	the	costs	incurred	for	that	benefit	in	the	self-insured	population	that	is	not	subject	to	the	mandate.		For	purposes	of	the	lower	bound,	the	self-insured	costs	stem	from	coverage	carriers	would	have	provided	on	their	own	or	because	of	other	federal	or	state	legal	requirements,	including	ACA	requirements.	If	an	ACA	coverage	requirement	applies	to	both	fully-	and	self-insured	plans,	then	that	requirement	does	not	interfere	with	the	methodology	employed	in	this	analysis;	it	would	not	contribute	to	a	difference	between	the	cost	of	coverage	for	fully-insured	plans	and	the	cost	for	self-insured	plans.		Indeed,	when	most	ACA	requirements	with	this	broader	applicability,	such	as	requirements	for	preventive	care	coverage,	interact	with	Massachusetts	mandates,	the	mandates	can	be	assumed	to	have	zero	incremental	cost.		Such	is	the	case	with	the	relationship	between	the	state	mandate	requiring	coverage	for	hormonal	contraceptives	and	the	ACA’s	broad	requirement	for	coverage	for	contraception.		The	body	of	this	analysis	identifies	these	cases.	The	ACA	creates	other	requirements,	including	minimum	coverage	standards	–	known	as	Essential	Health	benefits	(EHBs)	–	for	plans	offered	on	health	insurance	exchanges,	such	as	the	Massachusetts	Health	Connector,	and	for	some	other,	but	not	all,	fully-insured	plans.		The	ACA’s	requirements	for	EHBs	are	often	stated	generally,	and	expressed	more	precisely	in	the	offerings	of	a	state	“benchmark”	plan,	which	for	Massachusetts	is	a	specific	HMO	Blue	plan	from	Blue	Cross/Blue	Shield.		Identifying	the	effect	of	EHBs	on	the	cost	of	a	Massachusetts	mandate	requires	isolating	EHBs	that	arise	from	federally-sourced	requirements	from	those	present	only	because	the	state	mandate	exists.viii		If	a	Massachusetts	mandate	requires	coverage	for	a	service	which	federal	law																																									 																					vii	The	contraceptive	services	and	mental	health	mandates	were	treated	as	“mandates	with	potential	marginal	direct	cost”	in	the	2008	and	2012	studies.	viii	One	can	argue	that	because	the	Massachusetts	benchmark	plan	is	itself	subject	to	state	mandates,	EHB	requirements	indirectly	require	all	plans	subject	to	EHBs	to	follow	the	state	mandates	that	fall	within	the	EHB	service	categories,	and	therefore	that	the	cost	of	these	mandates	beyond	meeting	federal	requirements,	for	plans	subject	to	EHBs,	is	zero.		The	resolution	of	this	circularity	lies	in	asking	“what	would	EHBs	include	if	the	state	mandates	were	not	present?”	and	considering	only	EHB	requirements	that	appear	federal	in	origin.	
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(not	the	state	mandate)	already	deems	an	EHB,	the	cost	of	that	service	in	a	plan	subject	to	the	EHB	requirement	would	not	contribute	to	the	incremental	cost	of	the	mandate	in	that	plan.			As	noted,	ACA	requirements	that	apply	to	both	fully-	and	self-insured	plans	do	not	affect	this	analysis.		But	because	EHB	requirements	do	not	apply	to	self-insured	plans	–	and	indeed	do	not	apply	even	to	all	fully-insured	plans	–	the	lower	bound	methodology	discussed	above	might	not	cleanly	isolate	the	effect	of	EHB	requirements	from	the	effect	of	a	Massachusetts	mandate.		That	is,	if	a	Massachusetts	mandate	requires	coverage	for	a	specific	service	also	required	as	an	EHB,	then	some	of	the	difference	in	coverage	for	the	service	between	plans	subject	to	the	EHB	and	self-insured	plans	might	be	due	to	the	federal	EHB	requirement	and	not	due	just	to	the	Massachusetts	mandate.	Of	Massachusetts	mandates	not	completely	eclipsed	by	the	ACA,	only	a	few	(related	to	speech	and	audiology,	early	intervention,	and	possibly	hormone	replacement	therapy,	as	discussed	in	the	body	of	this	analysis)	arguably	are	preempted	by	EHB	requirements.		Because	the	relevant	EHBs	are	stated	only	generally	and	ACA	regulations	rely	on	benchmark	plans	for	further	specificity,	determining	if	EHBs	encompass	the	services	in	a	given	Massachusetts	mandate	is	difficult	and	in	some	cases	not	possible	within	the	scope	of	this	analysis,	as	is	isolating	the	precise	set	of	members	subject	to	the	EHB	requirement	within	the	fully-insured	population.		Furthermore	the	RDCs	for	these	few	mandates	do	not	place	them	among	mandates	that	contribute	a	great	deal	to	the	overall	cost	of	Massachusetts	mandates.		Attempting	to	exclude	these	costs	from	the	mandates	runs	the	risk	of	under-estimating	the	cost	impact	of	the	mandates.		Therefore	in	these	cases,	this	analysis	assumes	the	impact	is	the	result	of	the	state-mandated	services,	and	so	the	analysis	will	still	apply	the	lower-bound	methodology	in	these	cases.		By	not	subtracting	these	(hard	to	estimate)	costs	that	might	already	be	required	by	the	ACA’s	EHB	requirements,	the	cost	estimates	are	either	immaterially	affected	or	provide	a	slightly	conservatively	high	estimate	of	mandate	cost	impacts.	Finally,	Section	1311	of	the	Affordable	Care	Act	(ACA)24	requires	states	to	contribute	to	the	cost	of	subsidizing	health	insurance	coverage	for	selected	segments	of	the	population	to	pay	for	benefits	mandated	by	the	state	and	exceeding	EHB	requirements.		The	Massachusetts	Division	of	Insurance	and	the	Commonwealth	Health	Insurance	Connector	Authority	are	responsible	for	determining	any	potential	state	liability	under	that	law.	
Results	This	section	presents	results	of	both	the	efficacy	and	cost	reviews	for	mandates	with	potential	marginal	direct	cost	and	mandates	with	zero	marginal	direct	cost,	and	results	combining	the	two.	
Mandates	with	Potential	Marginal	Direct	Cost:	Service-Centered	Mandates	Results	for	the	individual	mandates	requiring	coverage	for	services	and/or	patient	conditions,	with	potential	marginal	direct	cost,	and	studied	with	primary	data,	follow.		Detailed	specifications	for	the	cost	calculations	for	these	mandates	are	available	from	CHIA	upon	request.	
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Autism	Spectrum	Disorders	The	autism	mandate	requires	coverage	for	treatment	for	Autism	spectrum	disorders	(ASDs)	on	a	“non-discriminatory	basis”,	meaning	on	the	same	terms	as	coverage	for	medical/surgical	conditions.		The	mandate	includes	in	the	treatment	of	ASDs:	habilitative	or	rehabilitative	care,	pharmacy	care,	psychiatric	care,	psychological	care,	and	therapeutic	care.		Coverage	for	psychiatric	and	psychological	care	is	also	required	by	the	mental	health	mandate.		The	mandate’s	primary	effect	is	to	require	coverage	for	medically-necessary	habilitative	care,	i.e.,	“professional,	counseling,	and	guidance	services	and	treatment	programs,	including	applied	behavior	analysis	supervised	by	a	Board	Certified	Behavior	Analyst.”25	Effect	of	the	mandate	on	health	ASDs	are	a	group	of	developmental	disabilities	characterized	by	persistent	impaired	social	interaction	and	communication	and	by	restricted	and	repetitive	patterns	of	behavior,	interests,	or	activities	present	in	early	developmental	stages	that	clinically	and	significantly	impair	social,	occupational,	or	other	areas	of	functioning.26,27		This	definition	incorporates	several	previously	distinct	diagnoses,	including	autism,	Asperger’s	disorder,	childhood	disintegrative	disorder,	and	pervasive	developmental	disorder	not	otherwise	specified.28	In	general,	children	with	autism	are	less	able	to	interpret	non-verbal	social	and	emotional	cues,	as	they	struggle	to	interpret	behaviors	such	as	body	language	and	facial	expressions.		They	also	struggle	with	reciprocal	social	interaction,	exhibit	inflexibility	in	their	behaviors,	have	difficulty	coping	with	change,	and	engage	in	restricted	and	repetitive	behaviors.29		While	these	behaviors	and	symptoms	may	change	over	time,	adults	with	ASD	continue	to	struggle	throughout	life	with:	language,	especially	perspective,	nuance,	humor,	and	implied	meanings;	self-sufficiency;	and	social	skills.	30		Adults	with	autism	are	much	less	likely	to	be	fully	self-supporting,	and	many	develop	psychiatric	issues	such	as	obsessive-compulsive	disorder	or	affective	disorders.31		ASDs	require	chronic	management	and	cannot	be	cured.		Outcomes	and	behaviors	for	individuals	change	over	time,	but	most	patients	remain	on	the	spectrum	as	adults.		ASDs	affect	a	person’s	mental	health,	as	well	as	his	ability	to	achieve	academically,	live	independently,	obtain	and	retain	employment,	and	establish	and	maintain	positive	social	relationships.32		Additionally,	ASD	patients	may	have	an	increased	incidence	of	seizure	and	gastrointestinal	disorders,	as	well	as	sleep	disturbances,	which	must	also	be	addressed	through	appropriate	medical	management.33	ASD	is	difficult	to	diagnose,	as	it	is	“a	neurodevelopmental	disability	or	phenomenological	disorder,	not	a	specific	disease.”34		Moreover,	while	symptoms	and	signs	are	usually	apparent	early	in	a	child’s	development,	the	behavior	patterns	and	social	deficits	may	not	be	identified	as	ASD	until	social,	occupational,	educational,	or	other	developmental	milestones	are	not	met.35		Variations	in	functional	limitations,	as	well	as	the	pattern	of	development,	also	contribute	to	difficulties	with	diagnosis.36		For	the	general	population,	the	U.S.	Preventive	Services	Task	Force	(USPSTF)	–	an	independent	panel	of	national	experts	in	prevention	and	evidence-based	medicine	that	recommends	clinical	preventive	services	such	as	screenings,	counseling	services,	and	preventive	medications37	–	recently	released	its	report	on	screening	for	ASD	in	children	ages	18	to	30	months,	concluding	“current	evidence	is	insufficient	to	assess	the	balance	of	benefits	and	harms	of	screening	
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for	[ASD]	in	young	children	for	whom	no	concerns	of	ASD	have	been	raised	by	their	parents	or	a	clinician.”38	
Prevalence	Even	with	these	difficulties,	estimates	of	the	prevalence	of	ASDs	–	such	as	those	below	from	the	Autism	and	Developmental	Disabilities	Monitoring	(ADDM)	Network	based	on	health	and	special	education	records	of	children	across	the	United	States	–	have	risen	dramatically	over	the	last	decade:	
Prevalence	of	Autism	Spectrum	Disorder	among	Children	Aged	8	Years	
Report	Year	 200739	 200940	 201241	 201442	
Data	Year	 2002		 2006		 2008		 2010			
	 	 	 	 	
Prevalence		 1	in	152	 1	in	110	 1	in	88	 1	in	68	
Per	1000	children	 6.6	 9.0	 11.3	 14.7	
Change	versus	previous	 -	 36.4%	 25.6%	 30.1%	
Change	versus	2002	 -	 36.4%	 71.2%	 122.7%	
	Information	for	these	estimates	was	collected	on	eight-year-old	children	because	previous	work	had	shown	that	most	children	with	ASD	have	been	identified	for	services	by	that	age.		The	median	age	of	first	ASD	diagnosis	is	approximately	4.5	years,	and	the	prevalence	among	boys	is	four	to	five	times	higher	than	among	girls.43		White	children	are	approximately	30	percent	more	likely	to	be	diagnosed	with	ASD	than	are	black	children,	and	almost	50	percent	more	likely	than	are	Hispanic	children.44	The	Centers	for	Disease	Control	and	Prevention	(CDC)	is	currently	studying	reasons	for	this	increase,	including	evaluation	of	“the	geographic	area	covered,	the	number	and	racial/ethnic	distribution	of	children	living	in	these	communities,	sociodemographic	population	characteristics,	and	other	factors	that	might	influence	the	prevalence	and	characteristics	of	children	with	ASD	in	the	population.”45		Other	factors	may	be	better	awareness	or	a	change	in	diagnostic	practices.		The	most	notable	change,	according	to	the	CDC,	is	the	number	of	children	identified	with	ASD	who	have	average	or	above-average	intellectual	ability.46		Overall,	the	CDC	has	pointed	out	that	due	to	its	behavioral	basis,	as	well	as	lack	of	consistent	identification,	genetic,	or	biologic	markers,	ASD	presents	challenges	to	epidemiological	investigation.47	
Treatment	The	primary	treatment	goals	for	ASD,	according	to	the	American	Academy	of	Pediatrics,	are	to	“maximize	the	child's	ultimate	functional	independence	and	quality	of	life	by	minimizing	the	core	autism	spectrum	disorder	features,	facilitating	development	and	learning,	promoting	socialization,	reducing	maladaptive	behaviors,	and	educating	and	supporting	families.”48		Interventions,	therefore,	should	be	designed	to	promote	development	and	learning;	improve	communication,	social	interaction	and	reciprocity;	diminish	repetitive	and	restricted	behaviors;	and	educate	and	support	families.49		A	wide	variety	of	therapies	are	available,	including:	behavior	and	
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communication	therapies,	pharmacological	therapies	to	treat	symptoms,	dietary	approaches,	and	complementary	and	alternative	medicine	therapies.50		Additional	supports	are	also	used	by	those	diagnosed	with	autism,	and	may	change	over	time	depending	on	individual	age	and	need,	including	educational,	vocational,	residential,	and	housing	support	services.51	Behavioral	and	communication	interventions	are	the	primary	therapies	for	ASD.		Broadly,	they	address	communication,	social,	daily-living,	play,	and	leisure	skills,	as	well	as	academic	achievement	and	maladaptive	behaviors.		Interventions	are	structured	to	help	the	child	acquire	the	skills	and	knowledge	necessary	for	independence	and	personal	responsibility	in	a	variety	of	environments.52		These	types	of	therapies	should	provide	structure,	direction,	and	organization	for	the	child,	and	encourage	family	participation.53		Models	have	most	often	been	developed	upon	a	“primary	philosophical	orientation,”	frequently	categorized	as	behavior	analytic,	developmental,	or	structured	teaching.54	The	most	widely	used	and	researched	type	of	behavioral	therapy	for	ASD	is	applied	behavior	analysis	(ABA).55		Based	on	psychology	research	and	its	resultant	principles	of	learning,	these	interventions	focus	on	helping	patients	learn	positive	behaviors	and	decrease	negative	ones,	while	developing	adaptive	strategies	to	new	situations.56		ABA	emphasizes	evaluation	and	measurement	of	behaviors,	leading	researchers	to	most	easily	apply	scientific	methods	when	evaluating	these	interventions.		In	fact,	“most	studies	of	comprehensive	treatment	programs	that	meet	minimal	scientific	standards	involve	treatment	of	preschoolers	using	behavioral	approaches.”57	ABA	encompasses	a	variety	of	methodologies	including	Pivotal	Response	Training	(PRT),	Early	Intensive	Behavioral	Intervention	(EIBI)	and	Verbal	Behavior	Intervention	(VBI).58		One	popular	method,	Discrete	Trial	Training	(DTT),	teaches	behaviors	and	responses	step-by-step.		Environments	are	highly	structured	and	lessons	are	reduced	to	their	simplest	parts,	using	positive	reinforcement	for	desired	behaviors.59		A	similar	intervention	is	TEACCH,	or	Treatment	and	Education	of	Autistic	and	Related	Communication	Handicapped	Children	program,	also	known	as	“structured	teaching.”		This	intervention	focuses	on	modifying	the	patient’s	environment	to	accommodate	the	individual’s	deficits,	as	well	as	on	improving	skills.		Visual	cues,	schedules,	routines	and	structured	work	and	activity	systems	are	part	of	this	method.60		Research	has	found	that	while	these	methods	can	teach	certain	skills,	they	cannot	be	generalized	for	“spontaneous	use	in	natural	environments.”61		Other	types	of	behavioral	and	communication	interventions	include	Developmental,	Individual	Differences,	Relationship-Based	Approach	(DIR;	also	called	"Floortime")	and	Picture	Exchange	Communication	System	(PECS);	likewise,	sensory	integration,	occupational	and	speech	therapies	are	additional	approaches	to	treatment.62	No	drugs	are	currently	approved	specifically	for	the	treatment	of	ASD.63		However,	medications	are	used	to	treat	specific	symptoms	and	“maladaptive	behaviors	such	as	aggression,	self-injurious	behavior,	repetitive	behaviors	(e.g.,	perseveration,	obsessions,	compulsions,	and	stereotypic	movements),	sleep	disturbance,	mood	lability,	irritability,	anxiety,	hyperactivity,	inattention,	destructive	behavior,	or	other	disruptive	behaviors.”64		Although	dietary	approaches	and	alternative	medicine	therapies	are	widely	used,	in	general,	research	has	not	proven	their	effectiveness;65	in	fact,	some	therapies,	such	as	intravenous	chelation	of	heavy	metals,	have	been	shown	to	be	dangerous.66	
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Evidence	exists	for	the	potential	effectiveness	of	early	intervention	for	children	with	ASDs,	making	early	identification	and	diagnosis	important	to	treatment	outcomes.67,68,69,70	The	National	Professional	Development	Center	on	Autism	Spectrum	Disorder	(NPDC-ASD),	which	evaluated	with	federal	funding	specific	interventions	used	in	treating	ASD,	identified	27	evidence-based	practices	that	“have	been	shown	through	scientific	research	to	be	effective	when	implemented	correctly	with	students	with	ASD.”71		The	National	Guideline	Clearing	House	under	the	federal	Agency	for	Healthcare	Research	and	Quality	(AHRQ)	includes	36	guidelines	for	the	diagnosis,	treatment,	and	management	of	ASD	which	have	likewise	been	shown	through	various	research	studies	to	be	effective.72		In	its	report	comparing	effectiveness	of	various	therapies,	AHRQ	called	for	more	research	but	concluded	the	following	based	on	a	review	of	existing	studies:73	
• Good	evidence	exists	(high	confidence;	consistent	results	from	good-quality	studies):	
o Behavioral	interventions:	
§ Use	of	cognitive	behavioral	therapy	is	effective	in	treating	anxiety	in	school-aged	children	without	cognitive	or	language	delays.		
o Medical	interventions:	
§ Aripiprazole	can	reduce	challenging	and	repetitive	behaviors;	it	is	associated	with	significant	weight	gain,	sedation,	and	other	side	effects	
• Moderate	evidence	exists	(findings	are	supported	but	further	research	could	change	conclusions):	
o Behavioral	interventions:	
§ Certain	child-focused	early	behavioral	and	developmental	interventions	can	improve	cognitive	and	language	outcomes	for	some	children.	
§ Play-	and	interaction-based	interventions	improve	joint	attention	skills	in	young	children	who	were	also	typically	receiving	early	intervention.	
§ Risperidone	can	reduce	challenging	and	repetitive	behaviors;	good	evidence	associates	it	with	significant	weight	gain,	sedation,	and	other	side	effects.	
• Some	evidence	exists	(very	few	studies,	or	existing	studies	are	flawed):	
o Behavioral	interventions:	
§ Parent-focused	early	intensive	behavioral	interventions	may	improve	language	skills	for	some	children.	
§ Social	skills	interventions	may	yield	short-term	improvements	in	social	interactions	and	emotion	recognition	for	school-aged	children	with	average	reasoning	and	language	skills.	
• Evidence	is	insufficient	to	understand	the	effectiveness,	benefits,	and	adverse	events	from	all	other	medical	interventions	(including	serotonin-reuptake	inhibitors	and	stimulant	medications),	educational	interventions,	or	any	allied	health	or	complementary	and	alternative	medicine	(CAM)	intervention.	ABA	is	an	entire	discipline	“concerned	with	the	application	of	behavioral	science	in	real-world	settings	such	as	clinics,	schools,	and	industry	with	the	aim	of	improving	socially	important	issues	such	as	behavior	problems	and	learning.”74,75		Comprehensive	interventions	focus	on	teaching	specific	skills	to	improve	intellectual,	social,	and	adaptive	functioning,	while	focused	interventions	are	more	time-limited	and	aimed	at	changing	specific	behaviors,	most	often	including	those	
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associated	with	aggression,	self-injury,	or	other	challenging	behaviors.76		ABA	encompasses	a	wide	array	of	behavioral	interventions;	some	of	these	services	have	been	shown	to	be	effective	in	treating	certain	symptoms	in	certain	patients	with	ASD,	and	are	identified	more	specifically	in	the	previous	list	as	well	as	in	guidelines	reviewed	by	the	NPDC-ASD.77		Estimate	of	the	cost	of	the	mandate	Regulations	on	required	benefits	for	2016	issued	pursuant	to	the	ACA	(45	CFR	§156.115(a)(5)(i))	include	in	EHBs	“habilitative	services”.		They	define	such	services	as	those	that	“help	a	person	keep,	learn,	or	improve	skills	and	functioning	for	daily	living	(habilitative	services).	Examples	include	therapy	for	a	child	who	is	not	walking	or	talking	at	the	expected	age.	These	services	may	include	physical	and	occupational	therapy,	speech-language	pathology	and	other	services	for	people	with	disabilities	in	a	variety	of	inpatient	and/or	outpatient	settings.”		But	the	specific	services	included,	and	whether	the	definitions	would	include	ABA,	are	left	to	the	states.78		This	analysis	will	assume	ABA	would	not	be	included	in	the	benchmark	plan	without	the	autism	services	mandate.		Such	services	are	absent	from	the	benchmark	plans	of	about	half	the	states,	suggesting	they	are	not	a	federal	requirement.79		In	addition,	the	definition	of	habilitative	was	even	less	well	fleshed-out	in	years	prior	to	2016,	which	make	up	the	measurement	period	for	this	analysis.	The	RDC	of	this	mandate	was	calculated	as	the	sum	of	paid	amounts	from	all	claims	reporting	an	ASD	diagnosis	and	a	procedure	code	indicating,	per	the	carrier	specification	review,	medically	necessary	ABA.		The	estimated	PMPM	RDC	paid	claim	amount	was	$1.39,	with	total	PMPM	cost,	after	administrative	loading,	of	$1.57	(or	0.36	percent	of	the	Commonwealth	total	premium).		Per	member	per	month	self-insured	allowed	expenses	for	these	services	were	found	to	be	$0.56	lower	than	fully-insured	PMPM	allowed	expenses,	resulting	in	a	lower	bound	cost	impact	estimate,	including	administrative	loading,	of	$0.60	PMPM,	or	0.14	percent	of	Commonwealth	premium.		Table	2	below	displays	a	summary	of	these	results	and	related	statistics.	
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Table	2	
Autism	Mandate	
Contribution	to	Premium	
	
Chiropractic	Medicine	The	chiropractic	services	mandate	requires	coverage	for	chiropractic	services.80		Note	Massachusetts	has	both	chiropractic	service	and	chiropractor	(provider-based)	mandates.		The	services	referred	to	in	this	chiropractic	services	mandate	are	provided	by	chiropractors	and	other	providers,	and	chiropractors	provide	both	chiropractic	and	other	services.		The	mandate	applies	to	medical	service	corporations	only.		That	is,	the	mandate	applies	to	Blue	Cross	Blue	Shield	of	Massachusetts,	Inc.	only	(but	not	Blue	Cross	Blue	Shield	of	Massachusetts	HMO	Blue,	Inc.).	Effect	of	the	mandate	on	health	Chiropractic	is	a	form	of	alternative	medicine	that	focuses	on	the	relationship	of	the	body’s	structure,	particularly	the	spine,	to	its	function.		The	goal	of	chiropractic	treatment	is	to	enable	the	body	to	self-heal	by	realigning	structure,	often	through	spinal	manipulation.81		Spinal	manipulation	is	practiced	by	a	variety	of	healthcare	professionals,	including	physical	therapists;	naturopathic,	osteopathic	and	medical	physicians;	and	chiropractors.82		Manipulation	is	conducted	by	applying	controlled	force	to	a	spinal	joint,	most	often	with	hands	or	another	device.83		Treatment	goals	include	pain	alleviation	and	physical	function	improvement.84	Chiropractic	care	accounted	for	77	to	82	percent	of	total	ambulatory	visits	by	US	adults	to	complementary	and	alternative	medicine	(CAM)	providers	between	2002	and	2008.85		As	the	most	common	and	established	of	CAM	modalities,	some	chiropractic	care	is	covered	by	Medicare	and	military	health	insurance	plans,	as	well	as	by	most	private	insurers	and	many	Medicaid	programs.		Research	has	been	largely	conducted	on	singular	treatment	modalities	or	conditions,	and	has	not	focused	on	the	entirety	of	chiropractic	medicine.86,87		The	use	of	spinal	manipulation	for	acute	lower	
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Sample	Users 1,672																 800																			
Sample	Units 1,762,930								 844,889											
Sample	Average	Members 1,871,491								 1,490,706								
Paid	PMPM 1.39$																 0.87$																 0.54$																
Paid	PMPM	With	Admin 1.57$																 0.98$																 0.60$																
Allowed	PMPM 1.44$																 0.89$																 0.56$																
	Upper	Bound	
Impact	
	Lower	Bound	
Impact*	
Insured	Population 2,362,745 2,362,745
Contribution	to	Total	Annual	Claims 39,537,136$			 15,246,865$			
Contribution	to	Total	Annual	Premium 44,423,749$			 17,131,309$			
Percent	of	Total	Premium 0.36% 0.14%
*Net	amounts	do	not	remove	overlap	in	mandated	services	between	the	autism	mandate
and	the	early	intervention	and	home	health	care	mandates.
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back	pain	has	also	been	integrated	into	the	clinical	guidelines	of	the	American	College	of	Physicians	and	the	American	Pain	Society.88			According	to	the	National	Center	for	Complementary	and	Integrative	Health,	one	of	the	federal	National	Institutes	of	Health,	spinal	manipulation	may	benefit	some	people	with	low-back	pain,	and	may	be	beneficial	as	treatment	for	some	headaches,	neck	pain,	upper-	and	lower-extremity	conditions,	and	disorders	associated	with	whiplash.89		Spinal	manipulation	may	also	result	in	temporary	headaches,	tiredness,	and	discomfort	in	the	part	of	the	body	that	were	treated.		Rare	reports	of	complications	such	as	stroke	have	occurred,	but	the	cause	is	unclear	and	research	into	the	safety	of	spinal	manipulation	is	ongoing.90	The	research,	however,	is	still	unclear,	despite	the	high	satisfaction	rates	of	patients	receiving	chiropractic	treatments.91		Outcomes	vary	based	on	the	exact	condition	studied	(e.g.,	acute,	subacute,	mixed	duration,	or	chronic	low-back	or	neck	pain),	the	benefit	sought	(e.g.,	pain	or	disability	relief),	the	timeframe	studied	(e.g.,	immediate,	short-term,	intermediate,	or	long-term;	during	the	course	or	following	completion	of	treatment),	and	the	treatments	compared	in	the	study	(e.g.,	no	treatment,	placebo,	pain	medication,	usual	care,	physiotherapy,	massage,	or	as	an	adjunctive	therapy).92		One	large	meta-analysis	that	reviewed	the	conclusions	of	25	separate	evaluations	of	spinal	manipulations	for	low	back	pain	or	neck	pain	found	mixed	results	that	ranged	from	significantly	effective	to	not	at	all	effective,	depending	on	the	specifics	of	the	research	design.93	Most	research	points	to	mild	to	moderate	short-term	benefits	of	chiropractic	services	for	acute	low	back	pain,94,95	although	these	results	were	sometimes	similar	to	those	obtained	through	other	treatments,	such	as	physiotherapy,	patient	educational	materials,	oral	medications,	acupuncture,	or	steroid	injections.96,97,98,99		Other	research	found	evidence	that	spinal	manipulation	provided	no	clinically	meaningful	benefit	in	the	treatment	of	chronic	low	back	pain.100		The	results	of	a	2010	study	into	the	effectiveness	of	manipulation/mobilization	therapies	found	evidence	of	the	following:101	
Effective	 Inconclusive	 Not	Effective	
• Acute,	subacute	and	chronic	low	
back	pain	
• Migraine	and	cervicogenic	
headache	
• Cervicogenic	dizziness	
• Extremity	joint	conditions	
• Acute/subacute	neck	pain	
(thoracic	
manipulation/mobilization)	
• Neck	pain	(cervical	manipulation/	
mobilization)	
• Mid-back	pain	
• Sciatica	
• Tension-type	headache	
• Coccydynia	
• Temporomandibular	joint	
disorders	
• Fibromyalgia	
• Premenstrual	syndrome	
• Pneumonia	(Older	adults)	
• Otitis	media	(children)	
• Enuresis	(children)	
• Asthma	(adults	and	children)	
• Dysmenorrhea	
• Stage	1	hypertension	
	As	with	many	medical	interventions,	side	effects	and	risks	also	exist.102		Studies	caution	that	chiropractic	manipulation	often	leads	to	mild	and	transient	side	effects,	including	headaches,	tiredness,	and	soreness	at	the	treatment	site.	103		Other	researchers	point	out	more	rare	but	serious	side	effects,	especially	with	upper	spinal	manipulation,	such	as	cerebrovascular	accidents,	ischemia,	
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other	neurological	complications,	and	possibly	stroke,	although	the	cause	of	these	is	unclear	and	more	research	is	needed.104,105,106,107	Estimate	of	the	cost	of	the	mandate	The	RDC	of	this	mandate	was	calculated	as	the	sum	of	paid	amounts	from	all	claims	with	procedure	codes	indicating	chiropractic	manipulative	treatment.ix		The	estimated	PMPM	RDC	paid	claim	amount	was	$1.35,	with	total	PMPM	cost,	after	administrative	loading,	of	$1.52	(or	0.02	percent	of	the	Commonwealth	total	premium).		Per	member	per	month	self-insured	allowed	expenses	for	these	services	were	found	to	be	$0.80	lower	than	fully-insured	PMPM	allowed	expenses,	resulting	in	a	lower	bound	cost	impact	estimate,	including	administrative	loading,	of	$0.53	PMPM,	or	0.01	percent	of	Commonwealth	premium.		Table	3	below	displays	a	summary	of	these	results	and	related	statistics.	
Table	3	
Chiropractic	Medicine	Mandate	
Contribution	to	Premium	
	
Cleft	lip	and	Cleft	palate	The	cleft	lip	and	cleft	palate	mandate	requires	coverage	for	children	under	age	18	for	medically-necessary	“medical,	dental,	oral	and	facial	surgery,	surgical	management	and	follow-up	care	by	oral	and	plastic	surgeons,	orthodontic	treatment	and	management,	preventative	and	restorative	dentistry	to	ensure	good	health	and	adequate	dental	structures	for	orthodontic	treatment	or	prosthetic	management	therapy,	speech	therapy,	audiology	and	nutrition	services…	consequent	to	the	treatment	of	the	cleft	lip,	cleft	palate	or	both.”108		
																																								 																					ix	CPT	codes	98940,	98941,	98942,	&	98943.	
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Sample	Users 11,109													 59,043													
Sample	Units 135,994											 511,776											
Sample	Average	Members 142,186											 990,666											
Paid	PMPM 1.35$																 0.81$																 0.47$																
Paid	PMPM	With	Admin 1.52$																 0.91$																 0.53$																
Allowed	PMPM 2.28$																 1.48$																 0.80$																
	Upper	Bound	 	Lower	Bound	
Insured	Population 165,174 165,174
Contribution	to	Total	Annual	Claims 2,677,008$					 939,196$									
Contribution	to	Total	Annual	Premium 3,007,874$					 1,055,277$					
Percent	of	Total	Premium 0.02% 0.01%
*Net	amounts	do	not	remove	overlap	in	mandated	services	between	the	chiropractor	
provider	mandate	and	the	chiropractic	services	mandate.
Comprehensive	Mandated	Benefit	Review	
compass Health Analytics 19 December 2016 
Effect	of	the	mandate	on	health	Orofacial	clefts,	the	collective	term	for	cleft	lip	and	cleft	palate,	are	birth	defects	that	occur	during	pregnancy	when	a	baby’s	lips	or	mouth	do	not	properly	join.109		During	the	fourth	to	seventh	weeks	of	pregnancy,	the	body	tissue	and	other	cells	from	the	sides	of	the	head	grow	toward	the	center	to	join	and	make	a	face,	creating	features	including	lips	and	mouth.110		If	the	tissue	around	the	lips	does	not	join	completely,	an	opening	known	as	a	cleft	lip	can	result	that	may	range	from	a	small	slit	to	a	large	gap	through	the	lip	into	the	nose;	this	may	occur	on	one	or	both	sides,	or	more	rarely,	in	the	middle.111		During	the	sixth	to	ninth	weeks	of	pregnancy,	the	bone,	muscle,	and	other	tissue	on	the	roof	of	the	mouth	forms	to	create	a	palate;	if	these	do	not	join	completely	together,	a	cleft	palate	is	formed,	and	can	include	the	front,	back,	or	both	parts	of	the	palate.112		Almost	70	percent	of	children	with	orofacial	clefts	have	both	cleft	palate	and	cleft	lip.113	Children	with	orofacial	clefts	often	have	problems	with	their	teeth,	feeding,	clear	speaking,	ear	infections,	and	hearing.114		They	are	also	more	likely	to	be	hospitalized	during	childhood	than	children	without	orofacial	clefts,	with	hospitalization	rates	higher	for	children	with	cleft	palate	present	than	for	children	with	cleft	lip	only.115,116		A	recent	study	also	found	that	children	born	with	orofacial	clefts	may	have	poorer	academic	outcomes	in	elementary	school	than	their	peers,	but	that	more	study	is	needed	to	confirm	results	and	track	outcomes	at	higher	grades.		The	study	does	not	differentiate	the	performance	of	children	based	on	their	level	of	cleft	repair.117	It	is	estimated	that	6.35	babies	per	10,000	are	born	annually	with	a	cleft	palate	without	cleft	lip	(1	in	1574),	and	a	total	of	10.6	babies	per	10,000	are	born	with	a	cleft	lip	with	or	without	a	cleft	palate	(1	in	940).118,119,120		Comparably,	as	of	2012,	9.2	babies	per	10,000	are	born	in	Massachusetts	with	an	orofacial	cleft.121		Isolated	orofacial	clefts,	occurring	without	another	major	birth	defect,	are	one	of	the	most	common	types	of	birth	defects	in	the	United	States,	and	comprise	approximately	75	percent	of	total	cases	of	children	with	birth	defects.122	While	the	causes	of	orofacial	clefts	are	unknown,	these	birth	defects	are	thought	to	be	the	result	of	a	combination	of	genetic	and	environmental	factors.		Babies	born	to	mothers	with	diabetes,	who	smoke	or	drink	alcohol,	or	who	use	certain	medications	during	the	first	trimester	of	pregnancy	face	an	increased	risk	of	orofacial	clefts.123,124		A	mother’s	healthy	diet	in	the	year	before	pregnancy	reduces	the	risk	of	orofacial	cleft,125	as	does	adequate	intake	of	folic	acid.126	Treatment	of	orofacial	clefts	vary	based	on	the	cleft’s	severity,	the	child’s	age,	needs,	and	other	birth	defects	or	syndromes	that	may	be	present.127		Surgical	repair	is	recommended	within	the	first	year	of	life	for	cleft	lip,	and	within	the	first	18	months	for	cleft	palate	(earlier	if	possible).128		Additional	surgeries	are	often	necessary	as	the	children	age,	including	those	to	improve	breathing,	hearing,	speech,	language	development,	and	appearance.129		Treatment	by	otorhinolaryngologists,	audiologists,	dentists,	orthodontists,	or	speech	or	language	therapists	may	also	be	necessary.130		Some	children	and	families	also	benefit	from	peer	and	other	emotional	support	resources.131		The	American	Cleft	Palate-Craniofacial	Association	recommends	that	children	with	orofacial	clefts	receive	treatment	through	specialized	cleft	and	craniofacial	teams	who	can	coordinate	the	variety	of	services	needed	throughout	infancy,	childhood,	adolescence,	and	if	necessary,	adulthood.132		Interdisciplinary	teams	include	health	professionals	from	medical,	dental,	surgical,	and	allied	health	
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disciplines.133		According	to	the	national	Cleft	Palate	Foundation,	there	are	four	such	teams	in	Massachusetts,	with	two	in	Boston,	and	one	each	in	Springfield	and	Worcester.134	While	no	study	was	found	evaluating	the	spectrum	of	services	mandated	for	treatment	of	orofacial	clefts	as	a	whole,	the	individual	services	outlined	within	the	legislation	have	been	proven	effective	for	the	specific	symptom	or	condition	they	address.	Estimate	of	the	cost	of	the	mandate	The	RDC	of	this	mandate	was	calculated	as	the	sum	of	paid	amounts	from	all	claims	with	a	primary	or	secondary	diagnosis	of	cleft	palate	or	cleft	lipx	for	members	aged	0-17.		The	estimated	PMPM	RDC	paid	claim	amount	was	$0.12,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$0.13	(or	0.03	percent	of	the	Commonwealth	total	premium).		Per	member	per	month	self-insured	allowed	expenses	for	these	services	were	found	to	be	$0.004	lower	than	fully-insured	PMPM	allowed	expenses,	resulting	in	a	lower	bound	cost	impact	estimate,	including	administrative	loading,	of	$0.004	PMPM,	or	0.001	percent	of	Commonwealth	premium.		Table	4	below	displays	a	summary	of	these	results	and	related	statistics.		
Table	4	
Cleft	lip	and	Cleft	palate	Mandate	
Contribution	to	Premium	
	
Diabetes-related	Services	and	Supplies	The	diabetes	mandate	requires	coverage	for	a	wide	range	of	services	and	supplies	related	to	diabetes	treatment,	including:	blood	glucose	monitoring	gear,	urine	glucose	strips,	ketone	strips,	lancets,	insulin,	insulin	syringes,	prescribed	diabetes	medications	that	influence	blood	sugar	level,	
																																								 																					x	Any	ICD-9	diagnosis	code	with	the	first	three	digits	“749.”		The	2014	analysis	period	was	prior	to	the	ICD-10	cutover.	
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Sample	Users 385																			 356																			
Sample	Units 29,083													 20,880													
Sample	Average	Members 1,871,491								 1,490,706								
Paid	PMPM 0.12$																 0.11$																 0.004$													
Paid	PMPM	With	Admin 0.13$																 0.13$																 0.004$													
Allowed	PMPM 0.12$																 0.12$																 0.004$													
	Upper	Bound	 	Lower	Bound	
Insured	Population 2,362,745 2,362,745
Contribution	to	Total	Annual	Claims 3,295,170$					 103,431$									
Contribution	to	Total	Annual	Premium 3,702,438$					 116,215$									
Percent	of	Total	Premium 0.03% 0.001%
*Net	amounts	do	not	remove	overlap	in	mandated	services	between	the	cleft	palate	and
lip	mandate	and	the	home	health	mandate.
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laboratory	tests,	insulin	pumps,	therapeutic	shoes	and	inserts,	supplies	and	equipment	approved	by	the	FDA,	and	outpatient	self-management	education,	including	medical	nutrition	therapy.135	Effect	of	the	mandate	on	health	Diabetes	is	one	of	the	most	serious	and	widespread	illnesses	in	the	U.S.,	in	which	it	is	the	seventh-leading	cause	of	death.		It	affects	9.1	percent	of,	or	29.1	million,	Americans,	including	21	million	diagnosed	and	an	estimated	8.1	million	undiagnosed	patients.136	Over	1.7	million	new	cases	were	diagnosed	in	2012,	and	another	37	percent	of	adults	in	the	U.S.,	including	51	percent	of	the	over-65	population,	have	pre-diabetes.137		Of	adults	in	Massachusetts,	7.7	percent	have	been	diagnosed	with	diabetes	as	of	2013,138	and	5.1	percent	have	at	some	point	been	told	they	have	pre-diabetes,	slightly	under	the	national	figure	of	5.9	percent.139	Diabetes	mellitus	is	caused	by	the	body’s	inability	to	produce	or	process	insulin,	the	hormone	used	by	the	body	to	absorb	and	utilize	glucose	for	energy.140		The	three	most	common	types	of	diabetes	are:	type	1diabetes,	in	which	a	body	is	unable	to	produce	insulin;	type	2	diabetes,	which	is	a	combination	of	a	body’s	resistance	to	insulin	and	insufficient	insulin	production;	and	gestational	diabetes,	a	pregnancy	complication.141	When	the	body’s	blood	glucose	levels	rise	above	normal,	metabolic	problems	occur	resulting	in	serious	complications	and	other	illnesses.		Diabetes	reduces	normal	life	expectancy	by	up	to	15	years,	and	increases	the	risk	of:142,143,144	
• Heart	disease,	stroke,	and	hypertension:	Diabetes	increases	the	risk	of	heart	disease	two	to	four	times.	
• Kidney	failure:	In	2011,	diabetes	was	the	primary	cause	of	kidney	failure	in	44	percent	of	new	cases.		
• Non-traumatic	lower	limb	amputation:		Diabetes	patients	account	for	over	60	percent	of	nontraumatic	lower	limb	amputations,	or	about	73,000	in	2010.	
• Complications	of	pregnancy,	including	major	birth	defects,	spontaneous	abortion,	and	excessively	large	babies,	as	well	as	type	2	diabetes	in	the	child.145	
• Nervous	system	disease,	including	impaired	sensation	in	hands	or	feet,	slow	digestion,	carpal	tunnel	syndrome,	and	erectile	dysfunction	
• Adult-onset	blindness	and	eye	problems	
• Dental	and	periodontal	(gum)	disease	
• Biochemical	imbalances,	including	diabetic	ketoacidosis	and	hyperosmolar	coma	
• Depression	Objectives	to	curb	and	control	diabetes	comprise	a	significant	part	of	Healthy	People	2020,	the	set	of	national	health	promotion	and	disease	prevention	goals	outlined	for	the	next	decade	by	the	U.S.	Department	of	Health	and	Human	Services.146		Key	diabetes	objectives	include	reductions	to	mortality	(all-cause,	diabetes-related,	and	cardiovascular	disease-related)	and	lower	extremity	amputations	in	part	through	the	following	measures	(this	list	is	not	exhaustive):147	For	all	those	diagnosed	with	diabetes:	
• Improve	glycemic	and	lipid	control	
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• Increase	the	proportion	who	control	their	blood	pressure,	receive	an	annual	dental	exam	and	urinary	microalbumin	measurement,	and	receive	formal	diabetes	education	
• Increase	the	proportion	who	are	diagnosed	For	adults	diagnosed	with	diabetes,	increase	the	proportion	who:	
• Receive	annual	foot		and	dilated	eye	examinations	
• Receive	at	least	a	semi-annual	glycosylated	hemoglobin	measurement	
• Perform	blood	glucose	self-monitoring	at	least	once	daily	For	those	at	high	risk	for	diabetes	with	pre-diabetes,	increase	the	proportion	who	report:	
• Increasing	their	level	of	physical	activity	
• Trying	to	lose	weight	
• Reducing	the	amount	of	fat	or	calories	in	their	diet	The	supplies	and	services	required	under	the	Massachusetts	mandate	are	necessary	to	effectively	manage	diabetes,	as	outlined	in	the	previous	list	of	evidence-based	measures.	Estimate	of	the	cost	of	the	mandate	The	RDC	of	this	mandate	was	calculated	as	the	sum	of	paid	amounts	from	all	claims	incurred	by	target-population	members	with	at	least	two	claims	with	a	primary	or	secondary	diagnosis	of	diabetes	during	the	calendar	2014	study	period	for	diabetes-related	services,	devices,	or	drugs.		The	estimated	PMPM	RDC	paid	claim	amount	was	$6.20,	with	total	PMPM	cost,	after	administrative	loading,	of	$6.97	(or	1.60	percent	of	the	Commonwealth	total	premium).		Self-insured	medical	costs	for	these	services	were	found	to	be	higher	than	fully-insured	medical	costs,	resulting	in	a	lower	bound	impact	estimate,	including	administrative	loading,	of	$0.		As	noted	above,	the	diabetes	services	and	supplies	mandate	RDC	estimate	increased	nearly	three-fold	(267	percent)	between	the	2012	study	and	the	present	study,	though	the	lower-bound	estimate	is	zero	in	both	cases	owing	to	the	equally	large	degree	to	which	self-insured	employers	pay	for	these	services.		This	result	is	driven	by	code	additions	to	the	mandate	specifications	by	the	carriers	as	well	as	ongoing	increases	in	diabetes	prevalence	and	price	and	service	mix	changes	since	the	analysis	period	(2009)	of	the	previous	report.	Table	5	below	displays	a	summary	of	these	results	and	related	statistics.	
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Table	5	
Diabetes-related	Services	and	Supplies	Mandate	
Contribution	to	Premium	
	
Early	Intervention	Services	This	mandate	requires	coverage	for	all	"early	intervention	services"	from	birth	until	age	three	for	children	with	or	at	risk	for	specified	developmental	delays	including	chromosomal	abnormality,	neurological	condition,	metabolic	disorder,	visual	impairments,	permanent	hearing	loss	of	any	degree,	and	delayed	cognitive,	physical,	communicative,	social,	or	emotional	development.148	Effect	of	the	mandate	on	health	Neuroscience	shows	that	early	in	life,	brains	grow	hierarchically	from	the	simplest	to	the	most	complex	circuits.	149		Sensory	pathways	develop	first,	including	vision	and	hearing,	followed	by	early	language	skills,	and	then	higher	cognitive	skills.150		In	the	first	few	years,	hundreds	of	neural	connections	are	made	every	second;	after	this	initial	rapid	growth,	these	connections	are	reduced	so	that	the	brain	functions	more	efficiently.		Connections	used	during	this	period	are	reinforced,	while	those	not	used	are	pruned.		This	means	that	“[e]arly	experiences	affect	the	nature	and	quality	of	the	brain’s	developing	architecture.”151		Brain	architecture	is	mostly	developed	during	the	first	three	years	of	life,	and	the	primary	mode	of	this	early	learning	is	the	interaction	between	a	child,	his	caregivers,	and	his	family	as	a	unit.152		For	children	born	at-risk	or	diagnosed	with	a	developmental	delay	or	disability,	these	interactions	can	be	compromised,	thus	impacting	lifelong	growth	and	development.	
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Bound	PMPMs	
Sample	Users 55,654													 60,696													
Sample	Units 49,743,314					 30,273,883					
Sample	Average	Members 1,437,788								 1,432,254								
Paid	PMPM 6.20$																 7.36$																 -$																		
Paid	PMPM	With	Admin 6.97$																 8.27$																 -$																		
Allowed	PMPM 7.09$																 8.21$																 (1.12)$														
	Upper	Bound	
Impact	
	Lower	Bound	
Impact*	
Insured	Population 2,362,745 2,362,745
Contribution	to	Total	Annual	Claims 175,791,850$	 -$																		
Contribution	to	Total	Annual	Premium 197,518,932$	 -$																		
Percent	of	Total	Premium 1.60% 0.00%
*Net	amounts	do	not	remove	overlap	in	mandated	services	between	the	diabetes
mandate	and	the	home	health,	nurse	practitioner,	podiatrist,	and	hypodermic
syringe	and	needle	mandates.
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Early	intervention	is	a	group	of	services	and	supports	designed	to	help	children	gain	basic	skills,	usually	in	the	first	two	years	of	life,	including	physical,	mental,	communication,	social,	and	emotional.153		Services	often	include	physical,	occupational	and/or	speech	therapy,	family	training,	nutrition	services,	case	management,	referrals,	and	services	for	hearing	impairment.154		Each	state	provides	its	own	set	of	programs	and	services	to	children	from	birth	to	age	2	who	have	been	diagnosed	with	developmental	disease	or	disability,	under	Part	C	of	Public	Law	108-77:	Individuals	with	Disabilities	Education	Improvement	Act	(2004),	or	"IDEA."155		Some	states,	including	Massachusetts,	extend	these	services	to	children	only	at-risk	for	such	delays	and	disabilities,	and	continue	them	until	age	3.	Early	intervention	services	have	been	shown	to	prevent	developmental	delay,	as	measured	by	placement	in	special	education	as	well	as	retention	in	grade	when	a	child	reaches	school	age.156		Moreover,	it	is	“deemed	essential	to	prevent	mental	retardation	and	poor	intellectual	development	in	children	whose	families	do	not	provide	adequate	stimulation	in	the	early	years	of	life.”157		Improved	outcomes	in	health,	language	and	communication,	cognitive	and	social/emotional	development,	as	well	as	academic	achievement,	labor	market	success,	and	a	reduction	in	delinquency,	crime,	and	social	welfare	program	use,	have	been	shown	in	children	who	receive	high	quality	early	intervention	services.158,159,160	Estimate	of	the	cost	of	the	mandate	Regulations	on	required	benefits	for	2016	issued	pursuant	to	the	ACA	(45	CFR	§156.115(a)(5)(i))	include	in	EHBs	“habilitative	services”.		They	define	such	services	as	those	that	“help	a	person	keep,	learn,	or	improve	skills	and	functioning	for	daily	living	(habilitative	services).	Examples	include	therapy	for	a	child	who	is	not	walking	or	talking	at	the	expected	age.	These	services	may	include	physical	and	occupational	therapy,	speech-language	pathology	and	other	services	for	people	with	disabilities	in	a	variety	of	inpatient	and/or	outpatient	settings.”		But	the	specific	services	included,	and	whether	the	definitions	would	include	early	intervention	services,	are	unclear	on	the	surface	and	left	to	the	states.161		For	reasons	cited	in	the	overview	of	the	methodology,	this	analysis	assumes	federal	EHB	requirements	do	not	address	state-mandated	early	intervention	services.		The	RDC	of	this	mandate	was	calculated	as	the	sum	of	paid	amounts	from	all	claims	for	specifically	identified	early	intervention	procedure	codesxi	plus	all	claims	for	evaluation	and	management	procedures	performed	by	certified	early	intervention	providersxii	for	members	under	three	years	of	age	in	the	target	population	and	period.		The	estimated	PMPM	RDC	paid	claim	amount	was	$0.91,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$1.02	(or	0.23	percent	of	the	Commonwealth	total	premium).		Per	member	per	month	self-insured	allowed	expenses	for	these	services	were	found	to	be	$0.10	lower	than	fully-insured	PMPM	allowed	expenses,	including																																									 																					xi	HCPCS	codes	96153,	H0031,	H0032,	H2012,	H2015,	H2019,	T1015,	T1023,	T1024,	T1025,	T1026,	and	T1027.	xii	Plans	differ	in	the	method	used	to	identify	EI	providers	in	their	claims	systems:	Some	plans	use	specific	early	intervention	procedure	code	modifiers,	others	use	an	early	intervention	provider	type	code.		Compass	extracted	claims	from	the	MA	APCD	extract	based	on	carrier-specific	rules	provided	in	the	carrier	specification	review.		
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administrative	loading,	of	$0.11	PMPM,	or	0.03	percent	of	Commonwealth	premium.		Table	6	below	displays	a	summary	of	these	results.	
Table	6	
Early	Intervention	Services	Mandate	
Contribution	to	Premium	
	
Hearing	Aids	for	Children	The	children’s	hearing	aid	mandate	requires	coverage	for	any	child,	age	21	years	or	younger,	for	one	hearing	aid	per	hearing-impaired	ear,	up	to	$2,000	for	each	hearing	aid,	every	36	months.		Coverage	includes	all	related	services	prescribed	by	an	audiologist	or	hearing	instrument	specialist,	including	the	initial	evaluation,	fitting	and	adjustments,	and	supplies,	including	ear	molds.162	Effect	of	the	mandate	on	health	Hearing	loss	can	occur	in	a	variety	of	ways	when	any	part	of	the	ear,	including	the	inner,	middle,	or	outer	ear,	the	acoustic	nerve,	or	auditory	system,	is	not	functioning	properly.163		Hearing	loss	may	be	caused	by	one	or	more	of	many	factors,	including	genetic	(approximately	50	percent	of	cases);	maternal	infection,	pregnancy	complications,	or	head	trauma	(25	percent);	or	an	unknown	cause	(25	percent).164,165		For	about	33	percent	of	babies	with	genetic	hearing	loss,	the	loss	is	related	to	another	“syndrome”	or	condition.166		Approximately	25	percent	of	children	with	hearing	loss	have	one	or	more	developmental	disabilities.167	Hearing	loss	is	categorized	in	a	variety	of	ways,	including:168	
• Type:	
o Conductive:	Something	stops	sound	from	reaching	the	outer	or	middle	ear.			
o Sensorineural:	Caused	by	inner	ear	or	nerve	problems.	
o Mixed:	Caused	by	both	conductive	and	sensoineural	issues.	
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Sample	Users 7,070																 5,237																
Sample	Units 1,123,227								 825,078											
Sample	Average	Members 1,871,491								 1,490,706								
Paid	PMPM 0.91$																 0.79$																 0.10$																
Paid	PMPM	With	Admin 1.02$																 0.88$																 0.11$																
Allowed	PMPM 0.93$																 0.83$																 0.10$																
	Upper	Bound	
Impact	
	Lower	Bound	
Impact*	
Insured	Population 2,362,745 2,362,745
Contribution	to	Total	Annual	Claims 25,716,707$			 2,780,295$					
Contribution	to	Total	Annual	Premium 28,895,176$			 3,123,927$					
Percent	of	Total	Premium 0.23% 0.03%
*Net	amounts	do	not	remove	overlap	in	mandated	services	between	the	early
intervention	mandate	and	the	home	health,	nurse	practitioner,	and	autism	mandates.
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o Auditory	Neuropathy	Spectrum	Disorder:	Damage	to	the	inner	ear	or	nerve	disrupts	the	brain’s	ability	to	organize	sound.	
• Degree	
o Mild:	May	hear	some	speech;	soft	sounds	are	difficult	to	hear.	
o Moderate:	Hears	almost	no	speech	at	normal	level.	
o Severe:	Hears	no	speech	at	normal	level;	only	some	loud	sounds	are	heard.	
o Profound:	Hears	no	speech	and	only	very	loud	sounds.	
• Unilateral	or	bilateral:	One	or	both	ears	
• Pre-lingual	or	post-lingual:	Before	or	after	person	learned	to	speak	
• Symmetrical	or	asymmetrical:	Same	in	both	ears	or	different	
• Progressive	or	sudden:	Hearing	worsens	over	time	or	happens	quickly	
• Fluctuating	or	stable:	Hearing	gets	better	or	worse	over	time	or	remains	the	same	
• Congenital	or	acquired	(delayed	onset):	Hearing	loss	present	at	birth	or	appears	sometime	later	Hearing	loss,	if	left	undetected,	can	hinder	a	child’s	development	in	many	ways,	leading	to	“difficulties	later	in	life,	including	problems	with	listening	and	speaking	skills,	literacy	skills,	academic	performance,	and	long-term	job	opportunities.”169			Estimates	of	the	prevalence	of	hearing	loss	in	children	vary.		One	study	found	almost	15	percent	of	children	ages	6	to	19	had	low	or	high	hearing	loss	in	one	or	both	ears	at	16-decibels,170	while	another	summarized	parent-reported	hearing	loss	in	their	children	at	20	percent	overall.171		A	study	of	8	year	old	children	concluded	that	1.4	per	1000	suffered	bilateral	hearing	loss	at	40	decibels	or	more.172		In	Massachusetts,	recent	findings	estimate	that	12.7	percent	of	infants	screened	are	found	to	have	hearing	loss,	or	2.2	per	1000	newborns;	these	numbers	are	higher	than	the	national	figures	of	9.8	percent	and	1.5	per	1000.173		These	figures,	however,	may	be	low	as	they	do	not	include	late-onset	hearing	loss	or	infants	not	screened	at	birth.	Hearing	loss	may	be	corrected	to	some	degree	depending	on	the	type,	severity,	and	cause	of	the	loss.174		Medications	and	surgery	may	be	used	to	correct	some	conductive	hearing	loss,	especially	those	caused	by	infection	or	malformation	of	the	outer	and/or	middle	ear.175		For	those	who	may	have	residual	hearing,	technology	can	maximize	the	hearing	that	remains.176		Those	with	severe	to	profound	hearing	loss	may	benefit	from	a	cochlear	implant,	a	device	surgically	implanted	into	the	ear	to	conduct	sound	directly	to	the	auditory	nerve.177	For	many	others	with	hearing	loss	of	varying	causes,	a	hearing	aid	can	be	used,	including	by	infants	and	children.		Hearing	aids	are	designed	to	amplify	and	sometimes	clarify	sounds.178		The	small	electronic	devices,	comprised	of	a	microphone,	amplifier,	and	speaker,	are	available	in	in-the-ear,	behind-the-ear,	or	in-the-canal	varieties.179		Sound	is	received	through	the	microphone,	converted	to	electronic	signals,	sent	to	the	amplifier	that	manipulates	the	power	of	the	signals,	and	then	to	the	ear	through	the	speaker.180		Middle-ear	implants	and	bone-anchored	hearing	aids	are	also	available,	but	must	be	surgically	implanted;	these	work	differently	than	other	types	of	hearing	aids,	helping	instead	to	increase	sound	vibration	transmission	to	the	inner	ear.181	
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Studies	have	found	that	hearing	aids	improve	communications	outcomes	for	children182,	and	the	“degree	of	improved	hearing	provided	by	[hearing	aids]	was	associated	with	better	speech	and	language	development	in	children.”183		Likewise,	quality	of	life	indicators	improve	for	hearing-impaired	children	and	their	families	with	use	of	hearing	aids.184		The	age	when	a	child	is	fit	for	a	device	is	a	significant	factor	in	outcomes	regarding	communication,	including	speech	perception	and	production,	as	well	as	spoken	language.185		Other	factors	influencing	outcomes	for	children	with	hearing	loss	who	were	fitted	with	hearing	aids	include	the	presence	or	absence	of	other	disabilities,	severity	of	hearing	loss,	gender,	and	maternal	education.186	Estimate	of	the	cost	of	the	mandate	The	RDC	of	this	mandate	was	calculated	as	the	sum	of	paid	amounts	from	all	claims	with	ICD-9	or	HCPCS	procedure	codes	indicating	a	hearing	aid-related	service	or	a	hearing	assessment	for	a	member	younger	than	22.		The	estimated	PMPM	RDC	paid	claim	amount	was	$0.24,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$0.27	(or	0.06	percent	of	the	Commonwealth	total	premium).		Self-insured	allowed	medial	costs	per	person	for	chiropractic	services	were	found	to	be	
higher	than	fully-insured	medical	costs,	resulting	in	a	lower	bound	impact	estimate,	including	administrative	loading,	of	$0.		Table	7	below	displays	a	summary	of	these	results	and	related	statistics.		Over	85	percent	of	the	claims	expense	volume	in	Table	7	is	comprised	of	routine	hearing	assessments	rather	than	hearing	aid-specific	device,	fitting,	and	service	expenses.		Assessment	services	are	included	in	the	statutory	language	for	this	mandate,	and	as	such	Table	7,	the	summary	exhibit,	and	the	aggregated	mandate	results	include	assessments	include	these	services,	but	hearing	assessments	were	mandated	elsewhere	before	passage	of	this	specific	mandate,	and	were	not	treated	as	incremental	to	the	mandate	in	CHIA’s	prospective	analysis	of	the	costs	of	this	mandate.187			Therefore,	to	provide	an	estimate	of	the	effect	of	the	child	hearing	aids	mandate	per	se,	Table	8	presents	separate	results	for	the	hearing	aid-specific	procedures,	including	device	and	fitting	costs	required	by	the	mandate.		
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Table	7	
Hearing	Aids	for	Children	Mandate	
Contribution	to	Premium	
	
	
Table	8	
Hearing	Aid-Specific	Procedures	for	Members	Less	than	22	Years	of	Age	
Contribution	to	Premium	
	
	The	results	in	Table	8	suggest	that	the	hearing	aid	device	and	hearing	aid-specific	services	(i.e.,	non-assessment)	provisions	of	the	hearing	aids	for	children	mandate	contributed	between	$0.004	and	
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Bound	PMPMs	
Sample	Users 74,236													 63,894													
Sample	Units 109,991											 94,925													
Sample	Average	Members 1,871,491								 1,490,706								
Paid	PMPM 0.24$																 0.30$																 -$																		
Paid	PMPM	With	Admin 0.27$																 0.34$																 -$																		
Allowed	PMPM 0.30$																 0.33$																 (0.03)$														
	Upper	Bound	
Impact	
	Lower	Bound	
Impact*	
Insured	Population 2,362,745 2,362,745
Contribution	to	Total	Annual	Claims 6,892,940$					 -$																		
Contribution	to	Total	Annual	Premium 7,744,876$					 -$																		
Percent	of	Total	Premium 0.06% 0.00%
*Net	amounts	do	not	remove	overlap	in	mandated	services	between	the	hearing	aids	for
children	mandate	and	the	speech,	language,	and	hearing	mandate.
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Bound	PMPMs	
Sample	Users 467																			 395																			
Sample	Units 1,770																 1,356																
Sample	Average	Members 1,871,491								 1,490,706								
Paid	PMPM 0.03$																 0.03$																 0.003$													
Paid	PMPM	With	Admin 0.04$																 0.03$																 0.004$													
Allowed	PMPM 0.04$																 0.03$																 0.004$													
	Upper	Bound	
Impact	
	Lower	Bound	
Impact*	
Insured	Population 2,362,745 2,362,745
Contribution	to	Total	Annual	Claims 963,113$									 92,459$											
Contribution	to	Total	Annual	Premium 1,082,150$					 103,887$									
Percent	of	Total	Premium 0.009% 0.001%
Comprehensive	Mandated	Benefit	Review	
compass Health Analytics 29 December 2016 
$0.04	(between	0.001	and	0.009	percent)	to	the	Commonwealth	average	fully-insured	commercial	monthly	health	care	insurance	premium.	
Home	Health	Care	The	home	health	care	mandate	requires	coverage	for	services	provided	by	a	home	health	agency	in	a	patient's	residence.188	Effect	of	the	mandate	on	health	Home	health	care	is	a	term	describing	a	broad	range	of	health	care	and	supportive	services	provided	in	the	home.189		Services	are	most	often	used	by	those	recovering	from	illness	or	injury,	the	disabled,	or	those	with	a	chronic	or	terminal	illness	who	need	nursing,	medical,	social,	or	therapeutic	treatment,	and/or	assistance	with	activities	of	daily	living.190		Home	health	care	is	often	provided	by	licensed	practical	nurses,	therapists,	or	home	health	aides.191	Provision	of	services	in	the	home	may	allow	for	more	rapid	discharge	from	inpatient	settings,	or	for	a	delay	in	need	for	long-term	nursing	home	or	other	institutional	care.192		Use	of	home	health	care	services	continues	to	grow	for	a	variety	of	reasons,	including	the	aging	of	the	population,	medical	advances	allowing	better	disease	management,	technological	advancements,	changes	to	inpatient	reimbursement,	increasing	cost	of	hospital,	nursing	home,	and	other	facilities,	and	patient	choice.193	Home	health	care	is	medically	based,	and	may	include:194	195	
• Occupational,	physical	and/or	speech	therapy	and	other	rehabilitative	services		
• Skilled	nursing	
• Case	management	
• Medical	social	services	and	counseling	
• Behavioral	and	mental	health	counseling	
• Medical	case	management	
• Medication	management	
• Pain	management	
• Parenteral	and	enteral	nutrition	therapy	(tube	feeding)	
• Infusion	therapy	
• Hospice	and	palliative	care	
• Telemedicine	
• Vaccination	
• Wound	care	
• Home	medical	equipment	assistance	
• Patient	and	caregiver	education	
• Home	safety	instruction	and	assistance	
• Assistance	with	daily	living	(including	bathing,	dressing,	and	eating)	
• Home	care	support	(including	housekeeping	and	cooking)	
	Given	the	wide	variety	of	available	services,	summarizing	the	clinical	effectiveness	of	home	health	care	is	especially	challenging.		However,	research	has	shown	that	the	provision	of	well-defined,	quality	home	health	care	services	can	provide	significant	clinical	benefits.		Some	studies	have	found	that	home	based	services	can	significantly	reduce	mortality	and	admissions	for	non-hospital	long-term	institutional	care,196,197	while	others	have	documented	that	those	services	decrease	the	rate	of	decline	of	functional	status.198		According	to	the	CMS,	“[h]ome	health	care	is	usually	less	expensive,	more	convenient,	and	just	as	effective	as	care…in	a	hospital	or	skilled	nursing	facility	(SNF).”199	
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Home	healthcare	has	also	been	shown	to	be	particularly	effective	for	the	care	of	the	terminally	ill.		Terminally	ill	patients	receiving	home	health	care	had	fewer	hospitalizations,	nursing	home	admissions,	and	other	healthcare	visits,	were	more	likely	to	be	able	to	die	at	home	according	to	their	wishes,	and	“expressed	significantly	higher	satisfaction”	with	their	care.200		Moreover,	provision	of	home	health	services	has	led	to	higher	quality	of	life	measures	for	terminally	ill	patients	and	their	caregivers,	and	rates	of	satisfaction	with	care	are	higher	for	both	patients	and	caregivers	for	both	terminal	and	non-terminal	illnesses.201	Estimate	of	the	cost	of	the	mandate	The	RDC	for	this	mandate	was	calculated	as	the	sum	of	paid	amounts	from	all	claims	for	all	procedures	where	the	place	of	service	indicated	on	the	claim	was	the	patient’s	residence.		The	estimated	PMPM	RDC	paid	claim	amount	was	$9.07,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$10.19	(or	2.34	percent	of	the	Commonwealth	total	premium).		Self-insured	allowed	medical	expenses	for	these	services	were	found	to	be	slightly	higher	than	fully-insured	allowed	medical	expenses,	resulting	in	a	$0	lower	bound	impact	estimate,	including	administrative	loading.		Table	9	below	displays	a	summary	of	these	results	and	related	statistics.	
Table	9	
Home	Health	Care	Mandate	
Contribution	to	Premium	
	
Hormone	Replacement	Therapy	(HRT)	The	hormone	replacement	therapy	(HRT)	mandate	requires	policies	covering	outpatient	services	or	outpatient	prescription	drugs	and	devices	to	provide	hormone	replacement	therapy	(services	and	drugs)	for	peri-	and	post-menopausal	women	under	the	same	terms	and	conditions	as	other	outpatient	services/drugs.202	
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Bound	PMPMs	
Sample	Users 177,244											 145,240											
Sample	Units 20,558,276					 19,654,385					
Sample	Average	Members 1,871,491								 1,490,706								
Paid	PMPM 9.07$																 9.28$																 -$																		
Paid	PMPM	With	Admin 10.19$													 10.43$													 -$																		
Allowed	PMPM 9.73$																 9.77$																 (0.04)$														
	Upper	Bound	
Impact	
	Lower	Bound	
Impact*	
Insured	Population 2,362,745 2,362,745
Contribution	to	Total	Annual	Claims 257,246,649$	 -$																		
Contribution	to	Total	Annual	Premium 289,041,179$	 -$																		
Percent	of	Total	Premium 2.34% 0.00%
*Net	amounts	do	not	remove	overlap	in	mandated	services	between	the	home	health
mandate	and	the	autism,	cleft	palate	and	lip,	diabetes	services,	early	intervention,
limb	prostheses,	low	protein	foods,	nonprescription	enterals	,	nurse	practitioner,
podiatrist,	scalp	hair	prostheses,	and	speech,	hearing,	and	language	mandates. Limb	Prosthesis	Mandate
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Effect	of	the	mandate	on	health	Menopause	is	the	phase	in	a	woman’s	life	in	which	menstruation	naturally	stops,	marking	the	end	of	her	reproductive	years.203		During	her	reproductive	phase,	a	woman’s	ovaries	produce	the	hormones	estrogen	and	progesterone	to	control	the	menstrual	cycle.		During	the	perimenopausal	years	leading	up	to	menopause,	the	levels	of	estrogen	begin	to	decrease,	causing	some	women	a	variety	of	mild	to	severe	symptoms.204			Fifty	to	eighty-two	percent	of	US	women	experience	hot	flashes,	or	a	sudden	feeling	of	heat	that	may	last	seconds	to	several	minutes,	causing	flushing,	chills,	clamminess,	perspiration,	anxiety,	sleep	disturbances	(night	sweats),	and	heart	palpitations.205,206		For	87	percent	of	these	patients,	such	vasomotor	episodes	occur	daily,	and	at	least	ten	times	per	day	for	33	percent	of	patients;	the	median	duration	of	symptoms	varies	from	4	to	10	years.207		Ten	to	forty	percent	of	patients	experience	vaginal	atrophy,	vaginal	dryness,	and	urinary	tract	changes	and	infections.208		Other	symptoms	include	osteoporosis,	or	the	loss	of	bone	density	leading	to	fractures	including	those	of	the	hip	or	spine,	mood	changes,	irregular	periods,	weight	gain,	and	slowed	metabolism.209,210	To	treat	the	perimenopausal	and	menopausal	symptoms	of	some	patients,	estrogen	is	used	as	hormone	replacement	therapy	(HRT),	or	“estrogen	therapy”	(ET).211		For	those	who	have	never	had	a	hysterectomy	and	still	have	a	uterus,	progestin	is	added	to	reduce	the	risk	of	endometrial	or	uterine	cancer,	in	a	treatment	known	as	“combined	hormone	therapy”	(CHT).212,213		While	certain	symptoms	may	be	treated	with	a	local	estrogen-only	regimen,	combination	therapy	is	administered	systemically	in	the	form	of	pills	or	a	skin	patch.214	Systemic	estrogen,	with	or	without	progestin,	is	the	most	effective	proven	treatment	for	relieving	hot	flashes	and	night	sweats.215		Systemic	estrogen	therapy	has	been	shown	to	protect	against	bone	loss	and	prevent	hip	and	spine	fracture.216		Combined	therapy	may	also	help	to	reduce	the	risk	of	colon	cancer,	and	systemic	or	local	estrogen	therapy	is	effective	in	relieving	vaginal	dryness.217			However,	hormone	therapy	is	also	associated	with	an	increased	risk	for	certain	diseases	and	conditions.		Estrogen	therapy	alone	increases	the	risk	of	endometrial	or	uterine	cancer,	as	the	treatment	causes	the	lining	of	the	uterus	to	grow;	use	of	progestin	in	combination	with	estrogen	decreases	this	risk.218		Estrogen	therapy	is	also	associated	with	a	small	increased	risk	for	gallbladder	disease,	which	may	be	reduced	with	non-oral	therapy	administration.219,220		Combined	therapy	is	associated	with	a	small	increased	risk	of	heart	attack;	this	risk	is	related	to	a	patient’s	age,	when	she	begins	therapy,	and	her	other	medical	conditions.		However,	for	women	younger	than	60	who	begin	combined	therapy	within	10	years	of	menopause,	the	combined	therapy	may	protect	against	heart	attack.221		Combined	therapy	is	also	associated	with	a	small	increased	risk	for	stroke	and	deep	vein	thrombosis	(DVT),	which	may	be	diminished	by	using	non-oral	therapy	routes.	222		Combined	hormone	therapy	is	also	associated	with	a	small	increased	risk	of	breast	cancer,	and	is	not	recommended	as	a	first-line	treatment	for	patients	with	a	history	of	hormone-sensitive	breast	cancer.223	Evidence	now	exists	to	support	certain	non-hormonal	treatment	of	menopausal	symptoms,	including	selective	serotonin	reuptake	inhibitors	and	selective	serotonin/norepinephrine	reuptake	
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inhibitors	(SSRI	and	SNRI,	types	of	anti-depressants),224	clonidine/Catapres	(a	drug	used	to	lower	blood	pressure),225	and	gabapentin/Neurotin	(a	drug	approved	to	treat	seizures)226	for	treatment	of	hot	flashes.227		However,	the	only	FDA-approved	non-hormonal	therapies	include	paroxetine	for	vasomotor	symptoms	(hot	flashes)228	and	ospemifene	for	dyspareunia	(difficult	intercourse),229	both	approved	in	2013.		Herbal	treatments,	estriol,	and	bio-identical	hormones	are	not	currently	FDA-approved	for	the	treatment	of	menopausal	symptoms.230	The	use	of	HRT	became	very	controversial	after	release	of	the	findings	of	the	landmark	1998	Women’s	Health	Initiative	(WHI)	clinical	trials.		These	studies,	conducted	by	the	National	Heart,	Lung	&	Blood	Institute,	focused	on	the	prevention	of	heart	disease,	breast	and	colorectal	cancer,	and	osteoporosis	in	postmenopausal	women	through	treatment	with	hormone	therapy,	dietary	patterns,	and	calcium/vitamin	D	supplements.231		Additional	similar	studies	included	the	collaborative	reanalysis	(CR)	and	the	Million	Women	Study	(MWS).		Researchers	from	these	studies	concluded	that,	while	hormone	therapy	reduced	risks	of	colorectal	cancer	and	fractures	from	osteoporosis,	it	potentially	increased	risks	for	coronary	heart	disease,	breast	cancer,	venous	thromboembolism,	stroke,	cholecystitis,	dementia,	and	lower	global	cognitive	function.232		Critics	of	the	studies’	designs	and	generalizability	questioned	these	results,233,234,235,236,237	yet	many	patients	and	clinicians	failed	to	differentiate	when	comparing	the	risk	and	rewards	of	using	HRT	for	treatment	of	menopausal	symptoms	versus	its	use	for	chronic	disease	prevention	in	postmenopausal	women.		This	confusion	led	many	clinicians	and	patients	to	abruptly	end	HRT,	which	caused	“a	significant	and	sudden	reduction	in	quality	of	life,”	and	led	patients	to	seek	alternative	treatments	that	had	not	been	studied	for	safety	and	efficacy	when	used	for	menopausal	symptoms.238	The	current	recommendations	of	the	American	College	of	Obstetricians	and	Gynecologists	related	to	the	treatment	of	menopausal	vasomotor	and	vaginal	symptoms	direct	patients	and	providers	to	discuss	the	individual’s	benefits	and	risks	from	HRT.		In	general,	patients	should	use	the	lowest	effective	dose	for	the	shortest	time	possible	to	treat	menopausal	symptoms,	and	should	be	reevaluated	yearly	to	continuously	assess	benefits	and	risks	of	treatment.		Additionally,	the	treatment	guidelines	published	by	the	Endocrine	Society	recommend	screening	for	breast	cancer	and	cardiovascular	risk	before	initiating	HRT.239	Researchers	who	retrospectively	examined	the	impact	of	the	WHI	results	on	HRT	use	concluded:	[Q]uestions	about	the	long-term	health	consequences	of	HRT	remain.	The	women	in	the	WHI	were	older	and	taking	higher	doses	of	estrogen	than	women	using	HRT	today.	In	addition,	a	number	of	other	hormonal	options	are	available,	yet	their	comparative	risks	and	benefits	are	unknown.	These	include	different	types	of	hormones	—	conjugated	and	synthetic	estrogens,	phytoestrogens,	synthetic	progestin,	and	natural	progesterone	—	and	modes	of	delivery	—	oral	tablets,	transdermal	patches,	local	creams,	and	intrauterine	devices.	Without	further	study,	deciding	on	the	best	treatment	plan	will	continue	to	involve	an	amount	of	guesswork.240	
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Current	guidelines	explicitly	recommend	against	the	use	of	HRT	to	prevent	postmenopausal	chronic	conditions,	including	coronary	heart	disease,241	breast	cancer,	or	dementia.242		The	USPSTF	recommends	against	the	use	of	HRT	only	when	used	for	the	prevention	of	chronic	medical	conditions,	stating:	This	recommendation	applies	only	to	postmenopausal	women	who	are	considering	hormone	therapy	for	the	primary	prevention	of	chronic	medical	conditions.	This	is	not	a	recommendation	about	the	use	of	hormone	therapy	to	treat	menopausal	symptoms,	such	as	hot	flashes	or	vaginal	dryness;	the	USPSTF	did	not	review	the	evidence	related	to	this	possible	indication	because	it	falls	outside	of	the	mission	and	scope	of	the	USPSTF.	This	recommendation	also	does	not	apply	to	women	younger	than	50	years	who	have	had	surgical	menopause.243	Estimate	of	the	cost	of	the	mandate	Regulations	issued	pursuant	to	the	ACA	(45	CFR	156.122)	require	EHBs	to	include	at	least	one	drug	in	each	USP	category	and/or	class.		The	effect	of	this	regulation	is	to	require	carriers	to	include	an	estrogen/progestin	in	their	formularies,	although	the	regulations	do	not	address	HRT	directly.		This	analysis	will	not	address	the	argument	that,	by	requiring	carriers	to	include	the	drugs	in	their	formularies,	the	federal	regulation	also	requires	them	to	pay	for	every	FDA-approved	use	of	the	drug;	i.e.,	this	analysis	will	not	assume	the	regulation	requires	carriers	to	pay	claims	for	those	drugs	specifically	for	treating	symptoms	of	menopause	in	peri-and	post-menopausal	women.	RDC	for	this	mandate	was	calculated	as	the	sum	of	paid	amounts	from	all	claims	for	specific	hormone	replacement	therapy	procedures	and	pharmaceuticals	as	well	as	Evaluation	and	Management	(E&M)	procedures	with	a	diagnosis	(in	any	of	the	top	five	diagnosis	columns)	associated	with	menopause-related	hormone	regulation.		The	estimated	PMPM	RDC	paid	claim	amount	was	$0.41,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$0.46	(or	0.11	percent	of	the	Commonwealth	total	premium).		Per	member	per	month	self-insured	allowed	expenses	for	this	mandate	were	found	to	be	$0.04	lower	than	fully-insured	PMPM	allowed	expenses,	resulting	in	a	lower	bound	expense	estimate,	including	administrative	loading,	of	$0.03	PMPM,	or	0.01	percent	of	Commonwealth	premium.		Table	10	below	displays	a	summary	of	these	results	and	related	statistics.	
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Table	10	
Hormone	Replacement	Therapy	Mandate	
Contribution	to	Premium	
	
Human	Leukocyte	Antigen	Testing	The	human	leukocyte	antigen	(HLA)	testing	mandate	requires	coverage	for	HLA	or	histo-compatibility	locus	antigen	testing	necessary	to	establish	the	suitability	of	a	bone	marrow	transplant	donor.244	Effect	of	the	mandate	on	health	HLA	testing	is	used	to	identify	good	matches	for	patients	in	need	of	tissue	grafts	or	organ	transplant,	and	may	be	used	to	diagnose	some	autoimmune	disorders,	monitor	certain	medication	treatments,	and	determine	parent/child	biological	relationships.245		Such	transplants	include	hematopoietic	(blood)	stem	cell	transplants	(HSCT),	which,	for	many	diseases,	is	part	of	standard	treatment,	and	others	for	which	HSCT	has	become	a	viable	option	and	may	be	the	only	available	cure.246		These	diseases	include	leukemia	and	certain	lymphoma,	metabolic,	blood,	autoimmune,	and	genetic	disorders.247		Transplants	are	intended	to	replace	unhealthy	with	healthy	blood-forming	cells,	and	can	come	from	one	of	three	sources:	bone	marrow	transplant	(BMT),	umbilical	cord	blood,	or,	most	commonly,	peripheral	blood.248,249		The	two	types	of	HSCTs	include	autologous,	in	which	a	patient’s	own	cells	are	used	for	transplant,	or	allogeneic,	which	uses	donor	cells.250		This	mandate	specifically	refers	to	bone	marrow	transplant,	and	does	not	include	umbilical	cord	or	the	more	common	peripheral	blood	transplants	in	its	language.	HLAs	are	proteins	found	in	most	cells	and	serve	as	immunologic	markers	which	the	body	uses	to	identify	which	cells	belong	to	a	patient	and	which	do	not.251		For	allogeneic	donations,	the	best	matches	for	BMTs	are	siblings	who	have	identical	markers.252		However,	sibling	matches	account	for	only	30	percent	of	BMTs,	leaving	70	percent	of	patients	in	need	of	an	unrelated	donation.253,254		
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Bound	PMPMs	
Sample	Users 19,386													 9,780																
Sample	Units 3,051,706								 1,522,383								
Sample	Average	Members 1,437,788								 1,432,254								
Paid	PMPM 0.41$																 0.41$																 0.03$																
Paid	PMPM	With	Admin 0.46$																 0.46$																 0.03$																
Allowed	PMPM 0.58$																 0.54$																 0.04$																
	Upper	Bound	
Impact	
	Lower	Bound	
Impact*	
Insured	Population 2,362,745 2,362,745
Contribution	to	Total	Annual	Claims 11,563,949$			 740,590$									
Contribution	to	Total	Annual	Premium 12,993,201$			 832,123$									
Percent	of	Total	Premium 0.11% 0.01%
*No	significant	overlaps	were	found	between	this	and	other	mandates.
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Due	to	growth	in	overall	numbers	and	population	diversity	in	the	National	Marrow	Donor	registry	(Be	The	Match™),	most	patients	who	will	benefit	from	HCT	will	have	a	suitable,	if	not	optimal,	donor.255	The	better	the	HLA	match	between	patient	and	donor,	the	better	a	patient’s	chances	for	survival.256		While	many	HLA	markers	exist,	only	a	small	number	are	critical	to	HSCT	outcomes.		The	National	Marrow	Donor	Program	(NMDP)	currently	requires	a	minimum	number	of	matches	from	a	series	of	eight	HLA	markers257	(two	A,	two	B,	two	C	and	two	DRB1)	for	a	transplant	to	be	received	from	its	donor	registry;	ideal	donors	match	the	patient	on	eight	of	the	eight	markers.258		In	2011,	the	overall	survival	rate	for	patients	with	related	donor	transplants	was	79	percent,	versus	69	percent	for	unrelated	donors;	this	latter	rate	is	rising	as	clinical	practices	have	changed,	and	HLA	typing	and	matching	have	improved.259		Mismatched	HLA	puts	a	patient	at	risk	for	acute	and	chronic	graft-versus-host	disease,	graft	rejection,	and	treatment	related	mortality.260		However,	according	to	the	NMDP,	an	imperfect	match	does	not	contraindicate	transplantation;	instead,	“[i]f	a	mismatch	is	unavoidable,	a…mismatched	donor	can	be	used	with	acceptable	risks	of	transplant-related	mortality.”261	Testing	for	the	HLA-C	marker	is	not	specifically	outlined	in	the	Massachusetts	mandate;	however,	the	language	of	the	mandate	does	require	“coverage	for	the	cost	of	human	leukocyte	antigen	testing	or	histocompatibility	locus	antigen	testing	that	is	necessary	to	establish	bone	marrow	transplant	donor	suitability.”262		The	mandate	also	includes	reference	to	M.G.L.	Chapter	111	Section	218	which	provide	that	HLA	testing	must	“conform	to	medical	eligibility	requirements	and	other	test	protocols	established	by	the…national	marrow	donor	program	registry”	which	now	includes	the	use	of	high	resolution	DNA	testing	for	HLA-A,	B,	C	and	DRB1	markers.263		This	analysis	presumes	that	the	mandate	covers	testing	under	the	current	guidelines	in	place	with	the	NMDP	for	BMTs.	Estimate	of	the	cost	of	the	mandate	RDC	for	this	mandate	was	calculated	as	the	sum	of	paid	amounts	from	all	claims	with	a	procedure	code	indicating	HLA	testingxiii	(per	the	carrier	specification	review)	and	a	primary	diagnosis	indicating	tissue	donation.xiv		The	estimated	PMPM	RDC	paid	claim	amount	was	$0.001,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$0.001	(or	0.0002	percent	of	the	Commonwealth	total	premium).		Self-insured	allowed	medical	expenses	for	these	services	were	found	to	be	slightly	
higher	than	fully-insured	allowed	medical	expenses,	resulting	in	a	$0	lower	bound	impact	estimate,	including	administrative	loading.		Table	11	below	displays	a	summary	of	these	results	and	related	statistics.	
																																								 																					xiii	CPT	codes	81377,	81383,	86812,	86813,	86816,	86817,	86821,	86822,	86825,	86826,	86828,	86829,	86830,	86831,	86832,	86833,	86834,	86835,	86812,	86813,	86816,	or	86817.	xiv	ICD-9	diagnosis	codes	V59.3,	V59.9,	or	V70.8.	
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Table	11	
Human	Leukocyte	Antigen	Testing	
Contribution	to	Premium	
	
Hypodermic	Syringes	or	Needles	This	mandate	requires	coverage	for	medically	necessary	hypodermic	syringes	or	needles.264		The	statutory	sections	requiring	coverage	for	syringes	and	needles	were	enacted	as	part	of	a	law	addressing	a	broad	set	of	issues	relating	to	preventing	transmission	of	blood-borne	diseases,	including	needle	distribution	programs	for	users	of	illegal	drugs.		However,	the	mandate	language	included	in	this	review	is	limited	to	medically	necessary	use	of	needles	covered	by	insurers.		While	theoretically	that	might	encompass	illegal	drug	injection,	addressing	scenarios	where	illegal	use	might	be	involved,	likely	or	not,	is	beyond	the	scope	of	this	review.	Effect	of	the	mandate	on	health	Many	medications	are	self-administered	by	injection,	requiring	the	use	of	sterile	hypodermic	needles	or	syringes.		A	wide	range	of	illnesses	are	treated	with	patient-delivered	injectable	therapies,	including	multiple	sclerosis,265	infertility,266	pernicious	anemia,267	iron	deficiency,268	cancer,269	diabetes,270	and	HIV/AIDS271	among	others.		Often	these	drugs	must	be	injected,	as	the	specific	medication	would	be	destroyed	in	the	digestive	process	or	is	not	tolerated	orally.272		Injectable	drugs	can	also	deliver	a	particular	dosage	of	a	drug	over	a	long	period	of	time,	up	to	several	months.273		One	disadvantage	of	injection,	particularly	self-injection,	is	the	risk	of	infection;	patients	also	may	have	a	fear	of	needles	or	may	be	unable	or	unwilling	to	self-administer	the	drug	by	injection,	making	treatment	adherence	an	issue.274,275,276		Conversely,	the	ability	for	a	patient	to	self-administer	may	improve	compliance	by	eliminating	the	time	and	expense	associated	with	additional	clinical	visits	for	these	injections;	patient	selection,	training	and	counseling,	and	simplicity	of	medication/syringe	preparation	may	improve	adherence.277,278		The	availability	of	newer	technologies,	such	as	pre-filled	injectable	pens,	for	some	conditions	may	reduce	the	use	of	
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Bound	PMPMs	
Sample	Users 230																			 224																			
Sample	Units 442																			 423																			
Sample	Average	Members 1,871,491								 1,490,706								
Paid	PMPM 0.001$													 0.001$													 -$																		
Paid	PMPM	With	Admin 0.001$													 0.001$													 -$																		
Allowed	PMPM 0.001$													 0.001$													 (0.00)$														
	Upper	Bound	
Impact	
	Lower	Bound	
Impact*	
Insured	Population 2,362,745 2,362,745
Contribution	to	Total	Annual	Claims 18,339$											 -$																		
Contribution	to	Total	Annual	Premium 20,606$											 -$																		
Percent	of	Total	Premium 0.0002% 0.00%
*No	significant	overlaps	were	found	between	this	and	other	mandates.
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hypodermic	needles	and	syringes	for	self-administration;	some	studies	conclude	that	patients	find	use	of	pens	easier,	more	convenient	and	less	stressful,279	while	use	of	the	devices	increases	the	accuracy	of	the	medication	dose.	280	Estimate	of	the	cost	of	the	mandate	The	RDC	of	this	mandate	was	calculated	as	the	sum	of	paid	amounts	from	all	claims	with	syringe	or	needle	procedure	or	national	drug	codes	(NDCs).		The	estimated	PMPM	RDC	paid	claim	amount	was	$0.04,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$0.04	(or	0.01	percent	of	the	Commonwealth	total	premium).		Self-insured	allowed	medical	expenses	for	these	services	were	found	to	be	higher	than	fully-insured	allowed	medical	expenses,	resulting	in	a	$0	lower	bound	impact	estimate,	including	administrative	loading.		Table	12	below	displays	a	summary	of	these	results	and	related	statistics.	
Table	12	
Hypodermic	Syringes	or	Needles	Mandate	
Contribution	to	Premium	
	
Infertility	Treatment	The	infertility	mandate	requires	coverage	for	infertility	treatments	for	members	covered	under	plans	that	include	pregnancy-related	benefits	to	the	same	extent	benefits	are	provided	for	other	pregnancy-related	procedures.281	Effect	of	the	mandate	on	health	Infertility	describes	the	inability	of	a	woman	or	man	to	conceive	a	child,	or	a	woman’s	ability	to	carry	a	pregnancy	to	term;	it	is	clinically	defined	as	the	inability	to	become	pregnant	after	one	year	of	trying	for	a	woman	of	normal	childbearing	age	(or	six	months	for	a	woman	over	age	35).282		An	
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Bound	PMPMs	
Sample	Users 15,904													 9,305																
Sample	Units 5,698,157								 3,275,925								
Sample	Average	Members 1,437,788								 1,432,254								
Paid	PMPM 0.04$																 0.07$																 -$																		
Paid	PMPM	With	Admin 0.04$																 0.07$																 -$																		
Allowed	PMPM 0.11$																 0.13$																 (0.02)$														
	Upper	Bound	
Impact	
	Lower	Bound	
Impact*	
Insured	Population 2,362,745 2,362,745
Contribution	to	Total	Annual	Claims 1,083,290$					 -$																		
Contribution	to	Total	Annual	Premium 1,217,180$					 -$																		
Percent	of	Total	Premium 0.01% 0.00%
*Net	amounts	do	not	remove	overlap	in	mandated	services	between	the		syringe
and	needle	mandate	and	the	diabetes	mandate.
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estimated	10.9	percent	of	women	age	15	to	44	have	an	impaired	ability	to	get	pregnant,	or	to	carry	a	baby	to	term	(impaired	fecundity).283		Between	2006	and	2010,	17	percent	of	women	age	25	to	44	or	their	partners	had	ever	used	infertility	services,	a	decrease	from	the	1995	level	of	20	percent.284	Research	shows	that	the	causes	of	infertility	are	approximately	evenly	divided	between	conditions	affecting	the	woman,	conditions	affecting	the	man,	and	unknown	causes.285		A	large	number	of	specific	conditions	are	described	within	those	categories.		For	women,	the	most	common	cause	is	problems	with	ovulation,	but	many	other	physical,	genetic,	or	environmental	causes	exist.286		For	men,	the	most	common	causes	of	infertility	are	problems	with	sperm	(production,	function,	or	delivery),	behavior	and	lifestyle	factors,	and	environmental	exposures.287	A	large	number	of	treatments	are	available	for	infertility,	and	choosing	among	them	depends	on	a	variety	of	factors,	including:	the	age	and	health	of	the	parents;	the	causes,	severity	and	duration	of	infertility;	side	effects;	and	treatment	preferences.288		Generally,	however,	treatments	can	be	categorized	as	behavioral	changes,	medication,	surgery,	intrauterine	insemination,	or	assisted	reproduction	techniques	(ART).289,290		Medications	are	most	often	used	either	to	induce	ovulation,	or	for	“controlled	ovarian	hyperstimulation”	(COH),	where	follicles	are	stimulated	to	grow,	mature,	and	ovulate.291		This	can	then	be	followed	by	artificial	insemination	or	intrauterine	insemination	if	necessary.		COH	is	also	part	of	ART,	which	are	more	complex	and	invasive	techniques	in	which	eggs	are	manipulated	and	fertilized	outside	of	the	body.		Multiple	fertilized	eggs	are	then	returned	to	a	uterus	for	implantation,	or	are	frozen	for	later	use.		Medication	or	surgery	therapies	are	used	in	85	to	90	percent	of	treated	infertility	cases;	in-vitro	fertilization	(IVF)	and	other	ART	“account	for	less	than	3	[percent]	of	infertility	services.”292	The	effectiveness	of	infertility	treatment	is	difficult	to	summarize	as	the	factors	leading	to	their	use	vary	for	each	patient.		Likewise,	many	treatments	have	not	been	evaluated	through	high-quality	studies,	and	the	definition	of	successful	treatment	is	not	standard.293,294		One	study	summarized,	“there	is	little	convincing	evidence	on	which	to	base	treatment	strategies	for	the	majority	of	infertile	couples.		More	high-quality	data	on	the	relative	superiority	of	each	treatment	option,	and	associated	adverse	events,	are	needed.”295		Testing	and	treatment	practices	of	infertility	specialists	continue	to	vary	widely	and	evolve,	while	the	age	of	couples	seeking	treatment	continues	to	rise.296	One	large	study	reviewed	research	findings	regarding	ovulation	induction,	COH	and	in-vitro	fertilization,	and	analyzed	short-term	outcomes	of	pregnancy,	live	birth,	multiple	gestation,	and	complications,	as	well	as	long-term	outcomes	of	pregnancy	and	post-pregnancy	complications	for	mothers	and	children.297		The	authors	found	that	high-quality	evidence	was	lacking	in	the	majority	of	the	studies	to	support	the	choice	of	specific	interventions.298		However,	there	was	evidence	that	pregnancy	and	live	birth	rates	were	improved	with	application	of	certain	specific	techniques.299		Other	studies	have	found	that	ART	treatments,	most	frequently	IVF	and	intracytoplasmic	sperm	injection	(ICSI),300	result	in	“reasonably	high	pregnancy	rates;”301	this	success	is	prompting	more	patients	to	seek	ART	treatments	sooner	for	their	infertility.302			However,	major	risks	are	associated	with	ART,	most	notably	multi-fetal	and	especially	higher-order	(triplets	or	more)	gestations.		More	than	30	percent	of	pregnancies	resulting	from	ART	are	twins	or	higher-order	multiple	gestations;303	the	complications	of	multiple	gestations	are	well-documented.		
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One	study	found	that	more	than	50	percent	of	ART-related	newborns	are	born	from	a	multifetal	gestation.304		For	singleton	pregnancies,	IVF	is	associated	with	a	slightly-increased	risk	of	birth	defects,	as	well	as	preterm	delivery,	perinatal	(associated	with	birth)	mortality,	and	infants	small	for	their	gestational	age.305		The	mother’s	risk	increases	for	preeclampsia,	gestational	diabetes,	placenta	previa,	placental	abruption,	and	cesarean	delivery.306		Beyond	these,	the	major	complication	of	ART	for	women	is	ovarian	hyperstimulation	syndrome.307		Children	born	via	such	treatments	are	at	risk	for	complications	associated	with	abnormal	placentation	or	implantation,	although	it	is	unclear	whether	this	is	due	to	the	treatment,	the	infertility,	or	both.308	Information	from	the	National	Institutes	of	Health	found	that,	for	women	treated	with	the	medication	clomiphene	or	clomiphine	citrate,	to	stimulate	hormones	to	help	eggs	mature	in	the	ovaries,	80	percent	ovulate;	of	these,	50	percent	are	able	to	achieve	a	pregnancy	or	live	birth.309		The	drugs	bromocriptine	or	cabergoline	reduce	the	levels	of	prolactin,	which	has	been	shown	to	stop	ovulation,	for	90	percent	of	women	with	abnormally	high	levels	of	prolactin;	85	percent	of	these	women	can	then	ovulate.310		The	success	of	surgical	treatment	for	infertility	caused	by	diseases	of	the	fallopian	types	are	low	and	can	increase	the	risk	of	ectopic	pregnancy;	on	the	other	hand,	surgeries	to	remove	entrometrial	patches	can	double	the	chances	for	pregnancy.311	Pregnancy	rates	from	ART	depend,	among	other	factors,	on	the	age	of	the	mother.		The	following	table	summarizes	national	ART	success	rates:	
2012	National	ART	Summary	Success	Rates	
	
Age	of	Women	
<35	 35-37	 38-40	 41-42	 43-44	 >44	
	
Fresh	embryos	from	non-donor	eggs:	Percentage	of	cycles	resulting	in	live	births	
Singleton		 28.0	 23.1	 17.5	 10.0	 4.0	 1.6	
Triplets	or	more	 0.5	 0.2	 0.2	 0.1	 0.0	 0.0	
All		 40.5	 31.3	 22.2	 11.7	 4.5	 1.8	
	
Frozen	embryos	from	non-donor	eggs:	Percentage	of	transfers	resulting	in	live	births	
Singleton		 31.9	 31.2	 26.7	 22.0	 15.3	 10.1	
Triplets	or	more	 0.4	 0.2	 0.2	 0.1	 0.1	 0.0	
All		 42.0	 39.3	 33.4	 25.9	 28.2	 19.4	
	
Donor	eggs:	Percentage	of	transfers	resulting	in	live	births	
	 Fresh	embryos	(all	ages)	 Frozen	embryos	(all	ages)	
Singleton	 37.2	 28.6	
All	 56.4	 46.7	
	Many	professional	societies	and	organizations	now	recommend	that	the	measurement	of	the	effectiveness	of	infertility	treatment,	specifically	ART,	should	be	the	birth	of	a	single,	healthy	child.312		They	caution,	however,	that	this	goal	may	not	be	accepted	for	many	reasons,	including	“insufficient	awareness	of	the	risks	and	costs	associated	with	multiple	pregnancy	among	the	general	public	and	policy	makers,”	limitations	in	certain	aspects	of	the	ART	process	itself,	the	cost	of	
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repeated	treatment	cycles,	and	competition	between	fertility	specialists	based	on	pregnancy	or	birth	rates	per	cycle.313	Estimate	of	the	cost	of	the	mandate	The	infertility	mandate	requires	coverage	for	infertility	treatments	for	members	covered	under	plans	that	include	pregnancy-related	benefits	to	the	same	extent	benefits	are	provided	for	other	pregnancy-related	procedures.		The	RDC	for	this	mandate	was	calculated	as	the	sum	of	paid	amounts	from	all	claims	for	infertility-related	procedure	codes	and	pharmaceuticals,	as	well	as	E&M	procedures	for	members	with	a	diagnosis	of	infertility.		The	estimated	PMPM	RDC	paid	claim	amount	was	$3.96,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$4.44	(or	0.95	percent	of	the	Commonwealth	total	premium).		Per	member	per	month	self-insured	allowed	expenses	for	this	mandate	were	found	to	be	$0.50	lower	than	fully-insured	PMPM	allowed	expenses,	resulting	in	a	lower	bound	expense	estimate,	after	administrative	loading,	of	$0.54	PMPM,	or	0.12	percent	of	Commonwealth	premium.		Table	13	below	displays	a	summary	of	these	results	and	related	statistics.	
Table	13	
Infertility	Treatment	Mandate	
Contribution	to	Premium	
	
Low	Protein	Foods	(LPF)	The	low	protein	foods	mandate	requires	coverage	for	low	protein	food	products	required	to	treat	infants	and	children	with	specified	metabolic	disorders	(for	inherited	amino	acid	and	organic	acid	diseases)	as	well	as	fetuses	of	pregnant	women	with	phenylketonuria.314	
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Bound	PMPMs	
Sample	Users 19,386													 9,780																
Sample	Units 391,000											 194,100											
Sample	Average	Members 1,162,496								 976,376											
Paid	PMPM 3.96$																 3.57$																 0.48$																
Paid	PMPM	With	Admin 4.44$																 4.01$																 0.54$																
Allowed	PMPM 4.16$																 3.66$																 0.50$																
	Upper	Bound	
Impact	
	Lower	Bound	
Impact*	
Insured	Population 2,206,099 2,206,099
Contribution	to	Total	Annual	Claims 104,727,260$	 12,672,869$			
Contribution	to	Total	Annual	Premium 117,671,078$	 14,239,178$			
Percent	of	Total	Premium 0.95% 0.12%
*No	significant	overlaps	were	found	between	this	and	other	mandates.
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Effect	of	the	mandate	on	health	Phenylketonuria	(PKU)	is	a	rare	metabolic	disorder	caused	by	a	defect	in	the	gene	that	helps	to	create	the	liver	enzyme	needed	to	break	down	the	amino	acid	phenylalanine	(Phe),	which	then	builds	up	in	the	blood	and	other	tissues.315,316,317		Untreated,	PKU	can	lead	to	microencephaly,	mental	retardation,	seizures,	congenital	heart	disease,	and	other	significant	physical,	mental,	behavioral,	and	developmental	disorders.318		Women	with	untreated	PKU	during	pregnancy	may	bear	children	prematurely,	or	who	suffer	from	birth	defects.319		The	prevalence	of	PKU	is	approximately	1	in	13,500	to	19,000	births.320	In	2012,	the	National	Institutes	of	Health	sponsored	a	PKU	Scientific	Review	Conference	to	address	new	research	and	outstanding	questions	regarding	the	management	of	PKU,	while	the	Agency	for	Healthcare	Research	and	Quality	(AHRQ)	Evidence-based	Practice	Center	(EPC)	conducted	an	evidence	review	of	the	comparative	effectiveness	of	PKU	treatment,	including	diet	and	pharmacological	interventions.321,322		The	result	of	these	collaborative	efforts	included	recognition	of	the	effectiveness	of	strict	dietary	control	to	lower	levels	of	the	Phe	amino	acid	in	the	body,	before	pregnancy	in	women	and	after	birth	for	children	with	PKU.323,324	The	low-Phe	diet	includes	medical	food	and	formulas,	minimal	animal	products,	and	fruits	and	vegetables	high	in	carbohydrates,	and	low	in	saturated	and	unsaturated	fat	and	cholesterol.325		This	restricted	diet	may	create	nutritional	deficits	in	some	patients,	especially	for	natural	proteins;	many	patients	take	amino	acid	supplements	as	well	as	other	vitamins	and	minerals	to	compensate	for	these	deficiencies.326		In	2007,	the	use	of	sapropterin	dihydrochloride	(Kuvan)	was	approved	for	the	treatment	of	PKU	for	patients	who	tolerate	and	respond	to	the	drug,	to	be	taken	in	addition	to	the	low-Phe	diet.327,328		Research	has	shown	the	drug	may	help	some	patients	to	control	Phe	concentrations	while	increasing	tolerance	of	dietary	Phe.329	To	reduce	the	risk	of	birth	defects	and	other	developmental	abnormalities,	mothers	at	risk	for	PKU	during	pregnancy	must	achieve	and	maintain	control	of	dietary	Phe,	preferably	three	months	before	conception.330,331		For	most	children	born	with	PKU	identified	through	newborn	screening	who	are	treated	early	in	life	and	can	comply	with	this	low-Phe	diet,	the	outcomes	have	shown	“remarkable	success	in	preventing	the	devastating	brain	damage	associated	with	untreated	PKU.”332		In	fact,	those	able	to	achieve	and	maintain	metabolic	control	“have	normal	health	and	development	and	can	likely	expect	a	normal	life	span.”333		However,	the	nutritional	treatment	is	difficult	to	maintain	and	complicated,	while	the	formulas	are	often	unpalatable	and	expensive.334,335		Moreover,	the	low-Phe	diet	is	not	completely	effective	for	all	patients,	as	adherence	is	difficult	and	some	patients	may	experience	neurocognitive	defects	and	progressive	cognitive	impairment	despite	therapy.336,337		For	these	reasons,	research	continues	to	explore	the	development	of	new	therapies.338,339		Overall,	however,	while	the	precise	level	of	phenylalanine	restriction	is	unclear,	research	has	shown	that	the	low-Phe	diet	is	effective	in	reducing	blood	phenylalanine	levels	and	improving	neuropsychological	outcomes	and	intelligence	quotient	for	patients	with	PKU.340,341	Estimate	of	the	cost	of	the	mandate	The	LPF	mandate	covers	low	protein	food	products	required	to	treat	infants	and	children	with	specified	metabolic	disorders	as	well	as	fetuses	of	pregnant	women	with	PKU.		Costs	of	the	mandate	
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were	estimated	as	the	sum	of	paid	amounts	from	all	claims	incurred	in	the	study	period	for	procedure	codes	indicating	the	purchase	of	low	protein	food	products.		The	estimated	RDC	PMPM	paid	claim	amount	was	$0.05,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$0.06	(or	0.01	percent	of	the	Commonwealth	total	premium).		Per	member	per	month	self-insured	allowed	expenses	for	this	mandate	were	found	to	be	$0.003	lower	than	fully-insured	PMPM	allowed	expenses,	resulting	in	a	lower	bound	impact	estimate,	including	administrative	loading,	of	$0.003	PMPM,	or	0.001	percent	of	Commonwealth	premium.		Table	14	below	displays	a	summary	of	these	results	and	related	statistics.	
Table	14	
Low	Protein	Foods	Mandate	
Contribution	to	Premium	
	
Nonprescription	Enteral	Formulas	The	enteral	formula	mandate	requires	"coverage	for	nonprescription	enteral	formulas	for	home	use…which	are	medically	necessary	for	the	treatment	of	mal-absorption	caused	by	Crohn's	disease,	ulcerative	colitis,	gastro-esophageal	reflux,	gastrointestinal	motility,	chronic	intestinal	pseudo-obstruction,	and	inherited	diseases	of	amino	acids	and	organic	acids.”342	Effect	of	the	mandate	on	health	Enteral	nutrition	(EN)	provides	patients	with	nutrients	or	food	via	a	tube	to	the	stomach	or	small	intestine	when	the	patient’s	diet	does	not	meet	her/his	nutritional	needs	and	results	in	continued	weight	loss	and	prolonged	starvation.343,344		Home	enteral	nutrition	(HEN)	is	used	most	often	for	patients	whose	intestinal	tract	is	functional,	but	have	some	degree	of	failure	in	the	esophagus	or	throat;	many	of	these	patients	have	difficulty	with	swallowing;	these	include	patients	with	certain	neurological	problems	or	head	and	neck	cancers.345		Other	patients	for	whom	HEN	is	necessary	include	those	with	certain	gastrointestinal	diseases,	eating	issues	caused	by	dementia	or	
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Bound	PMPMs	
Sample	Users 359																			 283																			
Sample	Units 392,448											 299,177											
Sample	Average	Members 1,871,491								 1,490,706								
Paid	PMPM 0.05$																 0.05$																 0.003$													
Paid	PMPM	With	Admin 0.06$																 0.06$																 0.003$													
Allowed	PMPM 0.06$																 0.05$																 0.003$													
	Upper	Bound	
Impact	
	Lower	Bound	
Impact*	
Insured	Population 2,362,745 2,362,745
Contribution	to	Total	Annual	Claims 1,525,909$					 78,313$											
Contribution	to	Total	Annual	Premium 1,714,505$					 87,993$											
Percent	of	Total	Premium 0.01% 0.001%
*Net	amounts	do	not	remove	overlap	in	mandated	services	between	the	low	protein
foods	mandate	and	the	nonprescription	enteral	formulas	and	home	health	mandates.
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psychological	disorders,	or	those	whose	energy	demands	cannot	be	met	with	oral	nutrition,	such	as	some	AIDS	patients.346,347		HEN	is	not	without	complications,	including	problems	with	tubes,	gastrointestinal	complications,	and	quality	of	life	impact.348		One	study	highlighted	the	very	limited	evidence	comparing	the	benefit	of	EN	compared	to	the	complications,	quality	of	life,	costs	and	cost-effectiveness.349		Research	suggests	that	indications	for	the	use	of	HEN	should	be	outcome-specific.350,351		Some	studies	have	found	that	“EN	has	been	accepted	and	implemented	despite	the	lack	of	convincing	scientific	support	of	efficacy,”	and	encouraged	providers	to	determine	the	effectiveness	of	such	therapy	by	specific	patient,	disease-state,	and	its	corresponding	research	and	evidence.352		A	recent	clinical	trial	concluded	that	while	HEN	improved	clinical	outcomes,	“[i]t	was	impossible…to	determine	precisely	which	factor	mattered	more:	the	artificial	diet	itself	or	the	introduction	of	complex	care.”353,354	In	summary,	studies	of	enteral	feeding	have	shown	that,	for	patients	whose	oral	intake	of	nutrition	is	inadequate	and	who	have	a	functional	gastrointestinal	tract,	EN	does	increase	nutritional	intake	and	thus	improve	nutritional	status;355,356	for	these	patients,	HEN	is	a	“life-sustaining	therapy.”357	Malnutrition	is	a	serious	complication	of	many	diseases,	and	enteral	feeding,	when	appropriately	prescribed	and	used,	can	minimize	complications	and	be	life-saving.358		Tube	feeding	helps	a	patient	to	increase	nutritional	intake	and	avoid	starvation	and	organ	failure,	and	serves	to	maintain	the	intestinal	tract’s	integrity	and	local	defense	barrier,	thereby	preventing	additional	digestive	deterioration	and	the	spread	of	destructive	bacteria.359		According	to	the	American	Gastroenterological	Association,	“[t]ube	feeding	should	be	considered	when	the	patient	cannot	or	will	not	eat,	the	patient	has	a	functional	gut,	and	a	method	of	access	can	be	safely	obtained.”360	Estimate	of	the	cost	of	the	mandate	The	mandate	requires	"coverage	for	nonprescription	enteral	formulas	for	home	use…which	are	medically	necessary	for	the	treatment	of	mal-absorption	caused	by	Crohn's	disease,	ulcerative	colitis,	gastro-esophageal	reflux,	gastrointestinal	motility,	chronic	intestinal	pseudo-obstruction,	and	inherited	diseases	of	amino	acids	and	organic	acids.”		Therefore,	paid	amounts	from	all	claims	with	a	procedure	code	indicating	purchase	of	such	formulas	and	a	primary	diagnosis	of	a	covered	disorder	were	summed	to	estimate	RDC.	The	estimated	PMPM	RDC	paid	claim	amount	was	$0.03,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$0.04	(or	0.01	percent	of	the	Commonwealth	total	premium).		Self-insured	allowed	medical	expenses	for	these	services	were	found	to	be	higher	than	fully-insured	allowed	medical	expenses,	resulting	in	a	$0	lower	bound	impact	estimate,	including	administrative	loading.		Table	15	below	displays	a	summary	of	these	results	and	related	statistics.	
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Table	15	
Nonprescription	Enteral	Formulas	Mandates	
Contribution	to	Premium	
	
Oral	Chemotherapy	Treatment	of	Cancer	The	oral	chemo	therapy	mandate	requires	coverage	for	cancer	chemotherapy	treatment	for	prescribed,	orally	administered	anticancer	medications	used	to	kill	or	slow	the	growth	of	cancerous	cells	on	a	basis	not	less	favorable	than	intravenously-administered	or	injected	cancer	medications	covered	as	medical	benefits.361	Effect	of	the	mandate	on	health	Chemotherapy	is	a	class	of	treatments	that	impede	living	cells	in	the	human	body,	with	the	intention	of	stopping	the	rapid	growth	and	reproduction	common	to	cancer	cells.362		In	use	since	the	mid-20th	century,	chemotherapy	is	most	often	infused	intravenously	into	a	patient,	where	the	therapy	disperses	throughout	the	body	through	the	blood	and	lymphatic	symptoms.363,364		This	method	is	effective	for	delivering	cytotoxic	therapies,	those	intended	to	kill	cells	and	normally	administered	in	the	maximum	dose	tolerable	to	a	patient.		Ordinarily,	cytotoxic	infusions	happen	during	short	intervals	of	treatment	most	often	separated	by	long	periods	of	rest;	for	example,	a	patient	may	receive	daily	chemotherapy	for	one	week	followed	by	no	treatment	for	six	weeks,	repeating	this	cycle	over	several	months.365	This	treatment	routine	is	necessary,	as	cytotoxic	chemotherapy	drugs	act	on	all	cells,	killing	or	harming	both	healthy	and	cancerous	cells,	or	cause	other	serious	illnesses.366		Serious	side	effects	are	common	to	certain	chemotherapy	treatments,	depending	on	the	toxicity	of	the	drug	combination,	the	type	of	cancer,	and	the	overall	health	of	the	patient.367		Over	time,	scientists	have	created	new	drugs,	combinations,	and	delivery	techniques;	new	targeted	therapies;	and	approaches	to	mitigate	side	effects,	all	in	an	effort	to	improve	treatment	while	minimizing	the	poisonous	effects	of	chemotherapy	on	the	body.368		These	improvements	have	been	variably	successful.	
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Bound	PMPMs	
Sample	Users 290																			 299																			
Sample	Units 364,972											 321,368											
Sample	Average	Members 1,871,491								 1,490,706								
Paid	PMPM 0.03$																 0.04$																 -$																		
Paid	PMPM	With	Admin 0.04$																 0.05$																 -$																		
Allowed	PMPM 0.03$																 0.05$																 (0.011)$												
	Upper	Bound	 	Lower	Bound	
Insured	Population 2,362,745 2,362,745
Contribution	to	Total	Annual	Claims 924,982$									 -$																		
Contribution	to	Total	Annual	Premium 1,039,306$					 -$																		
Percent	of	Total	Premium 0.01% 0.000%
*Net	amounts	do	not	remove	overlap	in	mandated	services	between	the	nonprescription
enteral	mandate	and	the	low	protein	foods	and	home	health	mandates.
Comprehensive	Mandated	Benefit	Review	
compass Health Analytics 45 December 2016 
As	regimens	have	developed	and	improved,	the	route	of	treatment	administration	has	continued	to	evolve.		While	scientists	increasingly	focus	on	targeted	agents,	oral	administration	is	becoming	more	common,	allowing	patients	to	take	chemotherapy	drugs	by	mouth	via	a	pill,	liquid,	or	film.369		Each	year,	a	larger	proportion	of	newly-approved	drugs	are	oral,	some	of	which	are	not	available	as	an	intravenous	equivalent.370		(To	receive	FDA	approval,	drugs	must	be	proven	through	significant	research	studies	to	be	safe	and	effective;	therefore,	as	more	oral	forms	of	treatment	have	received	FDA	approval,	they	have	been	proven	effective	for	their	labeled	conditions.371)		While	some	drugs	cannot	be	delivered	by	mouth	because	of	digestive	irritation	and	absorption	issues,	oral	delivery	has	the	potential	to	deliver	drugs	over	a	more	sustained	period	in	a	more	convenient	way,372	providing	patients	with	a	sense	of	more	control	over	their	disease	and	treatment.373		In	most	cases	with	oral	therapies,	patients	are	able	to	avoid	the	sometimes	daily	medical	visits	for	infusion,	but	in	turn	must	accept	more	individual	responsibility	for	treatment.374	While	patients	gain	convenience	and	control,	they	must	comply	strictly	with	instructions	on	when	and	how	to	take	medication,	monitor	for	complications,	appropriately	handle	and	store	medications,	and	continue	follow-up	with	their	healthcare	providers.375		With	the	shift	from	office-	to	home-based	treatment,	the	traditional	roles	of	the	patient,	oncology	treatment	professionals,	including	doctors,	nurses	and	pharmacists,	and	insurance	and	delivery	management	systems,	also	shift.376		Compliance	and	medication	errors	must	be	continuously	monitored	and	addressed	by	the	entire	team,	now	including	the	patient,	to	assure	maximum	treatment	effectiveness.377		And	with	oral	delivery,	patient	outcomes	are	also	impacted	by	food	and	drug	interactions,	which	affect	the	effectiveness	and	toxicity	of	the	drug.378,379		Research	has	found	that	patients’	shift	from	a	passive	to	a	more	active	treatment	role	has	created	a	need	to	provide	them	more	information	and	support	to	help	them	comply	with	their	regimens.380,381,382,383,384	Oral	therapies,	which	are	often	new	drugs	still	under	patent	protection,	are	often	much	more	expensive	than	intravenous	treatments.		To	the	extent	patients	are	responsible	for	the	costs	of	medication,	particularly	if	that	cost	is	very	high,	that	cost	might	affect	their	compliance	or	at	least	their	choice	of	treatment	if	infused	alternative	are	available.385		Prior	to	implementation	of	the	Massachusetts	mandate,	self-administered	drugs	would	often	have	proportionately	higher	cost	sharing	than	would	infused	drugs,	since	the	self-administered	drugs	were	typically	covered	under	a	pharmacy	benefit	while	infused	drugs	were	typically	covered	under	a	medical	benefit;	the	former	typically	has	higher	cost	sharing.	Estimate	of	the	cost	of	the	mandate	RDC	for	this	mandate	was	calculated	as	the	decrease	in	PMPM	patient	cost	sharing	(defined	as	the	difference	between	PMPM	allowed	expenses	and	PMPM	carrier-paid	expenses)	expenses	for	all	claims	reporting	a	procedure	or	NDC	code	indicating	an	orally-administered	cancer	medication	between	2012	(prior	to	implementation	of	the	law)	and	2014	(after	implementation	of	the	law).		The	lower	bound	impact	estimate	was	calculated	as	the	difference	between	the	fully-insured	cost	sharing	PMPM	and	the	self-insured	cost	sharing	PMPM	for	these	medications	between	2012	and	2014.		The	analysis	does	not	adjust	for	expected	changes	in	average	cost-sharing	for	these	products	between	the	two	years	in	the	absence	of	a	mandate;	such	an	analysis	is	outside	the	scope	of	this	study.		To	the	extent	that	average	patient	cost-sharing	for	these	products	would	have	been	higher	in	
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2014	than	2012	in	the	absence	of	the	mandate,	the	effect	of	the	mandate	is	understated	by	this	methodology.xv	The	estimated	PMPM	RDC	paid	claim	amount	was	$0.05,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$0.05	(or	0.013	percent	of	the	Commonwealth	total	premium).		The	fully-insured	allowed	medical	expense	PMPM	for	these	services	was	found	to	be	$0.02	higher	than	the	self-insured	allowed	medical	expense	PMPM,	resulting	in	a	lower	bound	impact	estimate,	including	administrative	loading,	of	$0.02	PMPM,	or	0.004	percent	of	Commonwealth	premium.		Table	16	below	displays	a	summary	of	these	results	and	related	statistics.	
Table	16	
Oral	Chemotherapy	Treatment	of	Cancer	Mandate	
Contribution	to	Premium	
	
Prosthetic	Devices	The	prosthetic	device	mandate	requires	coverage	for	prosthetic	devices	and	repairs	under	the	same	terms	and	conditions	that	apply	to	other	durable	medical	equipment	covered	under	the	policy;	the	mandate	restricts	carriers’	use	of	cost-sharing	and	coverage	limits	for	prosthetic	devices.386	Effect	of	the	mandate	on	health	Prosthetics	are	artificial	replacements	used	to	assist	with	ambulation	and	participation	in	activities	of	daily	living	among	those	with	an	amputation,	or	any	loss	of	a	limb	or	part	of	a	limb.387,388		Amputations	are	performed	for	several	reasons,	most	often	due	to	dysvascular	diseases	such	as																																									 																					xv	That	is,	if	patient	cost	sharing	is	measured	at	$0.06	PMPM	in	2012	and	$0.01	PMPM	in	2014,	but	in	the	absence	of	the	mandate	patient	cost	sharing	in	2014	would	have	been	$0.08,	$0.06	PMPM	-	$0.01	PMPM	=	$0.05	PMPM	understates	the	effect	of	the	mandate,	which	was	actually	$0.08	PMPM	-	$0.01	PMPM	=	$0.07.	Conversely,	if	for	some	reason	2014	cost-sharing	PMPM	would	have	been	lower	than	2012	for	these	products	even	in	the	absence	of	the	mandate,	$0.05	PMPM	would	overstate	the	effect	of	the	mandate.	
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Bound	PMPMs	
Sample	Users,	2014 7,452																 4,013																
Sample	Units,	2014 1,890,718								 1,040,780								
Sample	Average	Members,	2014 1,437,788								 1,432,254								
Decrease	in	Cost	Sharing	PMPM,	2012	to	2014	 0.05$																 0.03$																 0.02$																
Decreased	Cost	Sharing	with	Admin 0.05$																 0.04$																 0.02$																
	Upper	Bound	
Impact	
	Lower	Bound	
Impact*	
Insured	Population 2,362,745 2,362,745
Contribution	to	Total	Annual	Claims 1,378,028$					 489,691$									
Contribution	to	Total	Annual	Premium 1,548,347$					 550,214$									
Percent	of	Total	Premium 0.013% 0.004%
*No	significant	overlaps	were	found	between	this	and	other	mandates.
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diabetes	and	peripheral	arterial	disease	(54	percent),	trauma	(45	percent),	and	cancer	(under	two	percent).389,390		An	estimated	2.0	million	or	more	Americans	live	with	limb	loss,	and	over	185,000	amputations	occur	annually	in	the	United	States.391			To	understand	prevalence	of	individuals	with	limb	loss	and	incidence	rates	of	new	amputations,	considering	patient	age	is	critical.		Over	64	percent	of	dysvascular	disease-related	amputations	occur	among	adults	65	and	older.392		As	the	population	ages	and	the	number	of	individuals	diagnosed	with	diseases	such	as	diabetes	continue	to	rise,	annual	new	cases	of	amputations	are	expected	to	double	by	2050.393		The	severity	of	the	conditions	that	lead	to	amputation	in	this	older	population	limits	average	life	expectancy	in	that	group.		Five-year	mortality	for	patients	whose	vascular	disease	led	to	amputations	is	almost	50	percent,	higher	than	the	same	measure	for	breast,	colon,	Hodgkin’s	lymphoma,	and	prostate	cancers.394		For	patients	who	need	a	lower	extremity	amputation	due	to	diabetes,	the	five-year	mortality	rate	is	up	to	74	percent.395,396	By	2050,	the	number	of	people	living	with	a	lost	limb,	and	thus	in	need	of	prosthetics	and	related	services,	is	estimated	to	triple.397		This	is	due	to	the	age	of	the	patients:	although	only	16	percent	of	hospital	discharges	related	to	amputation	are	due	to	trauma,	trauma	cases	account	for	approximately	45	percent	of	people	living	with	limb	loss,	two	thirds	of	whom	are	adolescents	and	adults	younger	than	45.398	In	general,	amputations	are	categorized	as	upper	limb	(arm	and	hand)	and	lower	limb	(leg	and	foot).399		Overall,	younger	patients	are	more	likely	to	suffer	from	upper	limb	loss,	and	older	patients	from	lower	limb	loss.		Lower	limb	prosthetics	have	higher	rates	of	acceptance	and	daily	use,	while	upper	limb	prosthetics	have	higher	rates	of	abandonment.400		These	findings	may	be	attributable	to	overall	intended	functions	for	each	prosthetic	type.		Lower	limb	prostheses	are	designed	to	accomplish	gross	motor	tasks,	including	weight-bearing,	balance,	ambulation,	and	provide	more	natural	cosmetic	appearance,401	functions	“well	substituted	for	by	the	prosthesis.”402		For	upper	limbs,	prosthetics	must	perform	fine	motor	tasks	and	balance,	in	addition	to	movement	and	natural	cosmetic	appearance.403		Moreover,	in	the	case	of	thumb	amputation,	the	prosthesis	must	provide	opposition.		Generally,	fine	motor	functions	are	“not	well	served	by	a	prosthetic	device.”404		Acceptance	rates	and	functionality	improve	while	abandonment	decreases	with	early	prosthetic	fittings,	which	also	decreases	risk	of	phantom	pain.405	Complications	related	to	limb	loss	include:	psycho-social	adjustment;	soft	tissue	and	muscle	atrophy;	skin	disorders,	including	increased	moisture,	blisters,	allergic	reactions,	irritation	and	breakdown;	joint	contracture;	soft	tissue	and	bone	infections;	pain	and	phantom	limb	sensations;	overuse	syndromes	in	remaining	extremities	and	proximal	joints;	and	heterotopic	ossification,	or	an	overgrowth	of	bone	instead	of	scar	tissue.	406,407,408		In	the	short-term,	prosthetic	patients	are	more	likely	to	experience	depression	and	anxiety,	as	well	as	social	discomfort	and	body-image	anxiety.409	Each	type	of	amputation	requires	a	different	prosthetic,	each	with	its	own	rate	of	effectiveness.		Generally,	the	functionality	of	the	prosthesis	is	related	to:	the	number	of	joints	preserved	and	the	length	of	the	residual	limb;410	other	orthopedic,	cardiovascular,	neuromuscular,	and	respiratory	conditions;	vascular	and	visual	problems;	and	a	patient’s	emotional	and	mental	health,	activity	
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level,	degree	of	motivation,	age,	vocation,	and	support	system.411		Psychosocial	factors	are	also	important	to	understanding	quality	of	life	and	the	ability	level	of	patients,	as	well	as	their	own	self-image	and	sense	of	difference.412,413		As	summarized	by	one	study,	prosthetic	effectiveness	revolves	around	“what	people	can	practically	achieve	with	a	prosthetic	limb,	and	the	management	of	personal	information	and	identity.”414		In	fact,	while	most	amputees	with	prosthetics	used	them	extensively	and	expressed	satisfaction	with	the	device’s	overall	performance	and	quality,	a	large	number	were	dissatisfied	with	their	own	interpersonal	skills	with	the	prosthetic,	and	almost	33	percent	were	dissatisfied	with	their	comfort.415		These	psychosocial	effects	are	influenced	by	such	factors	as	time	since	amputation,	social	support,	satisfaction	with	prosthesis,	personality	disposition,	active	coping	attempts,	the	level	of	amputation,	and	the	level	of	pain	and	phantom	limb	sensation.416,417			The	needs	of	a	patient	with	an	amputation	span	the	patient’s	lifetime,	and	can	include,	besides	an	artificial	limb,	associated	services	such	as	fittings,	repairs,	and	upgrades	based	on	needs	or	improved	technology.418		To	the	extent	changes	in	coverage	required	under	this	mandate	improve	the	quality	of	devices	and	treatment	available	to	the	patient	and	consequently	the	patient’s	recovery	experience,	including	adjusting	to	limb	loss	and	to	a	device,	they	are	likely	to	lead	to	a	better	outcome,	that	is,	greater	ongoing	functionality,	for	the	patient.	Estimate	of	the	cost	of	the	mandate	The	limb	prostheses	mandate	requires	coverage	for	prosthetic	devices	and	repairs	under	the	same	terms	and	conditions	that	apply	to	other	durable	medical	equipment	covered	under	the	policy	and	places	restrictions	on	the	use	of	annual	or	lifetime	limits	for	prosthetic	devices.		The	RDC	of	this	mandate	was	calculated	as	the	sum	of	paid	amounts	from	all	claims	with	procedure	codes	for	limb	prosthetic	devices	and	repairs.		The	estimated	PMPM	RDC	paid	claim	amount	was	$0.14,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$0.15	(or	0.04	percent	of	the	Commonwealth	total	premium).		Self-insured	allowed	medical	expenses	for	these	services	were	found	to	be	slightly	
higher	than	fully-insured	allowed	medical	expenses,	resulting	in	a	$0	lower	bound	impact	estimate,	including	administrative	loading.		Table	17	below	displays	a	summary	of	these	results	and	related	statistics.	
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Table	17	
Prosthetic	Devices	Mandate	
Contribution	to	Premium	
	
Scalp	Hair	Prostheses	The	scalp	prostheses	mandate	requires	policies	providing	coverage	for	any	other	prosthesis	to	provide	coverage	for	scalp	hair	prostheses	worn	for	hair	loss	suffered	as	a	result	of	the	treatment	of	cancer	or	leukemia,	in	an	amount	not	to	exceed	$350	per	year.419	Effect	of	the	mandate	on	health	Hair	loss	is	a	side	effect	of	some	cancer	treatments,	including	chemotherapy	and	radiation	to	the	head.420		These	treatments	result	in	“chemotherapy-induced	alopecia”	(CIA)	or	damage	to	the	hair	follicles	leading	to	the	thinning	or	complete	loss	of	hair.		Alopecia	is	often	cited	as	the	“most	severe	side	effect	of	chemotherapy,”421	negatively	affecting	the	quality	of	life	for	many	cancer	patients,	especially	women	and	children.422,423		Studies	have	cited	loss	of	self-confidence,	depression,424	and	humiliation	as	side	effects.425		Likewise,	CIA	can	negatively	impact	overall	quality	of	life	by	affecting	body	image,426	sexuality,	self-esteem,	and	social	functioning.427		One	study	found	that	“[p]atients	who	fear	CIA	may	sometimes	select	regimens	with	less	favorable	outcomes	or	may	refuse	treatment.”428		And	while	research	continues	into	the	management	of	CIA,	methods	to	prevent	the	hair	loss	have	not	yet	proven	effective,	429	and	no	standard	of	care	for	treatment	exists	yet.430	Scalp	hair	prostheses	offer	some	patients	the	possibility	of	mitigating	the	side	effects	of	hair	loss,	though	some	studies	have	shown	that	“[r]egrowth	of	hair	and	other	adaptive	processes	do	not	normalize	or	improve	the	impaired	body	image	and	self-concept.”431		These	researchers	have	suggested	that	the	impact	of	CIA	may	not	be	“related	exclusively	to	alopecia,”	but	also	to	the	individual’s	coping	with	chemotherapy	and	how	that	may	be	further	amplified	by	alopecia.432		Others	have	suggested	that	treatment	providers	should	emphasize	the	psychological	support	for	
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Sample	Users 397																			 364																			
Sample	Units 5,517																 5,669																
Sample	Average	Members 1,871,491								 1,490,706								
Paid	PMPM 0.14$																 0.17$																 -$																		
Paid	PMPM	With	Admin 0.15$																 0.19$																 -$																		
Allowed	PMPM 0.15$																 0.18$																 (0.02)$														
	Upper	Bound	
Impact	
	Lower	Bound	
Impact*	
Insured	Population 2,362,745 2,362,745
Contribution	to	Total	Annual	Claims 3,868,008$					 -$																		
Contribution	to	Total	Annual	Premium 4,346,076$					 -$																		
Percent	of	Total	Premium 0.04% 0.00%
*Net	amounts	do	not	remove	overlap	in	mandated	services	between	the	limb
prosthesis	mandate	and	the	home	health	mandate.
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patients	experiencing	CIA,	and	the	use	of	creative	measures,	including	acquisition	of	scalp	prosthesis	even	before	hair	loss,	to	preserve	self-image.433	Estimate	of	the	cost	of	the	mandate	Scalp	hair	prostheses	offer	some	patients	the	possibility	of	mitigating	the	side	effects	of	hair	loss.	The	scalp	prostheses	mandate	requires	policies	providing	coverage	for	any	other	prosthesis	to	provide	coverage	for	scalp	hair	prostheses	worn	for	hair	loss	suffered	as	a	result	of	the	treatment	of	cancer	or	leukemia,	in	an	amount	not	to	exceed	$350	per	year.	The	RDC	of	this	mandate	was	calculated	as	the	sum	of	paid	amounts	from	all	claims	with	procedure	code	A9282:	“Wig,	any	type,	each.”	The	estimated	PMPM	RDC	paid	claim	amount	was	$0.01,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$0.02	(or	0.004	percent	of	the	Commonwealth	total	premium).		Non-GIC	self-insured	allowed	medical	expenses	for	these	services	were	found	to	be	slightly	higher	than	fully-insured	and	GIC	allowed	medical	expenses,	resulting	in	a	$0	lower	bound	impact	estimate,	including	administrative	loading.	Table	18	below	displays	a	summary	of	these	results	and	related	statistics.	
Table	18	
Scalp	Hair	Prostheses	Mandate	
Contribution	to	Premium	
	
Speech	and	Audiology	Services	This	mandate	requires	coverage	for	expenses	incurred	in	the	medically-necessary	diagnosis	and	treatment	of	speech,	hearing,	and	language	disorders	by	licensed	speech-language	pathologists	or	audiologists.434	Effect	of	the	mandate	on	health	Speech	and	language	disorders	and	delays	are	associated	with	a	wide	variety	of	conditions,	ranging	from	chronic	illnesses	such	as	cerebral	palsy	and	Parkinson’s	and	Huntington’s	diseases	to	acute	
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Bound	PMPMs	
Sample	Users 819																			 621																			
Sample	Units 857																			 654																			
Sample	Average	Members 1,871,491								 1,490,706								
Paid	PMPM 0.01$																 0.02$																 -$																		
Paid	PMPM	With	Admin 0.02$																 0.02$																 -$																		
Allowed	PMPM 0.02$																 0.02$																 (0.00)$														
	Upper	Bound	
Impact	
	Lower	Bound	
Impact*	
Insured	Population 2,362,745 2,362,745
Contribution	to	Total	Annual	Claims 410,990$									 -$																		
Contribution	to	Total	Annual	Premium 461,787$									 -$																		
Percent	of	Total	Premium 0.004% 0.00%
*Net	amounts	do	not	remove	overlap	in	mandated	services	between	the	scalp
hair	prosthesis	mandate	and	the	home	health	mandate.
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events	such	as	brain	injuries	and	strokes.		The	specific	problems	vary	widely,	as	do	treatment	methods	and	modalities.		For	children,	“[p]rimary	speech	and	language	delay/disorder	is	a	common	developmental	difficulty	which,	if	unresolved,	can	cause	difficulties	of	both	learning	and	socialisation	lasting	into	adolescence	and	beyond.”435		In	general,	“[s]peech	and	language	therapy	aims	to	maximize	ability	to	communicate	through	speech,	gesture,	and/or	supplementary	means,	such	as	communication	aids,	and	to	enable	[patients]	to	become	independent	communicators.”436,437	Most	studies	reviewed	suggest	the	effectiveness	of	treatment	for	speech,	hearing,	and	language	disorders	in	general;	however,	one	large	systematic	review	found	that	many	of	the	conclusions	are	based	on	“’clinical	opinion’	rather	than	on	controlled	clinical	trials.”438		Many	investigators	cited	the	need	for	additional	research	to	be	conducted	using	rigorous	scientific	methodology,	and	for	the	development	of	more	consistent	standards	of	treatment	methods	and	interventions,	as	well	as	evidence-based	practice	guidelines	for	the	variety	of	conditions	requiring	speech,	hearing,	and	language	therapies.439,	440,	441,	442,	443,444,445	Estimate	of	the	cost	of	the	mandate	Regulations	on	required	benefits	for	2016	issued	pursuant	to	the	ACA	(45	CFR	§156.115(a)(5)(i))	include	in	EHBs	“habilitative	services”.		They	define	such	services	as	those	that	“help	a	person	keep,	learn,	or	improve	skills	and	functioning	for	daily	living	(habilitative	services).		Examples	include	therapy	for	a	child	who	is	not	walking	or	talking	at	the	expected	age.		These	services	may	include	physical	and	occupational	therapy,	speech-language	pathology	and	other	services	for	people	with	disabilities	in	a	variety	of	inpatient	and/or	outpatient	settings.”		But	the	specific	services	included,	and	whether	the	definitions	would	include	speech	and	audiology	services,	are	unclear	on	the	surface	and	left	to	the	states.446		For	reasons	cited	in	the	overview	of	the	methodology,	this	analysis	assumes	federal	EHB	requirements	do	not	address	state-mandated	speech	and	audiology	services.	
Comprehensive	Mandated	Benefit	Review	
compass Health Analytics 52 December 2016 
Table	19	
Speech	and	Audiology	Services	
Contribution	to	Premium	
	
	This	mandate	provides	for	"expenses	incurred	in	the	medically	necessary	diagnosis	and	treatment	of	speech,	hearing	and	language	disorders	by	individuals	licensed	as	speech-language	pathologists	or	audiologists."		The	RDC	of	this	mandate	was	calculated	as	the	sum	of	paid	amounts	from	all	claims	for	speech	and	audiology	procedures	where	the	primary	diagnosis	indicates	a	covered	speech,	hearing,	or	language	disorder.		The	estimated	PMPM	RDC	paid	claim	amount	was	$0.25,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$0.28	(or	0.06	percent	of	the	Commonwealth	total	premium).		Self-insured	allowed	medical	costs	for	these	services	were	found	to	be	higher	than	fully-insured	allowed	costs,	resulting	in	a	lower	bound	impact	estimate	of	$0,	including	administrative	loading.		Table	19	above	displays	a	summary	of	these	results	and	related	statistics.	
Mandates	with	Potential	Marginal	Direct	Cost:	Provider-Centered	Mandates	This	study	includes	eight	“provider	mandates,”	which	mandate	coverage	for	specific	provider	types	rather	than	specific	services.		An	a	priori	assumption	that	these	non-physician	providers	are	cost-effective	would	be	supported	by	the	very	small	to	zero	(in	fact,	negative)	lower	bound	marginal	cost	estimates	for	most	of	these	mandates.		In	many	cases,	the	allowed	medical	expenses	PMPM	are	higher	in	the	self-insured	segment	than	in	the	fully	insured	segment.		Based	on	these	results,	it	would	be	reasonable	to	treat	these	mandates	as	“zero	marginal	cost”	mandates,	though	they	are	treated	here	as	potential-marginal	cost	mandates	(i.e.,	their	RDCs	are	included	in	the	upper	bound	estimates).	
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Bound	PMPMs	
Sample	Users 14,441													 12,063													
Sample	Units 48,605													 57,072													
Sample	Average	Members 1,871,491								 1,490,706								
Paid	PMPM 0.25$																 0.37$																 -$																		
Paid	PMPM	With	Admin 0.28$																 0.41$																 -$																		
Allowed	PMPM 0.30$																 0.41$																 (0.11)$														
	Upper	Bound	
Impact	
	Lower	Bound	
Impact*	
Insured	Population 2,362,745 2,362,745
Contribution	to	Total	Annual	Claims 7,116,174$					 -$																		
Contribution	to	Total	Annual	Premium 7,995,701$					 -$																		
Percent	of	Total	Premium 0.06% 0.00%
*Net	amounts	do	not	remove	overlap	in	mandated	services	between	the
speech	and	audiology	mandate	and	the	children's	hearing
aids	and	home	health	mandates.
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Categorizing	claims	by	provider	type	is	challenging.		In	particular,	it	is	generally	assumed	that	the	MA	APCD	does	not	measure	the	full	volume	of	services	provided	by	certain	allied	health	professionals,	such	as	advanced	practice	registered	nurses	and	physician	assistants,	whose	services	are	generally	billed	as	if	performed	by	the	supervising	physician	in	order	to	maximize	reimbursement.		However,	CHIA	is	required	by	M.G.L.	Chapter	3	§38C	to	estimate	the	cost	of	these	mandates,	and	the	following	analysis	estimates	their	costs	using	all	sample	claims	that	could	be	identified	as	having	been	performed	by	one	of	the	covered	practitioners,	as	the	cost	of	services	actually	performed	by	allied	health	professionals	but	billed	by	their	supervising	physicians	is	immeasurable	within	the	scope	of	this	study.		In	addition,	some	claims	coding	schemes	identify	the	service	provider	as	“nurse	practitioner	or	physician	assistant.”		In	these	cases,	Compass	grouped	ambiguous	results	under	the	mandate	covering	the	largest	group	of	members.		That	is,	because	the	statutory	language	of	the	physician	assistant	mandate	includes	self-insured	GIC	products	but	the	nurse	practitioner	mandate	does	not,	all	such	ambiguous	results	were	included	in	the	physician	assistant	mandate	sample.			Detailed	specifications	for	the	cost	calculations	for	these	mandates	are	available	from	CHIA	upon	request.	
Certified	Nurse	Midwives	The	certified	nurse	midwife	mandate	requires	plans	to	pay	for	services	rendered	by	certified	nurse	midwives	when	the	same	services	are	reimbursed	when	performed	by	any	other	practitioner	and	are	within	the	lawful	scope	of	practice	of	midwives.447	Effect	of	the	mandate	on	health	Certified	nurse-midwives	(CNMs)	are	Advanced	Practice	Nurses	(APRNs)	who	serve	as	primary	care	providers	of	healthcare	to	women,	providing	physical	exams,	counseling,	education,	and	prenatal,	gynecological,	labor	and	delivery,	and	postpartum	care,	as	well	as	ordering	lab	tests	and	prescribing	medications	including	contraceptives.448,449		CNMs	are	legally	authorized	to	practice,	and	prescribe	drugs,	in	all	fifty	states,	though	regulations	and	regulatory	authority	vary.450,451,452		In	Massachusetts,	CNMs	have	independent	practice	and	prescribing	authority,453	but	are	not	recognized	as	primary	care	providers.454		Reimbursement	in	all	state	Medicaid	programs,	as	well	as	Medicare,	is	mandatory	for	CNMs	at	100	percent	of	the	physician	reimbursement	rates.455	CNM	services	focus	primarily	on	reproductive	health	and	gynecological	and	obstetrical	care,	but	also	may	be	provided	to	male	partners	for	treatment	of	sexually	transmitted	diseases,	and	to	normal	newborns	during	the	first	month	after	birth.456		In	2013,	CNMs	and	certified	midwives	attended	almost	321,000	births	in	the	United	States.457		Today,	approximately	480	CNMs	are	licensed	in	Massachusetts,458,459	and	over	11,000	nationwide.460		As	Advanced	Practice	Nurses,	CNMs	are	also	registered	nurses	or	bachelors-prepared	nurses	who	have	completed	an	undergraduate	program	in	nursing	as	well	as,	at	minimum,	a	masters-level	graduate	program	in	midwifery.461			
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Terms	of	CNM	licensure	have	historically	varied	widely	by	state,	especially	in	the	degree	of	physician	oversight	required.		In	2008,	the	National	Council	of	State	Boards	of	Nursing	(NCSBN)	adopted	the	Consensus	Model	for	Advanced	Practice	Registered	Nurse	(APRN)	Regulation	in	an	attempt	to	create	consistent	regulations	and	legislation	across	the	United	States.462		The	group	is	attempting	to	standardize	licensure	to	practice,	APRN	program	accreditation,	national	certification	requirements,	and	educational	requirements.463	When	comparing	care	provided	during	labor	and	delivery	by	physicians	versus	CNMs,	a	large	systematic	review	found	that:	CNMs	used	fewer	interventions,	including	epidurals,	induced	labor,	and	episiotomies;	perineal	lacerations	were	lower	and	breastfeeding	rates	were	higher	for	CNM	patients;	and	infant	outcomes	including	Apgar	scores,	birth	weight,	and	neonatal	intensive	care	unit	admissions	did	not	differ	between	physicians	and	CNMs.464		Researchers	have	found	that	CNMs	“provide	a	safe	and	viable	alternative	to	maternity	care	in	the	United	States,	particularly	for	low	to	moderate	risk	women.”465		Another	study	of	obstetric	outcomes	in	a	primary	care	setting	found:466	
• Low-income,	uninsured,	and	underinsured	women	who	have	access	to	excellent	prenatal	care	with	supervised	certified	nurse-midwives	can	have	obstetric	outcomes	similar	to	women	having	prenatal	care	with	private	obstetricians.		
• Prenatal	care	with	supervised	certified	nurse-midwives	can	reduce	the	cesarean	section	rate	without	compromising	infant	outcome.		
• Utilization	of	certified	nurse-midwives	supervised	by	obstetricians	may	provide	the	optimum	model	for	perinatal	care,	particularly	for	those	women	who	are	at	high	risk	because	of	social	and	economic	factors	and	who	are	currently	underserved.	In	a	study	of	planned	home	births,	researchers	found	“that	women	who	have	home	births	attended	by	CNMs	have	safety	profiles	equal	to	or	better	than	profiles	of	women	who	had	hospital	births	in	similar	populations.”467		These	results	were	also	found	in	a	large	outcomes	study	of	CNM-attended	homebirths	which	concluded	that	“[l]ow-risk	women	in	this	cohort	experienced	high	rates	of	physiologic	birth	and	low	rates	of	intervention	without	an	increase	in	adverse	outcomes.”468		A	study	of	spontaneous	and	episiotomy-caused	perineal	injury	during	birth	found	both	severity	and	prevalence	were	significantly	lower	in	CNM-attended	births.469	In	a	joint	statement	of	policy	by	the	American	College	of	Nurse	Midwives	and	the	American	College	of	Obstetricians	and	Gynecologists,	the	professional	organizations	affirmed	their	shared	goal	“of	safe	women’s	health	care	in	the	United	States	through	the	promotion	of	evidence-based	models	provided	by	obstetricians-gynecologists,	certified	nurse-midwives,	and	certified	midwives.”		Their	statement	affirmed	their	commitment	to	educational	standards,	certification,	and	licensure;	the	need	for	options	and	preferences	of	women	in	health	care;	the	need	for	access	to	affordable	professional	liability	insurance,	hospital	privileges,	equivalent	reimbursement,	and	support	services;	and	outlined	how	the	organizations	differ	regarding	home	birth.470	
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Estimate	of	the	cost	of	the	mandate	
Table	20	
Certified	Nurse	Midwives	Mandate	
Contribution	to	Premium	
	
	The	certified	nurse	midwife	mandate	requires	plans	to	pay	for	services	rendered	by	certified	nurse	midwives	when	the	same	services	are	reimbursed	when	performed	by	any	other	practitioner	and	are	within	the	lawful	scope	of	practice	of	midwives.		The	RDC	of	this	mandate	was	calculated	as	the	sum	of	paid	amounts	from	all	claims	with	a	certified	nurse	midwife	provider	typexvi	indicator	or	a	procedure	code	modifierxvii	indicating	the	service	was	performed	by	a	nurse	midwife.		The	estimated	PMPM	RDC	paid	claim	amount	was	$0.19,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$0.21	(or	0.01	percent	of	the	Commonwealth	total	premium).		Self-insured	PMPM	allowed	expenses	for	these	services	were	found	to	be	higher	than	fully-insured	allowed	costs,	resulting	in	a	lower	bound	impact	estimate	of	$0,	including	administrative	loading.	Table	20	above	displays	a	summary	of	these	results	and	related	statistics.	
Certified	Registered	Nurse	Anesthetists	The	certified	registered	nurse	anesthetist	mandate	requires	plans	to	pay	for	services	rendered	by	certified	registered	nurse	anesthetists	when	the	same	services	are	reimbursed	when	performed	by	any	other	practitioner	and	are	within	the	lawful	scope	of	practice	of	nurse	anesthetists.471	Effect	of	the	mandate	on	health	Certified	registered	nurse	anesthetists	(CRNAs)	are	Advanced	Practice	Registered	Nurses	(APRNs)	licensed	to	provide	anesthesia	and	related	care,	as	well	as	pain	management	and	some	emergency	services.472		There	are	more	than	40,000	CRNAs	practicing	in	the	United	States,	providing	over	40	million	anesthetics	annually;473	over	1250	CRNAs	are	licensed	in	Massachusetts.474		According	to																																									 																					xvi	Provider	types	vary	by	carrier.		Compass	also	used	NPI	taxonomy	codes	where	possible	to	identify	claims	provided	by	the	various	mandated	providers.	xvii	HCPCS	Modifier	SB:	Nurse	midwife.	
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Bound	PMPMs	
Sample	Users 605																			 5,232																
Sample	Units 3,227																 24,639													
Sample	Average	Members 142,186											 990,666											
Paid	PMPM 0.19$																 0.20$																 -$																		
Paid	PMPM	With	Admin 0.21$																 0.22$																 -$																		
Allowed	PMPM 0.20$																 0.20$																 (0.01)$														
	Upper	Bound	
Impact	
	Lower	Bound	
Impact*	
Insured	Population 730,715 730,715
Contribution	to	Total	Annual	Claims 1,624,290$					 -$																		
Contribution	to	Total	Annual	Premium 1,825,045$					 -$																		
Percent	of	Total	Premium 0.01% 0.00%
*No	significant	overlaps	were	found	between	this	and	other	mandates.
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the	American	Association	of	Nurse	Anesthetists,	“[i]n	some	states,	CRNAs	are	the	sole	providers	in	nearly	100	percent	of	the	rural	hospitals,”	and	are	the	primary	anesthesia	providers	in	rural	America	overall,	providing	care	in	trauma	stabilization,	surgical,	obstetrical,	and	pain	management	cases.475	As	APRNs,	CRNAs	are	required	to	complete	a	baccalaureate	degree	program	in	nursing	or	other	appropriate	field,	a	graduate	degree	program	in	nurse	anesthesia,	and	they	must	pass	a	national	certification	exam	following	graduation.476		A	CRNA	must	be	licensed	as	a	registered	nurse	(RN),	and	spend	at	least	one	year	as	an	RN	in	a	critical	care	setting.477		In	Massachusetts,	CRNAs	are	certified	to	practice	as	an	Advanced	Practice	Clinical	Nurse	in	their	specific	clinical	category.478	The	federal	Centers	for	Medicare	and	Medicaid	Services	(CMS)	currently	requires	that	CNRAs	be	supervised	by	a	physician,	unless	the	state’s	own	regulations	do	not	require	the	CRNA	to	be	supervised.479		States	may	opt-out	of	this	requirement;480	since	2001,	17	states	have	formally	opted-out.481,482		However,	there	is	significant	disagreement	in	the	number	of	remaining	states	in	which	CRNAs	may	operate	independently	without	need	for	the	opt-out	filing,	with	estimates	ranging	from	18	to	40	states;	CRNA	independence	hinges	on	the	definition	of	“physician	supervision”	in	state	regulations.483		In	2008,	the	National	Council	of	State	Boards	of	Nursing	(NCSBN)	adopted	the	Consensus	Model	for	Advanced	Practice	Registered	Nurse	(APRN)	Regulation	in	an	attempt	to	create	consistent	regulations	and	legislation	across	the	United	States.484		The	group	is	attempting	to	standardize	licensure	to	practice,	APRN	program	accreditation,	national	certification	requirements,	and	educational	requirements.485	In	Massachusetts,	CRNAs	do	not	have	independent	prescribing	authority.		Instead,	they	must	have	a	written	agreement	outlining	physician	supervision	of	their	prescriptive	practice,486,487	the	physician’s	name	must	appear	on	the	prescription,	and	prescribing	practices	are	regulated	for	CRNAs	by	both	the	state	Board	of	Registration	in	Nursing	and	the	Board	of	Medicine.488		CRNA	prescriptive	practice	is	also	limited	to	“the	immediate	perioperative	care	of	a	patient.”489		These	regulations	make	Massachusetts	the	only	New	England	state	without	full	practice	authority	for	CRNAs	(although	Maine	requires	CRNAs	to	practice	under	physician	or	dentist	supervision).490		In	a	review	of	seven	years	of	Medicare	data	analyzing	patient	safety	outcomes	for	patients	provided	anesthesia,	researchers	found	that	“the	change	in	CMS	policy	allowing	states	to	opt	out	of	the	physician	supervision	requirement	for	certified	registered	nurse	anesthetist	reimbursement	was	not	associated	with	increased	risks	to	patients.”491		Other	studies	comparing	rates	of	complications	for	obstetrical	anesthesia	between	CRNAs	and	anesthesiologists	found	no	difference	between	the	two	staffing	models.492,493		In	a	large	study	comparing	the	safety	and	effectiveness	of	non-physician	anesthetists	(NPAs)	practicing	independently,	anesthesiologists,	and	NPAs	supervised	or	directed	by	physicians,	the	researchers	found	that	“[n]o	definitive	statement	can	be	made	about	the	possible	superiority	of	one	type	of	[anesthesia]	care	[provider]	over	another.”494	
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Estimate	of	the	cost	of	the	mandate	
Table	21	
Certified	Registered	Nurse	Anesthetists	Mandate	
Contribution	to	Premium	
	The	certified	registered	nurse	anesthetist	mandate	requires	plans	to	pay	for	services	rendered	by	certified	registered	nurse	anesthetists	when	the	same	services	are	reimbursed	when	performed	by	any	other	practitioner	and	are	within	the	lawful	scope	of	practice	of	nurse	anesthetists.		The	RDC	of	this	mandate	was	calculated	as	the	sum	of	paid	amounts	from	all	claims	with	a	registered	nurse	anesthetist	provider	type	indicator	or	a	procedure	code	modifier	indicating	the	service	was	performed	by	a	certified	registered	nurse	anesthetist.xviii		The	estimated	RDC	PMPM	paid	claim	amount	was	$0.78,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$0.88	(or	0.20	percent	of	the	Commonwealth	total	premium).		Self-insured	PMPM	allowed	medical	expenses	for	these	services	were	found	to	be	higher	than	fully-insured	allowed	medical	costs,	resulting	in	a	lower	bound	impact	estimate	of	$0,	including	administrative	loading.		Table	21	above	displays	a	summary	of	these	results	and	related	statistics.	
Nurse	Practitioners	The	nurse	practitioner	(NP)	mandate	requires	plans	to	cover	services	of	NPs	when	those	services	are	reimbursed	when	performed	by	any	other	practitioner	and	are	within	the	lawful	scope	of	practice	of	NPs.495		Also,	M.G.L.	c.	176R	allows	NPs	to	serve	as	primary	care	physicians	and	prohibits	carriers	from	subjecting	NPs	to	reduced	coverage	limits.496	Effect	of	the	mandate	on	health	Nurse	practitioners	(NPs)	are	Advanced	Practice	Nurses	(APNs)	who	are	licensed	as	Registered	Nurses	as	well	as	independent	practitioners.497		NPs	practice	as	primary	and/or	specialty	care	providers	in	the	full	range	of	health	care	settings,	emphasizing	health	promotion	and	disease																																									 																					xviii	HCPCS	Modifier	QX:	CRNA	service:	with	medical	direction	by	a	physician	or	QZ:	CRNA	service:	without	medical	direction	by	a	physician.		
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Bound	PMPMs	
Sample	Users 17,106													 26,987													
Sample	Units 210,928											 331,510											
Sample	Average	Members 1,049,386								 1,209,745								
Paid	PMPM 0.78$																 1.02$																 -$																		
Paid	PMPM	With	Admin 0.88$																 1.14$																 -$																		
Allowed	PMPM 0.82$																 1.08$																 (0.27)$														
	Upper	Bound	
Impact	
	Lower	Bound	
Impact*	
Insured	Population 2,362,745 2,362,745
Contribution	to	Total	Annual	Claims 22,094,293$			 -$																		
Contribution	to	Total	Annual	Premium 24,825,048$			 -$																		
Percent	of	Total	Premium 0.20% 0.00%
*No	significant	overlaps	were	found	between	this	and	other	mandates.
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prevention	in	addition	to	diagnosis,	treatment	and	management	of	chronic	and	acute	illness.498		More	than	80	percent	of	nurse	practitioners	are	trained	in	primary	care,	most	often	practicing	in	family,	geriatrics	and	adults,	women’s	health,	and	pediatrics.499		There	were	over	192,000	licensed	NPs	practicing	in	the	United	States	in	2014,	including	over	7,700	in	Massachusetts;500	over	900	million	visits	are	made	annually	to	NPs.501		In	Massachusetts,	an	NP	is	certified	to	practice	as	an	Advanced	Practice	Clinical	Nurse	in	a	specific	clinical	category.502	As	with	all	APNs,	NPs	must	complete	at	least	four	years	of	undergraduate	education	and	either	a	master’s,	post	master’s,	or	doctoral-level	graduate	program	for	NPs.503		Nurse	Practitioners	can	be	licensed	and	may	prescribe	medications	in	all	50	states,504,505	although	the	scope	of	practice	and	physician	oversight	requirements	may	vary	across	states.506,507		In	2008,	the	National	Council	of	State	Boards	of	Nursing	(NCSBN)	adopted	the	Consensus	Model	for	Advanced	Practice	Registered	Nurse	(APRN)	Regulation	in	an	attempt	to	create	consistent	regulations	and	legislation	across	the	United	States.508		The	group	is	attempting	to	standardize	licensure	to	practice,	APRN	program	accreditation,	national	certification	requirements,	and	educational	requirements.509	In	Massachusetts,	NPs	do	not	have	independent	prescribing	authority,	but	“must	have	a	collaborative	agreement	with	a	physician	or	a	physician's	supervision/delegation	in	order	to	prescribe	drugs.”510		NPs	must	have	a	written	agreement	in	place	outlining	physician	supervision	of	their	prescriptive	practice,511	the	physician’s	name	must	appear	on	the	prescription,	and	prescribing	practices	are	regulated	for	NPs	by	both	the	state	Board	of	Registration	in	Nursing	and	the	Board	of	Medicine.512		These	regulations	make	Massachusetts	the	only	New	England	state	without	full	practice	authority,	prompting	the	American	Academy	of	Nurse	Practitioners	to	place	it	among	the	12	“most	restrictive	of	practice	environments	in	the	nation.”513,514	In	a	review	of	articles	comparing	the	quality	and	safety	of	care	provided	by	NPs	to	that	provided	medical	doctors	(MDs),	researchers	found	that	outcomes	were	comparable	or	better	for	all	11	outcomes	reviewed,	including	strong	evidence	that	rates	were	similar	for	patient	satisfaction	with	provider/care,		functional	status,	numbers	of	unexpected	ED	visits,	hospitalization	rates,	patient	blood	pressure,	blood	glucose,	serum	lipids,	patient	outcomes	for	mortality,	and	self-reported	perceived	health	status.515		Another	review	of	randomized	controlled	trials	found	that	while	longer	term	outcomes	should	be	assessed	through	additional	studies,	“there	were	few	differences	in	primary	care	provided	by	APNs	and	physicians;	for	some	measures	APN	care	was	superior.”516		Another	review	found	that	ANPs	could	help	improve	primary	care	of	patients	with	chronic	disease,	and	that	independent	specialized	nurses:	…could	achieve	health	outcomes	that	were	similar	to	those	of	doctors,		reduce	hospital	visits	and	improve	certain	patient	outcomes	related	to	diabetes,	coronary	artery	disease,	or	heart	failure.		Patients	who	had	nurse-led	care	were	more	satisfied	and	tended	to	receive	more	tests	and	medications.	It	is	unclear	whether	specialized	nurses	improve	quality	of	life	or	doctor	workload.517	Estimate	of	the	cost	of	the	mandate	The	nurse	practitioner	(NP)	mandate	requires	plans	to	cover	services	of	nurse	practitioners	(NPs)	when	the	same	services	are	reimbursed	when	performed	by	any	other	practitioner	and	are	within	the	lawful	scope	of	practice	of	nurse	practitioners.		M.G.L.	c.	176R	allows	NPs	to	serve	as	Primary	Care	Physicians	and	prohibits	NPs	from	being	subject	to	reduced	coverage	limits.		The	RDC	of	this	
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mandate	was	calculated	as	the	sum	of	paid	amounts	from	all	claims	with	a	nurse	practitioner	provider	type	indicator	or	a	procedure	code	modifier	indicating	the	service	was	performed	by	a	nurse	practitioner.xix		The	estimated	RDC	PMPM	paid	claim	amount	was	$1.57,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$1.77	(or	0.41	percent	of	the	Commonwealth	total	premium).		Per	member	per	month	self-insured	allowed	expenses	for	this	mandate	were	found	to	be	$0.39	lower	than	fully-insured	PMPM	allowed	expenses,	resulting	in	a	lower	bound	expense	estimate,	including	administrative	loading,	of	$0.37	PMPM,	or	0.08	percent	of	Commonwealth	premium.		Table	22	below	displays	a	summary	of	these	results	and	related	statistics.	
Table	22	
Nurse	Practitioners	Mandate	
Contribution	to	Premium	
	
Physician	Assistants	The	physician	assistant	(PA)	mandate	requires	carriers	to	recognize	physician	assistants	as	participating	providers	and	include	coverage	on	a	nondiscriminatory	basis	for	care	provided	by	PAs.		Such	coverage	must	include	benefits	for	primary	care,	intermediate	care	and	inpatient	care,	in	a	full	range	of	settings,	when	rendered	by	a	PA	who	is	a	participating	provider	and	is	practicing	within	the	scope	of	his	or	her	professional	authority.		It	also	allows	PAs	to	serve	as	primary	care	physicians.518	Effect	of	the	mandate	on	health	PAs	are	medical	professionals	nationally	certified	and	licensed	to	practice	medicine	as	part	of	a	healthcare	delivery	team.519		Depending	on	their	specialty,	experience,	and	the	setting	in	which	they	practice,	PAs	diagnose	and	treat	illnesses,	assist	in	surgery,	counsel	patients	on	preventive	care,	and	manage	the	care	of	hospitalized	patients.520			
																																								 																					xix	HCPCS	Modifier	SA:	Nurse	practitioner	rendering	service	in	collaboration	with	a	physician.	
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Bound	PMPMs	
Sample	Users 97,794													 86,690													
Sample	Units 300,640											 252,782											
Sample	Average	Members 1,049,386								 1,209,745								
Paid	PMPM 1.57$																 1.30$																 0.33$																
Paid	PMPM	With	Admin 1.77$																 1.46$																 0.37$																
Allowed	PMPM 1.85$																 1.47$																 0.39$																
	Upper	Bound	
Impact	
	Lower	Bound	
Impact*	
Insured	Population 2,362,745 2,362,745
Contribution	to	Total	Annual	Claims 44,634,265$			 9,305,274$					
Contribution	to	Total	Annual	Premium 50,150,860$			 10,455,364$			
Percent	of	Total	Premium 0.41% 0.08%
*Net	amounts	do	not	remove	overlap	in	mandated	services	between	the	nurse
practitioner	mandate	and	the	diabetes,	early	intervention,	and	home	health	mandates.
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Most	PA	training	programs	last	26	months	over	3	academic	years,	and	require	approximately	3	years	of	additional	healthcare	training	and	experience.521		Students	fulfill	prerequisite	courses	similar	to	those	required	in	medical	school,	and	take	classes	in	basic	and	behavioral	sciences	as	well	as	clinical	medicine.522		PAs	are	then	required	to	complete	at	least	2,000	hours	of	clinical	rotation	in	family,	internal,	and	emergency	medicine,	pediatrics,	psychiatry,	surgery,	and	obstetrics	and	gynecology.523	To	practice	in	Massachusetts,	PAs	must	complete	a	bachelor’s	degree,	obtain	certification	by	passing	a	national	exam	administered	by	the	National	Commission	on	Certification	of	PAs,	and	obtain	state	licensure	from	the	Massachusetts	Board	of	Registration	of	Physician	Assistants	under	the	Division	of	Health	Professions	Licensure	in	the	Department	of	Health.524,525,526,527		PAs	are	also	required	to	complete	continuing	medical	education	to	remain	licensed	in	the	state.528		There	are	approximately	92,000	PAs	nationally	and	2,250	in	Massachusetts.529	While	PAs	must	by	supervised	by	a	physician,530	they	are	able	to	independently	prescribe	medications	in	Massachusetts	following	guidelines	developed	with	the	supervising	physician.531		Likewise,	for	major	invasive	procedures,	PAs	must	follow	written	protocols	developed	in	partnership	with	the	supervising	physician	which	specify	the	level	of	supervision	each	service	requires.532	Studies	of	the	effectiveness	of	physician	assistants	often	include	nurse	practitioners	as	well,	and	researchers	may	report	outcomes	related	to	both	professions	without	distinguishing	between	them.		Some	studies	indicate	that	PAs	are	effective	and	generate	outcomes	in	acute	care	settings	equivalent	to	those	generated	by	medical	residents,	providing	safe	care	in	the	emergency	department,	as	well	as	the	intensive	care,	critical	care,	and	neonatal	intensive	care	units.533,534,535,536,537		However,	one	meta-analysis	concluded	that	although	research	may	support	use	of	PAs	in	acute	and	intensive	care	settings,	the	level	of	evidence	provided	is	often	low.538		One	study	of	the	provision	of	primary	care	by	PAs	showed	results	similar	to	care	provided	by	physicians,	although	this	study	also	included	care	provided	by	nurse	practitioners.539	The	PA	mandate	requires	carriers	to	recognize	physician	assistants	as	providers	for	health	maintenance,	diagnosis,	and	treatment	of	patients,	and	cover	PAs	practicing	within	the	scope	of	their	licenses	for	providing	primary,	intermediate,	and	inpatient	care	in	hospitals,	clinics,	professional	offices,	home	and	long-term	care	settings,	mental	health	or	substance	abuse	programs,	or	other	settings.540		The	mandate	deems	PAs	qualified	to	be	designated	as	a	primary	care	provider	in	an	insurer	network.541	Estimate	of	the	cost	of	the	mandate	The	RDC	of	this	mandate	was	calculated	as	the	sum	of	paid	amounts	from	all	claims	with	a	physician	assistant	provider	type	indicator	or	a	procedure	code	modifier	indicating	the	service	was	performed	by	either	a	physician	assistant	or	a	nurse	practitioner.xx		The	estimated	RDC	PMPM	paid	
																																								 																					xx	HCPCS	Modifier	AS:	Physician	assistant,	nurse	practitioner,	or	clinical	nurse	specialist	services	for	assistant	at	surgery	or	HCPCS	Modifier	GF:	Non-physician	(e.g.	nurse	practitioner	(NP),	certified	registered	nurse	
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claim	amount	was	$1.45,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$1.63	(or	0.37	percent	of	the	Commonwealth	total	premium).		Per	member	per	month	self-insured	allowed	expenses	for	this	mandate	were	found	to	be	$0.09	lower	than	fully-insured	PMPM	allowed	expenses,	resulting	in	a	lower	bound	expense	estimate,	including	administrative	loading,	of	$0.08	PMPM,	or	0.02	percent	of	Commonwealth	premium.		Table	23	below	displays	a	summary	of	these	results	and	related	statistics.	
Table	23	
Physician	Assistants	Mandate	
Contribution	to	Premium	
	
Chiropractors	The	chiropractor	provider	mandate	requires	coverage	by	general	health	insurance	corporations	for	chiropractic	services	whether	performed	by	a	physician	or	chiropractor,	and	a	related	statute	(c.	176B	§	7)	prohibits	a	medical	service	corporation	from	discriminating	against	chiropractors	in	providing	chiropractic	services.		Note	both	chiropractic	service	(above)	and	chiropractor	provider	mandates	exist.		Chiropractors	provide	both	chiropractic	services	and	non-chiropractic	services,	and	chiropractic	services	are	provided	by	both	chiropractors	and	other	providers.542	Effect	of	the	mandate	on	health	Chiropractors,	or	doctors	of	chiropractic,	diagnose	and	treat	conditions	primarily	through	manipulation	and	realignment	of	the	musculoskeletal	and	nervous	systems.543		The	goals	of	chiropractic	care	include	improved	function,	pain	alleviation,	correction	of	alignment	problems,	and	support	to	allow	the	body	to	naturally	heal	itself.544		In	theory,	by	aligning	spinal	joints,	chiropractors	improve	the	function	of	the	body’s	nervous	system	and	improve	overall	health.			Chiropractors	are	required	to	complete	two	to	four	years	of	undergraduate	education	followed	by	four	to	five	years	at	a	chiropractic	college,	where	the	curriculum	includes	at	least	4200	hours	of																																									 																																								 																																								 																																								 																																			 	anesthetist	(CRNA),	certified	registered	nurse	(CRN),	clinical	nurse	specialist	(CNS),	physician	assistant	(PA))	services	in	a	critical	access	hospital).	
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Bound	PMPMs	
Sample	Users 97,790													 93,388													
Sample	Units 354,607											 327,560											
Sample	Average	Members 1,049,386								 1,209,745								
Paid	PMPM 1.45$																 1.46$																 0.07$																
Paid	PMPM	With	Admin 1.63$																 1.64$																 0.08$																
Allowed	PMPM 1.74$																 1.65$																 0.09$																
	Upper	Bound	
Impact	
	Lower	Bound	
Impact*	
Insured	Population 2,362,745 2,362,745
Contribution	to	Total	Annual	Claims 41,006,587$			 2,009,567$					
Contribution	to	Total	Annual	Premium 46,074,816$			 2,257,941$					
Percent	of	Total	Premium 0.37% 0.02%
*No	significant	overlaps	were	found	between	this	and	other	mandates.
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classroom,	laboratory,	and	clinical	experience.545		For	licensure	in	Massachusetts,	graduates	of	a	chiropractic	college	must	pass	parts	I,	II,	III,	and	IV	and	the	physiotherapy	section	of	examinations	administered	by	the	National	Board	of	Chiropractic	Examiners,	as	well	as	the	Massachusetts	jurisprudence	examination	administered	by	the	state	Board	of	Registration	of	Chiropractors.546		Massachusetts	also	requires	chiropractors	to	complete	12	hours	of	continuing	education	annually	to	maintain	and	renew	licensure.547	Licensed	chiropractors	are	recognized	by	Medicare	for	payment	as	a	physician	only	for	manual	spinal	manipulation	treatment	of	spinal	subluxation.548		Chiropractors	are	not	eligible	to	order	and/or	refer	for	Part	B	and	DMEPOS	(durable	medical	equipment,	prosthetics,	orthotics,	and	supplies)	Medicare	beneficiaries,549	but	may	act	as	a	supplier	of	durable	medical	equipment.550	Limited	research	is	available	comparing	outcomes	among	provider	types	who	perform	spinal	manipulation	(e.g.	chiropractor	versus	physician).		However,	one	large	meta-analysis	that	reviewed	the	results	of	39	randomized-controlled	trials	concluded	that	“[t]he	evidence	is	insufficient	to	conclude	that	benefits	of	manipulation	vary	according	to	the	profession	of	the	manipulator	(chiropractor	vs.	other	clinician	trained	in	manipulation).”551		Another	study	found	that,	when	comparing	orthopedic	surgeons,	primary	care	providers,	and	chiropractors,	the	time	to	functional	recovery,	complete	recovery,	and	return	to	work	after	treatment	for	lower	back	pain	was	similar	between	all	three	provider	types.552		The	same	study	found	that	costs	were	lowest	for	primary	care	providers,	and	patient	satisfaction	highest	for	chiropractors.553		A	more	recent	article	examining	the	costs	of	care	between	chiropractors	and	other	providers	was	equivocal	in	its	conclusions	and	called	for	additional	research.554	Estimate	of	the	cost	of	the	mandate	The	chiropractor	provider	mandate,	c.	175	§	108D,	requires	a	payer	to	pay	for	chiropractic	services	whether	they	are	performed	by	a	physician	or	chiropractor,	and	c.	176B	§	7	statute	prohibits	a	Medical	Services	Corporation	from	discriminating	against	chiropractors	in	providing	chiropractic	services.		Note	that	there	are	both	chiropractic	service	and	chiropractor	(provider-based)	mandates.		The	chiropractors	provide	both	chiropractic	services	and	non-chiropractic	services,	and	chiropractic	services	are	provided	by	both	chiropractors	and	other	providers.	The	RDC	of	this	mandate	was	calculated	as	the	sum	of	paid	amounts	from	all	claims	with	a	chiropractor	provider	type	indicator.		The	estimated	RDC	PMPM	paid	claim	amount	was	$0.91,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$1.02	(or	0.07	percent	of	the	Commonwealth	total	premium).		Per	member	per	month	self-insured	allowed	expenses	for	this	mandate	were	found	to	be	$0.15	lower	than	fully-insured	PMPM	allowed	expenses,	resulting	in	a	lower	bound	expense	estimate,	including	administrative	loading,	of	$0.10	PMPM,	or	0.01	percent	of	Commonwealth	premium.		Table	24	below	displays	a	summary	of	these	results	and	related	statistics.	
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Table	24	
Chiropractor	Provider	Mandate	
Contribution	to	Premium	
	
Dentists	This	mandate	requires	a	dentist	to	be	considered	a	physician	for	purposes	of	reimbursement	for	any	services	covered	by	the	medical	policy/contract	which	dentists	are	licensed	to	perform.555	Effect	of	the	mandate	on	health	Dentists	are	doctors	of	oral	health	focused	on	the	diagnosis,	treatment,	and	prevention	of	diseases	of	the	mouth	and	maxillofacial	area.556		To	practice	general	dentistry,	dentists	must	complete	an	undergraduate	degree,	as	well	as	four	years	of	dental	school;	residency	training	is	required	as	well,	spanning	an	additional	two	to	six	years	depending	on	specialty.557			To	obtain	a	license,	dentists	must	pass	Parts	I	and	II	of	the	National	Board	Dental	Examinations	written	tests	which	cover	basic	biomedical	sciences,	dental	anatomy,	ethics,	and	other	clinical	subjects	including	patient	management.558,559,560,561		All	states	also	require	an	additional	clinical	examination	which	focuses	on	performing	dental	procedures	on	patients;562	clinical	examinations	in	Massachusetts	are	administered	by	the	Commission	on	Dental	Competency	Assessments.563		Applicants	for	dental	licensure	in	Massachusetts	must	also	pass	the	Massachusetts	Dental	Ethics	and	Jurisprudence	Exam.564		Licensure	is	available	in	nine	specialties,	including:	dental	public	health;	endodontics;	oral	and	maxillofacial	pathology,	radiology,	and	surgery;	orthodontics	and	dentofacial	orthopedics;	pediatric	dentistry;	periodontics;	and	prosthodontics.565	Dentists	are	recognized	as	physicians	by	Medicare	when	providing	medically-necessary	services	while	acting	within	the	scope	of	the	dental	license.566		Dental	services	–	procedures	“primarily	provided	for	the	care,	treatment,	removal,	or	replacement	of	teeth	or	structures	supporting	the	teeth”	–	are	generally	excluded	from	Medicare	coverage.567		In	contrast,	services	that	may	be	considered	as	medical,	even	when	performed	by	a	dentist,	include	such	procedures	as	extractions	in	preparation	for	radiation	treatments	of	abnormal	growths	and	diseases	involving	the	jaw,	and	oral	
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Bound	PMPMs	
Sample	Users 4,684																 32,762													
Sample	Units 72,343													 455,012											
Sample	Average	Members 142,186											 990,666											
Paid	PMPM 0.91$																 0.85$																 0.09$																
Paid	PMPM	With	Admin 1.02$																 0.96$																 0.10$																
Allowed	PMPM 1.46$																 1.32$																 0.15$																
	Upper	Bound	
Impact	
	Lower	Bound	
Impact*	
Insured	Population 730,715 730,715
Contribution	to	Total	Annual	Claims 7,973,244$					 810,103$									
Contribution	to	Total	Annual	Premium 8,958,701$					 910,228$									
Percent	of	Total	Premium 0.07% 0.01%
*Net	amounts	do	not	remove	overlap	in	mandated	services	between	the	chiropractic	
services	mandate	and	the	chiropractor	provider	mandate.
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examinations	prior	to	kidney	or	heart	transplants	or	valve	replacements.568		Additionally	covered	may	be	procedures	related	to	orofacial	medical	conditions,	sleep	apnea,	myofacial	pain,	temporomandibular	joint	disorders,	oral	dysfunction,	trauma	to	the	teeth	or	jaws,	or	medically	necessary	periodontia,	implants,	or	radiography,	as	well	as	screenings	for	oral	cancers.569	This	analysis	uncovered	no	research	on	the	effectiveness	of	services	provided	by	dentists	compared	to	the	identical	services	provided	by	physicians	when	provided	under	the	scope	of	their	respective	licenses.	Estimate	of	the	cost	of	the	mandate	This	insurance	mandate	requires	a	dentist	to	be	considered	a	physician	for	purposes	of	reimbursement	for	any	services	covered	by	the	medical	policy/contract	which	dentists	are	licensed	to	perform.		The	RDC	of	this	mandate	was	calculated	as	the	sum	of	paid	amounts	from	all	medical	claims	with	a	dentist	or	oral	surgeonxxi	provider	type	indicator.		The	estimated	RDC	PMPM	paid	claim	amount	was	$0.16,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$0.18	(or	0.01	percent	of	the	Commonwealth	total	premium).		Self-insured	PMPM	allowed	medical	expenses	for	these	services	were	found	to	be	significantly	higher	than	fully-insured	allowed	medical	costs,	resulting	in	a	lower	bound	impact	estimate	of	$0,	including	administrative	loading.		Table	25	below	displays	a	summary	of	these	results	and	related	statistics.xxii	
Table	25	
Dentist	Mandate	
Contribution	to	Premium	
	
																																								 																					xxi	Maxillo-facial	surgeon	provider	types	were	not	included,	as	maxillo-facial	surgeons	hold	dual	licensure	as	dentists	and	medical	doctors.		Cases	where	the	maxillo-facial	and	oral	surgeon	provider	types	could	not	be	distinguished	were	also	excluded.	xxii	These	counterintuitive	results	may	be	a	result	of	missing,	miscoded,	or	unknown	provider	identifiers	or	provider	type	information	in	the	underlying	carrier	sample	data,	and	should	not	be	considered	conclusive.		Compass’s	investigation	into	the	results	was	inconclusive,	and	an	alternative	analysis	using	supplemental	data	did	not	significantly	improve	the	results.	
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Bound	PMPMs	
Sample	Users 616																			 13,635													
Sample	Units 1,537																 58,160													
Sample	Average	Members 142,186											 990,666											
Paid	PMPM 0.16$																 0.73$																 -$																		
Paid	PMPM	With	Admin 0.18$																 0.82$																 -$																		
Allowed	PMPM 0.20$																 0.79$																 (0.59)$														
	Upper	Bound	 	Lower	Bound	
Insured	Population 730,715 730,715
Contribution	to	Total	Annual	Claims 1,388,993$					 -$																		
Contribution	to	Total	Annual	Premium 1,560,666$					 -$																		
Percent	of	Total	Premium 0.01% 0.00%
*No	significant	overlaps	were	found	between	this	and	other	mandates.
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Optometrists	The	optometrist	mandate	requires	coverage	for	services	of	optometrists	when	those	services	are	reimbursed	when	performed	by	medical	or	osteopathic	physicians	and	within	the	lawful	scope	of	practice	of	optometrists.570	Effect	of	the	mandate	on	health	Optometrists,	or	doctors	of	optometry,	are	independent	health	care	professionals	who	diagnose	and	treat	eye	and	visual	system	diseases	and	disorders.571		Educational	requirements	for	optometrists	include	four	years	of	undergraduate	education	and	four	years	of	graduate	study	at	a	college	of	optometry.572		To	practice,	optometrists	must	obtain	state	licensure,	requiring	them	to	pass	a	set	of	national	examinations	administered	by	the	National	Board	of	Examiners	in	Optometry	(NBEO).		In	Massachusetts,	these	include	five	tests,	including	applied	basic	science,	patient	assessment	and	management	(PAM),	clinical	skills,	treatment	and	management	of	ocular	disease	(TMOD),	and	state	jurisprudence.573,574		Passing	these	examinations	also	grants	optometrists	certification	to	use	or	prescribe	diagnostic	pharmaceutical	agents	(DPA)	and	therapeutic	pharmaceutical	agents	(TPA).575		Licenses	must	be	renewed	annually576	and	must	include	evidence	of	continuing	education.577	Medicare	considers	optometrists	to	be	physicians	“with	respect	to	all	services	the	optometrist	is	authorized	to	perform	under	State	law	or	regulation.”578		This	review	found	no	published	studies	quantifying	the	efficacy	of	the	work	of	optometrists	specifically,	comparing	the	relative	quality	of	services	provided	by	optometrists	with	differing	amounts	of	education	or	training,	or	comparing	the	relative	quality	of	services		provided	by	optometrists	to	services	provided	by	other	provider	types.	The	ACA	requires	non-grandfathered	health	plans	in	the	individual	and	small	group	markets	to	cover	essential	health	benefits	(EHBs)	in	ten	categories	of	service	or	items.579		One	EHB	category,	pediatric	services,	includes	coverage	for	oral	and	vision	care	for	children.		(For	plans	effective	in	2017,	pediatric	vision	care	is	provided	through	a	supplementary	plan	under	the	Federal	Vision	Insurance	Program	(FEDVIP),	and	covers	routine	eye	exams	and	eyeglasses	for	children.580,581)		However,	while	coverage	for	pediatric	vision	services	is	required	as	an	EHB,	coverage	for	optometrists	per	se	is	not	required.582		Moreover,	routine,	non-pediatric	eye	exam	services	are	excluded	from	EHBs,	even	though	an	EHB	benchmark	plan	may	cover	them.583		Therefore,	the	ACA	and	its	EHB	requirements	do	not	affect	the	marginal	cost	of	this	mandate.	Estimate	of	the	cost	of	the	mandate	The	optometrist	mandate	requires	coverage	for	services	of	optometrists	when	services	are	reimbursed	when	performed	by	medical	or	osteopathic	physicians	and	are	within	the	lawful	scope	of	practice	of	optometrists.		The	RDC	of	this	mandate	was	calculated	as	the	sum	of	paid	amounts	from	all	claims	with	an	optometrist	provider	type	indicator.		The	estimated	RDC	PMPM	paid	claim	amount	was	$0.71,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$0.80	(or	0.06	percent	of	the	Commonwealth	total	premium).		Self-insured	PMPM	allowed	medical	expenses	for	these	services	were	found	to	be	higher	than	fully-insured	allowed	medical	costs,	resulting	in	a	lower	
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bound	impact	estimate	of	$0,	including	administrative	loading.		Table	26	below	displays	a	summary	of	these	results	and	related	statistics.	
Table	26	
Optometrists	Mandate	
Contribution	to	Premium	
	
Podiatrists	The	podiatrist	mandate	requires	coverage	for	services	of	podiatrists	when	those	services	are	reimbursed	when	performed	by	medical	or	osteopathic	physicians	and	within	the	lawful	scope	of	practice	of	podiatrists.584	Effect	of	the	mandate	on	health	A	podiatrist	is	a	doctor	of	podiatric	medicine	(DPM)	who	diagnoses	and	treats	conditions	affecting	the	lower	extremity.		According	to	the	American	Podiatric	Medical	Association,	podiatrists	are	foot	and	ankle	specialists	qualified	to:	“perform	comprehensive	medical	history	and	physical	examinations;	prescribe	drugs	and	order	and	perform	physical	therapy;	perform	surgeries	ranging	from	basic	to	complex	re-constructive	surgery;	repair	fractures	and	treat	sports–related	injuries;	prescribe	and	fit	orthotics,	durable	medical	goods,	and	custom–made	shoes;	and	perform	and	interpret	X–rays	and	other	imaging	studies.”585		An	estimated	15,000	podiatrists	practice	in	the	United	States.586			To	be	licensed	in	Massachusetts,	podiatrists	are	required	to	complete	four	years	of	undergraduate	education,	four	years	of	graduate	education	at	a	podiatric	medical	college,	and	three	years	of	residency	training	in	a	hospital.587,588,589		Additionally,	podiatrists	must	pass	oral,	written,	and/or	clinical	examinations	administered	by	the	state,590	and	complete	fifteen	hours	of	continuing	education	annually	to	renew	licensure.591		Massachusetts,	however,	is	one	of	four	states	nationally	that	includes	only	the	foot	and	does	not	include	the	ankle	in	the	scope	of	practice	for	podiatrists.592	Medicare	considers	a	podiatrist	a	physician	“only	with	respect	to	those	functions	which	he/she	is	legally	authorized	to	perform	in	the	State.”593		Podiatrists	are	eligible	to	order	and/or	refer	for	Part	
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Bound	PMPMs	
Sample	Users 9,153																 81,626													
Sample	Units 12,543													 115,173											
Sample	Average	Members 142,186											 990,666											
Paid	PMPM 0.71$																 0.95$																 -$																		
Paid	PMPM	With	Admin 0.80$																 1.07$																 -$																		
Allowed	PMPM 0.80$																 1.04$																 (0.24)$														
	Upper	Bound	
Impact	
	Lower	Bound	
Impact*	
Insured	Population 730,715 730,715
Contribution	to	Total	Annual	Claims 6,228,813$					 -$																		
Contribution	to	Total	Annual	Premium 6,998,666$					 -$																		
Percent	of	Total	Premium 0.06% 0.00%
*No	significant	overlaps	were	found	between	this	and	other	mandates.
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B	and	Durable	Medical	Equipment,	Prosthetics,	Orthotics	and	Supplies	(DMEPOS)	Medicare	beneficiaries.594		Further,	podiatrists	may	order	and	refer	for	Medicare	Part	A	Home	Health	Agency	(HHA)	beneficiary	services,	the	only	provider	type	besides	doctors	of	medicine	and	osteopathy	permitted	to	do	so.595	While	no	evidence	was	found	comparing	the	effectiveness	of	podiatric	care	provided	by	podiatrists	to	that	provided	by	nurses,	allied	health	professionals,	or	non-specialist	physicians,	some	evidence	exists	that	interdisciplinary	foot	care	including	podiatric	care	had	a	positive	impact	on	outcomes	for	patients	with	diabetes,	including	reductions	in	urgent	surgeries,	below-knee	amputation	rates,	major	amputations,	recurrence	of	foot	ulcers,	and	death	in	patients	with	diabetic	lower-extremity	ulcerations.596,597,598,599		Other	studies	have	found	that	for	patients	waiting	for	an	evaluation	by	an	orthopedic	surgeon,	podiatrists	can	provide	appropriate	triage	service,	resulting	in	more	timely	provision	of	non-surgical	care	and	better	targeted	use	of	orthopedic	surgical	resources.600,601	This	review	found	no	published	studies	quantifying	the	efficacy	of	the	work	of	podiatrists	specifically	(noting	the	distinction	between	podiatric	care	and	care	by	podiatrists),	comparing	the	relative	quality	of	services	provided	by	podiatrists	with	differing	amounts	of	education	or	training,	or	comparing	the	relative	quality	of	podiatrists	services	against	services	provided	by	other	provider	types.	Estimate	of	the	cost	of	the	mandate	The	podiatrist	mandate	requires	coverage	for	services	of	podiatrists	when	services	are	reimbursed	when	performed	by	medical	or	osteopathic	physicians	and	are	within	the	lawful	scope	of	practice	of	podiatrists.	The	RDC	of	this	mandate	was	calculated	as	the	sum	of	paid	amounts	from	all	claims	with	a	podiatrist	provider	type	indicator.		The	estimated	RDC	PMPM	paid	claim	amount	was	$0.58,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$0.65	(or	0.15	percent	of	the	Commonwealth	total	premium).		Per	member	per	month	self-insured	allowed	expenses	for	this	mandate	were	found	to	be	$0.04	lower	than	fully-insured	and	GIC	PMPM	allowed	expenses,	resulting	in	a	lower	bound	expense	estimate,	including	administrative	loading,	of	$0.03	PMPM,	or	0.01	percent	of	Commonwealth	premium.	Table	27	below	displays	a	summary	of	these	results	and	related	statistics.	
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Table	27	
Podiatrists	Mandate	
Contribution	to	Premium	
	
Aggregated	Results	of	Mandates	with	Potential	Marginal	Direct	Cost	The	aggregated	results	of	the	required	direct	cost	measurement	for	the	twenty-five	mandates	judged	to	have	potential	marginal	direct	cost,	with	overlap	(double-counting)	between	mandates	removed,	are	summarized	in	Table	28.		The	overall	RDC	was	calculated	as	the	sum	of	paid	amounts	from	all	claims	extracted	for	any	of	the	potential	marginal	direct	cost	mandates.		The	estimated	RDC	PMPM	paid	claim	amount	was	$25.01,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$28.10	(or	6.45	percent	of	the	Commonwealth	total	premium).		The	lower	bound	impact	was	calculated	as	the	sum	of	the	individual	mandate	lower	bound	estimates	net	of	mandate	overlapsxxiii	with	each	mandate’s	lower	bound	impact	estimate	lower	bounded	at	zero	(i.e.,	a	result	of	higher	self-insured	allowed	expenses	for	one	mandate	did	not	offset	higher	fully-insured	results	found	for	other	mandates).		The	resulting	lower	bound	expense	is	$1.86	PMPM	or	0.43	percent	of	Commonwealth	premium.		That	is,	the	additional	cost	of	mandated	services	in	plans	subject	to	the	mandates	compared	to	those	plans	not	subject	to	the	mandates	represents	approximately	one	half	of	one	percent	of	premium.			Table	28	below	displays	a	summary	of	these	results.		
																																								 																					xxiii	In	the	overall	calculations,	each	claim	extracted	in	the	analysis	of	any	potential	marginal	direct	cost	mandate	was	assigned	to	one	and	only	one	mandate.	
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Bound	PMPMs	
Sample	Users 28,137													 29,141													
Sample	Units 99,823													 105,346											
Sample	Average	Members 1,049,386								 1,209,745								
Paid	PMPM 0.58$																 0.62$																 0.03$																
Paid	PMPM	With	Admin 0.65$																 0.70$																 0.03$																
Allowed	PMPM 0.79$																 0.75$																 0.04$																
	Upper	Bound	
Impact	
	Lower	Bound	
Impact*	
Insured	Population 2,362,745 2,362,745
Contribution	to	Total	Annual	Claims 16,383,060$			 808,388$									
Contribution	to	Total	Annual	Premium 18,407,933$			 908,301$									
Percent	of	Total	Premium 0.15% 0.01%
*Net	amounts	do	not	remove	overlap	in	mandated	services	between	the	podiatrist
mandate	and	the	diabetes	and	home	health	mandates.
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Table	28	
Unduplicated	Combined	Potential	Marginal	Direct	Cost	Mandate	Results	
Contribution	to	Premium	
	
	Neither	the	RDC	estimate	in	Table	28	($796.8	million)	nor	the	lower	bound	marginal	cost	estimate	of	$52.7	million	provides	an	answer	to	the	question	of	what	additional	direct	costs	are	caused	by	the	mandate	laws,	though	the	mandate	impact	should	be	somewhere	in	this	rather	wide	range.		As	discussed	in	more	detail	below,	it	is	also	not	likely	to	be	near	either	of	the	two	extremes	produced	by	the	required	direct	cost	and	lower	bound	marginal	cost	estimates.			In	the	next	section,	we	address	results	for	the	mandates	judged	likely	to	have	zero	marginal	cost.	
Mandates	Judged	Likely	to	have	Zero	Marginal	Cost	The	RDC	results	for	each	of	the	mandates	analyzed	in	the	secondary	cost	analysis	phase	of	the	project	are	described	below.		As	discussed	above,	carrier	input	and/or	analysis	of	federal	mandate	requirements	supported	the	position	that	these	mandates	are	likely	to	have	little	or	no	marginal	direct	cost	–	that	is,	essentially	all	the	costs	of	these	services	would	be	incurred	even	if	the	associated	state	mandate	laws	were	not	in	effect.		The	estimates	presented	below,	then,	are	for	RDCs	only,	as	the	marginal	costs	(and	therefore	lower	bound	marginal	costs)	are	assumed	to	be	zero.		Detailed	specifications	for	the	cost	calculations	for	the	six	zero	marginal	cost	mandates	estimated	using	the	Massachusetts	MA	APCD	are	available	from	CHIA	upon	request.	
Bone	Marrow	Transplant	for	Breast	Cancer	The	bone	marrow	transplant	mandate	requires	coverage	for	bone	marrow	transplants	for	patients	with	metastatic	breast	cancer	if	they	meet	criteria	set	by	the	Department	of	Public	Health.602	Effect	of	the	mandate	on	health	Treatment	for	high-risk	breast	cancer	has	evolved	significantly	over	time,	with	the	development	of	new	interventions	as	well	as	publication	of	additional	research	findings.		At	one	time,	high-dose	chemotherapy	plus	autologous	bone	marrow	transplant	(HDC-ABMT)	was	used	as	a	last	resort	to	treat	advanced	breast	cancer,	or	breast	cancer	with	a	high	probability	of	recurrence,	as	it	reduced	the	probability	of	relapse.603,604	
Measures 	Upper	Bound	Impact	
	Lower	Bound	
Impact*	
Insured	Population 2,362,745 2,362,745
Paid	PMPM 25.01$																								 1.66$																		
Paid	PMPM	With	Admin 28.10$																								 1.86$																		
Contribution	to	Total	Annual	Claims 709,161,988$											 46,942,722$						
Contribution	to	Total	Annual	Premium 796,811,223$											 52,744,631$						
Percent	of	Total	Premium 6.45% 0.43%
*Results	are	net	of	all 	mandate	overlaps.
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However,	since	the	mid-1990s,	HDC-ABMT	has	been	discredited	as	a	standard	treatment	regimen	due	to	the	serious	side	effects	of	the	highly	toxic	chemotherapy,	including	an	increase	in	treatment-related	mortality,	and	because	the	treatment	did	not	offer	an	increased	chance	of	overall	survival	when	compared	to	standard-dose	chemotherapy.605,606,607,608,609,610,611,612,613,614		The	National	Comprehensive	Cancer	Network	has	excluded	HDC-ABMT	from	its	clinical	practice	guidelines	since	1996.615	The	use	of	HDC-ABMT	for	treatment	of	breast	cancer	is	most	often	recommended	“only…in	the	context	of	a	clinical	trial.”616,617		Some	already-concluded	and	ongoing	trials	have	shown	the	potential	application	of	this	treatment	for	more	narrowly-defined	groups	of	patients618,619,620	and/or	with	an	adjustment	to	the	previously-used	chemotherapy	regimen,	as	the	specific	treatments	may	increase	the	disease-free	survival	rate	for	certain	patients.621,622,623		The	data	are	not	yet	clear,	however,	and	experts	continue	to	press	for	additional	rigorous	clinical	studies,	with	several	now	underway.624,625,626	Despite	these	recommendations,	as	HDC-ABMT	remains	an	independently	mandated	benefit,	clinical	trials	have	faltered	due	to	the	inability	to	enroll	suitable	patients,	as	nine	out	of	ten	patients	have	chosen	to	receive	the	therapy	outside	of	the	context	of	a	clinical	trial,	thereby	avoiding	the	possibility	of	random	assignment	to	a	control	cohort.627,628	Discussion	of	the	cost	of	the	mandate	In	light	of	these	recommendations,	the	BMT	mandate	appears	to	be	redundant	to	the	separate	mandate	providing	benefits	for	cancer	clinical	trials,	which	is	also	a	zero	marginal	cost	mandate	(see	the	sub-section	analyzing	the	cancer	clinical	trials	mandate	below).	
Cardiac	Rehabilitation	The	cardiac	rehabilitation	mandate	requires	coverage	for	multidisciplinary,	medically	necessary	treatment	of	persons	with	documented	cardiovascular	disease.629	Effect	of	the	mandate	on	health	Almost	800,000	Americans	die	each	year	from	major	cardiovascular	diseases	(CVD),	the	leading	cause	of	morbidity	and	mortality	in	the	country,	accounting	for	almost	31	percent	of	all	deaths	in	the	U.S.630		In	a	2015	report	on	heart	disease	and	stroke	statistics,	researchers	reported	that	one	in	three	American	adults	suffers	from	some	form	of	heart	disease,	stroke,	or	other	blood	vessel	disease;	each	year,	795,000	will	suffer	a	stroke,	and	750,000	will	suffer	a	heart	attack.631	Cardiac	rehabilitation	(CR)	refers	to	multidisciplinary	programs	that	combine	exercise,	education,	and	psychological	support	in	medically-supervised	programs	designed	to	improve	physical,	mental,	and	social	functioning,	reduce	health	risks	and	disability,	and	foster	compliance,	healthy	behaviors,	and	active	lifestyles	for	people	with	cardiovascular	diseases.632		The	goal	of	CR	“is	to	stabilize,	slow,	or	even	reverse	the	progression	of	CVD,	which	in	turn	reduces	the	risk	of	a	future	cardiac	event.”633		Research	has	shown	such	programs	to	be	effective	in	improving	coronary	heart	disease	risk	factors	and	health-related	quality	of	life,	while	reducing	clinical	events,	risk	of	death,	and	costs.634		
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Specifically,	CR	improves	exercise	tolerance,	symptoms,	overall	psychosocial	well-being,	and	blood	lipid	levels	while	reducing	mortality,	stress,	and	cigarette	smoking.635,636		These	outcomes	are	similar	in	both	center-	or	home-based	programs,	although	programs	provided	at	home	are	associated	with	a	higher	level	of	patient	adherence	to	treatment.637	Research	so	clearly	demonstrates	the	benefit	of	CR	that,	in	a	search	for	cardiac	rehabilitation	guidelines	issued	by	U.S.-based	organizations,	58	different	recommendations	and	guidelines	for	use	of	CR	for	various	conditions	are	listed	on	the	National	Guideline	Clearinghouse,	a	public	resource	of	the	U.S.	Agency	for	Healthcare	Research	and	Quality	(AHRQ)	for	evidence-based	clinical	practice	guidelines.638		Despite	this,	however,	utilization	of	cardiac	rehabilitation	programs	remains	low,	“with	less	than	30	percent	of	eligible	patients	participating	in	a	cardiac	rehabilitation	program	after	a	cardiovascular	disease	event.”639		Patients	cite	inconvenient	clinic	location	and	hours,	insurance	cost-sharing	and	other	expenses,	and	a	lack	of	physician	referral	as	reasons	for	low	compliance	rates.640,641	Discussion	of	the	cost	of	the	mandate	The	cardiac	rehabilitation	mandate	covers	the	expense	of	cardiac	rehabilitation,	i.e.,	multidisciplinary,	medically	necessary	treatment	of	persons	with	documented	cardiovascular	disease.	For	this	analysis,	the	cost	of	the	cardiac	rehabilitation	mandate	reflected	in	insurance	premiums	is	estimated	as	the	total	cost	to	fully-insured	plans	subject	to	the	mandate	for	cardiac	rehabilitation	procedure	codes.xxiv		The	estimated	PMPM	RDC	paid	claim	amount	for	the	calendar	year	2014	study	period	was	$0.08,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$0.09	(or	0.02	percent	of	the	Commonwealth	total	premium).		Table	29	below	displays	a	summary	of	these	results	and	related	statistics.	
																																								 																					xxiv	HCPCS	code	91797,	93798,	G0422,	or	G0423.	
Comprehensive	Mandated	Benefit	Review	
compass Health Analytics 72 December 2016 
Table	29	
Cardiac	Rehabilitation	Mandate	
Required	Direct	Cost	Estimate	
	
Clinical	Trials	for	Treatment	of	Cancer	The	mandate	for	coverage	of	clinical	trials	for	treatment	of	cancer	requires	coverage	for	services	for	patients	enrolled	in	a	qualified	clinical	trial	to	the	same	extent	that	the	services	would	be	covered	if	the	patient	was	not	receiving	care	in	a	qualified	clinical	trial.		A	qualified	clinical	trial	must	be	cancer-related	and	must	meet	other	criteria	set	forth	in	the	law.642	Effect	of	the	mandate	on	health	According	to	the	Coalition	of	Cancer	Cooperative	Groups,	“[a]	clinical	trial	is	a	carefully	monitored	medical	research	study	in	which	people	participate	as	volunteers	to	test	new	methods	of	prevention,	screening,	diagnosis,	or	treatment	of	a	disease.”643		The	National	Cancer	Institute	defines	the	different	types	of	clinical	trials	to	be	for	treatment,	prevention,	screening,	or	quality	of	life/supportive/palliative	care.644		Clinical	trials	are	categorized	into	four	phases:	
• Phase	I	trials,	usually	the	first	to	involve	humans,	typically	enroll	15	to	30	people,	and	seek	to	determine	treatment	safety,	side	effects,	and	optimal	mode	of	administration.645	
• Phase	II	trials,	usually	enrolling	25	to	100	people,	attempt	to	determine	if	and	how	the	new	treatment	affects	a	certain	cancer	and	may	vary	dosage	levels	between	treatment	groups	while	continuing	to	monitor	side	effects.646	
• Phase	III	trials	typically	enroll	from	100	to	several	thousand	participants,	and	compare	the	new	treatment	or	use	with	the	current	standard,	randomizing	patients	into	test	groups.647		Seventy-five	percent	of	patients	in	clinical	trials	are	part	of	phase	III	trials.648	
• Phase	IV	trials,	if	conducted,	include	several	hundred	to	several	thousand	people,	and	assess	long-term	safety	and	effectiveness	of	a	treatment	that	has	already	been	approved	by	the	FDA.649	
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Bound	PMPMs	
Sample	Users 1,252																
Sample	Units 16,215													
Sample	Average	Members 1,871,491								
Paid	PMPM 0.08$																 N/A N/A
Paid	PMPM	With	Admin 0.09$																 N/A N/A
Allowed	PMPM 0.09$																 N/A N/A
	Required	
Direct	Cost	
	Upper	and	
Lower	Bound	
Insured	Population 2,362,745 2,362,745
Contribution	to	Total	Annual	Claims 2,279,569$					 -$																		
Contribution	to	Total	Annual	Premium 2,561,314$					 -$																		
Percent	of	Total	Premium 0.02% 0.00%
*	This	mandate	was	judged	by	carriers	to	contribute	$0	marginal	cost	to	premiums.
Required	direct	cost	was	estimated	using	the	Massachusestts	APCD.
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Phase	0	trials	are	also	possible,	in	which	patients	face	lower	risk	but	will	not	benefit	from	the	trial;	these	are	used	to	study	how	the	cancer,	body,	and	treatment	interact,	and	are	intended	to	hasten	and	streamline	the	approval	process.650	The	National	Cancer	Institute	cites	several	possible	benefits	of	participation	in	clinical	trials,	including	access	to	new	treatment,	close	monitoring	by	research	staff,	and	the	opportunity	to	help	future	patients.651		Trial	participants	who	are	randomized	into	control	groups	receive	the	best	known	standard	treatment,	while	those	in	the	test	groups	receive	the	new	treatment	intended	to	improve	upon	the	current	standard.652		The	American	Cancer	Society	(ACS)	also	points	out	that	participation	empowers	patients	to	actively	decide	their	cancer	treatment,	and	provides	an	opportunity	to	help	others	and	advance	research.653		Participation	drawbacks	may	be	that	the	new	treatment	is	not	as	effective	for	an	individual	as	the	current	standard,	or	may	cause	different	or	more	severe	side	effects	than	the	standard	treatment	protocol;	likewise,	clinical	trials	also	may	require	more	testing	or	clinical	appointments	than	would	standard	treatment.654	A	2013	study	on	public	and	patient	perspectives	of	clinical	trials	found	that	87	percent	of	respondents	were	“somewhat	willing”	or	“very	willing”	to	participate	in	clinical	trials.655		Yet	ACS	reports	that	the	biggest	barrier	to	the	completion	of	trials	is	that	fewer	than	5	percent	of	adults	participate	in	them,	with	the	most	common	reason	being	that	the	patient	did	not	know	the	studies	were	an	option	for	them.656		Of	patients	aware	of	their	eligibility,	only	25	percent	reported	participating.657		Participants	do	report	a	high	rate	of	satisfaction,	especially	with	the	quality	of	their	care;	over	75	percent	report	that	they	would	recommend	participation	to	others.658		Approximately	60	percent	of	children	under	age	15	participate,	and	this	has	been	credited	with	the	dramatic	increase	in	childhood	cancer	survival	rates	in	the	past	few	years.659	Discussion	of	the	cost	of	the	mandate	The	clinical	trials	for	treatment	of	cancer	mandate	requires	coverage	for	patient	care	services	for	patients	enrolled	in	a	qualified	clinical	trial	to	the	same	extent	as	the	services	would	be	covered	if	the	patient	was	not	receiving	care	in	a	qualified	clinical	trial.		A	qualified	clinical	trial	must	be	cancer-related	and	must	meet	other	criteria	set	forth	in	the	law.	Detailed	data	do	not	exist	to	specifically	identify	costs	associated	with	clinical	trials	for	the	treatment	of	cancer,	but	information	is	available	to	aid	in	its	estimation.		One	study	estimates	that	the	costs	of	clinical	trials	range	from	10	percent	lower	to	23	percent	higher	compared	to	standard	medical	care.660		Compass	obtained	2013	U.S.	cancer	prevalence	rates	by	10-year	age	band661	and	applied	these	rates	to	a	U.S.	Census	Bureau	estimate	of	Massachusetts	population	by	single	year	of	age	on	July	1,	2014,662	yielding	an	approximate	count	of	people	aged	0-59	in	Massachusetts	living	with	cancer	in	2014	of	74,160.		An	additional	70,062	cancer	patients	were	aged	60-69.		The	Census	data	on	Massachusetts	population	by	single	year	of	age	indicate	that	the	proportion	of	the	estimated	2014	Massachusetts	population	aged	60-69	who	were	aged	60-64	versus	60-69	was	55.1	percent.		Applying	this	proportion	to	the	estimated	Massachusetts	cancer	cases	in	the	age	60-69	age	group	and	adding	the	result	to	the	cases	in	the	population	aged	0-59	yields	a	2014	estimate	of	112,740	cancer	patients	aged	0-64	in	Massachusetts	in	2014.		However,	Massachusetts	has	a	higher	overall	incidence	rate	for	cancers	versus	the	nation	as	a	whole.		While	the	national	figure	for	2008-
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12	was	estimated	at	453.8	cases	per	100,000,	the	Massachusetts	number	was	approximately	6.5	percent	higher	at	483.1.663		Applying	a	factor	based	on	this	higher	rate	to	the	preliminary	number	of	cases	raises	the	estimate	of	cancer	cases	in	Massachusetts	under	age	65	to	120,019.	In	2010,	the	American	Cancer	Society	reported	that	the	proportion	of	adults	with	cancer	who	participate	in	clinical	trials	was	just	5	percent.664		Allowing	for	a	somewhat	higher	participation	rate	of	6	percent	in	Massachusetts,	owing	to	its	density	of	teaching	hospitals,	brings	the	estimate	of	clinical	trial	patients	in	Massachusetts	to	just	over	7,200.		U.S.	Census	Bureau	insurance	coverage	data	indicate	that	74.7	percent	of	the	under-65	population	in	Massachusetts	was	privately-insured	in	2014.665		Compass’s	insured	population	membership	model	estimates	that	49.1	percent	of	the	privately-insured	have	fully-insured	medical	coverage,	resulting	in	an	estimated	number	of	cases	of	privately-insured	under-65	individuals	in	Massachusetts	participating	in	clinical	trials	in	2014	of	2,742.	
Table	30	
Clinical	Trials	to	Treat	Cancer	Mandate	
Required	Direct	Cost	Estimate	
	
	The	National	Institutes	of	Health	estimated	the	total	2010	U.S.	cost	of	medical	care	for	cancer	at	$102.8	billion	dollars.666		Applying	this	amount	to	a	total	U.S.	2014	cancer	prevalence	estimate	of	14.1	million667	yields	a	cost	per	case	for	cancer	care	of	$7,270	annually.		For	the	Massachusetts	fully	insured	population	under	age	65,	the	cost	of	cancer	care	would	then	be	about	$22.8	million	in	total	after	trending	the	2010	cost	estimate	forward	to	2014.		The	incremental	cost	of	care	in	clinical	trials	for	cancer	is	estimated	at	10	percent,668	although	a	later	article	specifically	examining	NIH-sponsored	clinical	trials	calculated	this	figure	at	6.5	percent.669		Assuming	the	more	conservative	10	percent	estimate,	the	total	cost	of	cancer	clinical	trials	for	the	2.4	million	Massachusetts	fully-insured	under	65	population	is	$2.3	million,	or	$0.08	PMPM.		With	administrative	loading,	this	
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Bound	PMPMs	
Sample	Users N/A
Sample	Units N/A
Sample	Average	Members N/A
Paid	PMPM 0.08$																 N/A N/A
Paid	PMPM	With	Admin 0.09$																 N/A N/A
Allowed	PMPM N/A N/A N/A
	Required	
Direct	Cost	
	Upper	and	
Lower	Bound	
Impact*	
Insured	Population 2,362,745 2,362,745
Contribution	to	Total	Annual	Claims 2,275,297$					 -$																		
Contribution	to	Total	Annual	Premium 2,556,513$					 -$																		
Percent	of	Total	Premium 0.02% 0.00%
*	This	mandate	was	judged	by	carriers	to	contribute	$0	marginal	cost	to	premiums.
Required	direct	cost	was	estimated	using	secondary	data	sources.
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figure	rises	to	$0.09,	or	0.02	percent	of	the	overall	$436	PMPM	average	2014	premium.	These	results	are	summarized	in	Table	30	above.	
Contraceptive	Services	The	contraceptive	services	mandate	requires	coverage	for	outpatient	contraceptive	services	(consultations,	exams,	procedures,	etc.)	to	the	same	extent	as	other	outpatient	services	and	for	prescription	contraceptive	drugs	and	devices	under	the	same	terms	and	conditions	as	other	prescription	drugs	and	devices.		The	mandate	provides	exclusions	for	church-affiliated	employers.670	Effect	of	the	mandate	on	health	The	United	States	has	an	estimated	61	million	women	ages	15-44;671	of	these,	70	percent	are	sexually	active	but	do	not	want	to	become	pregnant.672	Massachusetts	has	1.44	million	women	of	reproductive	age,	of	whom	61	percent	are	sexually	active	and	do	not	wish	to	become	pregnant.673		In	the	United	States,	more	than	half	of	all	pregnancies	are	estimated	to	be	unintended.674		Family	planning	is	one	of	the	major	objectives	of	Healthy	People	2020,	the	set	of	evidence-based	national	health	promotion	and	disease	prevention	goals	outlined	for	the	next	decade	by	the	U.S.	Department	of	Health	and	Human	Services.675		According	to	Healthy	People,	“Family	planning	is	one	of	the	10	great	public	health	achievements	of	the	20th	century.		The	availability	of	family	planning	services	allows	individuals	to	achieve	desired	birth	spacing	and	family	size	and	contributes	to	improved	health	outcomes	for	infants,	children,	and	women.”676	The	benefits	of	contraception	include	improved	women’s	health	and	well-being,	reduced	maternal	mortality,	health	benefits	for	mother	and	child	associated	with	spacing	pregnancy,	female	workforce	engagement,	and	economic	self-sufficiency.677		Additionally,	contraceptive	use	may	decrease	menstrual	period	pain	and	bleeding,	and	reduce	gynecological	disorder	risks,	including	those	for	ovarian	and	endometrial	cancers.678		The	negative	consequences	of	unintended	pregnancies	are	numerous.		They	include:	delays	in	initiating	prenatal	care;	the	increased	risk	of	tobacco	and	alcohol	use	and	of	physical	violence	during	pregnancy;	premature	birth	and	low	birth	weight;	reduced	likelihood	of	breastfeeding;	poor	maternal	mental	health;	and	lower	relationship	quality	between	mother	and	child.679,680		Some	studies	show	that	children	born	from	an	unintended	pregnancy	may	be	more	likely	to	suffer	from	poor	physical	and	mental	health	in	childhood,	and	may	attain	lower	educational	and	behavioral	outcomes.681,682,683,684,685,686,687	Outcomes	are	worse	for	unintended	pregnancies	in	teen	mothers;	82	percent	of	pregnancies	among	mothers	age	15	to	19	are	unintended.688		An	adolescent	who	experiences	an	unintended	pregnancy	is	less	likely	to	graduate	from	high	school	or	attain	a	GED	by	age	30,	and	will	earn	approximately	$3500	less	per	year	on	average	than	her	peers	who	delay	having	children;	teen	fathers	experience	similarly	lower	educational	achievement	and	income.689,690		Teen	mothers,	on	average,	receive	twice	as	much	federal	aid	for	twice	as	long	as	non-parent	teens.691		Finally,	children	of	teenagers	have	more	behavioral	problems	and	lower	cognitive	abilities	than	others,	on	average;	in	fact,	sons	of	teen	mothers	are	more	likely	to	be	incarcerated,	while	daughters	are	more	likely	to	become	pregnant	as	teens.692	
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Furthermore,	adequate	pre-pregnancy	planning	allows	women	to	receive	appropriate	preconception	care,	the	importance	of	which	is	becoming	increasingly	evident.		Care	provided	before	pregnancy	allows	providers	to	reduce	the	risks	of	pregnancy	to	women,	as	well	as	some	pre-term	births	and	their	associated	birth	defects.693	Contraceptive	drugs	and	devices,	used	consistently	and	correctly,	and	paired	with	appropriate	associated	examination	and	consultation	services,	can	play	a	significant	role	in	family	planning.		While	30	percent	of	women	do	not	need	a	contraceptive	method,694	8	percent	of	women	are	at	risk	of	unintended	pregnancy	but	are	not	using	contraception.695		Of	the	women	not	using	contraception	and	at	risk	of	unintended	pregnancy,	larger	percentages	are	under	20	years	of	age,	have	never	married,	and	are	black.696	The	remaining	62	percent	of	women	of	reproductive	age	are	currently	using	a	contraceptive	method.697		While	almost	half	of	women	with	an	unintended	pregnancy	report	using	some	form	of	contraception,698	67	percent	of	women	at	risk	of	unintended	pregnancy	use	contraception	consistently	and	correctly,	and	account	for	only	5	percent	of	unintended	pregnancies.699		Proper	use	of	the	most	effective	methods	of	contraception	“virtually	eliminates”	the	risk	of	unintended	pregnancy,	while	using	any	method	reduces	the	chances	by	85	percent.700			Slightly	more	than	half	of	pregnancies	in	the	United	States	each	year	are	unintended;	of	these,	research	shows	that	95	percent	are	in	women	either	not	using	contraception	or	using	it	inconsistently.701		Most	women	(64	percent)	who	use	contraception	rely	on	non-permanent	methods,	while	the	remainder	rely	on	male	or	female	sterilization.702	Success	rates	depend	on	either	permanency	or	consistency	of	use;	permanent	sterilization	methods	result	in	a	failure	rate	of	less	then	1	percent	with	typical	use,	while	other	methods	vary	widely,	from	1	percent	failure	rates	for	implants	to	28	percent	failure	rates	for	spermicide	alone	with	typical	use.		However,	by	preventing	unintended	pregnancies,	“[c]ompared	with	nonuse,	even	with	a	time	horizon	as	short	as	1	year,	use	of	any	method	[of	contraception]…results	in	financial	savings	and	health	gains.”703		Table	31	summarizes	the	estimated	number	of	users	of	each	type	of	contraception	and	the	expected	proportion	of	pregnancies	expected	for	each.	
Table	31	
Methods	of	Birth	Control704,705,706	
Method	
Users	
	#	(000s)						Percent	
Number	of	pregnancies	expected	
per	100	women707	
				Perfect	use													Typical	use	
FDA-APPROVED	METHODS	
Permanent	
Sterilization	Implant	for	Women	(Transcervical	
Surgical	Sterilization	Implant)		 492
xxv	 1.31	 0.05	 0.05	
Sterilization	surgery	for	men	 3,084	 8.2	 0.10	 0.15	
Sterilization	Surgery	for	Women,	Surgical	Implant	
(Transabdominal	Surgical	Sterilization)	 9,443	 25.1	 0.5	(tubal	only)	 0.5	(tubal	only)																																									 																					
xxv	User	number	combines	permanent	sterilization	implant	and	removable	implantable	rod.	
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Method	
Users	
	#	(000s)						Percent	
Number	of	pregnancies	expected	
per	100	women707	
				Perfect	use													Typical	use	
Implant	
Implantable	rod	 4921	 1.31	 <1	 N/A	
Intrauterine	Device	(IUD)	w/progestin	
3,884	 10.3	
0.2	 0.2	
IUD	copper	 0.6	 0.8	
Hormonal	
Shot/injection	 1,697	 4.5	 0.2	 6	
Oral	contraceptives/	combined	pill,	progestin	only	
and	extended/continuous	use	 9,720	 25.9	 0.3	 9	
Patch	 217	 0.6	 0.3	 9	
Vaginal	contraceptive	ring	 759	 2.0	 0.3	 9	
Barrier	
Diaphragm	w/spermicide	
133xxvi	 0.42	
6	 12	
Sponge	w/spermicide	 9/20	 12/24	
Cervical	cap	w/spermicide	 N/A	 17/23	
Male	condom	 5,739	 15.3	 2	 18	
Female	condom	 N/A	 N/A	 5	 21	
Spermicide	alone	 	N/A	 N/A	 18	 28	
Emergency	Contraception	
Plan	B,	Plan	B	One	Step,	Next	Choice	
91	 0.2	
88	percentxxvii	
Ella	 60-70	percent3	
OTHER	METHODS	
Withdrawal	 1,817	 4.8	 4	 22	
Fertility	awareness-basedxxviii	 509	 1.4	 0.4-5	 24	
No	method,	at-risk	of	unintended	pregnancy	 4,175	 N/A		 85	 85	
No	method,	not	at	risk	 19,126	 N/A	 N/A	 N/A	
	In	general,	when	used	correctly	and	consistently,	contraceptives	are	effective	at	preventing	unintended	pregnancies	and	related	negative	health	impacts	on	women	and	children.		Contraceptive	effectiveness	varies	by	method:	permanent	sterilization	is	most	effective,	and	the	next	most	effective	contraceptives	are	long-acting	reversible	methods.		Consistent	and	effective	use	of	contraception,	as	well	as	use	of	more	effective	methods,	can	be	improved	by	reducing	cost	and	other	barriers	to	access,	as	well	as	by	providing	women	with	access	to	methods	that	are	medically-appropriate	and	consistent	with	their	social,	cultural,	emotional,	and	sexual	lifestyles.	Under	the	Patient	Protection	and	Affordable	Care	Act	(ACA),	non-grandfathered	health	insurance	plans	must	fully	cover	the	costs	of	contraceptive	methods	and	counseling	for	all	women,	as	prescribed	by	a	health	care	provider.708		When	provided	by	an	in-network	provider,	these	services	will	require	no	patient	cost-sharing	(no	deductibles,	coinsurances	or	copayments).709		Covered	methods	include	at	least	one	type	of	method	within	all	categories	of	prescribed	contraception																																									 																					
xxviAlso	includes	female	condom,	foam,	suppository,	jelly/cream,	and	other	methods.	
xxvii	Prevents	pregnancy	in	percent	of	women	who	would	have	otherwise	become	pregnant.	xxviii	Includes	cervical	mucus	methods,	body	temperature	methods,	and	periodic	abstinence.	
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approved	by	the	Food	and	Drug	Administration	(FDA),	including	sterilization	procedures,	implanted	devices,	barrier	and	hormonal	methods,	emergency	contraception,	and	education	and	counseling;	over-the-counter	contraception,	drugs	to	induce	abortions	and	sterilization	surgery	for	men	are	not	included	in	this	benefit.710		Health	plans	sponsored	by	certain	exempt	religious	organizations	may	not	be	covered	and	may	require	out-of-pocket	payment.711		Some	non-profit	religious	organizations	that	certify	religious	objections	do	not	have	to	contract,	arrange,	pay,	or	refer	for	contraceptive	coverage;	for	these	types	of	organizations,	insurers	or	third	party	administrators	may	make	separate	payments	for	contraceptive	services	to	in-network	providers	without	patient	cost-sharing.712 Estimate	of	the	cost	of	the	mandate	The	contraceptive	services	mandate	provides	coverage	for	outpatient	contraceptive	services	(consultations,	exams,	procedures,	etc.)	to	the	same	extent	as	other	outpatient	services	and	for	prescription	contraceptive	drugs	and	devices	under	the	same	terms	and	conditions	as	other	prescription	drugs	and	devices.	The	mandate	provides	exclusions	for	church-affiliated	employers.	The	federal	ACA	requires	contraception	coverage	as	an	essential	health	benefit	(EHB),	and,	in	addition	to	requiring	all	of	the	benefits	of	the	state	mandate,	requires	all	compliant	plans	to	cover	at	least	one	product	from	each	of	the	FDA’s	18	approved	contraception	methods	at	zero	cost-sharing.		Therefore,	this	analysis	assumes	the	Massachusetts	contraceptive	mandate	to	be	redundant	to	and	superseded	by	the	federal	ACA;	the	marginal	cost	of	the	state	mandate	is	therefore	zero.		The	contraception	provisions	of	the	ACA	were	required	in	all	new	health	insurance	plans	in	effect	on	or	after	August	1,	2012;	accordingly,	the	Massachusetts	contraception	mandate	was	treated	as	a	potential	marginal	cost	mandate	in	the	first	two	comprehensive	reviews.	Required	direct	costs	(RDCs)	of	this	mandate	were	determined	to	consist	of	paid	amounts	from	all	claims	for	female	members	for	outpatient	contraceptive	procedures	and	consultations	(IUD	insertion,	etc.),	all	claims	for	evaluation	and	management	(identified	by	the	evaluation	and	management,	or	E&M,	CPT4	codes)	with	a	contraception-related	diagnosis,	and	all	pharmacy	claims	for	contraceptive	drugs	and	devices	for	the	target	population.		The	estimated	RDC	PMPM	paid	claim	amount	for	the	calendar	year	2014	study	period	was	$3.32,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$3.73	(or	0.86	percent	of	the	Commonwealth	total	premium).		Table	32	below	displays	a	summary	of	these	results	and	related	statistics.	
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Table	32	
Contraception	Mandate	
Required	Direct	Cost	Estimate	
	
Cytological	Screening	(Pap	Smear)	The	cytological	screening	mandate	requires	coverage	for	cytological	screening	annually	for	women	18	years	and	older.713	Effect	of	the	mandate	on	health	According	to	the	American	Cancer	Society,	“[c]ervical	cancer	incidence	and	mortality	rates	have	decreased	by	more	than	50%	over	the	past	three	decades,	with	most	of	the	reduction	attributed	to	screening	with	the	Papanicolaou	(Pap)	test,	which	detects	cervical	cancer	and	precancerous	lesions.”714,715,716		Further,	the	survival	rate	for	women	with	precancerous	lesions	diagnosed	through	the	Pap	test	is	nearly	100	percent,	as	cancer	is	prevented	altogether,	and	women	with	localized	cervical	cancer,	most	often	detected	early,	have	a	five-year	survival	rate	of	91	percent.717,718		Yet	approximately	half	of	cervical	cancers	are	not	diagnosed	until	later	stages,	when	five-year	survival	rates	are	much	lower.		The	five-year	survival	rate	for	regional-stage	cervical	cancer	is	57	percent,	and	is	only	16	percent	for	distant-stage	cervical	cancer;719	most	women	diagnosed	at	these	stages	have	not	had	a	Pap	screening	within	the	five	years	prior	to	diagnosis.720	While	the	Pap	test	has	been	extremely	helpful	in	identifying	precancer	and	early	stage	cancer	in	women	who	are	screened,	cervical	cancer	remains	the	second	most	common	cancer	for	women	worldwide.721		Research	into	the	causes	and	progression	of	cervical	cancer	has	expanded	rapidly	in	recent	years,	and	these	studies	have	found	that	almost	all	cases	of	cervical	cancer	are	causally	related	to	persistent	infection	with	certain	types	of	human	papillomavirus	(HPV).722		HPV	is	the	most	common	sexually	transmitted	infection	in	the	US,	causing	90	percent	of	all	anal	cancers,	60	
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Bound	PMPMs	
Sample	Users 164,542											
Sample	Units 32,706,555					
Sample	Average	Members 1,437,788								
Paid	PMPM 3.32$																 N/A N/A
Paid	PMPM	With	Admin 3.73$																 N/A N/A
Allowed	PMPM 3.50$																 N/A N/A
	Required	
Direct	Cost	
	FI-SI	Allowed	
&	Lower	
Bound	PMPMs	
Insured	Population 2,362,745 2,362,745
Contribution	to	Total	Annual	Claims 94,197,565$			 -$																		
Contribution	to	Total	Annual	Premium 105,839,960$	 -$																		
Percent	of	Total	Premium 0.86% 0.00%
*	The	requirements	of	the	Massachusetts	mandate	have	been	superseded	by	the	ACA.
Required	direct	cost	was	estimated	using	the	Massachusestts	APCD.
Comprehensive	Mandated	Benefit	Review	
compass Health Analytics 80 December 2016 
percent	of	certain	types	of	oropharyngeal	cancers,	and	40	percent	of	vaginal,	vulvar,	and	penile	cancers.723		This	new	understanding	of	the	causes	of	these	cancers	has	led	to	a	shift	from	a	strategy	mostly	focused	on	screening	for	pre-cancers	and	cancers,	to	approaches	that	include	vaccination	against	HPV	to	prevent	infection,	as	well	as	screening	not	only	for	precancers	and	cancers,	but	also	HPV	itself.			Initial	infection	with	HPV	is	common	in	young	women	within	their	first	decade	of	sexual	activity.724		However,	less	than	10	percent	of	these	infections	persist	and,	relatively	slowly,	become	precancer,	most	often	between	5	and	10	years	after	initial	infection.725		From	these,	a	minority	of	cases	progress	to	invasive	cancer;	this	also	most	often	takes	many	years	or	decades,	with	the	risk	highest	in	women	35	to	55	years	old.726	Given	these	statistics,	agreement	is	near-universal	on	the	benefits	of	cytological	screening	for	women,	and	many	U.S.	government	agencies	and	medical	societies	now	agree	on	a	single	set	of	recommendations	regarding	testing	methods	and	intervals	released	in	March	2012.		These	recommendations	call	for	less-frequent	screening,	as	researchers	have	found	that:		[S]creening…	more	often	than	every	3	years	confers	little	additional	benefit,	with	large	increases	in	harms,	including	additional	procedures	and	assessment	and	treatment	of	transient	lesions.		Treatment	of	lesions	that	would	otherwise	resolve	on	their	own	is	harmful	because	it	can	lead	to	procedures	with	unwanted	side	effects,	including	the	potential	for	cervical	incompetence	and	preterm	labor.		Similarly,	the	frequency	of	HPV	testing	with	cytology	should	not	be	more	often	than	every	5	years	in	order	to	maintain	a	reasonable	balance	of	benefits	and	harms	similar	to	that	seen	with	cytology	alone	every	3	years.727	The	cytological	screening	mandate	in	Massachusetts	requires	coverage	for	screening	annually	for	women	18	years	and	older,	a	frequency	greater	than	that	in	the	current	guidelines.	The	USPSTF	currently	gives	the	recommendations	for	women	age	21	to	29	and	30	to	64	grades	of	“A”.		Under	the	ACA,	non-grandfathered	health	insurance	plans	must	fully	cover	the	costs	of	recommended	preventive	services	graded	“A”	or	“B”	without	patient	cost	sharing	(no	deductibles,	coinsurances	or	copayments).728,729		However,	the	USPSTF	recently	released	its	“Final	Research	Plan	for	Cervical	Cancer	Screening”,	indicating	it	will	again	conduct	a	systematic	review	of	research	to	form	the	basis	of	an	updated	recommendation.730	
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Cytological	Screening	Recommendations731	
Recommending	
organizations	
General	
recommendations	
Women	age	
21-29	 30-64	 65+	
• American	Cancer	
Society/	American	
Society	for	
Colposcopy	and	
Cervical	
Pathology/American	
Society	for	Clinical	
Pathology	
(ACS/ASCCP/ASCP)	
(adopted	March	
2012)732	
• US	Preventive	
Services	Task	
Force/American	
Academy	of	Family	
Physicians	
(USPSTF/AAFP)	
(adopted	March	
2012)733	
• American	College	of	
Obstetrics	and	
Gynecology	(ACOG)	
(adopted	December	
2013)734	
• No	annual	screening	
• No	screening	for	
women	under	age	21	
• No	screening	for	HPV	
for	women	under	age	
30	
• No	screening	for	
women	with	total	
hysterectomy	
• Routine	screening	
should	continue	for	
women	found	to	have	
a	high-grade	
precancerous	lesion	
within	past	20	years,	
regardless	of	age	
• Pap	test	every	
3	years	
Preferred:	
• HPV	and	Pap	
test	every	5	
years	
	
Acceptable:	
• Pap	test	every	
3	years	
No	more	tests	if:	
• No	history	of	
cervical	
intraspithelial	
neoplasia	2	or	
higher	within	
the	last	20	
years	–AND–	
• Adequate	
testing	history	
within	the	last	
10	years	(most	
recent	test	
within	the	past	
5	years)	of	
either	3	
consecutive	
negative	Pap	
tests	or	2	
consecutive	
negative	HPV	
and	Pap	tests		
	
	Discussion	of	the	cost	of	the	mandate		The	cytological	screen	mandate	requires	coverage	for	cytological	screening	(Par	smear)	annually	for	women	18	years	and	older.	For	this	analysis,	the	cost	of	the	cytological	screening	mandate	reflected	in	insurance	premiums	is	estimated	as	the	total	cost	to	fully-insured	plans	subject	to	the	mandate	for	cytological	screening	procedure	codes	(sample	collection	and	reading	and	interpretation	codes)xxix	for	women	aged	18	or	older	on	the	date	of	service.		The	estimated	RDC	PMPM	paid	claim	amount	for	the	calendar	year	2014	study	period	was	$0.62,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$0.69	(or	0.16	percent	of	the	Commonwealth	total	premium).		Table	33	below	displays	a	summary	of	these	results	and	related	statistics.	
																																								 																					xxix	HCPCS	codes	88141,	88142,	88143,	88147,	88148,	88155,	88164,	88165,	88174,	88175,	P3000,	P3001,	G0123,	G0124,	G0141,	G0143,	G0144,	G0145,	G0147,	G0148,	or	Q0091.	
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Table	33	
Cytological	Screening	(Pap	Smear)	Mandate	
Required	Direct	Cost	Estimate	
	
Hearing	Screening	for	Newborns	This	mandate	requires	coverage	for	hearing	screening	for	newborns.735	Effect	of	the	mandate	on	health	Permanent	congenital	hearing	loss	(PCHL)	affects	approximately	1.5	infants	screened	per	thousand	in	the	United	States	each	year.736		In	Massachusetts,	approximately	1300	newborns	each	year	fail	a	hearing	screening	before	leaving	the	hospital,	and	approximately	220	of	these	are	diagnosed	with	hearing	loss	after	more	extensive	testing.737		Hearing	loss,	if	left	undetected,	can	negatively	impact	a	child’s	development	in	many	ways,	resulting	in	“difficulties	later	in	life,	including	problems	with	listening	and	speaking	skills,	literacy	skills,	academic	performance,	and	long-term	job	opportunities.”738		Research	suggests	that	a	child’s	speech	and	language	development	is	most	intensive	during	the	first	three	years	of	life,	when	the	brain	is	creating	the	nerve	pathways	necessary	for	“understanding	auditory	information.”739	Age	at	diagnosis	influences	outcomes	for	children	with	PCHL:	the	earlier	the	detection,	the	more	options	and	opportunity	for	treatment,	and	the	better	the	outcome.740,741		As	research	continues	to	describe	the	rapid	development	of	the	brain	before	the	age	of	three,742	and	positive	outcomes	are	increasingly	associated	with	early	enrollment	of	hearing-impaired	children	into	treatment	programs,743	it	becomes	more	critical	to	lower	the	age	of	diagnosis	to	as	early	as	possible,	and	at	no	later	than	at	three	months	of	age.744	Universal	newborn	screening	leads	to	earlier	detection	and	treatment	of	PCHL.745		Newborn	screening	is	the	standard	of	care	nationwide,	as	recommended	by	the	Joint	Committee	on	Infant	
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Bound	PMPMs	
Sample	Users 230,421											
Sample	Units 281,588											
Sample	Average	Members 1,871,491								
Paid	PMPM 0.62$																 N/A N/A
Paid	PMPM	With	Admin 0.69$																 N/A N/A
Allowed	PMPM 0.62$																 N/A N/A
	Required	
Direct	Cost	
	Upper	and	
Lower	Bound	
Impact*	
Insured	Population 2,362,745 2,362,745
Contribution	to	Total	Annual	Claims 17,536,272$			 -$																		
Contribution	to	Total	Annual	Premium 19,703,676$			 -$																		
Percent	of	Total	Premium 0.16% 0.00%
*	This	mandate	was	judged	by	carriers	to	contribute	$0	marginal	cost	to	premiums.
Required	direct	cost	was	estimated	using	the	Massachusestts	APCD.
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Hearing	(JCIH),	the	U.S.	Centers	for	Disease	Control	and	Prevention,	the	National	Institute	on	Deafness	and	Other	Communication	Disorders	at	the	U.S.	National	Institutes	of	Health,	and	the	U.S.	Healthy	People	2020	initiative,	all	of	which	advocate	for	universal	screening	for	infants	before	one	month	of	age.746,747,748,749	The	Joint	Committee	on	Infant	Hearing	(JCIH)	endorses	early	detection	of	and	intervention	for	infants	with	hearing	loss,	“to	maximize	linguistic	competence	and	literacy	development	for	children	who	are	deaf	or	hard	of	hearing.”750		The	group	recommends	screening	for	all	infants	at	no	later	than	one	month	of	age,	with	comprehensive	audiological	evaluations	before	three	months	of	age	for	those	who	do	not	pass	the	initial	screening.751		Before	six	months	of	age,	those	with	confirmed	hearing	“should	receive	appropriate	intervention…from	health	care	and	education	professionals	with	expertise	in	hearing	loss	and	deafness	in	infants	and	young	children.”752		The	group	also	recommends	that	well-child	visits	for	all	children	include	“ongoing	surveillance	of	communicative	development	beginning	at	2	months	of	age	during	well-child	visits.”753	All	states	have	established	Early	Hearing	Detection	and	Intervention	(EHDI),	43	of	which	mandate	newborn	hearing	screening	programs.754		These	programs	are	making	progress	toward	the	goal	of	screening	all	infants,	and	earlier	diagnosis	and	treatment	enrollment	for	those	with	hearing	loss,	as	evidenced	by	a	CDC	Early	Hearing	Detection	and	Intervention	survey	of	46	U.S.	states	and	territories	showing	that	in	2013,	97	percent	of	infants	were	screened	for	hearing	impairments,	and	69	percent	of	infants	were	diagnosed	before	three	months	of	age.755		In	fact,	the	survey	shows	improvement	in	several	measures	for	diagnosis	and	treatment	of	PHCL.756,757	
CDC	EHDI	Survey	Data	for	2005	and	2013	
	 2005	 2013	
Improvement	
2005	to	2013	
Infants	received	hearing	screening	before	age	1	month	 80.1%	 91.7%	 14.5%	
Infants	received	recommended	diagnostic	follow-up	before	
age	3	months	 51.5%	 69.2%	 34.4%	
Infants	with	hearing	loss	enrolled	in	early	intervention	
before	age	6	months	 57.0%	 62.1%	 8.9%	
	The	USPSTF	currently	gives	a	“B”	rating	to	screening	for	hearing	loss	in	all	newborns,758	although	the	specific	recommendation	has	been	designated	“Inactive”.759		Under	the	ACA,	non-grandfathered	health	insurance	plans	must	fully	cover	the	costs	of	recommended	preventive	services	graded	“A”	or	“B”	without	patient	cost	sharing	(no	deductibles,	coinsurances	or	copayments).760,761	Discussion	of	the	cost	of	the	mandate		The	hearing	screening	for	newborns	mandate	requires	coverage	for	newborn	hearing	screening	tests.		The	cost	of	the	universal	newborn	hearing	screening	is	based	upon	the	number	of	newborns	in	the	state	who	were	tested	in	2014.		The	U.S.	Centers	for	Disease	Control	and	Prevention	(CDC)	reports	that	71,573	newborns	were	tested	under	the	program	in	2013.762		Applying	the	statewide	74.7	percent	private	health	insurance	rate	to	the	total	tested	newborns	and	the	49.1	percent	factor	representing	the	proportion	of	individuals	covered	by	Massachusetts-licensed	fully-insured	commercial	health	insurance	to	that	result	yields	an	estimated	26,225	fully-insured	and	GIC	
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newborns	tested.		The	average	cost	of	hearing	screening	tests	in	the	2014	MA	APCDxxx	was	approximately	$126.56.		This	brings	the	total	spent	by	insurers	for	the	newborn	screenings	to	$3.3	million,	or	$3.7	million	with	an	11	percent	administrative	load.		The	total	expense	PMPM	for	the	2.4	million	privately	fully-insured	and	GIC	under-65	individuals	is	then	$0.13,	or	0.03	percent	of	the	total	premium.		These	results	are	summarized	in	Table	34	below.	
Table	34	
Hearing	Screening	for	Newborns	Mandate	
Required	Direct	Cost	Estimate	
	
Hospice	Care	The	hospice	mandate	requires	coverage	for	licensed	hospice	services	for	terminally	ill	patients	with	a	life	expectancy	of	six	months	or	less.763	Effect	of	the	mandate	on	health	Research	into	the	medical	effectiveness	and	efficacy	of	hospice	care	is	difficult	to	conduct,	given	that	hospice	care	is	provided	to	dying	patients	no	longer	seeking	cures.		Hospice	care	is,	instead,	“a	program	of	palliative	and	supportive	care	services	providing	physical,	psychological,	social,	and	spiritual	care	for	dying	persons,	their	families,	and	other	loved	ones.”764		Services	are	provided	in	a	variety	of	settings,	including	the	home,	nursing	home,	and	hospital,	and	are	tailored	to	the	needs	of	individual	patients	and	families.		Outcomes	of	such	treatment	are	variable	and	subjective,	given	that	care	is	not	intended	to	improve	a	disease-state,	but	is	instead	a	multidisciplinary	approach	to	“caring	for	the	whole	person	including…physical,	emotional,	social	and	spiritual	needs.”765	Measures	of	the	quality	of	the	patient’s	life	are	a	difficult	proxy	to	use,	as	data	are	often	difficult	to	obtain	from	patients	in	the	period	immediately	preceding	death,	and	many	perceive	that	a	patient’s																																									 																					xxx	HCPCS	codes	92586,	92587,	and	92588.	
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Bound	PMPMs	
Sample	Users N/A
Sample	Units N/A
Sample	Average	Members N/A
Paid	PMPM 0.12$																 N/A N/A
Paid	PMPM	With	Admin 0.13$																 N/A N/A
Allowed	PMPM N/A N/A N/A
	Required	
Direct	Cost	
	Upper	and	
Lower	Bound	
Impact*	
Insured	Population 2,362,745 2,362,745
Contribution	to	Total	Annual	Claims 3,319,019$					 -$																		
Contribution	to	Total	Annual	Premium 3,729,235$					 -$																		
Percent	of	Total	Premium 0.03% 0.00%
*	This	mandate	was	judged	by	carriers	to	contribute	$0	marginal	cost	to	premiums.
Required	direct	cost	was	estimated	using	secondary	data	sources.
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quality	of	life	often	deteriorates	until	death.766		Despite	these	difficulties,	however,	some	studies	have	shown	hospice	care	to	be	associated	with	a	relatively	high	and	stable	quality	of	life,767	improved	pain	control,	decreased	hospitalizations,	and	decreased	tube	feedings	for	terminal	nursing	home	patients,768	improved	quality	of	death,769	and	a	reduction	in	mortality	for	the	widowed	spouse.770		A	Cochrane	review	found	that	home-based	hospice	care	increases	the	number	of	patients	who	die	at	home	versus	in	the	hospital,	which	is	more	in	line	with	their	personal	preferences.771		Two	oft-cited	studies	found	that	“for	certain	well-defined	terminally	ill	populations,	among	the	patients	who	died,	patients	who	choose	hospice	care	live	longer	on	average	than	similar	patients	who	do	not	choose	hospice	care,”772	although	the	authors	point	out	that	more	research	is	needed	before	generalizing	their	findings.773	Discussion	of	the	cost	of	the	mandate	In	2009,	22,406	persons	received	hospice	services	in	Massachusetts	through	Medicare	fee-for-service774	at	a	cost	of	almost	$231	million.775	Assessing	the	level	of	hospice	spending	in	Medicare	should	take	into	account	managed	care	plan	membership,	which	is	not	included	in	the	previously	cited	fee-for-service	figures.		In	2009,	23	percent	of	members	were	enrolled	in	Medicare	Advantage	plans.776		Assuming	that	Medicare	Advantage	members	utilize	hospice	services	at	the	same	rate	as	those	in	fee-for-service	plans,	the	estimated	spending	on	hospice	expense	for	Medicare	would	rise	to	approximately	$300	million	in	total.	According	to	the	Hospice	Association	of	America,	Medicare	represents	about	84.3	percent	of	spending	for	hospice	services.777		Based	on	this	proportion,	overall	spending	on	hospice	expenses	would	be	approximately	$356	million	in	2009.		National	Health	Expenditures	(NHE)	data	for	“other	health,	residential,	and	personal	care	expenditures”	reported	by	for	the	Centers	for	Medicare	and	Medicaid	Services	(CMS)	suggests	a	5-year	inflation	rate	of	21	percent	for	this	figure,778	yielding	an	estimate	of	$431	million	in	total	2014	hospice	spending.		The	portion	of	this	figure	paid	by	private	payers	is	approximately	7.8	percent,779	or	$33.6	million.		Applying	the	49.1	percent	Massachusetts	2014	fully-insured	factor	provides	an	estimate	of	$16.5	million	of	hospice	spending,	assuming	similar	per-case	costs	across	all	private	payers.		With	11	percent	administrative	loading,	the	total	spending	on	hospice	care	for	the	under-65	fully-insured	member	population	and	self-insured	GIC	enrollees	in	Massachusetts	in	2014	is	estimated	at	approximately	$18.5	million,	or	$0.65	PMPM,	representing	0.15	percent	of	the	overall	premium.		These	results	are	summarized	in	Table	35	below.	
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Table	35	
Hospice	Care	Mandate	
Required	Direct	Cost	Estimate	
	
Lead	Poisoning	Screening	The	lead	screening	mandate	requires	coverage	for	screening	for	lead	poisoning	for	all	children	under	age	six	and	for	others	deemed	at	risk.780	Effect	of	the	mandate	on	health	Elevated	blood	lead	levels	can	significantly	harm	many	of	the	body’s	systems,	including	cardiovascular,	immune,	endocrine,	and	neurological,	with	irreversible	negative	impact	on	cognitive	function,	especially	attention-related	behavior	and	academic	achievement.781		Numerous	studies	have	shown	that	even	low	blood	lead	levels	(BLLs;	below	10mg/dL)	harm	children.782	Over	time,	federal	and	state	legislation	has	directed	the	removal	of	lead	from	gasoline	and	residential	paints,	as	well	as	the	reduction	of	toxic	emissions	from	smelters	and	other	industrial	sources.783		This	has	resulted	in	a	reduction	in	the	median	national	BLL	for	children	under	age	5	from	15	mcg/dL	in	1980	(prior	to	full	implementation	and	effect	of	legislation)	to	3.6	mcg/dL	in	1991,	and	1.9	mcg/dL	by	1999.784		According	to	CDC	data,	the	percentage	of	children	in	Massachusetts	found	to	have	BLLs	greater	than	10	mcg/dL	has	fallen	from	3.23	percent	in	1997	to	0.32	percent	in	2013,	a	90	percent	reduction	over	16	years.785	While	exposure	risk	has	decreased	across	the	entire	population,	the	prevalence	of	higher	BLLs,	as	well	as	risk	of	exposure,	vary	significantly	within	population	subgroups	and	are	more	frequent	among	low-income	populations	more	likely	to	reside	in	buildings	constructed	before	1978.786		
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Bound	PMPMs	
Sample	Users N/A
Sample	Units N/A
Sample	Average	Members N/A
Paid	PMPM 0.58$																 N/A N/A
Paid	PMPM	With	Admin 0.65$																 N/A N/A
Allowed	PMPM N/A N/A N/A
	Required	
Direct	Cost	
	Upper	and	
Lower	Bound	
Impact*	
Insured	Population 2,362,745 2,362,745
Contribution	to	Total	Annual	Claims 16,486,810$			 -$																		
Contribution	to	Total	Annual	Premium 18,524,505$			 -$																		
Percent	of	Total	Premium 0.15% 0.00%
*	This	mandate	was	judged	by	carriers	to	contribute	$0	marginal	cost	to	premiums.
Required	direct	cost	was	estimated	using	secondary	data	sources.
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Moreover,	research	has	shifted	from	focusing	on	the	impact	of	high	BLLs	on	child	health	to	show	the	negative	impact	of	lower	BLLs	(below	10	mcg/dL)	on	childhood	development.	787	This	information	has	led	to	a	change	in	public	health	advocacy	from	recommending	screening	of	all	children	for	lead	exposure,	to	targeted	screening	for	certain	populations	and	a	primary	prevention	strategy	aimed	at	children	and	families	most	likely	to	live	in	homes	with	lead	hazards.		Many	of	the	recommendations	and	guidelines	issued	by	public	and	professional	medical	organizations	have	changed	over	time,	as	various	public	health	and	environmental	efforts	have	been	implemented	and	sometimes	phased	out,	with	other	approaches	evolving	and	replacing	them.788	For	example,	in	2012,	the	CDC	updated	its	recommendations	regarding	BLLs	in	children,	and	shifted	its	focus	to	primary	prevention	of	lead	exposure.		The	new	goals	are	to	eradicate	BLLs	greater	than	10	mcg/dL,	and	eliminate	average	risk	differences	that	exist	“based	on	race	and	social	class.”789		The	threshold	BLL	used	to	identify	children	who	need	medical	intervention	is	now	lower	and	will	be	periodically	adjusted,	rather	than	remaining	fixed	at	10	mcg/dL.790		This	public	health	initiative	is	part	of	the	National	Center	for	Environmental	Health's	Division	of	Emergency	and	Environmental	Health	Services,	and	is	in	line	with	the	Healthy	People	2020	program	of	the	federal	government,	which	revised	its	targets	for	reducing	BLLs	for	children	in	2014,	establishing	a	10	percent	improvement	goal	for	two	areas	of	measurement.791	According	to	the	American	Academy	of	Pediatrics	Bright	Futures	periodicity	table	of	Recommendations	for	Preventive	Pediatric	Health	Care,	a	lead	exposure	risk	assessment	is	recommended	at	preventive	health	visits	multiple	times	during	infancy	through	adolescence.792,793		Finger	stick	blood	sample	screenings	are	to	be	performed	at	the	12-	and	24-month	visits	if	a	patient	is	identified	through	screening,	lives	in	a	high-prevalence	area,	or	is	required	by	Medicaid	rules.794,795		These	rules	were	updated	for	children	eligible	for	Medicaid	Early	and	Periodic	Screening,	Diagnosis	and	treatment	(EPSDT)	services	in	June	2012	by	CMS.		This	policy	is	now	aligned	with	the	CDC	recommendations,	and	supports	a	targeted	screening	approach	“in	States	that	have	sufficient	data	to	support	this	action.”796	In	Massachusetts,	universal	screening	is	required	by	Department	of	Public	Health	regulations,	as	all	children	must	be	screened	for	lead	poisoning	at	least	twice:	once	between	nine	and	twelve	months	of	age,	and	again	between	two	and	three	years	of	age;	children	must	provide	evidence	of	screening	to	gain	entry	to	kindergarten.797		Children	living	in	areas	identified	as	high	risk	are	also	required	to	be	screened	at	age	four.798		Children	identified	by	health	care	providers	as	high-risk,	including	those	who	live	in	a	pre-1978	home	that	has	not	been	inspected	for	lead	paint,	or	who	have	siblings	identified	with	lead	poisoning,	should	be	screened	every	six	months	between	ages	six	months	and	three	years,	and	annually	at	ages	four	and	five.	799		And	children	living	in	a	pre-1978	home	undergoing	renovation	and	that	has	not	been	inspected	for	lead	paint	are	to	be	screened	within	four	weeks	of	the	start,	monthly	during,	and	once	after	completion	of	the	renovation.800	Only	those	screenings	conducted	at	age	four	for	children	living	in	areas	identified	as	high	risk,	or	those	for	children	identified	by	their	health	care	provider	as	high-risk,	are	subject	to	the	insurance	reimbursement	requirements	of	this	mandate.801	
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The	USPSTF	concludes	that	evidence	is	insufficient	to	recommend	routine	screening	for	at-risk	children,	as	there	is	not	enough	information	to	“assess	the	balance	between	potential	benefits	and	harms.”802		For	children	and	asymptomatic	pregnant	women	of	average	risk,	the	USPSTF	has	concluded	that,	“[g]iven	the	significant	potential	harms	of	treatment	and	residential	lead	hazard	abatement,	and	no	evidence	of	treatment	benefit,	...the	harms	of	[universal]	screening…outweigh	the	benefits.”803	Discussion	of	the	cost	of	the	mandate	For	this	analysis,	the	cost	of	the	lead	screening	mandate	reflected	in	insurance	premiums	is	estimated	as	the	total	cost	to	fully-insured	plans	subject	to	the	mandate	for	lead	screening	lab	tests	(HCPCS	code	83655)	and	collection	of	capillary	blood	specimens	(HCPCS	code	36416)	within	the	week	prior	to	the	lab	test	for	children	aged	5	or	younger	on	the	date	of	service.		The	estimated	RDC	PMPM	paid	claim	amount	for	the	calendar	2014	study	period	was	$0.04,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$0.05	(or	0.01	percent	of	the	Commonwealth	total	premium).		These	results	are	summarized	below	in	Table	36.	
Table	36	
Lead	Poisoning	Screening	Mandate	
Required	Direct	Cost	Estimate	
	
Mammography	The	mammography	mandate	requires	coverage	for	one	"baseline"	mammogram	between	ages	35	and	40,	and	annual	measurements	thereafter.804	Effect	of	the	mandate	on	health	According	to	the	CDC,	breast	cancer	is	the	most	common	cancer	for	women	in	the	United	States,	and	is	second	only	to	lung	cancer	in	mortality	rate.805		Mammography	can	detect	presymptomatic	breast	
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Bound	PMPMs	
Sample	Users 43,023													
Sample	Units 49,226													
Sample	Average	Members 1,871,491								
Paid	PMPM 0.04$																 N/A N/A
Paid	PMPM	With	Admin 0.05$																 N/A N/A
Allowed	PMPM 0.04$																 N/A N/A
	Required	
Direct	Cost	
	Upper	and	
Lower	Bound	
Insured	Population 2,362,745 2,362,745
Contribution	to	Total	Annual	Claims 1,200,660$					 -$																		
Contribution	to	Total	Annual	Premium 1,349,057$					 -$																		
Percent	of	Total	Premium 0.01% 0.00%
*	This	mandate	was	judged	by	carriers	to	contribute	$0	marginal	cost	to	premiums.
Required	direct	cost	was	estimated	using	the	Massachusestts	APCD.
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cancer	which	can	be	more	effectively	treated	at	this	early	stage.806		Screening	can	also	reduce	breast	cancer	mortality,	especially	for	women	ages	50	to	74.		The	U.S.	Preventive	Services	Task	Force	(USPSTF)	states	that	the	“strongest	evidence	for	the	greatest	benefit	is	among	women	aged	60	to	69	years.”807	However,	screening	also	can	result	in	unnecessary	additional	tests	and	treatments,	as	well	as	the	psychological	harm	associated	with	false-positive	results.808		Some	cancers	found	through	mammography	and	treated	may	not	become	“clinically	apparent	during	a	woman’s	lifetime”,	so-called	“over-diagnosis”,	or	may	become	clinically	apparent	but	not	result	in	a	shortened	life	expectancy.809		False-positive	results	are	more	common	in	women	age	40	to	49,	while	over-diagnosis	is	“a	greater	concern”	for	women	who	are	older.810	While	experts	agree	that	mammography	is	effective	in	identifying	breast	cancer,	the	recommended	screening	schedule	is	somewhat	controversial,	particularly	regarding	the	risks	and	benefits	of	annual	mammography	for	women	of	average	risk	between	40	and	50	years	of	age.		Various	organizations	have	changed	their	guidelines	multiple	times	within	the	past	10	to	15	years;	the	most	recent	guidelines	of	seven	leading	organizations	are	reflected	in	the	following	table.	
Screening	for	Breast	Cancer	for	Women	at	Average	Risk:	Comparative	Guideline	Table	
Issuing	Organization	(Year)	
Recommendation	for	Women	
Age	40-49													Age	50-74/75											Age	75+	
Based	on	
systematic	review	
American	Academy	of	Family	
Physicians811	(2013)	
Based	on	
counseling	and	
individual	decision	
Age	50-74	Screen	
every	1-2	years	
Insufficient	
evidence	for	
recommendation	
Yes	(USPSTF	cited)	
American	Cancer	Society812	
(2015)	
Screen	annually	
beginning	at	age	
45.		
Opportunity	for	
annual	screening	
for	women	age	40-
44.	
Screen	biennially.	
Opportunity	for	annual	screening,	
until	life	expectancy	is	less	than	10	
years.	
Yes813	
Previous	American	Cancer	
Society814	(2003;	revised	2014)	 Screen	annually	
Screen	annually	indefinitely	in	healthy	
patients	 No	
American	Congress	of	
Obstetricians	and	
Gynecologists815	(2011)	
Screen	annually	 Individualize	screening	
Yes	(based	on	
USPSTF)	
American	College	of	
Physicians816,817	(2007)	(ACP)	
Based	on	
counseling	and	
individual	decision	
Age	50-74	
Screen	annually	
Based	on	
counseling	and	
individual	
decision	
Yes	
American	College	of	
Radiology818	(2013)	 Screen	annually	
Screen	annually	until	life	expectancy	is	
less	than	5-7	years	 No	
Institute	for	Clinical	Systems	
Improvement819	(2013)	
Based	on	
counseling	and	
individual	decision	
Age	50-75	Screen	
every	1-2	years;	
consider	screening	
older	women	based	
on	shared	decision	
making	
Based	on	
counseling	and	
individual	
decision	
No	(USPSTF	cited)	
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Issuing	Organization	(Year)	
Recommendation	for	Women	
Age	40-49													Age	50-74/75											Age	75+	
Based	on	
systematic	review	
U.S.	Preventive	Service	Task	
Force	(2009)820	
Based	on	
counseling	and	
individual	decision;	
do	not	screen	
routinely	
Age	50-74	Screen	
biennially	
(Grade	B)	
Evidence	for	
screening	is	
insufficient	
Yes	
	The	Massachusetts	mandate	is	in	line	with	the	2003	American	Cancer	Society	(ACS),	American	College	of	Radiology	(ACR),	and	American	Congress	of	Obstetricians	and	Gynecologists	(ACOG)	recommendations	of	annual	mammography	for	women	beginning	at	age	40.821,	822,823	In	October	2015,	the	American	Cancer	Society	revised	its	guidelines,	based	on	its	systematic	review	of	evidence	on	breast	cancer	screening	published	to	date,	as	well	as	judgment	on	the	benefits	and	harms	of	screening	that	incorporated	the	values	and	preferences	of	patients	and	providers.824		Screening	is	now	recommended	annually	for	women	beginning	at	age	45.825	The	final	recommendations	of	the	USPSTF,	released	in	2016,	give	a	“B”	rating	to	the	recommendation	for	women	ages	50	to	74	to	receive	a	biennial	mammogram.	826		They	again	state	that	evidence	in	support	of	screening	for	women	ages	75	and	over	is	insufficient,	and	that	for	women	between	the	ages	of	40	and	49,	“[t]he	decision	to	start	screening	prior	to	age	50	years	should	be	an	individual	one.		Women	who	place	a	higher	value	on	the	potential	benefit	than	the	potential	harms	may	choose	to	begin	screening	between	the	ages	of	40	and	49	years.”827	Under	its	current	recommendations,	the	USPSTF	gave	the	recommendations	for	biennial	mammography	for	women	age	50	to	74	a	grade	of	“B”.828		Under	the	ACA,	non-grandfathered	health	insurance	plans	must	fully	cover	the	costs	of	recommended	preventive	services	graded	“A”	or	“B”	without	patient	cost	sharing	(no	deductibles,	coinsurances	or	copayments).829,830			Discussion	of	the	cost	of	the	mandate		The	mammography	mandate	requires	coverage	for	one	"baseline"	mammogram	between	ages	35	and	40,	and	annual	measurements	thereafter.	For	this	analysis,	the	cost	of	the	mammography	mandate	reflected	in	insurance	premiums	is	estimated	as	the	total	cost	to	fully-insured	plans	subject	to	the	mandate	for	one	bilateral	(HCPCS	code	77056	or	77057)	or	two	unilateral	mammograms	(HCPCS	code	77057),	plus	the	first	additional	thoracic	radiological	servicexxxi	incurred	subsequent	to	the	mammogram,	per	woman	aged	35	or	over	receiving	at	least	one	mammogram	during	2014.		The	estimated	RDC	PMPM	paid	claim	amount	for	the	calendar	year	2014	study	period	was	$0.62,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$0.70	(or	0.16	percent	of	the	Commonwealth	total	premium).		These	results	are	summarized	below	in	Table	37.	
																																								 																					xxxi	HCPCS	codes	77051,	77052,	77053,	or	77054.	
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Table	37	
Mammography	Mandate	
Required	Direct	Cost	Estimate	
	
Maternity	Care	and	Minimum	Maternity	Stay	The	maternity	care	mandate	requires	coverage	for	"prenatal	care,	childbirth	and	post	partum	care	to	the	same	extent	as	provided	for	medical	conditions	not	related	to	pregnancy"	with	a	"minimum	48	hours	of	in-patient	care	following	a	vaginal	delivery	and	a	minimum	of	96	hours	of	inpatient	care	following	a	caesarean	section	(c-section)."831	Effect	of	the	mandate	on	health	Prenatal	care	has	been	practiced	widely	in	the	U.S.	since	the	early	twentieth	century,	and	has	proven	effective	at	minimizing	maternal	mortality832	and	helping	to	reduce	fetal,	newborn,	and	perinatal	(associated	with	birth)	mortality.833		Further,	studies	have	shown	better	control	of	preeclampsia	(pregnancy-related	high	blood	pressure),834	gestational	diabetes,835	and	HIV836	through	prenatal	care.		Some	research	also	points	to	a	reduction	in	pre-term	delivery,	full-term	low	birth	weight,	and	babies	small	for	their	gestational	age	for	women	with	adequate	prenatal	care.837	
Length	of	maternity	stay	Studies	of	maternity	stays	have	found	that	hospital	discharges	for	newborns	at	any	time	less	than	48	hours	“significantly	increases	the	risk	for	readmission.”838		The	American	Academy	of	Pediatrics	(AAP)	and	the	American	College	of	Obstetricians	and	Gynecologists	(ACOG)	cite	a	myriad	of	problems	that	may	arise	if	a	hospital	stay	is	not	sufficiently	long	to	identify	problems	and	ensure	the	mother	“is	sufficiently	recovered	and	prepared	to	care	for	herself	and	her	newborn	at	home.”839		Issues	include	neonatal	cardiopulmonary	problems,	jaundice,	ductal-dependent	cardiac	lesions,	and	gastrointestinal	obstructions	for	the	newborn,	as	well	as	endometritis	and	other	significant	
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Bound	PMPMs	
Sample	Users 251,351											
Sample	Units 489,773											
Sample	Average	Members 1,871,491								
Paid	PMPM 0.62$																 N/A N/A
Paid	PMPM	With	Admin 0.70$																 N/A N/A
Allowed	PMPM 0.63$																 N/A N/A
	Required	
Direct	Cost	
	Upper	and	
Lower	Bound	
Impact*	
Insured	Population 2,362,745 2,362,745
Contribution	to	Total	Annual	Claims 17,692,055$			 -$																		
Contribution	to	Total	Annual	Premium 19,878,713$			 -$																		
Percent	of	Total	Premium 0.16% 0.00%
*	This	mandate	was	judged	by	carriers	to	contribute	$0	marginal	cost	to	premiums.
Required	direct	cost	was	estimated	using	the	Massachusestts	APCD.
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maternal	complications.840		Services	performed	in	the	post-partum/pre-discharge	stay	include	newborn	screenings	and	risk	assessment;	administration	of	immunizations;	maternal	and	family	counseling	and	assessments,	and	perinatal	education	on	issues	such	as	breast-feeding,	newborn	sleep	position,	tobacco	smoke	exposure,	car	seat	safety,	mental	health	including	post-partum	depression,	and	domestic	violence;	and	follow-up	care	planning	for	mother	and	baby.841	Post-partum	hospital	stays	for	mother	and	baby	have	changed	significantly	over	the	last	four	decades,	with	stays	for	vaginal	delivery	dropping	from	3.9	to	1.8	days	and	for	caesarian	deliveries	from	7.8	to	3.5	days	between	1970	and	1998.	842		Beginning	with	a	movement	to	“demedicalize”	childbirth,	followed	by	continued	pressure	to	reduce	costs,843	postpartum	lengths	of	stay	continued	to	decrease	until	the	mid-1990s.		In	1992,	the	AAP	and	ACOG	published	joint	guidelines	for	postpartum	hospital	stays,	including	a	48-hour	stay	for	an	uncomplicated	vaginal	birth,	and	a	96-hour	stay	for	an	uncomplicated	c-section,	excluding	the	day	of	delivery;	their	2007	publication	restated	these	guidelines.844		By	1997,	32	states	had	adopted	laws	intended	to	set	minimum	required	lengths	of	stay	following	delivery	for	both	mothers	and	newborns,	with	the	federal	government	enacting	the	federal	Newborns’	and	Mothers’	Health	Protection	Act	of	1996,	effective	in	1998.845		This	federal	law	provides	that	“[g]roup	health	plans	that	are	subject	to	the	Newborns’	Act	may	not	restrict	benefits	for	a	hospital	stay	in	connection	with	childbirth	to	less	than	48	hours	following	a	vaginal	delivery	or	96	hours	following	a	delivery	by	cesarean	section.	However,	the	attending	provider	may	decide,	after	consulting	with	the	mother,	to	discharge	the	mother	and/or	her	newborn	child	earlier.”846	In	some	states,	according	to	the	U.S.	Department	of	Labor,	“[b]ased	on	a	recent	preliminary	review	of	State	laws,	it	appears	that	State	law	applies	in	lieu	of	the	Federal	Newborns’	Act.”847,848	This	is	true	in	Massachusetts,	where	the	state	law	pertaining	to	minimum	inpatient	stays	following	birth	applies.		The	Massachusetts	statute	mandates	coverage	for	"expense	of	prenatal	care,	childbirth	and	postpartum	care	to	the	same	extent	as	provided	for	medical	conditions	not	related	to	pregnancy"	with	"minimum	48	hours	of	inpatient	care	following	a	vaginal	delivery	and	a	minimum	of	96	hours	of	inpatient	care	following	a	caesarean	section."849	The	most	current	APA	and	ACOG	recommendation	from	2013	states	that	“[t]he	length	of	stay	of	a	healthy	term	newborn	should	be	based	on	the	unique	characteristics	of	each	mother-infant	dyad,	including	the	health	of	the	mother,	the	health	and	stability	of	the	infant,	the	ability	and	confidence	of	the	mother	to	care	for	her	infant,	the	adequacy	of	support	systems	at	home,	and	access	to	appropriate	follow-up	care.”850,851		AAP	and	ACOG	further	outline	the	minimal	criteria	that	should	be	met	by	mother	and	newborn	when	the	physician	and	mother	want	a	shortened	hospital	stay,	stating	that	”[w]hen	no	complications	are	present,	the	postpartum	hospital	stay	usually	ranges	from	48	hours	for	vaginal	delivery	to	96	hours	for	cesarean	delivery,	excluding	the	day	of	delivery.”852,853		Other	studies	echo	this	conclusion,	stating	that	individualized	discharge	plans	“jointly	tailored	to	a	family's	needs	rather	than	to	a	set	timescale”	are	appropriate,	as	a	“lack	of	readiness”	for	postpartum	discharge	was	associated	with	poorer	health	outcomes	and	increased	health	care	use	by	patients	(mothers	and	newborns)	in	the	first	2	to	4	weeks	after	discharge.854	The	intended	and	observed	result	of	legislative	mandates	targeting	postpartum	length	of	stay	was	to	increase	average	length	of	stay	and	to	compress	variability	in	length	of	stay	among	population	
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sub-groups.855,856		Further,	evidence	has	shown	that	early	discharge	legislation	has	decreased	risk	for	infant	readmission,857,858	emergency	room	visits,859	morbidity,860	and	mortality.861		One	study	found	a	36	percent	reduction	in	infant	mortality	in	its	study	population,862	while	another	states	that	“one	infant	life	could	be	saved	for	each	1400	normal	newborns	moved	from	early	discharge	(less	than	30	h[ours])	to	longer	length	of	stay.”863		Other	research	suggests	that	mothers	who	stayed	only	one	night	after	vaginal	delivery	reported	more	distress,	fatigue,	and	pediatric	problems	than	mothers	who	stayed	two	nights,	and	used	more	outpatient	services	following	discharge.		Likewise,	these	mothers	were	less	likely	to	initiate	and/or	continue	breastfeeding.864		Some	research	suggests,	however,	that	improved	mortality	and	morbidity	rates	depend	on	the	content	of	post-partum	services,	which	should	be	more	uniformly	defined	and	administered.865,866		On	average,	the	biggest	increase	in	length	of	stay	was	for	uncomplicated	vaginal	deliveries,	as	c-section	and	more	complicated	deliveries	already	resulted	in	longer	stays.867		However,	other	research	has	shown	that	the	impact	on	both	length	of	stay	and	marginal	charges	is	much	more	moderate	than	was	reported	in	the	years	immediately	following	the	passage	of	the	legislation.868	
Home	visits	For	mothers	and	newborns	discharged	early,	(after	less	than	48	hours	for	vaginal	delivery	and	96	hours	for	cesarean	delivery),	the	mandate	provides	that	post-delivery	care	must	include	“home	visits,	parent	education,	assistance	and	training	in	breast	or	bottle	feeding	and	the	performance	of	any	necessary	and	appropriate	clinical	tests.”869		The	first	home	visit	must	be	“conducted	by	a	registered	nurse,	physician,	or	certified	nurse	midwife,”	with	subsequent	clinically-necessary	visits	to	be	conducted	by	a	licensed	health	care	provider.	According	to	the	AAP,	following	post-partum	discharge,	home	visits	are	intended	to	verify	the	overall	health,	hydration,	and	extent	of	jaundice	of	the	infant;	identify	new	problems;	assess	mother’s	mental	health	and	maternal-infant	bond;	conduct	additional	screens	and	provide	immunizations;	and	reinforce	education	and	health	care	planning	and	maintenance.870		Yet	while	these	visits	are	not	common	practice	in	the	United	States,871	they	are	recommended	by	many	health	and	public	organizations,	including	the	AAP,872	the	US	Advisory	Board	on	Child	Abuse	and	Neglect,873	and	the	CDC’s	Task	Force	on	Community	Preventive	Services.874,875		These	visits	have	been	found	to	be	cost-effective	based	solely	on	the	observed	reduction	in	costs	associated	with	readmission,	and	the	need	for	other	hospital-based	services	in	the	first	10	days	of	life.876		However,	beyond	these	savings,	a	variety	of	significant	health	benefits	to	both	child	and	mother	have	resulted	from	these	visits,	including	a	decrease	in	missed	well-infant	visits;877	identification	of	psychosocial	issues	and	post-partum	depression	and	improvement	in	the	maternal-child	bond;878	a	reduction	of	incidence	of	child	abuse	or	neglect;879,880	fewer	emergency	department	visits	and	unintentional	injuries,	ingestions,	and	poisonings;881	and	a	reduction	in	sudden	infant	death	syndrome.882	Under	the	ACA,	non-grandfathered	health	insurance	plans	must	fully	cover	the	costs	of	recommended	preventive	services	without	patient	cost	sharing	(no	deductibles,	coinsurances	or	copayments).883,884		These	include	services	graded	“A”	or	“B”	by	the	USPSTF;	immunizations	recommended	by	the	CDC	Advisory	Committee	on	Immunization	Practices	(ACIP);	and	screenings	and	preventive	care	for	infants,	children,	adolescents	and	women	listed	in	the	comprehensive	
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guidelines	supported	by	the	Health	Resources	and	Services	Administration	(HRSA).885		For	pregnant	women,	mandated	preventive	services	include	a	wide	range	of	screenings	and	other	services.886		For	newborns,	mandated	preventive	services	include	screenings	listed	from	the	previously	cited	organizations,	as	well	as	from	the	AAP’s	Bright	Futures	Recommendations	for	Preventive	Pediatric	Health	Care.887,888,889	Discussion	of	the	cost	of	the	mandate		The	Massachusetts	statute	mandates	coverage	for	"expense	of	prenatal	care,	childbirth	and	post	partum	care	to	the	same	extent	as	provided	for	medical	conditions	not	related	to	pregnancy"	with	"minimum	48	hours	of	inpatient	care	following	a	vaginal	delivery	and	a	minimum	of	96	hours	of	inpatient	care	following	a	caesarean	section."	A	January	2013	study	estimated	average	2010	Massachusetts	private-payer	costs	for	prenatal,	delivery,	and	postpartum	care	at	$16,888	for	vaginal	births	and	$20,620	for	cesarean	births.890		Trending	these	costs	forward	to	2014	using	the	NHE	hospital	expenditures	data891	results	in	2014	expenses	per	birth	of	$21,360	and	$26,080	for	vaginal	and	cesarean	births,	respectively.		The	Massachusetts	Department	of	Public	Health’s	2014	births	report	indicates	there	were	13,559	privately-insured	cesarean	births	and	28,426	vaginal	births	in	the	state	in	that	year,892	resulting	in	total	privately-insured	maternity	care	costs	of	$960.8	million.		Applying	the	49.1	percent	fully-insured	and	GIC	factor	to	this	result	yields	a	claims	estimate	of	$471.3	million,	or	$16.62	PMPM.		With	administrative	loading,	the	total	expense	is	$529.5	million,	or	$18.68	PMPM	(4.28	percent	of	total	Commonwealth	fully-insured	premium).		These	results	are	summarized	in	Table	38.	
Table	38	
Maternity	Care	Mandate	
Required	Direct	Cost	Estimate	
	
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Bound	PMPMs	
Sample	Users N/A
Sample	Units N/A
Sample	Average	Members N/A
Paid	PMPM 16.62$													 N/A N/A
Paid	PMPM	With	Admin 18.68$													 N/A N/A
Allowed	PMPM N/A N/A N/A
	Required	
Direct	Cost	
	Upper	and	
Lower	Bound	
Impact	
Insured	Population 2,362,745 2,362,745
Contribution	to	Total	Annual	Claims 471,273,073$	 -$																		
Contribution	to	Total	Annual	Premium 529,520,307$	 -$																		
Percent	of	Total	Premium 4.28% 0.00%
*	This	mandate	was	judged	by	carriers	to	contribute	$0	marginal	cost	to	premiums.
Required	direct	cost	was	estimated	using	secondary	data	sources.
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Mental	Health	Care	The	mental	health	care	(or	mental	health	parity)	mandate	requires	coverage	for	services	to	treat	certain	mental	illnesses	–	including	schizophrenia,	bipolar	disorder,	obsessive-compulsive	disorder,	affective	disorders,	eating	disorders,	PTSD,	and	autism,	and	any	biologically-based	disorders	recognized	by	the	Commissioner	of	the	Department	of	Mental	Health	–	on	a	nondiscriminatory	basis,	meaning	the	policy	does	not	contain	any	annual	or	lifetime	dollar	or	unit	of	service	limitation	on	coverage	for	the	diagnosis	and	treatment	of	such	mental	disorders	which	is	less	than	any	such	limitation	imposed	on	coverage	for	the	diagnosis	and	treatment	of	physical	conditions.		The	mandate	defines	the	types	of	services	for	which	coverage	is	required,	including	qualifying	facilities,	levels	of	care,	and	provider	types	(psychiatrist,	psychologist,	clinical	social	worker,	alcohol	and	drug	counselor,	etc.).893	Effect	of	the	mandate	on	health	Mental	illness	is	the	leading	cause	of	disability	in	America,	accounting	for	25	percent	of	all	years	of	life	lost	to	disability	and	premature	mortality.894		Moreover,	suicide,	most	often	attributable	to	mental	illness,	is	the	tenth	leading	cause	of	death	in	America,	with	over	40,000	cases	each	year.895	According	to	Healthy	People	2020,	mental	health	is	“a	state	of	successful	performance	of	mental	function,	resulting	in	productive	activities,	fulfilling	relationships	with	other	people,	and	the	ability	to	adapt	to	change	and	to	cope	with	challenges.”896		Mental	illness	occurs	when	a	person	experiences	an	abnormality	in	thinking	(cognition)	or	perception,	emotion	or	mood,	or	behavioral	integration,	such	as	planning	and	social	interactions.897		The	American	Psychiatric	Association	(APA)’s	Diagnostic	and	Statistical	Manual,	5th	edition	(DSM-V),	defines	a	mental	disorder	as:	[A]	syndrome	characterized	by	clinically	significant	disturbance	in	an	individual’s	cognition,	emotion	regulation,	or	behavior	that	reflects	a	dysfunction	in	the	psychological,	biological,	or	developmental	processes	underlying	mental	functioning.		Mental	disorders	are	usually	associated	with	significant	distress	or	disability	in	social,	occupational,	or	other	important	activities.898	Major	diagnostic	categories	of	mental	disorders	include:899	
• Neurodevelopmental	disorders	
• Schizophrenic	spectrum	and	other	psychotic	disorders	
• Bipolar	and	related	disorders	
• Depressive	disorders	
• Anxiety	disorders	
• Obsessive-compulsive	and	related	disorders	
• Trauma-	and	stressor-related	disorders	
• Dissociative	disorders	
• Somatic	symptom	and	related	disorders	
• Feeding	and	eating	disorders		
• Sleep-wake	disorders	
• Sexual	dysfunctions	
• Gender	dysphoria	
• Disruptive,	impulse-control	and	conduct	disorders	
• Substance-related	and	addictive	disorders	
• Neurocognitive	disorders	
• Personality	disorders	
• Paraphilic	disorders	
• Medication-induced	movement	disorders	and	other	adverse	effects	of	medication	
• Other	mental	disorders	
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The	National	Institutes	of	Health	estimates	that	18.5	percent	of	adults	have	a	mental,	behavioral,	or	emotional	disorder	(excluding	developmental	and	substance	use	disorders)	diagnosed	currently	or	within	the	past	year	of	duration	sufficient	“to	meet	diagnostic	criteria	specified	within	the	4th	edition	of	the	Diagnostic	and	Statistical	Manual	of	Mental	Disorders	(DSM-IV).”900		In	a	2013	survey	of	the	population	over	age	12,	8.2	percent	were	classified	with	a	substance	abuse	or	dependence	disorder	based	on	the	DSM-IV.901		For	adults	age	18	and	over	with	any	mental	illness,	17.5	percent	abused	or	were	dependent	on	alcohol	or	illicit	drugs;	this	number	rose	to	23	percent	for	those	with	a	serious	mental	illness.902	For	children	ages	13	to	18,	the	lifetime	prevalence	of	a	mental	disorder	is	43.8	percent,	and	over	20	percent	either	currently	or	at	some	point	in	their	lives	have	had	a	seriously	debilitating	mental	disorder.903		The	most	common	illness	for	children	was	attention	deficit-hyperactivity	disorder	with	a	prevalence	rate	of	8.6	percent,	followed	by	3.7	percent	with	mood	disorders,	and	2.7	percent	with	major	depression.904		In	2014,	14.8	percent	of	adults	in	the	United	States	received	treatment	(inpatient	or	outpatient	counseling	or	prescription	medication)	for	a	mental	health	problem,905	up	from	13.4	percent	in	2008.		Of	adults	with	any	mental	illness,	44.7	percent	received	treatment,	while	68.5	percent	for	those	with	serious	mental	illness	received	treatment.906	For	children	ages	8-15	with	a	diagnosed	mental	disorder,	50.6	percent	used	mental	health	services	in	the	last	year.907		Overall,	for	children	ages	12-17,	13.6	percent	received	specialty	mental	health	services	in	2014.908			Studies	linking	physical	and	mental	health	issues	continue	to	show	successful	treatment	of	mental	illness	is	critical	to	both	mental	and	physical	health.		Simply	put,	those	with	mental	illnesses	are	less	able	to	exercise	health-promoting	behaviors,	while	individuals	with	chronic	illnesses	are	more	likely	to	suffer	from	mental	health	issues	that	may	in	turn	impede	treatment	and	recovery.		Treatments	generally	fall	into	the	broad	categories	of	psychotherapy	and	medication,	and	may	incorporate	multimodal	therapy,	or	a	combination	of	the	two.		Psychotherapy	is	used	to	help	patients	understand	their	illnesses,	and	provides	tools	to	manage	symptoms	and	improve	function.		It	includes	such	commonly	used	methods	as	cognitive	behavioral	therapy,	dialectical	behavioral	therapy,	interpersonal	therapy,	and	family-focused	therapy.909		Other	therapies	include	psychodynamic,	light,	expressive	or	creative	arts,	animal-assisted,	and	play.910		Pharmacological	therapy	for	mental	illness	generally	refers	to	drugs	categorized	as	antipsychotics,	antidepressants,	mood	stabilizers,	antianxiety,	and	stimulants.911		New	treatments	include	brain	stimulation	therapy,	the	direct	activation	or	touching	of	the	brain	with	electricity,	magnets,	or	implants.912	Treatments	vary	by	individual,	illness,	and	other	factors	that	also	influence	a	patient’s	outcomes;	research	on	effectiveness	reflects	these	and	other	variables.	The	seminal	1999	U.S.	Surgeon	General’s	report	on	mental	illness	noted	that	“[t]he	efficacy	of	mental	health	treatments	is	well	documented,	and…a	range	of	treatments	exists	for	most	mental	disorders.”913		The	U.S.	Substance	Abuse	and	Mental	Health	Services	Administration	lists	almost	400	mental	health	and	substance	abuse	interventions	in	its	National	Registry	of	Evidence-Based	Programs	and	Practices.914,915		The	National	Institute	on	Drug	Abuse	(NIDA)	published	its	“Principles	of	Effective	Treatment”	for	substance	abuse	disorders,	outlining	general	points	that	research	has	shown	improve	outcomes	of	
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treatment	for	this	chronic	disease.916		In	general,	NIDA	states	that	while	“[e]ach	approach	to	drug	treatment	is	designed	to	address	certain	aspects	of	drug	addiction	and	its	consequences	for	the	individual,	family,	and	society,”	effective	treatment	is	based	on	the	premises	that:917	
• Addiction	is	a	complex	but	treatable	disease	that	affects	brain	function	and	behavior.	
• No	single	treatment	is	appropriate	for	everyone.	
• Treatment	needs	to	be	readily	available;	remaining	in	treatment	for	an	adequate	period	of	time	is	critical.	
• Many	addicted	individuals	have	other	mental	disorders;	effective	treatment	attends	to	all	needs	of	the	individual,	not	just	drug	abuse.	
• Behavioral	therapies—including	individual,	family,	or	group	counseling—are	the	most	common	forms	of	drug	abuse	treatment.	
• Medications	are	an	important	element	of	treatment,	especially	when	combined	with	counseling	and	other	behavioral	therapies.	
• Medically-assisted	detoxification	is	only	the	first	stage	of	addiction	treatment	and	by	itself	does	little	to	change	long-term	drug	abuse.			
• A	treatment	plan	must	be	assessed	continually	and	modified	as	necessary.	
• Treatment	does	not	need	to	be	voluntary	to	be	effective.	
• Drug	use	during	treatment	must	be	monitored	continuously.	
• Treatment	programs	should	test	patients	for	the	presence	of	HIV/AIDS,	tuberculosis,	hepatitis,	and	other	infectious	diseases	and	provide	risk-reduction	counseling,	linking	patients	to	needed	treatment.	
Research	continues	on	the	efficacy	of	specific	treatments	for	specific	mental	illnesses	and	co-morbidities,	reflected	in	recommendations	such	as	those	from	the	USPSTF.		For	example,	in	a	series	of	2016	recommendations	specific	to	major	depressive	disorder	(MDD),	the	USPSTF	found	that:	[e]ffective	treatment	of	depression	in	adults	generally	includes	antidepressants	or	specific	psychotherapy	approaches	(eg,	CBT	or	brief	psychosocial	counseling),	alone	or	in	combination.		Given	the	potential	harms	to	the	fetus	and	newborn	child	from	certain	pharmacologic	agents,	clinicians	are	encouraged	to	consider	CBT	or	other	evidence-based	counseling	interventions	when	managing	depression	in	pregnant	or	breastfeeding	women.918	For	adolescents,	the	USPSTF	concluded	that:	[t]reatment	options	for	MDD	in	children	and	adolescents	include	pharmacotherapy,	psychotherapy,	collaborative	care,	psychosocial	support	interventions,	and	complementary	and	alternative	medicine	approaches.		Fluoxetine	is	approved	by	the	FDA	for	treatment	of	MDD	in	children	aged	8	years	or	older,	and	escitalopram	is	approved	for	treatment	of	MDD	in	adolescents	aged	12	to	17	years.		The	FDA	has	issued	a	boxed	warning	for	antidepressants,	recommending	that	patients	of	all	ages	who	start	antidepressant	therapy	be	monitored	appropriately	and	observed	closely	for	clinical	worsening,	suicidality,	or	unusual	changes	in	behavior.		Collaborative	care	is	a	multicomponent,	health	care	system–level	intervention	that	uses	care	managers	to	link	primary	care	providers,	patients,	and	mental	health	specialists.919	Under	the	ACA,	non-grandfathered	health	insurance	plans	must	fully	cover	the	costs	of	recommended	preventive	services	graded	“A”	or	“B”	without	patient	cost	sharing	(no	deductibles,	coinsurances	or	copayments).920,921		For	mental	health	preventive	services,	the	USPSTF	currently	gives	a	grade	“B”	rating	to:	
• Screening	adults,	including	pregnant	and	postpartum	women,	for	depression	when	staff-assisted	depression	care	supports	are	in	place	to	assure	accurate	diagnosis,	effective	treatment,	and	follow-up922	
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• Screening	adults	18	years	or	older	for	alcohol	misuse	and	providing	persons	engaged	in	risky	or	hazardous	drinking	with	brief	behavioral	counseling	interventions	to	reduce	alcohol	misuse923	
• Screening	adolescents	(12-18	years	of	age)	for	major	depressive	disorder	(MDD)	when	systems	are	in	place	to	ensure	accurate	diagnosis,	psychotherapy	(cognitive-behavioral	or	interpersonal),	and	follow-up924	Estimate	of	the	cost	of	the	mandate	The	ACA	requires	coverage	for	treatment	of	inpatient	and	outpatient	mental	health/substance	abuse	disorder	as	an	essential	health	benefit	and	requires	qualified	health	plans	to	comply	with	the	Mental	Health	Parity	and	Addiction	Equity	Act	of	2008	(MHPAEA).		The	MHPAEA	requires	parity	between	coverage	for	mental	health/substance	use	disorder	benefits	and	medical/surgical	benefits.	The	state	mental	health	parity	mandate	explicitly	requires	coverage	for	“intermediate	services.”		The	MHPAEA	categorizes	such	services	as	inpatient	or	outpatient,	and	this	analysis	assumes	that	such	an	interpretation	applies	also	to	the	scope	of	the	services	required	under	the	ACA,	and	therefore	the	ACA	requires	coverage	even	for	intermediate	services,	as	well	as	inpatient	and	outpatient	services.		Therefore,	this	analysis	assumes	the	Massachusetts	mental	health	care	mandate	to	be	superseded	by	federal	law;	the	marginal	cost	of	the	state	mandate	is	therefore	zero.	The	estimated	RDC	PMPM	paid	claim	amount	was	$16.06,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$18.05	(or	4.14	percent	of	the	Commonwealth	total	premium).		Table	39	below	displays	a	summary	of	these	results	and	related	statistics.	
Table	39	
Mental	Health	Care	Mandate	
Required	Direct	Cost	Estimate	
	
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Bound	PMPMs	
Sample	Users 295,071											
Sample	Units 5,752,331								
Sample	Average	Members 1,871,491								
Paid	PMPM 16.06$													 N/A N/A
Paid	PMPM	With	Admin 18.05$													 N/A N/A
Allowed	PMPM 19.09$													 N/A N/A
	Required	
Direct	Cost	
	Upper	and	
Lower	Bound	
Impact*	
Insured	Population 2,362,745 2,362,745
Contribution	to	Total	Annual	Claims 455,398,794$	 -$																		
Contribution	to	Total	Annual	Premium 511,684,038$	 -$																		
Percent	of	Total	Premium 4.14% 0.00%
*	The	requirements	of	the	Massachusetts	mandate	have	been	superseded	by	federal	law.
Required	direct	cost	was	estimated	using	the	Massachusestts	APCD.
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Off-label	Use	of	Prescription	Drugs	to	Treat	Cancer	This	mandate	requires	the	Commissioner	of	Insurance	to	establish	a	panel	of	experts	to	review	off-label	uses	of	prescription	drugs	for	the	treatment	of	cancer	for	medical	appropriateness	and	to	direct	insurers	to	make	payments	consistent	with	those	recommendations.925	Effect	of	the	mandate	on	health	The	off-label	use	of	prescription	drugs	to	treat	cancer	mandate	requires	the	Commissioner	of	Insurance	to	establish	a	panel	of	experts	to	review	off-label	uses	of	prescription	drugs	for	the	treatment	of	cancer	for	medical	appropriateness	and	to	direct	insurers	to	make	payments	consistent	with	those	recommendations.	The	Federal	Food,	Drug	and	Cosmetics	Act	of	1938	created	the	Food	&	Drug	Administration	(FDA)	in	part	to	control	the	activities	of	pharmaceutical	and	medical	device	manufacturers	in	the	United	States.926		The	act	specifically	regulates	manufacturer’s	activities,	but	not	physician	prescribing	practices.927		When	the	FDA	approves	a	drug	for	market,	it	also	approves	its	labeling.		Labeling	is	specific	to	the	approved	indications	for	use,	dosage,	patient	population,	and	method	of	administration.928		Physicians,	however,	are	not	limited	to	prescribing	the	drug	according	to	its	label,	and	may	prescribe	drugs	for	“off-label”	uses,	or	those	not	specifically	approved	by	the	FDA.		However,	manufacturers	may	not	provide	information	about	off-label	uses	to	health	care	providers	or	patients,	except	reprints	of	peer-reviewed	research	articles	as	submitted	to	the	FDA,	and	only	for	those	products	for	which	the	manufacturer	is	seeking	supplemental	use	approval.929		Off-label	use	is	not	the	same	as	expanded	access	or	special	exemption,	which	are	FDA	processes	allowing	patients	not	eligible	for	clinical	trials	access	to	investigational	treatments	not	yet	FDA-approved.930	The	approval	process	for	drugs	can	take	between	eight	and	twelve	years;	for	every	5,000	to	10,000	compounds	that	begin	the	process,	only	one	receives	marketing	approval.931		Because	of	the	expense	and	time	needed	to	obtain	FDA-approved	use	of	a	drug,	off-label	prescribing	has	become	“an	integral	part	of	contemporary	medicine.”932		One	study	found	that	57	percent	of	new	drug	uses	come	from	field	discovery,	and	not	through	clinical	trials.933		Another	study,	published	in	2006,	found	that	21	percent	of	prescriptions	written	in	the	U.S.	were	for	off-label	use.934		The	practice	is	so	widespread	that	Consumer	Reports	magazine	publishes	a	guide	to	off-label	prescription	drugs,935	as	well	as	explanations	of	the	risks	and	benefits	of	off-label	uses.936		A	2008	survey	found	that	80	percent	of	oncologists	prescribe	off-label	treatments,	and	that	50	percent	of	chemotherapy	treatments	are	off-label	uses.937	Off-label	use	is	common	in	cancer	treatment	for	a	variety	of	reasons.		First,	certain	drugs	approved	for	treatment	of	specific	tumor	types	are	effective	against	a	broader	array	of	tumors.		Second,	cancer	is	often	treated	with	drug	combinations,	including	one	or	more	off-label.		These	combinations	change	frequently,	as	evidence	gathers	about	their	effectiveness.		Third,	cancer	treatment	continues	to	evolve	quickly.		Fourth,	oncologists	often	treat	terminal	patients	whose	approved	treatment	options	may	be	exhausted.		And	finally,	oncologists	may	be	more	open	than	are	other	specialists	to	experimenting	with	off-label	treatments	for	their	patients.938	
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But	this	practice	is	not	without	significant	risks	and	controversy.		Critics	stress	the	risks	of	drugs	where	rigorous	scientific	evidence	does	not	exist	for	additional	applications;	such	dangers	may	range	from	a	drug’s	ineffectiveness	to	its	causing	outright	harm.		Clinical	study	protocols	and	the	FDA	itself	were	created	to	protect	patients	from	the	harm	of	unknown	outcomes	and	experimental	practices.		While	the	FDA	cannot	regulate	physician	prescribing,	malpractice	suits	against	practitioners	and	class	action	suits	against	manufacturers	have	increasingly	admitted	the	court	system	into	this	area	of	medicine,	bringing	with	them	the	threat	of	significant	financial	risk	and,	more	recently,	criminal	penalties.939,940		The	provider	community	itself	is	divided;	the	same	survey	of	oncologists	that	revealed	widespread	off-label	prescribing	found	that	“attitudes	and	practices…vary	substantially.”941	Despite	the	risks,	approved	treatment	options	remain	limited	for	certain	patients,	leaving	doctors	to	continue	to	prescribe	off-label	uses	for	drugs.		However,	no	widely	systematic	or	transparent	method	currently	exists	to	collect	information	on	off-label	use,	and	manufacturers	are	prohibited	from	distributing	any	such	information	they	collect.		One	study	found	the	use	of	off-label	medication	to	be	quite	common	in	outpatient	care,	with	most	(73	percent)	occurring	“without	scientific	support.”942		Further,	“[s]tudies	suggest	that	many	physicians	rely	on	experience,	anecdotal	reports,	and	opinion	leaders	to	guide	their	treatment	decisions,	often	failing	to	demand	solid	evidence	for	their	prescribing	choices.”943		Since	the	decision	to	prescribe	the	off-label	drug	is	a	professional	judgment,	and	the	mandate	is	by	nature	broad,	it	is	inevitable	that	some	uses	are	efficacious	while	others	are	not.	Professional	medical	societies	defend	the	rights	of	physicians	to	prescribe	pharmaceuticals	for	off-label	uses,	although	they	differ	in	the	strength	of	their	advocacy.		The	American	Medical	Association	(AMA)	“confirms	its	strong	support	for	the	autonomous	clinical	decision-making	authority	of	a	physician	and	that	a	physician	may	lawfully	use	an	FDA	approved	drug	product	or	medical	device	for	an	unlabeled	indication	when	such	use	is	based	upon	sound	scientific	evidence	and	sound	medical	opinion,”	and	calls	for	full	reimbursement	of	such	prescriptions	as	“reasonable	and	necessary	medical	care.”944		The	American	College	of	Physicians	(ACP)	states	that	“physicians	should	continue	to	be	able	to	prescribe	covered	drugs	for	accepted	off-label	uses,”	but	“opposes	any	efforts	to	weaken	FDA	authority	to	demand	rigorous	evaluations	of	drugs	and	medical	devices	for	both	safety	and	effectiveness	based	on	sound	scientific	and	medical	evidence	and	opposes	legislative	attempts	to	curtail	FDA	authority	to	establish	and	maintain	standards	of	safety	and	effectiveness	for	approval	of	drugs	and	medical	devices.”945		While	these	societies	leave	treatment	decisions	to	physicians,	each	encourages	its	members	to	study	available	information	to	determine	whether	off-label	prescribing	is	in	the	best	interest	of	the	patient.			For	anticancer	chemotherapeutic	regimens,	CMS	cites	three	compendia	recognized	in	the	Social	Security	Act	as	“authoritative	sources	for	use	in	the	determination	of	a	‘medically-accepted	indication’	of	drugs	and	biologicals	used	off-label	in	an	anticancer	chemotherapeutic	regimen.”946		These	include	the	American	Medical	Association	Drug	Evaluations	(AMA-DE),	United	States	Pharmacopoeia-Drug	Information	(USP-DI),	and	the	American	Hospital	Formulary	Service-Drug	Information	(AHFS-DI).947		Yet	a	study	of	these	found	that	while	oncologists	rely	on	compendia	for	off-label	indications	and	reimbursement	information,	even	these	“lack	transparency,	cite	little	
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current	evidence,	and	lack	systematic	methods	to	review	or	update	evidence.”948		The	ACP	states	that	“[w]hen	considering	an	innovative	therapy	that	has	no	precedent,	the	physician	should	consult	with	peers,	an	institutional	review	board,	or	other	expert	group	to	assess	the	risks,	potential	adverse	outcomes,	potential	consequences	of	foregoing	a	standard	therapy,	and	whether	the	innovation	is	in	the	patient's	best	interest.”949	Reimbursement	for	off-label	prescriptions	is	inconsistent	and	complex.		Many	states,	like	Massachusetts,	mandate	coverage	for	off-label	prescriptions	for	certain	types	of	drugs.		Likewise,	Medicare	Part	D	only	covers	payment	for	drugs	with	FDA	approval,	or	for	uses	supported	in	their	approved	drug	compendia,	including	DRUGDEX,	USP-DI,	and	AMA-DE.950		Further,	Part	B	will	pay	for	oral	anticancer	drugs	with	the	same	active	ingredients	and	indications	as	chemotherapy	drugs,	even	if	they	have	not	received	FDA	approval	for	that	use.951		However,	as	the	AMA-DE	and	USP-DI	are	no	longer	published,	the	issue	of	acceptable	compendia	has	become	even	more	complex.952			In	response	to	advocates’	calls	for	expanded	access	to	drugs	for	additional	uses,	the	FDA	has	done	much	in	recent	years	to	change	its	rulings	and	guidance	to	enable	distribution	of	therapies	which	have	proven	effective,	especially	in	cases	in	which	formal	approval	has	not	been	applied	for	or	granted.		The	2007	FDA	Amendments	Act	made	changes	that	impacted	off-label	prescribing.953		First	it	expands	information	collected	and	studied	about	drugs	following	approval.		The	agency	now	has	more	authority	to	monitor	safety	after	approval,	and	has	funding	to	set	up	a	stronger	post-marketing	surveillance	system	as	well	as	an	active	monitoring	system	to	discover	adverse	events	involving	a	drug.954		The	agency	is	empowered	to	use	large	clinical	databases	to	determine	a	drug’s	safety,	including	when	used	off-label,	and	may	now	order	manufacturers	to	conduct	post-approval	studies	to	identify	risks.	955		Second,	manufacturers	must	now	register	their	studies,	making	the	information	on	off-label	use	more	robust	and	available	to	physicians	and	the	public,	and	further	preventing	the	industry	from	hiding	negative	results	about	their	products.956		And	third,	the	FDA	has	more	power	to	act	when	a	product	appears	harmful,	including	the	ability	to	change	labeling	to	outline	harms	of	certain	off-label	drug	applications.957		An	example	is	labeling	changes	to	anti-depressants,	long	prescribed	off-label	to	teenagers	and	children	without	FDA	approval;	studies	demonstrated	that	these	drugs	may	increase	suicidal	thoughts	and	tendencies	in	younger	populations,	and	the	FDA	recently	added	this	warning	to	its	labels	for	prescribers	and	patients.		Furthermore,	the	FDA	can	limit	distribution	of	certain	drugs	only	to	physicians	with	specialized	training.	958		More	recently,	in	2009,	the	FDA	issued	non-binding	guidance	outlining	means	by	which	manufacturers	may	inform	physicians	of	unapproved	uses	for	approved	drugs	by	distributing	articles	from	independent	medical	and	scientific	resources.959	Despite	these	changes,	off-label	prescribing	is	still	widespread	in	the	practice	of	medicine.		However,	most	patients	are	not	aware	that	it	happens	at	all.		Physicians	are	not	required	to	inform	a	patient	that	a	prescribed	treatment	is	not	FDA	approved;	therefore,	patients	may	not	be	aware	of	the	treatment’s	uncertainty	and	potential	risks,	nor	of	the	potential	additional	cost	of	an	off-label	treatment	that	may	not	be	reimbursable.		In	fact,	one	poll	has	shown	that	half	of	patients	mistakenly	think	that	doctors	may	only	prescribe	drugs	for	FDA	approved	uses,	while	another	25	percent	are	not	sure	if	a	drug	must	be	approved	to	be	prescribed,	meaning	only	one-quarter	of	patients	are	aware	that	drugs	may	be	prescribed	for	unapproved	uses.		In	the	same	study,	almost	half	state	that	
Comprehensive	Mandated	Benefit	Review	
compass Health Analytics 102 December 2016 
doctors	should	not	be	able	to	prescribe	off-label	uses	and	62	percent	believe	off-label	prescribing	should	be	permitted	only	during	an	approved	clinical	trial.960		However,	as	the	disclosure	that	a	prescribed	drug	is	used	off-label	is	not	legally	required	and	is	left	to	the	discretion	of	the	treating	physician,	the	American	Academy	of	Pediatrics	has	concluded,	for	example,	that	“discussion	about	the	off-label	status	of	a	drug	may,	as	a	matter	of	professional	judgment,	be	part	of	the	information	provided	to	the	patient	or	parents.”961	Discussion	of	the	cost	of	the	mandate	An	estimate	of	the	costs	of	off-label	drug	use	for	cancer	treatment	would	require	a	large,	dedicated	research	effort,	a	comprehensive	claim	database	(preferably	from	Massachusetts),	and	extensive	clinical	definition	of	potential	off-label	use,	associated	diagnoses,	etc.	Even	with	such	an	effort,	ambiguities	would	likely	remain	in	the	results.	Moreover,	it	was	also	the	opinion	of	the	participating	health	plans	that	these	costs	would	be	incurred	by	the	plans	even	without	the	mandate	laws	in	place	(and	therefore,	the	marginal	cost	of	the	mandate	is	zero)	because	it	would	be	difficult	to	identify	and	monitor	such	prescribing	practices.	While	there	was	general	consensus	among	the	plans	about	the	treatment	benefits	of	using	off-label	drugs,	the	cost-effectiveness	of	such	treatments	have	not	been	studied	comprehensively.	
Off-label	Use	of	Prescription	Drugs	to	Treat	HIV/AIDS	The	general	issues	arising	from	the	practice	of	prescribing	off-label	drugs	are	outlined	in	the	preceding	section	on	off-label	uses	of	drugs	for	cancer	treatment.		This	mandate	requires	coverage	for	prescription	drugs	for	off-label	use	in	the	treatment	of	HIV/AIDS	if	the	drug	is	recognized	for	treatment	of	such	indication	in	one	of	the	standard	reference	compendia	or	in	the	medical	literature.962	Effect	of	the	mandate	on	health	The	preceding	section	on	off-label	uses	of	drugs	for	cancer	treatment	outlines	the	general	issues	arising	from	prescribing	off-label	drugs.		Off-label	prescriptions	do	not	comply	with	the	diagnostic	or	condition	indications,	and/or	the	administration	dosage	requirements	validated	as	safe	and	effective	by	the	FDA.963		Drugs	are	often	used	off-label	in	response	to	unmet	medical	needs,	the	needs	of	poorly-studied	or	unstudied	populations,	or	urgent	public	health	needs,	when	it	is	reasonable	to	assume	that	the	drug	could	effectively	treat	a	given	condition.964		Yet	off-label	use	is	complicated	by	a	lack	of	information	regarding	safety	and	effectiveness,	appropriate	route,	use	and	dosage,	as	well	as	complex	reimbursement	issues,	especially	in	relation	to	insurance	coverage	for	non-approved	pharmaceuticals.		This	mandate	requires	coverage	for	prescription	drugs	for	off-label	use	in	treating	HIV/AIDS	if	the	drug	is	recognized	for	treatment	of	such	in	one	of	the	standard	reference	compendia	or	in	the	medical	literature.	Off-label	prescribing	became	standard	practice	early	in	the	history	of	the	U.S.	AIDS	crisis.		This	was	especially	true	in	medicine’s	attempt	to	stop	or	limit	the	spread	of	opportunistic	infections,	as	approved-use	treatments	were	not	available,965	and	a	large	body	of	scientific	evidence	had	not	yet	been	developed	to	specifically	treat	the	disease.		Doctors	learned	in	the	field,	finding	new	uses	for	
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old	drugs	with	similar	application	or	approved	for	a	different	population.		These	treatment	attempts	were	sometimes	the	only	hope	of	survival	for	a	dying	patient.			The	HIV/AIDS	crisis,	and	the	lack	of	effective	treatments	for	the	condition	and	its	complications,	led	directly	to	significant	changes	by	the	FDA	to:	1)	make	experimental	drugs	more	widely	available	to	severely	ill	patients	with	life	threatening	diseases;	and	2)	speed	the	review	and	approval	process	for	these	treatments.966		In	1987,	the	FDA	created	expanded	access	mechanisms	that	allow	patients	to	use	certain	investigational	drugs	outside	of	a	clinical	trial	because	they	have	no	other	therapeutic	options,	as	other	available	treatments	have	proven	ineffective	or	are	not	tolerated.		These	regulations	were	revised	and	expanded	in	2009.967		Moreover,	the	FDA	created	parallel	track	mechanisms	in	1992	specifically	for	those	with	HIV/AIDS	who	could	not	participate	in	controlled	clinical	trials;	only	one	drug	was	submitted	to	the	FDA	for	consideration.968	While	investigational	therapies	have	thus	become	more	widely	available	before	formal	approval,	the	FDA	has,	over	time,	also	created	procedures	and	review	designations	to	reduce	approval	time	for	therapies,	including	the:	
• AA	priority	category	(1987)	giving	all	applications	for	potential	AIDS	therapies	the	highest	priority	in	the	review	process	
• So-called	Subpart	E	regulations	(1988)	
• Accelerated	approval	regulations	(1992)	
• Priority	review	policies	(1997)	
• Fast-track	drug	development	programs	(1997)	
• Breakthrough	therapy	programs	(2013)969		These	systems	are	intended	to	prioritize	and	speed	review	for	new	drugs	and	biologics	to	encourage	their	development,	and	to	provide	incentives	to	the	developers	to	pursue	formal	approval.	Thirty-two	therapies	are	now	approved	to	treat	complications	related	to	HIV/AIDS	since	the	first	was	approved	in	1981.970		Antiretroviral	drugs	used	to	treat	the	HIV	infection,	which	may	prevent	or	stall	progression	to	AIDS	and	minimize	its	complications,	were	first	approved	in	1987;	37	anti-retrovirals	have	received	FDA-approval,971	including	35	for	pediatric	use972	and	33	in	generic	form.973	Given	these	developments,	the	availability	of	more	approved	treatments,	and	research	regarding	their	safety	and	efficacy,	it	is	not	known	how	widely	off-label	treatments	are	used	for	HIV/AIDS,	or	their	effectiveness.		Research	on	off-label	use	continues	to	be	scarce,	as	gathering	data	regarding	these	applications	is	challenging,974	and	access	to	these	treatments	is	often	limited	through	actual	supply	or	because	of	complex	reimbursement	issues.		One	recent	long-term	study	of	the	use	of	off-label	anti-retroviral	drugs	for	children	with	HIV/AIDS	concluded	that	off-label	use	was	common,	as	were	“adverse	events”	related	to	over-	or	under-dosing;	the	study	authors	highlighted	the	need	for	more	studies	to	prevent	such	mis-dosing	which	may	lead	to	treatment	failure.975	
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Discussion	of	the	cost	of	the	mandate		For	reasons	similar	to	those	presented	above	for	off-label	drug	use	in	cancer	treatment	it	is	not	feasible	to	measure	costs	of	off-label	prescription	drug	use	for	the	treatment	of	HIV/AIDS	in	Massachusetts.	It	was	the	opinion	of	the	participating	health	plans	that	these	costs	would	be	incurred	by	the	plans	even	without	the	mandate	laws	in	place	because	it	would	be	difficult	for	the	health	plans	to	identify	and	monitor	such	prescribing	practices,	and	therefore,	the	marginal	cost	of	the	mandate	is	estimated	to	be	zero.		
Preventive	Care	for	Children	to	Age	Six	The	preventive	care	mandate	requires	coverage	for	preventive	and	primary	care	services	for	children	up	to	age	six,	including	physical	exams,	sensory	screening,	neuropsychiatric	evaluation	and	developmental	screening,	hereditary	and	metabolic	screening	at	birth,	appropriate	immunizations,	blood	tests,	and	urinalysis.976	Effect	of	the	mandate	on	health	Child	health	has	been	defined	as	“the	extent	to	which	individual	children	or	groups	of	children	are	able	or	enabled	to	(1)	develop	and	realize	their	potential;	(2)	satisfy	their	needs;	and	(3)	develop	the	capacities	to	allow	them	to	interact	successfully	with	their	biological,	physical,	and	social	environments.”977		Given	this	broad	definition,	pediatric	care	in	America	has	evolved	over	time,	changing	its	focus	from	the	prevention	and	treatment	of	illness	and	infection	to	a	focus	on	prevention	and	the	promotion	of	healthy	physical,	cognitive,	social,	and	emotional	development,978	as	well	as	the	family’s	capacity	and	functioning.979	As	care	changed,	criticism	arose	as	to	the	inconsistency	of	the	content	and	quality	of	well-child	care,	as	well	as	a	lack	of	research	proving	the	effectiveness	of	each	of	its	elements.980,981		Minority	children,982	children	receiving	Medicaid,983	and	children	without	special	health	care	needs984	were	shown	to	receive	less	adequate	care	than	comparison	groups.		In	response	to	such	observations,	researchers	began	to	review	the	content	and	quality	of	well-child	care	as	well	as	the	methods	by	which	it	is	studied;	at	present,	much	of	pediatric	medicine	is	considered	to	be	“evidence-informed,	rather	than	fully	evidence-driven.”985	Disease	detection,	disease	prevention,	health	promotion,	and	anticipatory	guidance	are	now	advocated	as	part	of	the	American	Academy	of	Pediatrics	(AAP)/Bright	Futures	model.		The	Bright	Futures	program	began	in	1990	to	“to	improve	the	quality	of	health	services	for	children	through	health	promotion	and	disease	prevention;”986	and	has	developed	a	robust	set	of	recommendations	for	providing	well-child	care,	including	a	newly-revised	periodicity	schedule	that	provides	evidence	of	the	effectiveness	of	each	recommendation	and	intervention.987		This	model,	and	its	periodicity	schedule	of	preventive	services,	was	formally	incorporated	into	the	federal	ACA	in	2010.		The	law	requires	that	all	children	enrolled	in	all	individual	and	group	non-grandfathered	health	care	plans	are	covered	without	cost-sharing	for	all	routine	immunizations	recommended	by	the	CDC	Advisory	Committee	on	Immunization	Practices	(ACIP),988	and	all	evidence-informed	preventive	care	screening	and	services	recommended	in	the	comprehensive	guidelines	supported	by	the	Health	
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Resources	and	Services	Administration	(HRSA).989,990		This	latter	category	includes	a	schedule	of	services	outlined	in	the	Bright	Futures	Guidelines	for	Health	Supervision	of	Infants,	Children,	and	Adolescents,991,992	and	the	Recommendations	of	the	Secretary’s	Advisory	Committee	on	Heritable	Disorders	in	Newborns	and	Children,	including	its	Uniform	Screening	Panel.993		The	rationale	and	evidence	for	the	various	elements	of	the	American	Academy	of	Pediatrics	Bright	Futures	Guidelines	and	the	Uniform	Screening	Panel	is	summarized	in	Chapter	13	of	the	Bright	Futures	publication.994	Discussion	of	the	cost	of	the	mandate	The	preventive	care	mandate	requires	coverage	for	preventive	and	primary	care	services	for	children	up	to	age	six,	including	physical	exams,	sensory	screening,	neuropsychiatric	evaluation	and	developmental	screening,	hereditary	and	metabolic	screening	at	birth,	appropriate	immunizations,	blood	tests,	and	urinalysis.	Under	Section	2713	of	the	ACA,	commercial	insurance	plans	must	provide	coverage	for	a	range	of	preventive	services	without	imposing	cost-sharing	requirements	(such	as	copayments,	deductibles,	or	co-insurance).		For	infants,	children,	and	adolescents,	these	services	include	evidenced-informed	preventive	care	and	screenings	recommended	by	the	Health	Resources	and	Services	Administration	and	outlined	in	the	Bright	Futures	Guidelines.		These	preventive	health	services	apply	to	all	commercial	plans	(individual,	small	group,	large	group,	and	self-insured	plans),	unlike	other	essential	health	benefits	(EHBs)	that	apply	only	to	individual	and	small	group	plans.995	To	calculate	the	effect	of	the	preventive	care	mandate	on	commercial	insurance	costs	in	Massachusetts,	Compass	reviewed	a	2005	study	that	examined	components	of	preventive	care	for	both	“not-at-risk”	and	“at-risk”	children.	Multiplying	each	average	preventive	service	cost	by	an	estimated	42,000	children	and	summing	the	product	results	in	an	estimate	of	$106	million,	or	$2.95	PMPM.		These	costs	do	not	include	neuropsychiatric	evaluations,	as	they	were	not	included	in	the	cited	cost	study.		However,	the	costs	do	include	newborn	hearing	screening,	costs	for	which	were	estimated	in	the	“Newborn	Hearing	Screening”	section	above.		Lacking	more	specific	data,	Compass	assumes	that	the	costs	for	hearing	screening	and	neuropsychiatric	evaluations	are	approximately	equal,	and	that	any	difference	is	within	the	range	of	estimation	error	for	the	preventive	care	mandate	as	a	whole.		Based	on	this	assumption,	Compass	trended	the	2005	estimate	forward	to	2014	using	NHE	physician	and	clinical	expense	private	insurer	expense	data996	to	obtain	a	2014	estimated	PMPM	paid	claim	amount	for	preventive	care	for	children	under	age	6	of	$4.31	PMPM	($122.1	million),	or	a	$4.84	total	cost	PMPM	amount	($137.2	million)	and	a	1.11	percent	of	total	Commonwealth	premium	calculation	with	11	percent	administrative	loading.	These	results	are	summarized	in	Table	40	below.	
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Table	40	
Preventive	Care	for	Children	to	Age	Six	Mandate	
Required	Direct	Cost	Estimate	
	
Summary	of	Mandate	Cost	Estimates	Table	41	below	displays	a	summary	of	the	cost	estimates	for	all	39	mandates,	including	those	estimated	using	secondary	data	sources.		The	first	column	displays	total	required	direct	costs,	or	RDCs,xxxii	which	measure	the	claim	costs	for	services	described	in	the	mandate	laws,	and	so	include	both	costs	for	services	that	would	be	provided	voluntarily	in	the	absence	of	the	mandates	and	incremental	costs	resulting	from	the	mandates,	and	are	estimated	to	be	$1.9	billion	after	elimination	of	overlaps	in	cost	between	mandates,	and	$2.1	billion	with	administrative	costs.		This	estimate	is	not	a	measure	of	the	impact	of	the	mandates,	as	it	includes	the	portion	of	the	costs	that	would	be	provided	voluntarily	in	the	absence	of	the	mandate	laws.		The	lower	bound	marginal	claims	estimate	of	$46.9	million	in	the	second	column	represents	the	marginal	impact	of	the	mandates	on	claims	spending	calculated	from	per	person	mandated	benefit	allowed	expensexxxiii	differences	between	the	fully-insured	population	subject	to	the	mandates,	and	the	self-insured	population	not	subject	to	the	mandates.xxxiv		This	difference	represents	$1.66	PMPM,	or	0.43	percent	of	premium,	meaning	that	the	additional	medical	claim	spending	on	mandated	services	in	plans	subject	to	the	mandates	compared	to	those	plans	not	subject	to	the	mandates	represents	approximately	one	half	of	one	percent	of	premium.																																									 																					xxxii	Required	Direct	Costs,	defined	in	the	report	introduction	and	Appendix	B.	xxxiii	Allowed	Amount	=	Insurer	Paid	Amount	+	Member	Cost	Sharing	Amounts	xxxiv	Note	that	the	zero	marginal	cost	mandates	have	been	treated	as	having	zero	marginal	cost,	and	that	a	number	of	the	mandates	with	potential	marginal	cost	were	measured	to	have	zero	marginal	cost	relative	to	self-insured	plan	spending.	
Measures
Sample	FI	
Amount
	Sample	SI	
Amount	
	FI-SI	Allowed	
&	Lower	
Bound	PMPMs	
Sample	Users N/A
Sample	Units N/A
Sample	Average	Members N/A
Paid	PMPM 4.31$																 N/A N/A
Paid	PMPM	With	Admin 4.84$																 N/A N/A
Allowed	PMPM N/A N/A N/A
	Required	
Direct	Cost	
	Upper	and	
Lower	Bound	
Impact*	
Insured	Population 2,362,745 2,362,745
Contribution	to	Total	Annual	Claims 122,141,048$	 -$																		
Contribution	to	Total	Annual	Premium 137,237,132$	 -$																		
Percent	of	Total	Premium 1.11% 0.00%
*	This	mandate	was	judged	by	carriers	to	contribute	$0	marginal	cost	to	premiums.
Required	direct	cost	was	estimated	using	secondary	data	sources.
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To	measure	the	mandates’	full	impact,	insurer	administrative	costs	need	to	be	added.		In	the	next	two	columns	of	Table	41	the	lower	bound	estimate	of	$46.9	million	becomes	$52.7	million	with	administration,	and	the	upper	bound	estimate	becomes	$796.8	million	after	removing	zero	marginal	cost	mandates	and	adding	administrative	expense.			The	range	of	the	marginal	direct	cost	impact	of	all	39	mandate	laws	studied,	including	administrative	costs,	is	therefore	between	$52.7	million	and	$796.8	million.		The	true	value	is	not	likely	to	be	near	either	end	of	this	range.		The	upper	end	of	the	range	includes	all	RDCs	except	those	for	mandates	judged	by	the	carriers	likely	to	have	zero	marginal	costs,	and	includes	an	additional	provision	for	carrier	administrative	costs.		This	upper	bound	estimate	assumes	that	100	percent	of	the	RDC	for	mandates	with	potential	marginal	direct	cost	is	marginal,	and	that	carriers	would	pay	zero	dollars	in	claims	for	the	services	described	by	the	mandates	in	the	absence	of	the	mandate	laws.		The	lower	end	of	the	range	subtracts	from	the	RDCs	the	dollars	implied	by	the	per	person	spending	rate	in	the	self-insured	market,	which	is	not	subject	to	the	mandate	laws.		This	estimate	assumes	that	100	percent	of	the	spending	for	the	mandates	with	potential	marginal	direct	cost	in	the	self-insured	market	would	occur	in	the	absence	of	the	mandate	laws,	and	that	none	of	the	spending	is	influenced	by	the	mandated	spending	levels	in	the	fully-insured	market.	The	range	of	estimates	is	associated	with	between	0.43	percent	of	premium	for	the	low-end	estimate	and	6.45	percent	for	the	high-end	estimate.		The	estimated	range	does	not	consider	indirect	costs,	which,	as	noted	above,	previous	research	finds	will	increase	costs	for	some	mandates	and	offset	costs	for	others.			The	two	most	expensive	mandates	in	the	potential	marginal	direct	cost	group	are	home	health	care	services	($0	to	$289	million	gross	of	mandate	overlaps)	and	diabetes-related	services	and	supplies	($0	to	$197.5	million	gross	of	mandate	overlaps).		Both	are	provided	in	the	self-insured	market	at	the	same	or	higher	levels	than	they	are	provided	in	the	fully-insured	market,	suggesting	that	these	benefits	are	cost-effective,	popular	with	employees,	or	both.		Combined,	and	with	overlaps	removed,	these	two	mandates	have	a	low-end	estimate	of	0	percent	of	premium	and	a	high-end	estimate	of	3.8	percent	of	premium.	
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Table	41	
Summary	of	Estimated	Costs	for	Massachusetts	Mandated	Benefits	as	of	2014	
Dollars	in	Millions	(000,000s)	
	We	note	that,	owing	in	part	to	general	cost	inflation	but	in	large	part	to	an	expansion	of	the	service	codes	that	carriers	have	provided	as	services	covered	under	the	mandates,	the	RDCs	in	the	current	study	at	$1.9	billion	are	far	higher	than	the	$1.2	billion	in	the	2012	study.		However,	relative	to	the	2012	results	these	additional	RDCs	had	a	minimal	effect	on	the	upper	bound	estimate	because	the	mental	health	and	contraceptive	services	coverage	are	now	required	by	federal	law.		They	also	had	a	minimal	impact	on	the	lower	bound	estimate	since	self-insured	plans	also	tend	to	cover	both	contraceptive	services	and	mental	health	at	or	near	the	levels	provided	by	fully-insured	plans,	and	also	cover	many	of	the	additional	service	codes	in	the	carriers’	expanded	lists.	
Required	Direct	Cost	
Claims	Estimate
Lower	Bound	
Marginal	Claims	
Estimate
Lower	Bound	
Estimate	with	
Admin	Exp
Upper	Bound		
Estimate	with	
Admin	Exp
Lower	Bound	
Percent	of	
Premium
Upper	Bound	
Percent	of	
Premium
Unduplicated	Total	All	Mandates 1,912.96$																			 46.94$																			 52.74$														 796.81$														 0.43% 6.45%
Mandates	with	Potential	Marginal	Direct	Cost
Service	Mandates
Autism	Spectrum	Disorders	Services 39.54$																								 15.25$																			 17.13$														 44.42$																 0.14% 0.36%
Chiropractic	Services 2.68$																											 0.94$																					 1.06$																 3.01$																		 0.01% 0.02%
Child	Hearing	Aids 6.89$																											 -$																							 -$																		 7.74$																		 0.00% 0.06%
Cleft	Palate	and	Lip 3.30$																											 0.10$																					 0.12$																 3.70$																		 0.00% 0.03%
Diabetes-related	Services	and	Supplies 175.79$																						 -$																							 -$																		 197.52$														 0.00% 1.60%
Early	Intervention	Services 25.72$																								 2.78$																					 3.12$																 28.90$																 0.03% 0.23%
Home	Health	Care 257.25$																						 -$																							 -$																		 289.04$														 0.00% 2.34%
Hormone	Replacement	Therapy	(HRT) 11.56$																								 0.74$																					 0.83$																 12.99$																 0.01% 0.11%
Human	Leukocyte	Antigen	Testing 0.02$																											 -$																							 -$																		 0.02$																		 0.00% 0.00%
Hypodermic	Syringes	or	Needles 1.08$																											 -$																							 -$																		 1.22$																		 0.00% 0.01%
Infertil ity	Treatment 104.73$																						 12.67$																			 14.24$														 117.67$														 0.12% 0.95%
Low	Protein	Food	Products	for	Inherited	Amino	
			Acid	and	Organic	Acid	Diseases	(PKU)
Nonprescription	Enteral	Formulas 0.92$																											 -$																							 -$																		 1.04$																		 0.00% 0.01%
Oral	Cancer	Drugs 1.38$																											 0.49$																					 0.55$																 1.55$																		 0.00% 0.01%
Prosthetic	Limbs	and	Associated	Services 3.87$																											 -$																							 -$																		 4.35$																		 0.00% 0.04%
Scalp	Hair	Prostheses	for	Cancer	Patients 0.41$																											 -$																							 -$																		 0.46$																		 0.00% 0.00%
Speech,	Hearing	and	Language	Disorders 7.12$																											 -$																							 -$																		 8.00$																		 0.00% 0.06%
Provider	Mandates
Certified	Nurse	Midwives 1.62$																											 -$																							 -$																		 1.83$																		 0.00% 0.01%
Certified	Registered	Nurse	Anesthetists 22.09$																								 -$																							 -$																		 24.83$																 0.00% 0.20%
Chiropractors 7.97$																											 0.81$																					 0.91$																 8.96$																		 0.01% 0.07%
Dentists 1.39$																											 -$																							 -$																		 1.56$																		 0.00% 0.01%
Nurse	Practitioners 44.63$																								 9.31$																					 10.46$														 50.15$																 0.08% 0.41%
Optometrists 6.23$																											 -$																							 -$																		 7.00$																		 0.00% 0.06%
Physician	Assistants 41.01$																								 2.01$																					 2.26$																 46.07$																 0.02% 0.37%
Podiatrists 16.38$																								 0.81$																					 0.91$																 18.41$																 0.01% 0.15%
Mandates	Judged	to	Have	Zero	Marginal	Cost
Bone	Marrow	Transplants	for	Treatment	of	Breast	Cancer -$																													 -$																							 -$																		 -$																				 0.00% 0.00%
Cardiac	Rehabilitation 2.28$																											 -$																							 -$																		 -$																				 0.00% 0.00%
Clinical	Trials	(to	treat	cancer) 2.28$																											 -$																							 -$																		 -$																				 0.00% 0.00%
Contraceptive	Services 94.20$																								 -$																							 -$																		 -$																				 0.00% 0.00%
Cytologic	Screening 17.54$																								 -$																							 -$																		 -$																				 0.00% 0.00%
Hearing	Screening	for	Newborns 3.32$																											 -$																							 -$																		 -$																				 0.00% 0.00%
Hospice	Care 16.49$																								 -$																							 -$																		 -$																				 0.00% 0.00%
Lead	Poisoning	Screening 1.20$																											 -$																							 -$																		 -$																				 0.00% 0.00%
Mammography 17.69$																								 -$																							 -$																		 -$																				 0.00% 0.00%
Maternity	Health	Care	(including	minimum	maternity	stay) 471.27$																						 -$																							 -$																		 -$																				 0.00% 0.00%
Mental	Health	Care 455.40$																						 -$																							 -$																		 -$																				 0.00% 0.00%
Preventive	Care	for	Children	Up	to	Age	Six	 122.14$																						 -$																							 -$																		 -$																				 0.00% 0.00%
Off-Label	Uses	of	Prescription	Drugs	to	Treat	Cancer -$																													 -$																							 -$																		 -$																				 0.00% 0.00%
Off-Label	Uses	of	Prescription	Drugs	to	Treat	HIV/AIDS -$																													 -$																							 -$																		 -$																				 0.00% 0.00%
0.01%1.53$																											 0.08$																					 1.71$																		0.09$																 0.00%
Comprehensive	Mandated	Benefit	Review	
compass Health Analytics 109 December 2016 
Discussion	and	Conclusions	The	explicit	empirical	results	of	the	study	produce	a	wide	range	of	potential	impacts	of	mandated	benefits	on	health	insurance	direct	costs	in	the	fully-insured	market.		At	one	extreme,	summing	the	costs	of	all	the	benefits	described	in	the	39	mandates	in	total	represented	in	2014	approximately	$2.1	billion	in	required	direct	costs,	including	administrative	costs,	or	17.4	percent	of	the	average	fully-insured	commercial	premium	in	the	Commonwealth.		Removing	the	cost	of	those	benefits	that	carriers	say	they	would	provide	even	without	the	mandate	laws,	the	total	is	$796.8	million	or	6.45	percent	of	premium.		At	the	other	extreme,	the	difference	in	allowed	expense	per-person	between	fully-insured	and	self-insured	employers	implies	a	direct	cost	impact	of	only	$52.7	million,	or	0.43	percent	of	premium.		Table	42	displays	this	impact	range	in	percent	of	premium,	PMPM,	and	total	implied	spending	in	the	fully-insured	market.		Examining	the	assumptions	required	to	use	either	of	these	numbers	as	an	impact	estimate	makes	it	clear	that	the	direct	cost	impact	is	neither	as	low	as	$52.7	million	nor	as	high	as	$796.8	million.	
Table	42	
Cost	Implications	of	Impact	Assumptions	
	The	$796.8	million	estimate	is	far	too	high	as	a	measure	of	direct	costs.		This	estimate	requires	us	to	assume	that	all	mandated	benefits	would	be	dropped	completely	by	all	insurers	in	Massachusetts	if	the	laws	were	repealed.		No	fully-insured	policies	would	include	any	of	the	mandated	benefits,	including	home	health	care,	diabetes	services	and	supplies,	nurse	practitioner	services,	or	any	of	the	other	mandates.		If	instead,	after	mandates	were	hypothetically	repealed,	some	of	these	benefits	were	offered	and	purchased,	then	the	impact	estimate	of	$796.8	million	is	too	large	by	the	amount	of	voluntarily	offered	benefits,	since	not	all	of	that	spending	would	have	been	compelled	by	the	state	mandate	laws.		Many	of	the	larger-dollar	benefits	are	offered,	perhaps	at	lower	levels,	in	states	without	mandate	laws,	either	voluntarily	or	as	a	result	of	federal	mandates.		Home	health,	a	benefit	not	likely	to	be	eliminated,	accounts	for	$289	million	of	the	total,	and	many	other	benefits	such	as	nurse	practitioners,	CRNAs,	and	diabetes-related	services	would	be	unlikely	to	disappear	from	benefit	packages.		Without	being	able	to	analytically	arrive	at	an	alternative,	it	would	seem	that	$796.8	million	is	hundreds	of	millions	of	dollars	too	high	as	an	impact	estimate.	The	$52.7	million	estimate	implied	by	the	allowed	expense	difference	between	fully-insured	and	self-insured	plans	requires	us	to	assume	that	the	presence	of	the	mandate	laws	places	no	upward	
Percent	of	
Premium PMPM
Dollars	
(millions)
0.5% 2.18$																 61.81$													
1.0% 4.36$																 123.62$											
2.0% 8.72$																 247.24$											
3.0% 13.08$													 370.85$											
4.0% 17.44$													 494.47$											
5.0% 21.80$													 618.09$											
6.0% 26.16$													 741.71$											
6.5% 28.34$													 803.52$											
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pressure	on	the	benefits	offered	by	self-insured	firms.		However,	the	need	for	self-insured	firms	to	not	disadvantage	themselves	in	the	labor	market	in	the	presence	of	the	fully-insured	firms	with	mandated	benefit	coverage	seems	certain	to	influence	benefit	levels.		The	magnitude	of	any	such	effect	would	increase	the	impact	estimate	above	$52.7	million,	and	would	vary	by	mandate.		Certain	highly-visible	and	expensive	benefits	such	as	infertility	treatment	($117.7	million)	would	seem	most	subject	to	upward	pressure	of	the	labor	market.		On	the	other	hand,	for	many	of	the	mandates	in	Table	41,	the	per-person	allowed	costs	are	actually	higher	in	the	self-insured	market	than	in	the	fully-insured	market	(those	with	a	zero	lower-bound),	suggesting	no	upward	pressure	induced	by	the	fully-insured	market.			Applying	both	these	lines	of	reasoning	to	narrow	the	range	displayed	in	Table	42,	it	seems	likely	that	the	direct	cost	impact	of	the	mandates	is	somewhere	between	one	percent	and	four	percent	of	total	premium.			In	addition	to	the	direct	cost	impacts,	there	are	indirect	cost	effects	on	other	service	categories	not	directly	affected	by	the	mandate	that	Compass	is	not	able	to	address	in	this	study.		Some	of	these	indirect	costs	may	increase	overall	costs,	such	as	additional	births	resulting	from	fertility	treatment,	while	others	would	reduce	costs,	such	as	hospitalizations	avoided	as	result	of	diabetes	coverage.		To	the	extent	that	mandates	induce	utilization	increases	within	the	services	addressed	by	a	mandate,	such	costs	are	covered	in	both	the	RDC	upper	bound	estimates	and	the	lower	bound	estimates.		About	75	percent	of	the	total	estimated	direct	cost	stems	from	three	of	the	mandates:		home	health,	diabetes	services	and	supplies,	and	infertility;	nearly	an	additional	20	percent	is	comprised	by	the	provider	mandates.		Consideration	of	these	eleven	mandates	and	their	likely	indirect	cost	effects	would	provide	most	of	the	required	information	on	how	the	direct	costs	might	be	increased	or	reduced	by	indirect	cost	effects.		It	is	possible	that	after	consideration	of	indirect	cost	effects,	the	net	impact	of	these	eleven	mandates	is	cost	reducing,	though	we	cannot	estimate	that	impact	in	this	study.		Finally,	there	are	individual	and	socially	beneficial	impacts	aside	from	health	care	spending	that	these	mandates	may,	and	in	many	cases	certainly	do,	provide.		Benefit	mandates	are	often	enacted	when	such	beneficial	effects	are	widely	perceived	but	something	short	of	government	provision	of	the	benefit	is	the	balance	point	of	the	political	process.997			 	
Comprehensive	Mandated	Benefit	Review	
compass Health Analytics 111 December 2016 
Appendices	
Appendix	A:	 Summary	of	Health	Insurance	Benefit	Mandates	
Appendix	B:	 Methodology	of	Cost	Estimation	
Appendix	C:	 Estimation	of	Population	Subsets	
Appendix	D:	 Cost	by	Type	of	Service	for	Mandates	with	Potential	Marginal	Direct	Cost	
Appendix	E:	 List	of	Study	Acronyms	
		
Comprehensive	Mandated	Benefit	Review		
compass Health Analytics 112 December 2016 
Appendix	A:		Summary	of	Health	Insurance	Benefit	Mandates	
Service	mandates	
Mandate	 Statute	 Summary	
In	2012	
Report	
Autism	 c.175	§47AA;	c.176A	
§8DD;	c.176B	§4DD;	
c.176G	§4V;	c.32A	§25	
Mandates	coverage	for	treatment	for	autism	spectrum	disorder,	on	a	“non-discriminatory	
basis,”	meaning	on	the	same	terms	as	coverage	for	physical	conditions.		The	mandate	
includes	in	the	treatment	of	ASDs:	habilitative	or	rehabilitative	care,	pharmacy	care,	
psychiatric	care,	psychological	care,	therapeutic	care,	some	of	which	are	covered	by	the	
mental	health	services	mandate.		The	primary	net	effect	is	to	mandate	coverage	for	
medically	necessary	habilitative	care,	i.e.,	“professional,	counseling,	and	guidance	services	
and	treatment	programs,	including	applied	behavior	analysis	supervised	by	a	Board	
Certified	Behavior	Analyst.”	
Yes	
Bone	marrow	
transplants	for	
treatment	of	breast	
cancer	
c.175	§47R;	c.176A	§8O;	
c.176B	§4O;	c.176G	§4F;	
c.32A	§17D	
Provides	coverage	for	bone	marrow	transplants	for	breast	cancer	patients	who've	
progressed	to	metastatic	disease	if	they	meet	criteria	provided	by	DPH.	
Yes	
Cardiac	rehabilitation	 c.175	§47D;	c.176A	§8G;	
c.176B	§4F;	c.176G	§4	
Covers	the	expense	of	cardiac	rehabilitation,	i.e.,	multidisciplinary,	medically	necessary	
treatment	of	persons	with	documented	cardiovascular	disease.	
Yes	
Chiropractic	services	 c.176B	§4L	 Covers	expenses	of	chiropractic	services.		Applies	to	medical	service	corporations	only.	 Yes	
Cleft	palate	and	cleft	lip	 c.175	§47BB;	c.176A	
§8EE;	c.176G	§4W;	c.32	
§17J	
Requires	coverage	for	the	cost	of	treating	cleft	lip	and	cleft	palate	for	the	child,	including	
medical,	dental,	oral	and	facial	surgery,	surgical	management	and	follow-up	care	by	oral	
and	plastic	surgeons,	orthodontic	treatment	and	management,	preventive	and	restorative	
dentistry	to	ensure	good	health	and	adequate	dental	structures	for	orthodontic	treatment	
or	prosthetic	management	therapy,	speech	therapy,	audiology,	and	nutrition	services.	
No	
(enacted	
2013)	
Clinical	trials	(to	treat	
cancer)	
c.175	§110L;	c.176A	§8X;	
c.176B	§4X;	c.176G	§4P	
Mandates	coverage	for	patient	care	services	for	patients	enrolled	in	a	qualified	clinical	trial	
to	the	same	extent	as	the	services	would	be	covered	if	the	patient	was	not	receiving	care	in	
a	qualified	clinical	trial.		A	qualified	clinical	trial	must	be	cancer-related	and	must	meet	
other	criteria	set	forth	in	the	law.	
Yes	
Contraceptive	services	 c.175	§47W;	c.176A	
§8W;	c.176B	§4W;	
c.176G	§4O	
Requires	coverage	for	outpatient	contraceptive	services	and	prescription	contraceptive	
drugs	and	devices.		Provides	exclusions	for	church-affiliated	employers.	
Yes	
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Mandate	 Statute	 Summary	
In	2012	
Report	
Cytological	screening	 c.175	§§47G	and	110(L);	
c.176A	§8J;	c.176G	§4	
Mandates	coverage	for	cytological	screening	(Pap	smear)	annually	for	women	18	years	and	
older.	
Yes	
Diabetes-related	
services	and	supplies	
c.175	§47N;	c.176A	§8P;	
c.176B	§4S;	c.176G	§4H;	
c.32A	§17G	
Mandates	coverage	for	items	medically	necessary	for	diabetics	that	fall	within	a	category	of	
benefits	and	services	for	which	coverage	is	otherwise	afforded	and	that	have	been	
prescribed	by	a	healthcare	professional:	includes	blood	glucose	monitors,	monitoring	
strips,	lancets,	insulin,	syringes,	lab	tests,	urine	&	lipid	profiles,	special	shoes,	etc.	
Yes	
Early	Intervention	
services	
c.175	§47C;	c.176A	§8B;	
c.176B	§4C;	c.176G	§4	
Mandates	coverage	for	early	intervention	services	from	birth	to	age	3	for	children	with	or	
at	risk	for	specific	developmental	delays	including	chromosomal	abnormality,	neurological	
condition,	metabolic	disorder,	visual	impairments,	permanent	hearing	loss,	and	delayed	
cognitive,	physical,	communicative,	social,	or	emotional	development.	
Yes	
Hearing	aids	for	children	 c.175	§47X;	c.176A	§8Y;	
c.176B	§4EE;	c.176G	
§4N;	c.32	§23	
Mandates	coverage	for	any	child,	21	years	of	age	or	younger	for	the	cost	of	1	hearing	aid	
per	hearing-impaired	ear	up	to	$2,000	for	each	hearing	aid	every	36	months.	Coverage	
includes	all	related	services	prescribed	by	a	licensed	audiologist	or	hearing	instrument	
specialist,	including	the	initial	evaluation,	fitting	and	adjustments,	and	supplies,	including	
ear	molds.	
No	
(enacted	
2013)	
Hearing	screening	for	
newborns	
c.175	§47C	(c.111	§67F);	
c.176A	§8B;	c.176B	§4C	
(c.111	§67F);	c.176G	
§§4,	4K	(c.111	§67F);	
c.32A	§17F	
Mandates	coverage	for	newborn	hearing	screening	tests.	 Yes	
Home	health	care	 c.175	§110(K);	c.176A	
§8I;	c.176G	§4C	
Mandates	coverage	for	home	care	services:	services	provided	by	a	home	health	agency	in	a	
patient's	residence.	
Yes	
Hormone	replacement	
therapy	
c.175	§47W;	c.176A	
§8W;	c.176B	§4W;	
c.176G	§4O	
Requires	policies	providing	outpatient	services	to	provide	hormone	replacement	therapy	
for	peri-	and	post-menopausal	women.	
Yes	
Hospice	care	 c.175	§47S;	c.176A	§8R;	
c.176B	§4Q;	c.176G	§4L;	
c.32A	§17B	
Mandates	coverage	for	licensed	hospice	services	to	terminally	ill	patients	with	a	life	
expectancy	of	six	months	or	less.	
Yes	
Human	leukocyte	
antigen	testing	
c.175	§47V;	c.176A	§8V;	
c.176B	§4V;	c.176G	§4Q;	
c.32A	§17H	
Mandates	coverage	for	the	cost	of	human	leukocyte	antigen	testing	or	histocompatibility	
locus	antigen	testing	necessary	to	establish	bone	marrow	transplant	donor	suitability.	
Yes	
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Mandate	 Statute	 Summary	
In	2012	
Report	
Hypodermic	syringes	or	
needles	
c.175	§47Y;	c.176A	
§8CC;	c.176B	§4CC;	
c.176G	§4U	
Mandates	coverage	for	medically	necessary	hypodermic	syringes	or	needles.	 Yes	
Infertility	treatment	 c.175	§47H;	c.176A	§8K;	
c.176B	§4J;	c.176G	§4	
Requires	policies	including	pregnancy-related	benefits	to	provide,	to	the	same	extent	
benefits	are	provided	for	other	pregnancy-related	procedures,	coverage	for	medically	
necessary	expenses	of	diagnosis	and	treatment	of	infertility.	
Yes	
Lead	poisoning	
screening	
c.175	§47C;	c.176A	§8B;	
c.176B	§4C;	c.176G	§4	
Mandates	coverage	for	screening	for	lead	poisoning	for	all	children	under	age	six	and	
others	deemed	at	risk.	
Yes	
Low	protein	food	
products	
According	to	DOI	
c.175	§47I;	c.176A	§8L;	
c.176B	§4K;	c.176G	§4D	
But	possibly	
c.175	§47C;	c.176A	§8B;	
c.176B	§4C;	c.176G	§4	
Mandates	coverage	for	low	protein	food	products	required	to	treat	infants	and	children	
with	specified	metabolic	disorders	(for	inherited	amino	acid	and	organic	acid	diseases)	as	
well	as	fetuses	of	pregnant	women	with	PKU.	
Yes	
Mammography	 c.175	§§47G	and	110(L);	
c.176A	§8J;	c.176G	§4	
Mandates	coverage	for	one	"baseline"	mammogram	between	ages	35	and	40,	and	annual	
measurements	thereafter.	
Yes	
Maternity	health	care	
(including	minimum	
maternity	stay)	
c.175	§47F;	c.176A	§8H;	
c.176B	§4H;	c.176G	§§4,	
4I;	c.32A	§17C	
Benefits	providing	for	"expense	of	prenatal	care,	childbirth	and	post	partum	care	to	the	
same	extent	as	provided	for	medical	conditions	not	related	to	pregnancy"	with	"minimum	
48	hours	of	in-patient	care	following	a	vaginal	delivery	and	a	minimum	of	96	hours	of	
inpatient	care	following	a	caesarean	section."	
Yes	
Mental	health	care	 c.175	§47B;	c.176A	§8A;	
c.176B	§4A;	c.176G	
§4M;	c.32A	§22	
Requires	coverage	for	the	diagnosis	and	treatment	of	specified	biologically-based	mental	
disorders	including	schizophrenia,	bipolar	disorder,	obsessive-compulsive	disorder,	
affective	disorders,	eating	disorders,	PTSD,	and	autism,	and	any	biologically-based	
disorders	recognized	by	the	Commissioner	of	the	Department	of	Mental	Health.	
Yes	
Nonprescription	enteral	
formulas	
c.175	§47I;	c.176A	§8L;	
c.176B	§4K;	c.176G	§4D;	
c.32A	§17A	
Mandates	coverage	for	nonprescription	enteral	formulas	for	home	use	when	medically	
necessary	to	treat	malabsorption	caused	by	Crohn's	disease,	ulcerative	colitis,	
gastroesophageal	reflux,	gastrointestinal	motility,	chronic	intestinal	pseudo-obstruction,	
and	inherited	diseases	of	amino	acids	and	organic	acids,	in	an	amount	not	to	exceed	$2,500	
annually.	
Yes	
Off-label	uses	of	
prescription	drugs	to	
treat	cancer	
c.175	§§47K,	47L;	c.176A	
§8N;	c.176B	§4N;	c.176G	
§4E	
Requires	the	Commissioner	of	Insurance	to	establish	a	panel	of	experts	to	review	off-label	
uses	of	prescription	drugs	for	the	treatment	of	cancer	for	medical	appropriateness	and	to	
direct	insurers	to	make	payments	consistent	with	those	recommendations.	
Yes	
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Mandate	 Statute	 Summary	
In	2012	
Report	
Off-label	uses	of	
prescription	drugs	to	
treat	HIV/AIDS	
c.175	§§47O,	47P;	
c.176A	§8Q;	c.176B	§4P;	
c.176G	§4G	
Mandates	coverage	for	prescription	drugs	for	off-label	use	in	the	treatment	of	HIV/AIDS	if	
the	drug	is	recognized	for	treatment	of	such	indication	in	one	of	the	standard	reference	
compendia	or	in	the	medical	literature.	
Yes	
Oral	chemotherapy	 c.175	§47DD;	c.176A	
§8FF;	c.176B	§4FF;	
c.176G	§4X;	c.32	§17K	
Mandates	medical	expense	coverage	for	cancer	chemotherapy	treatment	for	prescribed,	
orally-administered	anticancer	medications	used	to	kill	or	slow	the	growth	of	cancerous	
cells	on	a	basis	not	less	favorable	than	intravenously	administered	or	injected	cancer	
medications	that	are	covered	as	medical	benefits.		
No	
(enacted	
2013)	
Preventive	care	for	
children	to	age	six		
c.175	§47C;	c.176A	§8B;	
c.176B	§4C;	c.176G	§4	
Mandates	coverage	for	preventive	and	primary	care	services	for	children	up	to	age	six,	
including	physical	exams,	sensory	screening,	neuropsychiatric	evaluation	and	
developmental	screening,	hereditary	and	metabolic	screening	at	birth,	appropriate	
immunizations,	blood	tests,	and	urinalysis.	
Yes	
Prosthetic	Devices	 c.175	§47Z;	c.176A	
§8AA;	c.176B	§4AA;	
c.176G	§4S;	c.32A	§17I	
Requires	coverage	for	prosthetic	devices	and	repairs	under	the	same	terms	and	conditions	
that	apply	to	other	durable	medical	equipment	covered	under	the	policy;	however	the	
mandate	places	restrictions	on	the	use	of	annual	or	lifetime	limits	for	prosthetic	devices.		
Yes	
Scalp	hair	prostheses	for	
cancer	patients	
c.175	§47T;	c.176A	§8T;	
c.176B	§4R;	c.176G	§4J;	
c.32A	§17E	
Requires	policies	providing	coverage	for	any	other	prosthesis	to	provide	coverage	for	scalp	
hair	prostheses	worn	for	hair	loss	suffered	as	a	result	of	the	treatment	of	cancer	or	
leukemia,	in	an	amount	not	to	exceed	$350	per	year.	
Yes	
Speech	and	audiology	
services	
c.175	§47X;	c.176A	§8Y;	
c.176B	§4Y;	c.176G	§4N;	
c.32A	§23	
Mandates	coverage	for	expenses	incurred	in	the	medically	necessary	diagnosis	and	
treatment	of	speech,	hearing	and	language	disorders	by	individuals	licensed	as	speech-
language	pathologists	or	audiologists.	
Yes	
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Provider-centered	mandates	
Mandate	 Statute*	 Summary	
In	2012	
Report	
Certified	Nurse	Midwives	 c.175	§47E;	c.176B	§4G;	
also	c.176B	§7	
Mandates	benefits	for	services	of	midwives	when	services	are	reimbursed	when	
performed	by	any	other	practitioner	and	are	within	the	lawful	scope	of	practice	of	
midwives.		(Not	in	HMO	or	HSC	statutes.)		Also,	c.	176B	§	7	provides	no	MSC	shall	
"discriminate	in	any	way	against	participating	nurse	midwives	in	the	furnishing	of	
midwifery	service."		This	is	redundant	to	§	4G.	
Yes	
Certified	Registered	Nurse	
Anesthetists	
c.175	§47Q;	c.176A	§8S;	
c.176B	§4T;	c.176G	§4	
Mandates	benefits	for	services	of	nurse	anesthetists	when	services	are	reimbursed	when	
performed	by	any	other	practitioner	and	are	within	the	lawful	scope	of	practice	of	nurse	
anesthetists.	
Yes	
Nurse	Practitioners	 c.175	§47Q;	c.176A	§8S;	
c.176B	§4T;	c.176G	§4;	
also	c.176R	
Statute	sections	affecting	various	forms	of	insurance,	plus	c.	176R,	require	all	forms	of	
insurance	(and	GIC	under	c.	176R)	to	cover	services	of	nurse	practitioners	(NPs)	when	
services	are	reimbursed	when	performed	by	any	other	practitioner	and	are	within	the	
lawful	scope	of	practice	of	NPs.		c.	176R	allows	NPs	to	serve	as	PCPs	and	prohibits	NPs	
from	being	subject	to	smaller	coverage	limits.	
Yes	
Chiropractors	 c.175	§108D;	c.176B	§7	
see	also	“chiropractic	
services”	(c.176B	§4L)	
c.	175	§	108D	requires	a	payer	to	pay	for	chiropractic	services	whether	they	are	
performed	by	a	physician	or	chiropractor,	and	c.	176B	§	7	statute	prohibits	an	MSC	from	
"discriminating"	against	chiropractors	in	providing	chiropractic	services.		(Not	in	HSC	or	
HMO	statutes.)		This	mandate	is	technically	different	from	the	chiropractic	services	
mandate,	but	analysis	of	this	mandate	will	probably	overlap	with	it.	
Yes	
Dentists	 c.175	§108B	 The	insurance	statute	requires	a	dentist	to	be	considered	a	physician	for	purposes	of	
paying	for	any	oral	surgical	care,	services,	or	benefits	covered	by	the	policy/contract	
which	dentists	are	licensed	to	perform.		(The	insurance	statute	might	reach	MSCs.		Not	in	
HSC	or	HMO	statutes.)	
Yes	
Optometrists	 c.175	§108(8)(D);	c.175	
§110(F)	
Requires	coverage	for	services	of	optometrists	when	services	are	reimbursed	when	
performed	by	physicians	or	optometrists	and	are	within	the	lawful	scope	of	practice	of	
optometrists.		(Not	in	HSC,	MSC,	or	HMO	statutes.)	
Yes	
Podiatrists	 c.175	§110(I);	c.176G	§1	
(See	“nondiscriminatory”)	
Requires	coverage	for	services	of	podiatrists	when	services	are	reimbursed	when	
performed	by	physicians	or	podiatrists	and	are	within	the	lawful	scope	of	practice	of	
podiatrists.		(Not	in	HSC	or	MSC	statute.)	
Yes	
*	Note	that	many	provider-centered	mandates,	unlike	the	typical	service-centered	mandate,	are	not	uniform	across	the	standard	forms	of	health	care	
insurance	license	(general	insurance	company,	medical	and	hospital	service	corporation,	HMO).		
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Appendix	B:	Methodology	of	Cost	Estimation	
Definition	of	population	and	costs	measured	This	study	estimates	the	calendar	year	2014	costs	to	the	Massachusetts	health	care	system	of	state	mandates	in	force	during	that	year.		This	study	estimates	health	care	costs	only	for	that	portion	of	the	Massachusetts	population	with	health	insurance	subject	to	health	benefit	mandate	laws,	which	is	composed	of	two	segments.		First,	all	of	the	mandates	in	the	study	apply	to	those	with	coverage	in	fully-insured	commercial	products	regulated	by	the	Massachusetts	Division	of	Insurance.		Second,	a	subset	of	the	mandates	in	this	study	also	applies	to	coverage	for	public	employees	provided	under	the	Group	Insurance	Commission	(GIC).		The	great	majority	of	the	GIC	coverage	is	provided	on	a	self-insured	basis,	with	the	remainder	included	among	the	fully	insured	plans	subject	to	all	the	mandates.		However,	self-insured	GIC	plans	voluntarily	follow	all	benefit	mandates.		The	fully-insured	and	GIC	segment	of	the	commercial	insurance	market	comprised	approximately	49.1	percent	of	the	4.8	million	member	under-65	commercial	market	in	2014,	with	the	other	50.9	percent	provided	by	self-insured	employers	not	subject	to	state	benefit	mandates	(other	than	the	approximately	261,400	under-65	members	of	self-insured	GIC	plans).		A	more	detailed	discussion	of	the	study	population	is	contained	below.	Costs	associated	with	mandated	benefits	are	a	relatively	small	subset	of	the	total	health	care	costs	for	the	affected	population;	to	begin	to	address	by	how	much	mandate	laws	impact	total	costs	it	will	be	helpful	to	define	terminology	for	the	purpose	of	this	report.		The	general	cost	concepts	defined	below	will	aid	in	interpreting	the	results	of	the	study.		In	practice	these	cost	sub-categories	are	difficult	to	measure,	and	no	precise	measurement	of	these	cost	breakouts	can	be	achieved	within	the	scope	of	this	project,	although	conceptual	definition	will	aid	in	interpreting	the	results	of	the	analysis.		There	are	two	general	types	of	costs	that	may	be	associated	with	any	mandate:	
• Required	direct	costs.		These	are	the	costs	of	services	that	are	explicitly	described	in	a	mandate	law,	used	by	covered	members	and	paid	for	by	the	regulated	insurance	plans,	whether	or	not	some	or	all	of	the	costs	would	have	been	incurred	in	the	absence	of	the	mandate	through	voluntary	provision	of	the	benefits.		These	costs	are	the	primary	focus	of	this	study,	and	are	the	most	easily	measurable.	Required	direct	costs	(RDCs)	are	the	sum	of	base	direct	costs	and	marginal	direct	costs.			
o Base	direct	costs	(BDCs)	are	those	costs	that	would	be	present	even	if	the	mandate	law	were	not	in	force.		Mandate	laws	may	require	benefits	that	would	be	provided,	wholly	or	in	part,	voluntarily	(by	some	or	all	of	the	market)	or	that	are	required	by	another	mandate	law	(state	or	federal).		
o Marginal	direct	costs	(MDCs)	are	those	additional	costs	beyond	the	base	direct	costs	that	the	imposition	of	the	mandate	impels.			
• Indirect	costs.		Indirect	costs	are	those	costs	that	may	be	added	as	a	result	of	the	related	delivered	services	associated	with	the	mandate	(e.g.,	costs	of	additional	complicated	births	associated	with	infertility	treatment)	or	those	service	costs	avoided	(these	would	be	“negative	costs”	or	cost	offsets)	as	a	result	of	the	mandate	(e.g.,	fewer	
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emergency	department	visits	for	diabetics	due	to	coverage	for	diabetes	services	and	supplies).		While	we	can	measure	RDCs	reasonably,	measuring	their	breakdown	into	base	and	marginal	direct	costs	is	far	more	difficult,	and	measuring	indirect	costs	even	more	difficult.		As	a	hypothetical	example	of	the	distinction	between	base	and	marginal	direct	costs,	if	a	mandate	law	requiring	coverage	of	an	annual	EKG	were	passed,	additional	(marginal)	direct	costs	for	this	service	would	likely	result,	but	significant	dollars	are	already	being	covered	under	existing	policies	(base	direct	costs)	for	this	service.		Measurement	of	the	RDC	for	this	mandate	after	passage	of	the	law	could	be	calculated	as	the	number	of	persons	receiving	the	test	once	or	more	per	year,	times	the	average	cost	per	test.		The	resulting	RDC	would	contain	a	mix	of	base	and	marginal	RDC,	since	a	large	portion	of	the	cost	was	already	being	incurred	voluntarily	(i.e.,	a	large	number	of	covered	EKG	tests	would	have	been	paid	for	by	carriers	anyway).		Any	indirect	effects,	such	as	increased	interventional	cardiology	costs	or	avoided	heart	attack	admissions,	would	be	difficult	to	quantify	directly.	To	measure	the	true	cost	impact	of	a	mandate	law	on	the	regulated	insurance	product	premiums,	one	would	need	to	include	only	marginal	costs,	which	would	consist	of	marginal	direct	costs	and	marginal	indirect	costs	(those	indirect	costs	associated	with	the	marginal	utilization	produced	by	the	mandate	law).		Since	marginal	indirect	costs	may	be	either	positive	or	negative,	the	net	impact	of	any	one	mandated	benefit	on	total	costs	may	be	either	increasing	or	decreasing,	depending	on:	
• How	much	of	the	direct	cost	associated	with	the	mandate	is	marginal	(i.e.,	attributable	to	the	imposition	of	the	mandate)	
• Whether	indirect	costs	are	positive	or	negative	on	net	
• The	size	of	those	indirect	costs	relative	to	the	direct	costs	While	not	within	the	scope	of	this	study,	a	well-conducted	multi-variate	statistical	analysis	using	multi-state	data	would	be	better	able	to	estimate	marginal	costs	that	include	both	direct	and	indirect	components.		Some	multivariate	econometric	studies	comparing	benefit	mandates	and	cost	levels	across	states	have	shown	that	some	specific	mandated	benefits	decrease	costs	on	net,	while	others	increase	costs	on	net.998			This	study	provides	some	information	that	may	be	useful	in	understanding	the	proportion	of	the	required	direct	costs	that	are	likely	to	be	marginal	for	the	mandates.		The	scope	of	this	study	does	not	attempt	to	measure	precisely	the	amount	of	RDC	that	is	marginal	(which	would	require	multi-state	data),	and	the	report	does	not	include	evaluation	of	indirect	costs.		As	a	result,	it	is	not	possible	to	ascertain	from	the	information	in	this	study	the	net	impact	on	health	care	costs	in	the	Commonwealth	associated	with	the	mandate	laws,	but	previous	research	suggests	that	total	RDCs	will	greatly	overstate	the	net	effect	of	the	mandates,	that	offsetting	indirect	cost	savings	can	be	larger	than	direct	cost	effects	(making	the	net	effect	of	a	mandate	cost	decreasing),	and	that	the	impact	of	mandate	laws	on	insurance	premium	levels	will	not	be	directly	inferable	from	the	RDC	estimates	contained	herein.999			
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This	report	does,	however,	present	a	comparison	of	the	fully-insured	and	self-insured	GIC	population	RDCs	to	the	RDCs	observed	in	the	Massachusetts’	non-GIC	self-insured	sector	not	subject	to	the	mandate	laws,	the	difference	between	which	provides	one	estimate	of	the	direct	marginal	differences	(that	is,	net	direct	cost	impact)	introduced	by	the	mandate	legislation.		Previous	research	has	found	that	benefit	levels,	including	mandated	benefits,	are	similar,	if	not	richer,	in	the	self-insured	market.1000		Mandate	laws	may	have	small	effects	if	firms	offer	the	benefits	voluntarily.		However,	in	that	employers	in	Massachusetts	that	self-insure	must	compete	in	the	labor	market	with	fully-insured	firms	that	must	offer	the	mandated	benefit	package	and	public-sector	employers	offering	GIC	plans	that	voluntarily	include	all	mandated	health	insurance	benefits	(even	when	the	text	of	the	mandate	laws	does	not	reach	the	self-insured	GIC),	the	benefits	in	the	non-GIC	self-insured	firms	are	likely	to	be	at	least	somewhat	richer	than	they	would	be	in	the	absence	of	the	mandate	laws.		This	competitive	labor	market	effect	would	shrink	the	cost	difference	between	fully-insured	and	self-insured	GIC	plans	and	non-GIC	self-insured	plans	and	understate	(or	provide	a	lower	bound	for)	the	implied	impact	of	benefit	laws	on	health	care	costs	provided	by	the	difference	between	fully-insured	and	self-insured	GIC	costs	and	non-GIC	self-insured	costs.	The	measurement	of	costs	in	this	study	was	carried	out	in	one	of	two	ways	for	each	of	the	mandated	benefit	laws	currently	in	effect	in	Massachusetts,	summarized	above	in	Appendix	A.i		The	exhibit	displays	39	mandated	benefit	laws,	and	describes	in	summary	fashion	the	requirements	of	the	mandate.		The	next	section	describes	in	detail	the	two	approaches	used	for	measurement.			
Methodology	and	data	sources	
Project	organization	and	study	design	In	initial	project	discussions	with	CHIA,	it	was	decided	that	major	health	insurance	carriers	in	Massachusetts	would	be	approached	to	provide	input	about	the	specifications	for	measuring	the	cost	of	each	mandate.		The	following	nine	carriers	provided	input	on	the	mandates:	
• Blue	Cross	Blue	Shield	of	Massachusetts	
• Fallon	Community	Health	Plan	
• Harvard	Pilgrim	Health	Care	
• Health	New	England	
• Minuteman	Health,	Inc.	
• Neighborhood	Health	Plan	
• Tufts	Health	Plan	
• UniCare	
• UnitedHealthcare	Insurance	Company	Government	relations	staff	at	each	carrier	served	as	contact	points,	and	in	turn	consulted	their	colleagues,	including	medical	directors,	other	clinical	experts,	actuarial	staff,	and	data	management																																									 																					i	As	discussed	above,	this	list	includes	mandated	benefits	and	provider	mandates.		This	study	does	not	address	population	coverage	mandates.	
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and	analysis	staff.		In	addition,	the	Massachusetts	Association	of	Health	Plans	(MAHP)	provided	assistance	with	coordination	and	communication	with	its	participating	member	plans.			An	initial	discussion	with	participating	health	plans	and	MAHP	reviewed	the	process	that	had	been	used	for	the	2012	study	and	described	the	new	mandates	to	be	added	to	the	current	study.		In	the	original	2008	study,	a	collaborative	process	with	the	carriers	was	used	to	develop	the	data	to	measure	the	costs	of	the	mandates.		At	that	time,	CHIA	did	not	have	data	available	for	the	analysis,	so	it	was	agreed	that	extraction	of	claim	data	from	the	carriers	would	be	the	best	approach;	it	was	also	clear	that	this	would	require	significant	effort	on	the	part	of	the	carriers	if	all	26	mandates	included	in	the	2008	analysis	were	to	be	studied	this	way.		To	reduce	the	burden	on	the	carriers	to	a	reasonable	level,	a	prioritization	process	was	conducted,	during	which	mandates	were	categorized	into	one	of	two	groups.		The	first	group	consisted	of	mandates	that	were	considered	by	the	carriers	to	be	most	relevant	for	the	study	due	to	meeting	the	following	criteria:	
• The	mandate	required	benefits	that	were	judged	likely	to	be	reduced	or	eliminated	if	the	mandate	were	to	be	repealed.	
• The	mandate	covered	benefits	which	were	judged	to	be	currently	clinically	relevant	and	being	drawn	on	and	paid	for	by	the	carriers.	
• The	services	related	to	the	mandate	could	be	readily	identified	and	extracted	from	claim	history	files.	The	mandates	meeting	these	criteria	were	included	in	the	potential	marginal	direct	cost	portion	of	the	study;	cost	estimates	for	these	mandates	relied	on	primary	claim	data	analysis	using	claims	extracted	by	the	carriers.		The	mandates	failing	to	meet	one	or	more	of	the	criteria	listed	above	were	included	in	the	zero	marginal	direct	cost	portion	of	the	study.		Cost	estimates	for	these	mandates	were	produced	using	secondary	data	sources	(e.g.,	literature	review)	where	possible.		These	mandates:	
• Were	judged	to	require	benefits	that	the	carriers	would	substantially	provide	regardless	of	the	mandate	law,	or		
• Had	become	clinically	obsolete,	or		
• Could	not	be	feasibly	measured	as	part	of	the	study,	nor	monitored	by	the	carriers,	regardless	of	the	presence	of	a	mandate.	For	both	the	2012	study	and	the	present	study,	the	original	potential	marginal	direct	cost	and	zero	marginal	direct	cost	mandate	designations	were	reviewed	and	confirmed	by	the	carriers.		In	addition,	in	light	of	federal	benefit	requirements	in	the	Mental	Health	Parity	and	Addiction	Equity	Act	of	2008	(MHPAEA)	and	the	Patient	Protection	and	Affordable	Care	Act	of	2010	(ACA),	Compass	re-classified	the	mental	health	and	contraceptive	services	mandates	as	zero	marginal	direct	cost	mandates	in	the	present	study.ii		RDC	estimates	for	these	two	mandates	were	prepared	with	MA	APCD	data.		In	the	present	study,	the	MA	APCD	also	allowed	estimation	of	the	RDCs	for	four	of	the	original	zero	marginal	direct	cost	mandates	(cardiac	rehabilitation,	cytological	screening,	lead																																									 																					ii	The	contraceptive	services	and	mental	health	mandates	were	treated	as	“mandates	with	potential	marginal	direct	cost”	in	the	2008	and	2012	studies.	
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poisoning	screening,	and	mammography)	with	claim	data.		RDCs	for	the	remaining	zero	marginal	direct	cost	mandates	identified	by	the	carriers,	where	measurable,	were	calculated	using	secondary	data	sources.	Each	carrier	participating	in	the	current	study	was	asked	to	review	the	data	specifications	used	for	the	2012	study	to	update	them	for	any	changes	in	clinical	practice,	coding,	or	other	relevant	factors.		Five	mandates	were	added	to	the	mandate	list	for	the	present	study:	autism	services,iii	cleft	palate	and	cleft	lip	services,	hearing	aids	for	children,	oral	cancer	drugs,	and	physician	assistants.		The	autism	services	specification	developed	for	the	2012	study	by	a	volunteer	carrier	was	included	in	the	above	specification	review	process,	as	well	as	Compass-developed	initial	specifications	for	the	hearing	aids	for	children,	oral	cancer	drugs,	and	physician	assistant	mandates.		Two	carriers	developed	specifications	for	the	cleft	palate	and	cleft	lip	mandate	at	CHIA’s	request.	
Data	sources	Since	the	initial	study	was	published,	CHIA	developed	health	care	claim	database	resources.		The	allowed	amount	and	paid	claims	PMPM	estimates	developed	from	claim	data	for	the	present	study	drew	upon	calendar	year	2014	data	from	CHIA’s	Massachusetts	All	Payer	Claim	Database	(MA	APCD),1001	Release	4.0.iv		CHIA	collects	and	manages	data	from	commercial	carriers,	third	party	administrators,	and	public	programs.1002		CHIA	works	with	each	carrier	to	conduct	a	quality	control	process	on	the	MA	APCD	data,	and	“clears”	data	through	this	process	on	a	carrier-by-carrier	basis	as	this	process	is	complete.		This	quality-controlled	sample	of	carriers	comprises	approximately	87	percent	of	total	commercial	fully-insured	and	GIC	primary	medical	membership	under	age	65	in	the	Commonwealth.v		Compass	relied	upon	this	quality-controlled	data	sample	after	verifying	basic	reasonableness	checks	on	membership	and	expenses.		The	analogous	figure	for	pharmacy	membership	is	somewhat	lower,	at	60	percent;	the	quality	control	process	is	ongoing,	and	focused	on	the	medical	claims	initially.		Therefore,	fewer	carriers’	pharmacy	claims	have	been	cleared	through	CHIA’s	quality	control	process.		Cost	estimates	contained	in	this	report	assume	that	the	PMPM	costs	obtained	from	the	MA	APCD	sample	data	are	representative	of	the	overall	fully-insured	commercial	under-65	population.	Compass	used	the	MA	APCD	claims,	eligibility,	product,	and	provider	data	to	extract	claims	and	estimate	per	member	costs	for	services	required	by	the	25	potential	marginal	direct	cost	mandates.		The	MA	APCD	contains	both	fully-insured	and	self-insured	claims,vi	allowing	Compass	to	compare	
																																								 																					iii	The	autism	services	mandate,	effective	for	policy	renewals	on	or	after	January	1,	2011,	was	discussed	in	the	2012	report,	but	no	cost	estimates	were	presented,	given	that	the	report	study	period	was	2009.	iv	Service	year	2014	(paid	through	June	30,	2015)	is	the	most	recent	full	year	available	in	Release	4.0.	v	Total	average	fully-insured	commercial	primary	medical	insurance	membership	under	age	65	reported	in	the	MA	APCD	for	all	carriers	is	approximately	2	million,	or	94	percent	of	Compass’s	2014	fully-insured	commercial	membership	estimate	of	2.1	million.		Total	average	under-65	fully-insured	and	self-insured	GIC	primary	medical	insurance	membership	from	the	MA	APCD	is	2.1	million,	or	90	percent	of	Compass’s	2.4	million	population	estimate	(not	all	carriers’	GIC	accounts	can	be	identified	in	the	MA	APCD;	these	accounts	are	excluded	from	the	2.1	million	estimate).	vi	On	1	March,	2016,	the	U.S.	Supreme	Court	decided,	in	Gobeille	v.	Liberty	Mut.	Ins.	Co.,	that	self-insured	plans	regulated	under	ERISA	can	not	be	compelled	to	submit	data	to	state	APCDs.		This	decision	will	imply	a	
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the	per-person	spending	level	in	the	fully-insured	and	self-insured	GIC	business	(subject	to	the	mandates)	to	the	per-person	costs	in	the	non-GIC	self-insured	business	(not	subject	to	the	mandates)	to	generate	estimates	of	the	mandates’	impact.	The	potential	direct	marginal	cost	mandates	are	shown	in	Table	B-1	below.	
Table	B-1	
Mandates	with	Potential	Marginal	Direct	Cost	
	In	the	terminology	defined	above,	for	these	mandates	it	was	assumed	possible	that	both	RDC	and	MDC	were	greater	than	zero,	and	thus	they	were	the	focus	of	more	precise	measurement	using	claim	data.	The	mandates	judged	likely	to	have	little	or	no	marginal	direct	costs	are	shown	in	Table	B-2	below.		Treatment	of	breast	cancer	using	bone	marrow	transplant	was	demonstrated	to	be	clinically	obsolete	in	the	2008	study	by	analysis	of	Commonwealth	employee	claims,	and	thus	was	assumed	to	no	longer	have	marginal	cost	to	the	system.		As	discussed	in	more	detail	above,	in	this	study	it	is	included	within	the	clinical	trials	mandate	analysis.		Two	mandates	were	judged	to	be	not																																									 																																								 																																								 																																								 																																			 	significant	methodological	change	in	future	reports	in	the	likely	event	that	self-insured	groups	cease	MA	APCD	submissions	in	light	of	this	decision.	
Service	Mandates
Autism	Spectrum	Disorders
Child	Hearing	Aids
Chiropractic	Services
Cleft	Palate	and	Lip
Diabetes-related	Services	and	Supplies
Early	Intervention	Services
Home	Health	Care
Hormone	Replacement	Therapy	(HRT)
Human	Leukocyte	Antigen	Testing
Hypodermic	Syringes	or	Needles
Infertil ity	Treatment
Limb	Prostheses
Low	Protein	Food	Products	for	Inherited	Amino	
			Acid	and	Organic	Acid	Diseases	(PKU)
Nonprescription	Enteral	Formulas
Oral	Cancer	Drugs
Scalp	Hair	Prostheses	for	Cancer	Patients
Speech,	Hearing	and	Language	Disorders
Provider	Mandates
Certified	Nurse	Midwives
Certified	Registered	Nurse	Anesthetists
Chiropractors
Dentists
Nurse	Practitioners
Optometrists
Physician	Assistants
Podiatrists
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measurable	within	the	scope	of	the	original	study:		Off-label	uses	of	prescription	drugs	to	treat	HIV/AIDS	and	off-label	uses	of	prescription	drugs	to	treat	cancer.		Because	the	off-label	uses	of	prescription	drugs	are	not	considered	monitorable	or	manageable,	elimination	of	these	mandates	would	be	likely	to	have	little	effect	on	utilization.	The	remaining	mandates	in	Table	B-2	were	judged	to	be	benefits	the	carriers	would	likely	pay	for	even	if	the	state	mandate	law	was	repealed,	due	to	proven	cost-effectiveness,	demand	from	members,	or	redundancy	with	federal	mandates.		In	all	cases	the	marginal	cost	(i.e.,	cost	caused	by	the	presence	of	the	mandate	law)	associated	with	the	mandates	in	Table	B-2	was	assumed	to	be	at	or	near	zero.		In	previous	studies,	RDCs	for	all	measurable	zero	marginal	direct	cost	mandates	were	estimated	using	secondary	data	sources.		In	the	present	study,	availability	of	the	MA	APCD	allowed	estimation	of	the	RDCs	for	six	of	the	zero	marginal	direct	cost	mandates	(cardiac	rehabilitation,	contraceptive	services,	mental	health	services,	cytological	screening,	lead	poisoning	screening,	and	mammography)	with	claim	data.		RDCs	for	the	remaining	measurable	zero	marginal	direct	cost	mandates	were	calculated	using	secondary	data	sources.		Compass	reviewed	and	updated	these	models,	using	Massachusetts	(rather	than	national	or	regional)	data	wherever	possible	for	the	utilization	rates,	prevalence	figures,	and	other	components	underlying	the	calculations.			With	marginal	costs	assumed	to	be	zero,	the	estimated	total	RDCs	for	these	14	mandates		were	added	to	the	RDC	costs,	but	no	additional	costs	were	included	in	the	marginal	cost	estimates	for	these	mandates	(more	precisely,	zero	was	added	to	the	marginal	cost	estimates).	The	methodologies	used	in	the	analysis	of	both	the	potential	marginal	direct	cost	and	zero	marginal	direct	cost	mandates	are	discussed	in	detail	further	below.	
Table	B-2	
Mandates	Judged	to	Have	Zero	Marginal	Cost	
	
	
Bone	Marrow	Transplants	for	Treatment	of	Breast	Cancer
Cardiac	Rehabilitation
Clinical	Trials	(to	treat	cancer)
Contraceptive	Services
Cytologic	Screening
Hearing	Screening	for	Newborns
Hospice	Care
Lead	Poisoning	Screening
Mammography
Maternity	Health	Care	(including	minimum	maternity	stay)
Mental	Health	Care
Preventive	Care	for	Children	Up	to	Age	Six	
Off-Label	Uses	of	Prescription	Drugs	to	Treat	Cancer
Off-Label	Uses	of	Prescription	Drugs	to	Treat	HIV/AIDS
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Applicable	population	Laws	mandating	insurance	benefits	in	the	Commonwealth	of	Massachusetts	vary	in	the	populations	to	which	they	apply.		This	study	estimates	the	effect	of	mandates	on	health	care	costs	only	for	people	in	Massachusetts	with	health	insurance	plans	subject	to	health	benefit	mandate	laws;	those	plans	fall	into	two	main	groups.		First,	all	mandates	in	the	study	apply	to	fully-insured	commercial	plans	regulated	by	the	Massachusetts	Division	of	Insurance.		Second,	a	subset	of	the	mandates	in	this	study	also	applies	to	coverage	for	public	employees	provided	under	the	GIC.		The	great	majority	of	the	GIC	coverage	is	provided	on	a	self-insured	basis,	with	the	remainder	included	among	the	fully-insured	plans	subject	to	all	the	mandates.		However,	self-insured	GIC	plans	voluntarily	follow	all	benefit	mandates.		Therefore,	in	this	analysis	Compass	has	treated	both	fully-insured	and	self-insured	GIC	plans	as	part	of	the	mandate-affected	population	for	all	mandates.	State	health	insurance	benefit	mandates	do	not	apply	to	individuals	covered	under:	
• Self-insured	policies	(except	the	GIC	population,	as	discussed	throughout	this	appendix),	as	these	policies	are	governed	by	federal	ERISA	statutes	and	not	subject	to	state	mandate	laws	
• Medicare	and	Medicare	Advantage	plans,	the	benefits	of	which	are	qualified	by	Medicare	
• Federally-funded	plans	including	the	Veterans	Administration,	TRICARE	(covering	military	personnel	and	dependents),	and	the	Federal	Employee’s	Health	Benefit	Plan	This	analysis	excludes	members	of	fully-insured	plans	over	64	years	of	age,	and	does	not	address	potential	effects	on	Medicare	supplement	plans	(which	generally	cover	patient	cost	sharing	within	the	Medicare	benefit	structure)	even	to	the	extent	they	are	regulated	by	state	law.		Finally,	some	Massachusetts	mandate	laws	affect	MassHealth,	which	administers	the	Massachusetts	Medicaid	program;	however,	this	analysis	does	not	address	the	potential	effect	of	those	mandates	on	MassHealth	expenditures.	U.S.	Census	Bureau	data	on	the	Massachusetts	population	and	percent	covered	by	employer-sponsored	plans	and	MA	APCD	eligibility	data1003	lead	to	an	estimate	of	3.8	million	Massachusetts	residents	under	age	65	covered	by	employer-sponsored	plans	in	2014,	approximately	1.8	million	of	whom	are	fully-insured.		Compass	used	Massachusetts	Department	of	Insurance	(DOI),1004,1005	MA	APCD	eligibility,1006	and	CHIA	enrollment	trends1007	data	to	develop	an	estimate	of	approximately	139,000	additional	individuals	under	age	65	residing	in	other	states	are	covered	by	Massachusetts-issued	fully-insured	employer-sponsored	insurance	subject	to	the	mandates.		Finally,	MA	APCD	eligibility	data1008	yielded	an	estimate	of	approximately	170,000	persons	under	age	65	purchased	insurance	in	the	non-group	market	in	2014,	for	a	total	estimate	of	2.1	million	fully-insured	members.	Because	self-insured	GIC	plans	follow	the	mandates	voluntarily,	an	additional	261,000	members	are	added	to	the	covered	population	(based	on	GIC	annual	reports)1009	for	a	total	of	2.4	million	individuals.		Appendix	C	contains	more	details	about	these	population	calculations.	The	statutory	language	varies	across	the	mandates	as	to	which	of	the	geographic	categories	and	license	types	contained	in	the	insurance	statutes	the	mandate	is	applicable.		Generally,	the	
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mandates	apply	to	residents	of	Massachusetts	and	to	those	with	a	principal	place	of	employment	in	Massachusetts,	and	so	effectively	apply	to	all	members	covered	by	fully-insured	policies	issued	in	Massachusetts.		There	are	a	few	exceptions	to	this	general	case	apparent	in	the	statutory	language.		First,	the	infertility	mandate	applies	only	to	Massachusetts	residents.		The	infertility	sample	cost	estimates	therefore	include	only	those	claims	and	members	indicating	a	member	state	of	residence	of	Massachusetts,	and	the	population	paid	expenses	PMPM	are	calculated	over	the	member-resident	insured	population	only.		Second,	four	provider	mandates	(certified	nurse	midwives,	chiropractors,	dentists,	and	optometrists)	do	not	have	language	in	Chapter	176G	(the	HMO	license).		As	a	result,	in	our	calculations	we	have	not	applied	the	cost	estimates	to	this	population	for	these	four	mandates.		Third,	the	chiropractic	services	mandate	applies	only	to	medical	service	corporations	(Chapter	176B),	and	as	a	result	the	cost	estimates	are	applied	only	to	the	BCBSMA	membership.	
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Table	B-3	
Populations	to	Which	Mandates	Apply	
	Table	B-3	summarizes	the	license	types	and	populations	to	which	the	mandates	apply	per	the	statutory	language,	and	the	applicable	population	used	in	the	Compass	analysis	(which	always	includes	the	self-insured	GIC).		The	PMPM	cost	estimate	from	our	sample	data	for	each	mandate	was	multiplied	by	the	indicated	estimated	member	population	number	to	arrive	at	the	total	dollar	cost	estimate	for	each	mandate.vii	For	calculating	the	percent	of	premium,	the	analysis	uses	as	a	member-months	denominator	the	sum	of	member-months	for	all	license	types	(for	Massachusetts	residents	and	non-residents	with	a	principal	place	of	employment	in	Massachusetts),	since	it	estimates	the	per-person	costs	of	the																																									 																					vii	As	discussed	below,	for	aggregated	cost	estimates,	overlap	between	mandates	is	removed	when	summing	total	dollars.	
Mandate Applicable	Population
Estimated	
Statute	
Membership
Est.	Effective	
Membership	
(incl.	SI	GIC)
Certified	Nurse	Midwives
Chiropractors
Dentists
Optometrists
Chiropractic	Services Blue	Cross	Blue	Shield	fully-
insured	members,	excluding 	HMO	
Blue
												165,174	 												165,174	
Infertil ity	Services All	fully-insured	Massachusetts-
resident	members
									1,962,021	 									2,206,099	
Certified	Registered	Nurse	Anesthetists
Early	Intervention
Home	Health	Care
HRT
Infertil ity
Low	Protein	Foods
Nurse	Practitioner
Podiatrist
Syringe
Cardiac	Rehab
Clinical	Trials	for	Cancer
Contraception
Cytologic	Screening
Lead	Screening
Mammography
Off-label	Uses	of	Prescription	Drugs	-	Cancer
Off-label	Uses	of	Prescription	Drugs	-	HIV/AIDS
Preventive	Care	to	Age	6
Autism	Services
Child	Hearing	Aids
Cleft	Palate	and	Lip
Diabetes
HLA	Testing
Limb	Prosthesis
Mental	Health
Nonprescription.	Enteral	Formulas
Oral	Cancer	Drugs
Physician	Assistants
Scalp	Hair	Prosthesis
Speech	&	Hearing
Bone	Marrow	Transplants	for	Breast	Cancer
Hearing	Screening	for	Newborns
Hospice	Care
Maternity	Care
												730,715	
									2,362,745	
									2,362,745	
Indemnity	and	Blue	Cross	Blue	
Shield	fully-insured	members 												479,865	
All 	fully-insured	members	and	all 	
GIC	members		(fully	and	self-
insured)
									2,362,745	
All 	fully-insured	members 									2,101,336	
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benefits	with	respect	to	the	overall	average	fully-insured	health	insurance	premium.		However,	for	the	five	mandates	that	apply	to	less	than	the	entire	fully-insured	population,	estimated	claims	were	included	in	the	numerator	only	for	the	sub-groups	indicated	in	Table	B-3,	as	these	are	the	only	claims	related	to	benefits	required	by	those	mandates.		The	self-insured	GIC	was	included	in	both	the	numerator	claims	and	denominator	membership	for	all	mandates.		The	resulting	estimates	represent	the	impact	on	the	average	fully-insured	premium,	not	on	the	premium	for	the	sub-group(s)	to	which	the	mandate	applies.		
Sample	population	To	develop	the	dollar	estimates	in	the	study,	PMPM	claim	expense	estimates	were	developed	from	the	data	sources	described	above.		Paid	claim	expenses	PMPM	from	representative	samples	were	developed,	and	then	multiplied	by	the	applicable	populations	discussed	in	the	preceding	section.	In	general,	the	PMPM	claim	expense	estimates	developed	from	claim	data	drew	upon	CHIA’s	MA	APCD	Release	4.0.		The	MA	APCD	quality-controlled	medical	claim	data	sample	described	above	in	the	data	sources	section	includes	27	carriers	(including	MassHealth).		This	quality-controlled	sample	comprises	approximately	2	million	members,	or	87	percent	of	Compass’s	estimate	of	2.4	million	total	commercial	fully-insured	and	GIC	primary	medical	membership	under	age	65	in	the	Commonwealth.	viii	Compass	joined	claims	for	the	27	quality-controlled	medical	carriers	to	de-duplicated	eligibility	data	to	review	match	rates	and	average	PMPM	allowed	amount	expenses	by	carrier.		The	11	medical	carriers	with	at	least	95	percent	of	claims	matching	to	a	primary	medical	insurance	eligibility	span	and	a	reasonable	resulting	“matched”	2014	average	PMPM	allowed	expenditure	comprised	the	analytical	sample.		Combined	fully-insured,	self-insured,	and	GIC	matched	2014	average	PMPM	allowed	expenditures	by	payer	in	the	medical	sample	ranged	from	$214	for	one	small	individual-market	carrier	to	$402	for	a	carrier	whose	sample	data	are	likely	comprised	almost	exclusively	of	GIC	accounts,	as	described	below.	The	average	fully-insured	and	self-insured	GIC	medical	membership	subject	to	the	mandates	represented	in	the	11-carrier	sample	passing	this	additional	quality-control	step	for	2014	is	1.9	million,	or	79	percent	of	the	estimated	2.4	million	total	average	membership	for	the	fully-insured,	self-insured	GIC,	non-Medigap	population	under	age	65	in	Massachusetts.			The	MA	APCD	quality-controlled	pharmacy	claim	data	sample	includes	four	carriers	(including	MassHealth).		The	average	membership	under	age	65	represented	in	this	sample	for	commercial	fully-insured	non-Medigap	and	self-insured	GIC	products	for	calendar	year	2014	was	1.4	million.		This	represents	60	percent	of	the	2.4	million	total	average	fully-insured	and	self-insured	GIC	population.		Combined	fully-insured,	self-insured,	and	GIC	matched	2014	average	PMPM	allowed	expenditures	by	payer	in	the	pharmacy	sample	ranged	from	$81	to	$88,	and	the	claims	to	eligibility																																									 																					viii	Total	average	fully-insured	commercial	primary	medical	insurance	membership	under	age	65	reported	in	the	MA	APCD	is	approximately	2	million,	or	94	percent	of	Compass’s	2014	fully-insured	commercial	membership	estimate	of	2.1	million.		Total	average	under-65	fully-insured	and	self-insured	GIC	primary	medical	insurance	membership	from	the	MA	APCD	is	2.1	million,	or	90	percent	of	Compass’s	2.4	million	population	estimate	(not	all	carriers’	GIC	accounts	can	be	identified	in	the	MA	APCD;	these	accounts	are	excluded	from	the	2.1	million	estimate).	
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match	rate	for	the	three	quality-controlled	pharmacy	carriers	ranged	from	94	to	99	percent.		Data	for	all	three	commercial	carriers	in	CHIA’s	quality-controlled	sample	were	therefore	used	in	the	analysis.		Cost	estimates	contained	in	this	report	assume	that	the	PMPM	costs	obtained	from	the	MA	APCD	sample	data	are	representative	of	the	overall	fully-insured	commercial	under-65	population.			In	general,	the	entire	database	sample	population	was	used	for	calculations.		Exclusions	from	the	sample	data	were	made	where	the	analysis	of	applicable	populations	above	indicated	this	would	be	appropriate:	
• For	one	carrier,	the	sample	includes	only	the	38	percent	of	claims	and	24	percent	of	reported	membership	identifiable	as	indemnity	products.		The	remaining	62	percent	of	claims	volume	for	this	payer	matched	to	products	with	a	medical	services	corporation/hospital	services	plan	carrier	license	type,	or	matched	to	products	for	which	carrier	license	type	could	not	be	determined.		Given	that	the	carrier	is	not	licensed	as	a	medical	service	corporation	or	hospital	service	plan	in	Massachusetts,	the	medical	service	corporation/hospital	service	plan	and	license	type	unknown	volume	were	excluded	from	this	analysis	under	the	assumption	the	situs	of	the	plans	was	not	Massachusetts	(no	situs	indicator	was	available	on	Release	4.0	of	the	MA	APCD).		Upon	further	review	of	the	indemnity	portion	of	the	data,	Compass	noted	that	although	the	products	were	not	identified	as	GIC	products	in	the	MA	APCD,	the	associated	membership	was	a	near-match	to	the	GIC’s	reported	membership	for	the	same	carrier	for	fiscal	year	2014.	Given	this	fact,	and	the	high	matched	2014	average	allowed	expenses	PMPM	for	these	products	($402),	suggesting	rich	benefits	on	average,	Compass	treated	these	indemnity	claims	and	eligibility	as	GIC	products.	
• The	chiropractic	services	mandate	applies	only	to	Blue	Cross	and	Blue	Shield	of	Massachusetts	(BCBSMA),	the	data	for	which	are	represented	in	the	MA	APCD	sample.		Therefore,	only	BCBSMA	data	were	used	to	calculate	the	PMPM	for	this	mandate.ix	
• For	the	six	mandates	including	pharmaceuticals	among	their	mandated	services,	all	of	which	also	include	medical	components,	only	the	three	commercial	carriers	in	the	MA	APCD	pharmacy	sample	were	used	to	calculate	both	the	medical	and	pharmacy	PMPMs.			
• Identifying	claims	by	provider	type	required	knowledge	and	coding	of	carrier-specific	provider	type	identifiers.		Therefore,	for	the	eight	provider-centered	mandates,	only	data	for	the	three	largest	carriers	(all	of	whom	provided	guidance	in	their	specification	review	responses	on	identifying	the	provider	types	in	their	data)	were	used	to	calculate	the	PMPMs	for	these	mandates.		Review	of	preliminary	results	indicated	that	the	provider	type	and	specialty	information	provided	by	one	carrier	did	not	reliably	identify	claims	performed	by	the	specific	provider	types	in	question.		Therefore,	this	carrier’s	data	were	dropped	from	the	sample,	leaving	two	of	the	three	largest	carriers	in	the	initial	provider	mandate	sample.	
																																								 																					ix	In	this	case,	since	the	applicable	population	membership	and	the	sample	population	membership	are	the	same,	the	dollars	measured	in	the	MA	APCD	data	were	used	directly	as	the	aggregate	dollar	impact	of	the	mandate.		In	most	cases,	however,	the	sample	is	smaller	than	the	population,	and	the	resulting	sample	PMPM	was	multiplied	times	the	larger	population	membership	estimate	to	arrive	at	a	population	estimate	for	aggregate	dollars.	
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• Furthermore,	four	of	the	eight	provider-centered	mandates	do	not	apply	to	HMO	licenses.		Review	of	the	preliminary	results	for	these	four	mandates	showed	that	effectively	all	fully-insured	volume	for	the	smaller	of	the	two	carriers	in	the	initial	provider	mandate	sample	was	identified	as	HMO-licensed.		Therefore,	this	carrier	was	dropped	from	the	sample	for	these	four	mandates	(chiropractors,	certified	nurse	midwives,	dentists,	and	optometrists).		Both	carriers’	data	were	used	for	the	four	provider	mandates	including	all	license	types	(certified	registered	nurse	anesthetists,	podiatrists,	nurse	practitioners,	and	physician	assistants).		In	addition,	not	all	carriers’	GIC	accounts	can	be	identified	in	the	MA	APCD;	these	accounts	are	excluded	from	the	1.9	million	fully-insured	and	self-insured	GIC	sample	population	estimate.		In	the	analysis,	these	products,	where	applicable,	are	included	in	the	1.5	million	member	non-GIC	self-insured	comparison	population.	With	respect	to	data	extraction	from	the	MA	APCD,	there	was	one	additional	relevant	issue	related	to	the	study	population.		Identifying	average	costs	for	the	six	mandates	including	pharmaceuticals	must	take	into	account	that	the	carriers	have	some	accounts	that	use	a	third-party	pharmacy	benefit	manager	(PBM),	and	that	for	some	of	these	accounts	(particularly	those	that	are	self-insured)	pharmacy	claims	were	not	included	in	the	three-carrier	MA	APCD	sample.		As	a	result,	the	sample	pharmacy	membership	and	their	associated	claims	are	smaller	than	the	medical	membership	and	associated	claims.		To	address	this	issue,	medical	PMPMs	were	calculated	for	the	medical	data	using	the	medical	membership,	and	the	pharmacy	data	PMPMs	were	calculated	using	the	pharmacy	membership.		The	PMPMs	were	then	added	together,	and	were	multiplied	by	the	population	membership	to	calculate	the	estimated	total	dollar	impact.		The	total	dollar	estimates	were	then	divided	by	medical	membership	to	derive	combined	pharmacy	and	medical	PMPMs.		This	prevented	a	downward	bias	to	the	PMPM	estimates	that	would	otherwise	have	been	caused	by	missing	pharmacy	claims.		For	estimates	of	the	total	dollar	impact	in	the	Commonwealth,	the	full	population	membership	(all	fully-insured	and	self-insured	GIC	members	in	the	Commonwealth)	is	multiplied	by	the	estimated	PMPMs	calculated	without	carved	out	pharmacy	benefit	accounts.x	
Cost	estimation	methodology	for	mandates	with	potential	marginal	direct	cost	The	mandates	with	potential	marginal	direct	cost	were	analyzed	using	detailed	clinical	data	specifications	applied	to	detailed	claim	data.		CHIA	provided	an	extract	from	the	Massachusetts	MA	APCD	Release	4.0	as	the	data	source	for	required	direct	cost	estimates	of	the	mandated	benefits	shown	in	Table	B-2.		Compass	studied	calendar	year	2014	(paid	through	June	30,	2015,	the	most	recent	full	year	of	data	available	in	this	extract)	claims	and	membership	from	the	extract	for	this	review.		The	availability	of	the	MA	APCD	data	(and	the	Health	Care	Quality	and	Cost	Containment	2009	data	extract	made	available	to	Compass	by	CHIA	for	the	2012	study)	allowed	Compass	to	address	two																																									 																					x	Note	that	this	assumes	that	the	overall	PMPM	cost	profiles	(including	pharmaceuticals)	for	the	plans	with	and	without	carved-out	pharmacy	benefits	are	similar.	
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significant	shortcomings	in	other	state-level	impact	analyses	that	were	reviewed	prior	to	commencing	this	study.1010		First,	the	data	used	in	the	study	are	specifically	from	Massachusetts,	rather	than	national	data	or	data	from	other	states.		The	MA	APCD	medical	data	sample	used	in	the	analysis	represents	approximately	79	percent	of	the	fully-insured	and	self-insured	GIC	population	under	age	65	in	Massachusetts.		Second,	the	data	largely	allow	measurement	specifically	of	the	fully-insured	population	subject	to	the	mandate	laws	and	the	self-insured	GIC	population	voluntarily	provided	the	mandated	benefits	even	when	not	required	by	law,	and	allow	for	a	comparison	to	the	non-GIC	self-insured	population	(unregulated	and	not	subject	to	mandate	laws),	rather	than	inappropriately	mixing	these	populations	together.	The	approach	taken	to	RDC	measurement	involved	rigorous	definition	of	costs	associated	with	the	mandate	laws’	required	benefits,	and	careful	measurement	based	on	the	definitions.			There	were	four	general	steps	in	the	cost	measurement:	
• Review	and	updating	of	specifications	developed	for	the	previous	comprehensive	mandate	review	study,	and	development	of	new	specifications	for	more	recently	enacted	mandates.	
• Quality	control	assessment	of	specifications	and	follow-up	by	Compass.	
• Extracting	and	quality	checking	the	data	using	programming	language	to	implement	the	specifications.	
• Summarization	of	totals	and	adjustments	to	arrive	at	meaningful	aggregate	values.	The	specification	of	the	data	requirements	included	the	following	steps:	
• Initial	Completion	or	Revision	of	Data	Specification	Templates.		Each	carrier	participating	in	the	current	study	was	asked	to	review	the	data	specifications	used	or	developed	for	the	2012	study	and	Compass-developed	initial	specifications	for	the	hearing	aids	for	children,	oral	cancer	drugs,	and	physician	assistant	mandates	to	edit	them	for	any	changes	in	clinical	practice,	coding,	or	other	relevant	factors.		Two	carriers	developed	specifications	for	the	cleft	palate	and	cleft	lip	mandate	at	CHIA’s	request.	
• Review	and	refinement	of	the	specifications.		Compass	reviewed	the	feedback	for	each	specification	and	translated	each	of	the	specifications	into	programming	code	to	extract	and	summarize	the	data.		In	general,	carrier-recommended	additions	of	services,	products,	or	diagnoses	were	incorporated	into	the	specifications.		Compass	did	not	remove	services,	products,	or	diagnoses	from	the	specifications	at	a	carrier’s	recommendation	unless	independent	research	of	the	codes	marked	for	removal	validated	the	recommendation.		
• Quality	checking	the	data.		The	data	extracted	for	each	mandate	included	in	the	2012	study	were	summarized	and	compared	to	the	2012	results.		Results	for	newly-enacted	mandates	were	compared	to	CHIA’s	prospective	mandated	benefit	review	studies,	the	results	for	similar,	previously-studied	mandates,	and/or	independent	publically-available	data	sources.		Where	mandate	results	diverged	significantly	from	the	previous	
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study	or	other	benchmarks,	Compass	reviewed	the	specifications	and	programming	code	for	errors	and	corrected	results	as	necessary.	Where	these	results	continued	to	diverge	from	expected	results,	Compass	drilled	into	the	results	(by	carrier,	code,	etc.)	and	performed	further	research	to	validate	or	further	refine	the	results.	Comparing	the	present	study	to	the	2012	reports	shows	that	RDC	results	for	some	mandates	have	changed	dramatically;	most	notably,	the	RDC	estimates	for	diabetes	services	and	supplies	and	mental	health	care	show	nearly	three-fold	and	two-fold	increases,	respectively.		The	main	drivers	of	these	and	other	significant	differences,	illustrated	by	selected	examples,	follow.	
• Carrier	Input	
o For	the	mental	health	mandate,	the	carriers	provided	an	extensive	list	of	procedure	and	diagnosis	codes	to	be	added	to	the	cost	model	specifications	they	had	provided	in	the	two	previous	iterations	of	this	study	(2008	and	2012).		
o This	was	also	true	for	the	speech,	hearing,	and	language	and	the	non-prescription	enteral	formulas	mandates,	which	had	many-fold	cost	increases	(but	very	small	absolute	RDCs	even	after	the	large	increases	shown	in	this	study).	
o Significant	additions	were	also	made	to	the	diabetes	services	and	supplies	specification	to	include	new	products,	such	as	the	new	insulin	pumps	discussed	below.	
• Price	and	service	mix	changes	
o A	recent	study	found	that	the	average	price	of	insulin	has	tripled	in	the	past	decade.1011			
o New	and	expensive	insulin	pumps	have	also	become	popular	with	clinicians	and	diabetes	patients	in	recent	years.1012		
• Clinical	practice	and	guideline	changes	
o Decreased	frequency	guidelines	for	mammographic	and	cytological	screening	(Pap	smear)	have	been	released	by	U.S.	government	agencies	and	medical	societies	since	the	previous	study	period.1013,1014	After	completion	of	the	quality	control	process,	a	number	of	calculations	were	carried	out	to	produce	the	results	of	the	study.		Prior	to	executing	those	calculations,	a	claim	analysis	was	performed	to	eliminate	overlap	between	mandates.		Claims	for	which	coverage	is	mandated	by	multiple	mandates	in	the	study	(“mandate	overlap”)	must	be	identified	and	quantified	to	avoid	double-counting	in	aggregate	analyses.		To	quantify	overlaps,	all	claims	in	the	MA	APCD	sample	were	flagged	for	inclusion	in	each	mandate.		Areas	of	overlap	were	identified	where	the	same	claim	was	flagged	for	inclusion	in	multiple	mandates.		Total	sample	claims	expense	(in	millions	of	dollars)	for	the	observed	areas	of	overlap	are	summarized	in	Table	B-4.			
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Table	B-4	
Summary	of	Mandate	Overlaps	(in	millions	of	dollars)	
	Overlap	amounts	must	be	subtracted	from	the	totals	for	the	mandates	when	calculating:	(i)	costs	across	mandates,	or	(ii)	the	incremental	cost	attributable	to	the	given	mandate,	i.e.	the	amount	that	mandated	coverage	costs	to	the	Massachusetts	healthcare	system	would	be	reduced	if	a	given	mandate,	and	only	that	mandate,	were	repealed.		The	mandate-level	results	include	the	overlap	amounts;	the	overall	aggregated	result	for	all	mandates	with	potential	marginal	direct	cost	removed	the	overlapping	(double-counted)	amounts,	that	is,	each	claim	identified	as	a	mandated	service	for	any	primary	data	analysis	mandate	is	only	summed	once	in	these	aggregated	results.xi	Paid	claim	expenses	PMPM	were	calculated	for	each	mandate,	and	administrative	loading	(the	additional	costs	over	and	above	health	care	claim	costs	required	to	administer	the	health	plan)	was	added.		According	to	CHIA’s	September	2016	report	on	the	performance	of	the	Massachusetts	health	care	system,1015	average	administrative	loading	(including	profit)	in	the	fully-insured	commercial	market	was	estimated	to	be	11	percent	in	2014.		Therefore,	to	arrive	at	estimates	of	total	healthcare	premium	costs,	claim	costs	were	divided	by	one	minus	the	11	percent	administrative	load	(1	–	0.11),	or	0.89.xii		Individual	mandates	may	add	more	or	less	administrative	cost	than	the	average;	determining	the	level	of	additional	administrative	cost	required	for	any	individual	mandate	would	require	more	effort	than	is	required	to	estimate	the	medical	expense	portion	of	the	estimate,	but	only	represents	about	11	percent	of	total	costs.		Variations	in	the	relatively	small	administrative	cost	levels	around	the	average	would	be	covered	by	the	ranges	provided	for	the	cost	impacts	contained	in	this	study.	
																																								 																					xi	Amounts	larger	than	those	shown	in	Table	B-4	were	removed	from	the	aggregated	study	totals,	as	the	sample	amounts	shown	in	the	table	were	adjusted	to	the	total	population	level	at	the	same	time	that	the	sample	PMPMs	were	adjusted	to	the	population-level	RDCs.	xii	This	assumes	that	the	carriers	apply	the	same	percentage	gross	up	for	these	incremental	claim	expenses	as	for	their	baseline	claim	expenses.		If	a	carrier	elects	to	only	apply	incremental	variable	expenses,	then	the	incremental	premium	may	be	2-3	percent	lower,	based	on	an	assumption	that	2-3	percent	of	a	carrier's	administrative	cost	structure	represents	fixed	overhead	that	is	independent	of	claim	volume.		The	actual	percentages	would	vary	by	carrier.	
Mandate A B C D E F G H I J K L M N O P
A Autism	Services	Mandate 0.1$			 23.8$	
B Children's	Hearing	Aids	Mandate 1.0$			
C Chiropractor	Provider	Mandate 0.6$			
D Chiropractic	Services	Mandate
E Cleft	Palate	and	Lip	Mandate 0.1$			
F Diabetes	Services	Mandate 12.1$	 0.2$			 0.1$			 0.5$			
G Early	Intervention	Services	Mandate 14.9$	 0.3$			
H Home	Health	Services	Mandate 2.7$			 1.2$			 0.7$			 0.3$			 0.1$			 0.3$			 0.2$			
I Limb	Prosthesis	Mandate
J Low	Protein	Foods	Mandate 0.4$			
K Nonprescription	Enteral	Formulas	Mandate
L Nurse	Practitioner	Provider	Mandate	
M Podiatrist	Provider	Mandate
N Scalp	Hair	Prosthesis	Mandate
O Speech,	Hearing,	and	Language	Services	Mandate
P Syringe	and	Needle	Mandate
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Total	cost	in	the	healthcare	system	associated	with	each	mandated	benefit	was	computed	by	multiplying	the	paid	claim	plus	administration	PMPM	estimate	by	the	estimated	number	of	persons	subject	to	Commonwealth	mandates	from	Table	B-3.	These	estimated	premium	amounts	were	calculated	as	an	approximate	percentage	of	healthcare	premiums	in	Massachusetts	by	using	the	estimated	average	commercial	fully-insured	2014	premium	of	$436.00	from	CHIA’s	September	2016	report.1016		As	discussed	in	the	introduction,	we	are	unable	within	the	scope	of	this	study	to	produce	precise	estimates	of	the	marginal	cost	of	the	mandates	to	the	system,	the	focus	of	this	study	being	primarily	on	required	direct	cost,	that	is,	the	total	cost	to	the	system	of	benefits	described	in	the	statutory	language	of	the	various	mandates.		The	only	information	available	for	the	study	that	can	shed	some	light	on	the	question	of	marginal	costs	is	the	MA	APCD	non-GIC	self-insured	data.		Since	these	self-insured	plans	are	subject	to	Federal	ERISA	law	and	are	not	regulated	by	The	Division	of	Insurance,	they	are	not	required	to	comply	with	the	mandates,	and	are	free	(subject	to	competitive	labor	market	constraints)	to	reduce	or	remove	these	benefits	from	their	health	benefit	packages.		Because	labor	market	pressures	may	compel	the	non-GIC	self-insured	employers	to	offer	richer	benefits	than	they	would	if	other	employers	(fully-insured	employers	or	those	offering	GIC	plans	voluntarily	including	the	mandated	benefits)	were	not	required	to	offer	the	mandated	benefits,	any	differences	identified	between	the	non-GIC	self-insured	and	fully-insured	and	self-insured	GIC	benefit	costs	are	likely	to	be	underestimates	of	the	true	impact	of	the	mandate.		However,	they	may	provide	useful	lower	bound	estimates	of	the	marginal	direct	cost,	or	actual	direct	mandate	cost	impact	to	the	system.			In	the	cost	estimates	displayed	in	the	Results	section,	these	lower-bound	estimates	are	derived	from	the	difference	between	insurer	spending	in	the	fully-insured	and	self-insured	GIC	population	for	the	mandated	benefit	and	the	insurer	spending	in	the	non-GIC	self-insured	population	for	the	same	benefit.		To	reduce	the	impact	that	differences	in	average	patient	cost	sharing	between	these	populations	may	have	on	the	result,	the	calculation	is	performed	by	computing	the	percentage	by	which	the	fully-insured	and	self-insured	GIC	allowed	(before	cost	sharing)	expense	PMPM	exceeds	the	non-GIC	self-insured	allowed	expense	PMPM,	and	applying	that	percentage	to	the	fully-insured	and	self-insured	GIC	paid	claim	expense	PMPM.		The	result	is	a	lower-bound	estimate	of	the	impact	of	the	mandate	on	fully-insured	and	self-insured	GIC	health	insurance	expenditures.		Where	the	non-GIC	self-insured	allowed	expense	PMPM	is	higher	than	the	fully-insured	and	self-insured	GIC	allowed	expense	PMPM,	we	treat	the	impact	as	zero,	rather	than	negative;	we	assume	that	if	non-GIC	self-insured	firms	on	average	have	a	higher	spending	level	than	fully-insured	and	self-insured	GIC	products	subject	to	the	mandates,	it	is	not	caused	by	the	existence	of	the	mandate.		That	is:	Lower	Bound	Marginal	Cost	=	[(FIxiii	Allowed	–	SI	Allowed)/FI	Allowed]*FI	paid	RDC,	if	FI	Allowed	–	SI	Allowed	>	0	Lower	Bound	Marginal	Cost	=	0,	otherwise	
																																								 																					xiii	In	this	and	other	equations	and	exhibits	in	this	report,	the	abbreviation	“FI”	refers	to	the	fully-insured	and	self-insured	GIC	population	subject	to	the	mandates,	and	“SI”	refers	to	the	non-GIC	self-insured	comparison	population.	
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An	upper-bound	claim	cost	estimate	is	also	provided	for	each	mandate,	which	includes	the	entire	RDC,	except	for	those	mandates	judged	by	the	carriers	likely	to	have	zero	marginal	costs.		This	upper-bound	estimate	assumes	that	100	percent	of	the	RDC	for	mandates	with	potential	marginal	direct	cost	is	marginal,	and	that	carriers	would	pay	zero	dollars	in	claims	for	the	services	described	by	the	mandates	in	the	absence	of	the	mandate	laws.		For	most	mandates	there	is	good	reason	to	believe	the	actual	marginal	cost	is	far	lower,	though	we	do	not	have	a	direct	method	of	estimating	by	how	much.		For	example,	home	health	care	services	are	widely	considered	to	be	cost-effective	in	many	contexts.		In	all	likelihood	carriers	would	cover	this	benefit,	if	at	a	somewhat	lower	level,	in	the	absence	of	the	mandate.		
Cost	estimation	methodology	for	mandates	judged	likely	to	have	zero	marginal	cost	As	described	above,	14	mandates	were	judged	likely	to	have	zero	marginal	cost.		Also	as	discussed	above,	it	was	not	feasible	to	calculate	RDCs	for	three	of	the	mandates	(bone	marrow	transplants	for	treatment	of	breast	cancer	and	off-label	uses	of	prescription	drugs	to	treat	cancer	and	HIV/AIDS).		For	another	six	of	the	14	mandates	(cardiac	rehabilitation	services,	contraception	services,	cytological	screening,	child	lead	screening,	mammography,	and	mental	health)	RDCs	were	calculated	from	the	MA	APCD	following	the	upper-bound	methodology	described	above	for	the	potential	marginal	direct	cost	mandates.	The	estimation	process	for	the	remaining	five	mandates	(clinical	trials	for	the	treatment	of	cancer,	hospice	care,	maternity	care,	newborn	hearing	screening,	and	preventive	care	up	to	age	six)	judged	likely	to	have	zero	marginal	cost	drew	upon	secondary	data	sources	rather	than	primary	claim	and	membership	data	from	the	MA	APCD.		The	modeling	for	these	five	mandates	had	the	following	methodological	features	in	common:	
• Estimates	were	produced	for	the	same	under-65,	commercial,	fully-insured	and	self-insured	GIC	Massachusetts	population	analyzed	for	the	25	potential	marginal	direct	cost	mandates.	
• Literature	and	internet	data	sources,	along	with	some	calculations	using	MA	APCD	data,	were	drawn	upon	for	the	individual	facts	that	were	combined	into	calculations	for	the	estimated	cost	of	each	mandate.			
• For	each	mandate,	adjustments	were	made	to	make	the	estimate	applicable	to	the	relevant	population.		For	example,	if	a	national	commercial	population	estimate	was	available	and	deemed	to	be	reasonably	applicable	to	Massachusetts,	the	national	per	person	rate	was	applied	to	the	number	of	persons	in	the	under-65	commercial	fully-insured	and	self-insured	GIC	population	in	Massachusetts.	
• Total	cost,	PMPM	cost,	and	percent	of	premium	estimates	were	calculated	using	the	population	numbers	from	Table	B-3	and	the	same	$436.00	average	premium	and	11	percent	administrative	load	figures	cited	above.	
• The	enabling	statutory	language	for	each	mandate	was	adhered	to	as	closely	as	possible	given	the	limitations	of	the	approach	described.	The	form	of	each	calculation	was	dependent	to	a	significant	extent	on	the	data	available.		For	example,	in	some	cases	cost	per	person	per	year	data	were	available,	but	in	others	data	on	
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incidence	of	an	illness	and	cost	per	episode	of	that	illness	were	multiplied	together	to	produce	the	estimate.		In	all	cases,	the	costs	estimated	were	total	required	direct	costs.		As	discussed	above,	marginal	direct	cost	for	each	mandate	in	the	secondary	cost	group	is	assumed	to	be	zero.			Most	of	the	estimates	relying	on	secondary	data	drew	on	sources	that	were	not	specific	to	the	fully-insured	population	in	Massachusetts.		As	a	result,	data	from	broader	populations	(e.g.,	Massachusetts	statewide)	had	to	be	adjusted	to	the	sub-population	using	population	estimates	drawn	from	a	number	of	sources,	including	Census	Bureau	data	and	a	model	of	the	Massachusetts	insured	population	developed	by	Compass	for	its	work	for	CHIA.		These	estimates	and	their	sources	are	summarized	in	Appendix	C.		 	
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Appendix	C:	Estimation	of	Population	Subsets	Membership	potentially	affected	by	a	proposed	mandate	may	include	Massachusetts	residents	with	fully-insured	employer-sponsored	health	insurance	issued	by	a	Massachusetts	licensed	company	(including	through	the	GIC),	non-residents	with	fully-insured	employer-sponsored	insurance	issued	in	Massachusetts,	Massachusetts	residents	with	individual	(direct)	health	insurance	coverage,	and	lives	covered	by	GIC	self-insured	coverage	(which	complies	with	the	mandates	voluntarily).		Membership	projections	for	2017	to	2021	are	derived	from	the	following	sources.	The	2014	Massachusetts	All	Payer	Claim	Database	(MA	APCD)	formed	the	base	for	the	projections.		The	APCD	provided	fully-insured	and	self-insured	membership	by	insurance	carrier.		The	APCD	was	also	used	to	estimate	the	number	of	non-residents	covered	by	a	Massachusetts	policy.		These	are	typically	cases	in	which	a	non-resident	works	for	a	Massachusetts	employer	offering	employer-sponsored	coverage.	The	Massachusetts	Center	for	Health	Information	and	Analysis	(CHIA)	uses	supplemental	information	beyond	the	data	in	the	MA	APCD	to	develop	their	enrollment	trends	reports	and	provided	us	with	information	on	where	they	sourced	the	data	in	their	report	(MA	APCD	and	supplemental	carrier	information).		We	adjusted	our	membership	estimates	for	the	data	not	in	the	MA	APCD	where	appropriate.		The	2014	combined	membership	projection	by	carrier	was	compared	to	Massachusetts	Department	of	Insurance	(DOI)	reports	estimating	fully-insured	covered	members	by	insurance	carrier.		The	membership	projections	were	increased	to	include	insurance	carriers	that	were	reported	by	the	DOI	but	not	in	the	MA	APCD	or	CHIA	supplementary	report.		These	were	typically	insurance	carriers	with	small	membership	in	the	state.		The	distribution	of	members	by	age	and	gender	was	estimated	using	MA	APCD	population	distribution	ratios	and	was	checked	for	reasonableness	and	validated	against	the	U.S.	Census1017.		Membership	was	projected	forward	from	the	2014	base	year	through	2021	using	Census	Bureau	population	growth	rate	estimates	by	age	and	gender1018.		Projections	for	the	GIC	self-insured	lives	were	developed	using	GIC	base	data	for	2013,1019	2014,1020	and	2015,1021	and	the	same	projected	growth	rates	from	the	Census	Bureau	that	were	used	for	the	Massachusetts	population.		Breakdowns	of	the	GIC	self-insured	lives	by	gender	and	age	were	based	on	the	Census	Bureau	distributions.		 	
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Appendix	D:	Cost	by	Type	of	Service	for	Mandates	with	Potential	Marginal	Direct	Cost	This	appendix	presents	required	direct	claims	cost	(RDC)	broken	down	by	service	category	for	the	twenty-five	mandates	judged	to	have	potential	marginal	direct	cost	that	were	analyzed	using	the	MA	APCD.	
Table	D-1:	Autism	Spectrum	Disorders	
Autism	Spectrum	Disorders	Mandate	
Summary	of	Services	Used	by	Category	
	
Table	D-2:	Chiropractic	Medicine	
Chiropractic	Medicine	Mandate	
Summary	of	Services	Used	by	Category	
		 	
Category Raw	Sample	Claims
Adjusted	to	
Fully	Insured	
Population PMPM
Behavioral	Health	and/or	Substance	Abuse	Treatment	Services $31,316,705 $39,537,136 1.39$						
All	Services $31,316,705 $39,537,136 1.39$						
Category Raw	Sample	Claims
Adjusted	to	
Fully	Insured	
Population PMPM
Chiropractic	Manipulative	Treatment $2,304,438 $2,677,008 1.35$				
All	Services $2,304,438 $2,677,008 1.35$				
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Table	D-3:	Cleft	lip	and	Cleft	palate	
Cleft	lip	and	Cleft	palate	Mandate	
Summary	of	Services	Used	by	Category	
	
Category Raw	Sample	Claims
Adjusted	to	
Fully	Insured	
Population PMPM
Inpatient	Services $690,412 $871,641 0.031$	
Surgery,	Digestive	System $525,878 $663,917 0.023$	
Anesthesia $275,765 $348,151 0.012$	
Surgery,	Respiratory	System $160,822 $203,037 0.007$	
Office/Other	Outpatient	Services $156,818 $197,982 0.007$	
Hospital	Observation	Services $107,889 $136,210 0.005$	
Surgery,	Musculoskeletal	System $102,106 $128,908 0.005$	
Surgery,	Integumentary	System $98,350 $124,166 0.004$	
Special	Otorhinolaryngologic	Services $81,405 $102,773 0.004$	
Inpatient	Neonatal	Intensive,	and	Pediatric/Neonatal	Critical	Care	Services $71,858 $90,720 0.003$	
Behavioral	Health	and/or	Substance	Abuse	Treatment	Services $41,161 $51,966 0.002$	
Pathology	&	Laboratory $35,582 $44,922 0.002$	
Dental	Procedures $32,477 $41,003 0.001$	
Temporary	National	Codes	Est.	by	Private	Payers $32,189 $40,638 0.001$	
Enteral	and	Parenteral	Therapy $30,534 $38,549 0.001$	
Surgery,	Auditory	System $23,907 $30,182 0.001$	
Hospital	Inpatient	Services $16,754 $21,152 0.001$	
Radiology $14,483 $18,285 0.001$	
Durable	Medical	Equipment $13,180 $16,640 0.001$	
Drugs	Other	Than	Chemotherapy $12,101 $15,277 0.001$	
Transport	Services	Including	Ambulance $11,322 $14,294 0.001$	
Preventive	Medicine	Services $10,523 $13,286 0.000$	
Consultations $10,301 $13,005 0.000$	
CMS	Hospital	Outpatient		Payment	System $9,322 $11,769 0.000$	
Immune	Globulins,	Serum,	or	Recombinant	Prods $8,679 $10,957 0.000$	
Temporary	National	Codes	Est.	by	Medicaid $8,438 $10,653 0.000$	
Unclassified	Services $4,205 $5,309 0.000$	
Immunization	Administration	for	Vaccines/Toxoids $4,153 $5,243 0.000$	
Surgery,	Male	Genital	System $3,217 $4,062 0.000$	
Emergency	Department	Services $2,567 $3,240 0.000$	
Ophthalmology $2,226 $2,811 0.000$	
Central	Nervous	System	Assessments/Tests	(Neuro-Cognitive,	Mental	Status,	Speech	Testing)$1,904 $2,403 0.000$	
Medical	&	Surgical	Supplies $1,745 $2,203 0.000$	
Cardiovascular $1,657 $2,092 0.000$	
Psychiatry $1,184 $1,494 0.000$	
Health	&	Behavior	Assessment/Intervention $1,177 $1,486 0.000$	
Temporary	Procedures	&	Professional	Services $979 $1,236 0.000$	
Vaccines,	Toxoids $811 $1,024 0.000$	
Critical	Care	Services $794 $1,003 0.000$	
Special	Services,	Procedures,	and	Reports $535 $675 0.000$	
Newborn	Care	Services $362 $457 0.000$	
Pulmonary $102 $129 0.000$	
Qualifying	Circumstances	for	Anesthesia $66 $84 0.000$	
Hydration,	Therapeutic,	Prophylactic,	Diagnostic	Injections	&	Infusions,	and	Chemotherapy	&	Other	Highly	Complex	Drug	or	Highly	Complex	Biologic	Agent	Administration$41 $51 0.000$	
Temporary	Codes	for	Durable	Medical	Equipment	Regional	Carriers $28 $35 0.000$	
Other	Services	&	Procedures $23 $28 0.000$	
Surgery,	Cardiovascular	System $19 $23 0.000$	
All	Services $2,610,049 $3,295,170 0.12$				
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Table	D-4:	Diabetes-related	Services	and	Supplies	
Diabetes-related	Services	and	Supplies	Mandate	
Summary	of	Services	Used	by	Category	
	
Table	D-5:	Early	Intervention	Services	
Early	Intervention	Services	Mandate	
Summary	of	Services	Used	by	Category	
	
Table	D-6:	Hearing	Aids	for	Children	
Hearing	Aids	for	Children	Mandate	
Summary	of	Services	Used	by	Category	
	
Category Raw	Sample	Claims
Adjusted	to	Fully	
Insured	Population PMPM
Pharmacy	Claims $87,417,466 $143,654,795 5.067$	
Administrative,	Miscellaneous	&	Investigational $4,891,877 $8,038,916 0.284$	
Pathology	&	Laboratory $4,101,261 $6,739,681 0.238$	
Medical	&	Surgical	Supplies $3,853,956 $6,333,280 0.223$	
Durable	Medical	Equipment $3,391,982 $5,574,109 0.197$	
Temporary	Procedures	&	Professional	Services $1,496,366 $2,459,007 0.087$	
Medical	Nutrition	Therapy $1,117,904 $1,837,073 0.065$	
Ophthalmology $387,196 $636,286 0.022$	
Surgery,	Integumentary	System $187,048 $307,380 0.011$	
Endocrinology $54,092 $88,890 0.003$	
Preventive	Medicine	Services $44,919 $73,816 0.003$	
Drugs	Other	Than	Chemotherapy $13,032 $21,416 0.001$	
Temporary	National	Codes	Est.	by	Private	Payers $10,795 $17,740 0.001$	
Orthotics $5,758 $9,462 0.000$	
All	Services $106,973,652 $175,791,850 6.20$				
Category Raw	Sample	Claims
Adjusted	to	
Fully	Insured	
Population PMPM
Behavioral	Health	and/or	Substance	Abuse	Treatment	Services $14,216,047 $17,947,666 0.633$	
Temporary	National	Codes	Est.	by	Medicaid $4,683,775 $5,913,236 0.209$	
Health	&	Behavior	Assessment/Intervention $1,469,498 $1,855,232 0.065$	
Consultations $225 $284 0.000$	
Office/Other	Outpatient	Services $171 $216 0.000$	
Preventive	Medicine	Services $57 $72 0.000$	
All	Services $20,369,774 $25,716,707 0.91$				
Category Raw	Sample	Claims
Adjusted	to	
Fully	Insured	
Population PMPM
Special	Otorhinolaryngologic	Services $4,701,980 $5,936,219 0.209$	
Hearing	Services $753,459 $951,237 0.034$	
Surgery,	Auditory	System $4,344 $5,485 0.000$	
All	Services $5,459,783 $6,892,940 0.24$				
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Table	D-7:	Home	Health	Care	
Home	Health	Care	Mandate	
Summary	of	Services	Used	by	Category	
	
Category Raw	Sample	Claims
Adjusted	to	
Fully	Insured	
Population PMPM
Drugs	Other	Than	Chemotherapy $54,578,177 $68,904,593 2.430$	
Behavioral	Health	and/or	Substance	Abuse	Treatment	Services $40,163,888 $50,706,647 1.788$	
Durable	Medical	Equipment $26,135,778 $32,996,250 1.164$	
Medical	&	Surgical	Supplies $18,237,749 $23,025,039 0.812$	
Temporary	National	Codes	Est.	by	Private	Payers $13,660,316 $17,246,060 0.608$	
Unclassified	Services $9,529,481 $12,030,907 0.424$	
Orthotics $7,042,962 $8,891,693 0.314$	
Administrative,	Miscellaneous	&	Investigational $6,760,780 $8,535,441 0.301$	
Temporary	Procedures	&	Professional	Services $5,592,887 $7,060,983 0.249$	
Enteral	and	Parenteral	Therapy $5,068,539 $6,398,998 0.226$	
Inpatient	Services $4,804,697 $6,065,899 0.214$	
Prosthetics $3,171,974 $4,004,596 0.141$	
Temporary	Codes	for	Durable	Medical	Equipment	Regional	Carriers $2,506,788 $3,164,803 0.112$	
Home	Health	Procedures/Services $2,058,987 $2,599,457 0.092$	
Temporary	National	Codes	Est.	by	Medicaid $1,332,662 $1,682,477 0.059$	
Psychiatry $537,907 $679,104 0.024$	
Pulmonary $524,226 $661,831 0.023$	
Physical	Medicine	&	Rehabilitation $291,259 $367,713 0.013$	
Special	Otorhinolaryngologic	Services $260,045 $328,305 0.012$	
Home	Services $252,856 $319,229 0.011$	
Vision	Services $219,560 $277,194 0.010$	
Pathology	&	Laboratory $173,408 $218,926 0.008$	
Temporary	Codes	Assigned	by	CMS $155,657 $196,516 0.007$	
Chemotherapy	Drugs $103,538 $130,716 0.005$	
Surgery,	Musculoskeletal	System $94,206 $118,935 0.004$	
Immune	Globulins,	Serum,	or	Recombinant	Prods $70,925 $89,542 0.003$	
Neurology	&	Neuromuscular	Procedures $67,448 $85,153 0.003$	
Hearing	Services $62,335 $78,697 0.003$	
Health	&	Behavior	Assessment/Intervention $54,879 $69,285 0.002$	
Dialysis $45,710 $57,708 0.002$	
Surgery,	Maternity	Care	&	Delivery $28,763 $36,314 0.001$	
Vaccines,	Toxoids $20,090 $25,363 0.001$	
Transport	Services	Including	Ambulance $18,439 $23,279 0.001$	
Surgery,	Nervous	System $17,000 $21,462 0.001$	
Hydration,	Therapeutic,	Prophylactic,	Diagnostic	Injections	&	
Infusions,	and	Chemotherapy	&	Other	Highly	Complex	Drug	or	
Highly	Complex	Biologic	Agent	Administration $13,844 $17,478 0.001$	
Cardiovascular $13,547 $17,103 0.001$	
Preventive	Medicine	Services $10,153 $12,819 0.000$	
Domicil iary,	Rest	Home	(boarding	home)	or	Custodial	Care	Services $10,110 $12,764 0.000$	
Hospital	Inpatient	Services $8,770 $11,073 0.000$	
Office/Other	Outpatient	Services $8,118 $10,249 0.000$	
Central	Nervous	System	Assessments/Tests	(Neuro-Cognitive,	
Mental	Status,	Speech	Testing) $6,869 $8,673 0.000$	
Domicil iary,	Rest	Home	(assisted	l iving	facil ity)	or	Home	Plan	
Oversight	Services $6,684 $8,439 0.000$	
Laboratory	Services $6,122 $7,729 0.000$	
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Home	Health	Care	Mandate	
Summary	of	Services	Used	by	Category	(cont’d)	
		 	
Adjusted	to	
Fully	Insured	
Population PMPM
Anesthesia $5,608 $7,080 0.000$	
Education	&	Training	for	Patient	Self-Management $4,270 $5,390 0.000$	
Special	Dermatological	Procedures $2,943 $3,715 0.000$	
Surgery,	Integumentary	System $2,602 $3,285 0.000$	
Radiology $1,869 $2,360 0.000$	
Immunization	Administration	for	Vaccines/Toxoids $1,640 $2,070 0.000$	
Ophthalmology $1,636 $2,065 0.000$	
Special	Services,	Procedures,	and	Reports $1,525 $1,925 0.000$	
Diagnostic	Radiology	Services $1,331 $1,680 0.000$	
Surgery,	Eye	&	Ocular	Adnexa $1,250 $1,578 0.000$	
Care	Plan	Oversight	Services $1,228 $1,550 0.000$	
Surgery,	Male	Genital	System $1,126 $1,422 0.000$	
Other	Services	&	Procedures $966 $1,220 0.000$	
Surgery,	Cardiovascular	System $774 $977 0.000$	
Surgery,	Digestive	System $706 $891 0.000$	
Newborn	Care	Services $655 $827 0.000$	
Consultations $591 $746 0.000$	
Chiropractic	Manipulative	Treatment $534 $674 0.000$	
Case	Management	Services $380 $480 0.000$	
Nursing	Facil ity	Services $261 $330 0.000$	
Surgery,	Auditory	System $138 $175 0.000$	
Other	Evaluation	and	Management	Services $115 $145 0.000$	
Noninvasive	Vascular	Diagnostic	Studies $107 $135 0.000$	
Surgery,	Female	Genital	System $81 $102 0.000$	
Medical	Nutrition	Therapy $79 $100 0.000$	
Surgery,	Respiratory	System $77 $98 0.000$	
Moderate	(conscious)	Sedation $74 $93 0.000$	
Surgery,	Urinary	System $73 $92 0.000$	
Allergy	&	Clinical	Immunology $2 $3 0.000$	
Prolonged	Services $0 $0 -$						
All	Services $203,760,773 $257,246,649 9.07$				
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Table	D-8:	Hormone	Replacement	Therapy	
Hormone	Replacement	Therapy	Mandate	
Summary	of	Services	Used	by	Category	
	
Table	D-9:	Human	Leukocyte	Antigen	Testing	
Human	Leukocyte	Antigen	Testing	Mandate	
Summary	of	Services	Used	by	Category	
	
Table	D-10:	Hypodermic	Syringes	or	Needles	
Hypodermic	Syringes	or	Needles	Mandate	
Summary	of	Services	Used	by	Category	
		 	
Category Raw	Sample	Claims
Adjusted	to	
Fully	Insured	
Population PMPM
Pharmacy	Claims $5,873,488 $9,652,016 0.340$	
Office/Other	Outpatient	Services $711,427 $1,169,101 0.041$	
Preventive	Medicine	Services $398,042 $654,110 0.023$	
Pathology	&	Laboratory $23,108 $37,974 0.001$	
Consultations $15,544 $25,544 0.001$	
Surgery,	Integumentary	System $11,183 $18,377 0.001$	
Drugs	Other	Than	Chemotherapy $4,154 $6,827 0.000$	
All	Services $7,036,946 $11,563,949 0.41$				
Category Raw	Sample	Claims
Adjusted	to	
Fully	Insured	
Population PMPM
Pathology	&	Laboratory $14,526 $18,339 0.001$	
All	Services $14,526 $18,339 0.001$	
Category Raw	Sample	Claims
Adjusted	to	
Fully	Insured	
Population PMPM
Pharmacy $496,900 $816,566 0.029$	
Medical	&	Surgical	Supplies $162,308 $266,724 0.009$	
All	Services $659,209 $1,083,290 0.04$				
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Table	D-11:	Infertility	Treatment	
Infertility	Treatment	Mandate	
Summary	of	Services	Used	by	Category	
	
Table	D-12:	Low	Protein	Foods	(LPF)	
Low	Protein	Foods	(LPF)	Mandate	
Summary	of	Services	Used	by	Category	
	
Table	D-13:	Nonprescription	Enteral	Formulas	
Nonprescription	Enteral	Formulas	Mandate	
Summary	of	Services	Used	by	Category	
		 	
Category Raw	Sample	Claims
Adjusted	to	
Fully	Insured	
Population PMPM
Pharmacy	Claims $28,614,597 $54,302,681 2.051$	
Temporary	National	Codes	Est.	by	Private	Payers $17,916,345 $34,000,324 1.284$	
Surgery,	Female	Genital	System $3,677,979 $6,979,798 0.264$	
Pathology	&	Laboratory $2,224,355 $4,221,218 0.159$	
Office/Other	Outpatient	Services $1,641,581 $3,115,273 0.118$	
Radiology $431,432 $818,741 0.031$	
Preventive	Medicine	Services $239,984 $455,424 0.017$	
Surgery,	Auditory	System $224,577 $426,186 0.016$	
Consultations $150,025 $284,707 0.011$	
Special	Otorhinolaryngologic	Services $35,647 $67,649 0.003$	
Surgery,	Digestive	System $20,129 $38,200 0.001$	
Surgery,	Maternity	Care	&	Delivery $8,990 $17,060 0.001$	
All	Services $55,185,642 $104,727,260 3.96$				
Category Raw	Sample	Claims
Adjusted	to	
Fully	Insured	
Population PMPM
Enteral	and	Parenteral	Therapy $1,144,495 $1,444,918 0.051$	
Temporary	National	Codes	Est.	by	Private	Payers $64,152 $80,992 0.003$	
All	Services $1,208,647 $1,525,909 0.05$				
Category Raw	Sample	Claims
Adjusted	to	
Fully	Insured	
Population PMPM
Enteral	and	Parenteral	Therapy $732,663 $924,982 0.033$	
All	Services $732,663 $924,982 0.03$				
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Table	D-14:	Oral	Chemotherapy	Treatment	of	Cancer	As	discussed	above	in	the	report	body,	the	oral	chemotherapy	mandate	is	a	cost-sharing	mandate	only.		The	claims	summarized	below	include	all	2014	sample	and	estimated	population	carrier	payments	for	oral	cancer	drugs	claims	used	to	derive	the	mandate	cost	estimate,	and	will	therefore	not	match	the	oral	chemotherapy	mandate	results	presented	above.	
Oral	Chemotherapy	Treatment	of	Cancer	Mandate	
Summary	of	Services	Used	by	Category	
	
Table	D-15:	Prosthetic	Devices	
Prosthetic	Devices	Mandate	
Summary	of	Services	Used	by	Category	
	
Table	D-16:	Scalp	Hair	Prostheses	
Scalp	Hair	Prostheses	
Summary	of	Services	Used	by	Category	
		 	
Category Raw	Sample	Claims
Adjusted	to	
Fully	Insured	
Population PMPM
Pharmacy $44,508,253 $73,141,263 2.580$	
Drugs	Other	Than	Chemotherapy $12,323 $20,251 0.001$	
All	Services $44,520,576 $73,161,515 2.58$				
Category Raw	Sample	Claims
Adjusted	to	
Fully	Insured	
Population PMPM
Prosthetics $3,063,784 $3,868,008 0.136$	
All	Services $3,063,784 $3,868,008 0.14$				
Procedure	Code Description Raw	Sample	Claims
Adjusted	to	
Fully	Insured	
Population PMPM
A9282 Wig,	any	type,	each $325,539 $410,990 0.014$	
All	Services $325,539 $410,990 0.01$				
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Table	D-17:	Speech	and	Audiology	Services	
Speech	and	Audiology	Services	
Summary	of	Services	Used	by	Category	
		 	
Category Raw	Sample	Claims
Adjusted	to	
Fully	Insured	
Population PMPM
Special	Otorhinolaryngologic	Services $3,210,954 $4,053,808 0.143$	
Hearing	Services $735,387 $928,422 0.033$	
Surgery,	Auditory	System $711,401 $898,140 0.032$	
Prosthetics $600,349 $757,937 0.027$	
Inpatient	Services $280,689 $354,368 0.012$	
Central	Nervous	System	Assessments/Tests	(Neuro-
Cognitive,	Mental	Status,	Speech	Testing) $37,459 $47,292 0.002$	
Temporary	Procedures	&	Professional	Services $24,772 $31,275 0.001$	
Surgery,	Digestive	System $7,928 $10,009 0.000$	
Hospital	Observation	Services $7,618 $9,617 0.000$	
Surgery,	Integumentary	System $3,258 $4,113 0.000$	
Radiology $3,073 $3,880 0.000$	
Surgery,	Musculoskeletal	System $2,927 $3,695 0.000$	
Pathology	&	Laboratory $2,879 $3,635 0.000$	
Drugs	Other	Than	Chemotherapy $2,612 $3,297 0.000$	
Cardiovascular $1,833 $2,314 0.000$	
Anesthesia $1,669 $2,108 0.000$	
Medical	&	Surgical	Supplies $618 $780 0.000$	
Neurology	&	Neuromuscular	Procedures $517 $653 0.000$	
Temporary	National	Codes	Est.	by	Private	Payers $305 $385 0.000$	
CMS	Hospital	Outpatient		Payment	System $177 $223 0.000$	
Pulmonary $97 $122 0.000$	
Temporary	Codes	Assigned	by	CMS $71 $89 0.000$	
Surgery,	Cardiovascular	System $9 $12 0.000$	
Ophthalmology $2 $2 0.000$	
Surgery,	Respiratory	System $0 $0 0.000$	
Administrative,	Miscellaneous	&	Investigational $0 $0 -$						
All	Services $5,636,603 $7,116,174 0.25$				
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Table	D-18:	Certified	Nurse	Midwives	
Certified	Nurse	Midwife	Services	
Summary	of	Services	Used	by	Category	
		 	
Category Raw	Sample	Claims
Adjusted	to	
Fully	Insured	
Population PMPM
Surgery,	Maternity	Care	&	Delivery $187,264 $962,380 0.110$			
Preventive	Medicine	Services $29,820 $153,249 0.017$			
Pathology	&	Laboratory $26,547 $136,430 0.016$			
Unclassified	Services $23,392 $120,216 0.014$			
Office/Other	Outpatient	Services $20,466 $105,178 0.012$			
Drugs	Other	Than	Chemotherapy $15,298 $78,618 0.009$			
Vaccines,	Toxoids $3,830 $19,685 0.002$			
Immunization	Administration	for	Vaccines/Toxoids $3,332 $17,123 0.002$			
Surgery,	Female	Genital	System $2,533 $13,018 0.001$			
Temporary	Codes	Assigned	by	CMS $822 $4,222 0.000$			
Surgery,	Integumentary	System $591 $3,037 0.000$			
Hydration,	Therapeutic,	Prophylactic,	Diagnostic	Injections	&	Infusions,	and	Chemotherapy	&	Other	Highly	Complex	Drug	or	Highly	Complex	Biologic	Agent	Administration$571 $2,932 0.000$			
Hospital	Observation	Services $556 $2,858 0.000$			
Immune	Globulins,	Serum,	or	Recombinant	Prods $467 $2,399 0.000$			
Home	Services $156 $802 0.000$			
Emergency	Department	Services $149 $764 0.000$			
Surgery,	Male	Genital	System $99 $511 0.000$			
Temporary	National	Codes	Est.	by	Private	Payers $90 $463 0.000$			
Surgery,	Cardiovascular	System $79 $406 0.000$			
Hospital	Inpatient	Services $0 $0 -$							
All	Services $316,062 $1,624,290 0.19$					
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Table	D-19:	Certified	Registered	Nurse	Anesthetists	
Certified	Registered	Nurse	Anesthetist	Services	
Summary	of	Services	Used	by	Category	
		 	
Category Raw	Sample	Claims
Adjusted	to	
Fully	Insured	
Population PMPM
Anesthesia $9,772,491 $22,003,254 0.776$			
Surgery,	Nervous	System $11,644 $26,218 0.001$			
Preventive	Medicine	Services $4,596 $10,347 0.000$			
Surgery,	Digestive	System $3,653 $8,224 0.000$			
Surgery,	Eye	&	Ocular	Adnexa $3,494 $7,866 0.000$			
Office/Other	Outpatient	Services $3,067 $6,905 0.000$			
Surgery,	Cardiovascular	System $2,859 $6,437 0.000$			
Radiology $2,074 $4,669 0.000$			
Surgery,	Female	Genital	System $2,068 $4,656 0.000$			
Drugs	Other	Than	Chemotherapy $1,725 $3,884 0.000$			
Surgery,	Musculoskeletal	System $1,300 $2,927 0.000$			
Hospital	Inpatient	Services $1,293 $2,911 0.000$			
Moderate	(conscious)	Sedation $1,068 $2,405 0.000$			
Inpatient	Neonatal	Intensive,	and	Pediatric/Neonatal	Critical	
Care	Services $825 $1,858 0.000$			
Cardiovascular $750 $1,689 0.000$			
Qualifying	Circumstances	for	Anesthesia $666 $1,499 0.000$			
Consultations $425 $957 0.000$			
Surgery,	Urinary	System $382 $861 0.000$			
Surgery,	Respiratory	System $256 $576 0.000$			
Hydration,	Therapeutic,	Prophylactic,	Diagnostic	Injections	&	
Infusions,	and	Chemotherapy	&	Other	Highly	Complex	Drug	or	
Highly	Complex	Biologic	Agent	Administration $218 $492 0.000$			
Emergency	Department	Services $210 $473 0.000$			
Pulmonary $196 $441 0.000$			
Immunization	Administration	for	Vaccines/Toxoids $131 $295 0.000$			
Vaccines,	Toxoids $107 $241 0.000$			
Surgery,	Maternity	Care	&	Delivery $82 $186 0.000$			
Pathology	&	Laboratory $46 $104 0.000$			
Ophthalmology $6 $14 0.000$			
Unclassified	Services -$2,707 -$6,095 (0.000)$	
All	Services $9,812,925 $22,094,293 0.78$					
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Table	D-20:	Nurse	Practitioners	
Nurse	Practitioner	Services	
Summary	of	Services	Used	by	Category	
		 	
Category Raw	Sample	Claims
Adjusted	to	
Fully	Insured	
Population PMPM
Office/Other	Outpatient	Services $11,107,518 $25,009,134 0.882$					
Preventive	Medicine	Services $3,039,299 $6,843,134 0.241$					
Psychiatry $934,552 $2,104,191 0.074$					
Immunization	Administration	for	Vaccines/Toxoids $672,655 $1,514,516 0.053$					
Chemotherapy	Drugs $513,553 $1,156,290 0.041$					
Vaccines,	Toxoids $475,106 $1,069,724 0.038$					
Surgery,	Integumentary	System $435,571 $980,709 0.035$					
Drugs	Other	Than	Chemotherapy $263,777 $593,908 0.021$					
Allergy	&	Clinical	Immunology $262,762 $591,621 0.021$					
Behavioral	Health	and/or	Substance	Abuse	Treatment	Services $241,484 $543,712 0.019$					
Temporary	Procedures	&	Professional	Services $230,139 $518,170 0.018$					
Hospital	Inpatient	Services $223,490 $503,199 0.018$					
Emergency	Department	Services $210,139 $473,139 0.017$					
Hydration,	Therapeutic,	Prophylactic,	Diagnostic	Injections	&	Infusions,	
and	Chemotherapy	&	Other	Highly	Complex	Drug	or	Highly	Complex	
Biologic	Agent	Administration $202,404 $455,722 0.016$					
Consultations $115,437 $259,912 0.009$					
Temporary	National	Codes	Est.	by	Medicaid $100,044 $225,254 0.008$					
Pathology	&	Laboratory $88,411 $199,062 0.007$					
Surgery,	Cardiovascular	System $78,101 $175,849 0.006$					
Surgery,	Musculoskeletal	System $64,701 $145,678 0.005$					
Inpatient	Neonatal	Intensive,	and	Pediatric/Neonatal	Critical	Care	
Services $50,337 $113,337 0.004$					
Surgery,	Respiratory	System $49,570 $111,609 0.004$					
Temporary	Codes	Assigned	by	CMS $33,266 $74,901 0.003$					
Central	Nervous	System	Assessments/Tests	(Neuro-Cognitive,	Mental	
Status,	Speech	Testing) $33,186 $74,721 0.003$					
Surgery,	Female	Genital	System $30,924 $69,626 0.002$					
Special	Otorhinolaryngologic	Services $27,710 $62,391 0.002$					
Surgery,	Urinary	System $27,235 $61,321 0.002$					
Home	Health	Procedures/Services $25,078 $56,463 0.002$					
Temporary	National	Codes	Est.	by	Private	Payers $25,070 $56,447 0.002$					
Cardiovascular $24,816 $55,874 0.002$					
Nursing	Facil ity	Services $20,998 $47,278 0.002$					
Pulmonary $20,552 $46,273 0.002$					
Surgery,	Digestive	System $17,243 $38,824 0.001$					
Hospital	Observation	Services $17,091 $38,481 0.001$					
Surgery,	Nervous	System $15,720 $35,393 0.001$					
Surgery,	Maternity	Care	&	Delivery $14,362 $32,336 0.001$					
Critical	Care	Services $14,178 $31,923 0.001$					
Surgery,	Auditory	System $14,034 $31,599 0.001$					
Newborn	Care	Services $14,031 $31,591 0.001$					
Photodynamic	Therapy $13,964 $31,441 0.001$					
Anesthesia $13,051 $29,386 0.001$					
Radiology $10,609 $23,887 0.001$					
Neurology	&	Neuromuscular	Procedures $9,732 $21,913 0.001$					
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Nurse	Practitioner	Services	
Summary	of	Services	Used	by	Category	(cont’d)	
		 	
Category Raw	Sample	Claims
Adjusted	to	
Fully	Insured	
Population PMPM
Gastroenterology $6,780 $15,266 0.001$					
Physical	Medicine	&	Rehabilitation $6,733 $15,160 0.001$					
Special	Services,	Procedures,	and	Reports $4,732 $10,654 0.000$					
Medical	Nutrition	Therapy $4,199 $9,454 0.000$					
Orthotics $3,713 $8,360 0.000$					
Home	Services $2,929 $6,595 0.000$					
Endocrinology $2,377 $5,353 0.000$					
Surgery,	Male	Genital	System $2,111 $4,754 0.000$					
Surgery,	Eye	&	Ocular	Adnexa $1,600 $3,603 0.000$					
Prolonged	Services $1,462 $3,292 0.000$					
Special	Dermatological	Procedures $1,066 $2,399 0.000$					
Other	Services	&	Procedures $1,063 $2,394 0.000$					
Surgery,	Hemic	and	Lymphatic	Systems $945 $2,128 0.000$					
Noninvasive	Vascular	Diagnostic	Studies $742 $1,670 0.000$					
Immune	Globulins,	Serum,	or	Recombinant	Prods $638 $1,437 0.000$					
Surgery,	General $573 $1,290 0.000$					
Medical	&	Surgical	Supplies $448 $1,009 0.000$					
Durable	Medical	Equipment $410 $922 0.000$					
Health	&	Behavior	Assessment/Intervention $358 $806 0.000$					
Surgery,	Endocrine	System $289 $651 0.000$					
Ophthalmology $289 $651 0.000$					
Moderate	(conscious)	Sedation $152 $343 0.000$					
Domicil iary,	Rest	Home	(boarding	home)	or	Custodial	Care	Services $142 $320 0.000$					
Administrative,	Miscellaneous	&	Investigational $108 $244 0.000$					
Chiropractic	Manipulative	Treatment $14 $32 0.000$					
Hearing	Services $13 $28 0.000$					
Unclassified	Services -$1,993 -$4,487 (0.000)$				
All	Services $19,823,794 $44,634,265 1.57$							
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Table	D-21:	Physician	Assistants	
Physician	Assistant	Services	
Summary	of	Services	Used	by	Category	
		 	
Category Raw	Sample	Claims
Adjusted	to	
Fully	Insured	
Population PMPM
Office/Other	Outpatient	Services $8,227,023 $18,523,554 0.653$	
Preventive	Medicine	Services $3,225,276 $7,261,871 0.256$	
Surgery,	Musculoskeletal	System $1,124,869 $2,532,698 0.089$	
Pathology	&	Laboratory $793,004 $1,785,488 0.063$	
Drugs	Other	Than	Chemotherapy $656,447 $1,478,023 0.052$	
Surgery,	Integumentary	System $536,993 $1,209,066 0.043$	
Vaccines,	Toxoids $505,590 $1,138,361 0.040$	
Psychiatry $369,187 $831,243 0.029$	
Hospital	Inpatient	Services $367,589 $827,645 0.029$	
Surgery,	Digestive	System $345,418 $777,726 0.027$	
Immunization	Administration	for	Vaccines/Toxoids $286,280 $644,574 0.023$	
Allergy	&	Clinical	Immunology $222,408 $500,762 0.018$	
Emergency	Department	Services $172,171 $387,652 0.014$	
Surgery,	Nervous	System $157,655 $354,968 0.013$	
Surgery,	Female	Genital	System $154,704 $348,324 0.012$	
Temporary	Procedures	&	Professional	Services $123,065 $277,086 0.010$	
Nursing	Facil ity	Services $122,731 $276,336 0.010$	
Surgery,	Maternity	Care	&	Delivery $110,779 $249,425 0.009$	
Hospital	Observation	Services $80,820 $181,970 0.006$	
Critical	Care	Services $74,723 $168,242 0.006$	
Temporary	National	Codes	Est.	by	Private	Payers $74,545 $167,842 0.006$	
Surgery,	Cardiovascular	System $69,213 $155,836 0.005$	
Hydration,	Therapeutic,	Prophylactic,	Diagnostic	Injections	&	
Infusions,	and	Chemotherapy	&	Other	Highly	Complex	Drug	or	
Highly	Complex	Biologic	Agent	Administration $65,363 $147,169 0.005$	
Anesthesia $45,544 $102,545 0.004$	
Pulmonary $32,183 $72,461 0.003$	
Health	&	Behavior	Assessment/Intervention $31,346 $70,578 0.002$	
Temporary	Codes	Assigned	by	CMS $31,045 $69,899 0.002$	
Central	Nervous	System	Assessments/Tests	(Neuro-Cognitive,	
Mental	Status,	Speech	Testing) $28,644 $64,494 0.002$	
Surgery,	Urinary	System $16,307 $36,716 0.001$	
Cardiovascular $16,243 $36,573 0.001$	
Surgery,	Respiratory	System $15,327 $34,510 0.001$	
Surgery,	Auditory	System $14,065 $31,667 0.001$	
Special	Otorhinolaryngologic	Services $11,884 $26,758 0.001$	
Inpatient	Neonatal	Intensive,	and	Pediatric/Neonatal	Critical	
Care	Services $9,678 $21,790 0.001$	
Surgery,	Male	Genital	System $9,316 $20,976 0.001$	
Physical	Medicine	&	Rehabilitation $9,171 $20,650 0.001$	
Orthotics $8,038 $18,098 0.001$	
Unclassified	Services $7,614 $17,144 0.001$	
Special	Dermatological	Procedures $6,486 $14,603 0.001$	
Domicil iary,	Rest	Home	(boarding	home)	or	Custodial	Care	
Services $5,400 $12,159 0.000$	
Radiology $4,566 $10,281 0.000$	
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Physician	Assistant	Services	
Summary	of	Services	Used	by	Category	(cont’d)	
		 	
Category Raw	Sample	Claims
Adjusted	to	
Fully	Insured	
Population PMPM
Surgery,	Endocrine	System $4,460 $10,042 0.000$	
Special	Services,	Procedures,	and	Reports $4,411 $9,933 0.000$	
Consultations $3,889 $8,757 0.000$	
Medical	Nutrition	Therapy $3,883 $8,744 0.000$	
Behavioral	Health	and/or	Substance	Abuse	Treatment	Services $3,720 $8,376 0.000$	
Surgery,	Operating	Microscope $3,286 $7,398 0.000$	
Newborn	Care	Services $2,862 $6,445 0.000$	
Immune	Globulins,	Serum,	or	Recombinant	Prods $2,619 $5,897 0.000$	
Chemotherapy	Drugs $2,377 $5,351 0.000$	
Surgery,	Eye	&	Ocular	Adnexa $1,891 $4,259 0.000$	
Home	Services $1,854 $4,175 0.000$	
Surgery,	Hemic	and	Lymphatic	Systems $1,787 $4,024 0.000$	
Neurology	&	Neuromuscular	Procedures $1,516 $3,413 0.000$	
Medical	&	Surgical	Supplies $1,012 $2,278 0.000$	
Other	Services	&	Procedures $964 $2,171 0.000$	
Surgery,	Mediastinum	&	Diaphragm $845 $1,902 0.000$	
Prolonged	Services $693 $1,559 0.000$	
Durable	Medical	Equipment $648 $1,460 0.000$	
Photodynamic	Therapy $468 $1,053 0.000$	
Gastroenterology $352 $793 0.000$	
Surgery,	General $292 $658 0.000$	
Chiropractic	Manipulative	Treatment $35 $78 0.000$	
Temporary	National	Codes	Est.	by	Medicaid $15 $34 0.000$	
Laboratory	Services $10 $23 0.000$	
Administrative,	Miscellaneous	&	Investigational $0 $0 -$						
All	Services $18,212,602 $41,006,587 1.45$				
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Table	D-22:	Chiropractors	
Chiropractor	Provider	Mandate	Services	
Summary	of	Services	Used	by	Category	
		 	
Category Raw	Sample	Claims
Adjusted	to	
Fully	Insured	
Population PMPM
Physical	Medicine	&	Rehabilitation $795,453 $4,087,950 0.466$	
Chiropractic	Manipulative	Treatment $603,976 $3,103,920 0.354$	
Office/Other	Outpatient	Services $139,158 $715,154 0.082$	
Radiology $11,883 $61,068 0.007$	
Psychiatry $464 $2,385 0.000$	
Temporary	Procedures	&	Professional	Services $320 $1,645 0.000$	
Medical	Nutrition	Therapy $130 $668 0.000$	
Osteopathic	Manipulative	Treatment $66 $341 0.000$	
Surgery,	Cardiovascular	System $22 $113 0.000$	
Ophthalmology $0 $0 -$						
Special	Services,	Procedures,	and	Reports $0 $0 -$						
All	Services $1,551,472 $7,973,244 0.91$				
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Table	D-23:	Dentists	
Dentist	Services	
Summary	of	Services	Used	by	Category	
		 	
Category Raw	Sample	Claims
Adjusted	to	
Fully	Insured	
Population PMPM
Durable	Medical	Equipment $55,029 $282,803 0.032$	
Office/Other	Outpatient	Services $53,189 $273,346 0.031$	
Dental	Procedures $50,663 $260,365 0.030$	
Surgery,	Musculoskeletal	System $32,024 $164,578 0.019$	
Temporary	National	Codes	Est.	by	Private	Payers $24,826 $127,584 0.015$	
Surgery,	Digestive	System $23,568 $121,119 0.014$	
Surgery,	Respiratory	System $10,174 $52,285 0.006$	
Physical	Medicine	&	Rehabilitation $7,472 $38,400 0.004$	
Radiology $4,656 $23,927 0.003$	
Pathology	&	Laboratory $3,996 $20,538 0.002$	
Hospital	Inpatient	Services $1,326 $6,812 0.001$	
Surgery,	Integumentary	System $1,146 $5,890 0.001$	
Surgery,	Female	Genital	System $1,000 $5,139 0.001$	
Surgery,	Nervous	System $472 $2,424 0.000$	
Moderate	(conscious)	Sedation $396 $2,037 0.000$	
Surgery,	Auditory	System $227 $1,169 0.000$	
Medical	&	Surgical	Supplies $80 $411 0.000$	
Hydration,	Therapeutic,	Prophylactic,	Diagnostic	Injections	&	Infusions,	and	Chemotherapy	&	Other	Highly	Complex	Drug	or	Highly	Complex	Biologic	Agent	Administration$32 $167 0.000$	
Drugs	Other	Than	Chemotherapy $0 $0 -$						
Temporary	National	Codes	Est.	by	Medicaid $0 $0 -$						
All	Services $270,277 $1,388,993 0.16$				
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Table	D-24:	Optometrists	
Optometrist	Services	
Summary	of	Services	Used	by	Category	
		 	
Category Raw	Sample	Claims
Adjusted	to	
Fully	Insured	
Population PMPM
Ophthalmology $1,070,692 $5,502,446 0.628$	
Office/Other	Outpatient	Services $81,961 $421,210 0.048$	
Vision	Services $34,101 $175,250 0.020$	
Temporary	National	Codes	Est.	by	Private	Payers $14,213 $73,043 0.008$	
Surgery,	Eye	&	Ocular	Adnexa $4,832 $24,831 0.003$	
Surgery,	Musculoskeletal	System $3,659 $18,806 0.002$	
Psychiatry $610 $3,134 0.000$	
Radiology $570 $2,928 0.000$	
Orthotics $497 $2,557 0.000$	
Neurology	&	Neuromuscular	Procedures $355 $1,826 0.000$	
Surgery,	Integumentary	System $329 $1,688 0.000$	
Physical	Medicine	&	Rehabilitation $213 $1,093 0.000$	
All	Services $1,212,032 $6,228,813 0.71$				
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Table	D-25:	Podiatrists	
Podiatrist	Services	
Summary	of	Services	Used	by	Category	
		 	
Category Raw	Sample	Claims
Adjusted	to	
Fully	Insured	
Population PMPM
Office/Other	Outpatient	Services $3,567,939 $8,033,394 0.283$			
Surgery,	Integumentary	System $1,680,783 $3,784,368 0.133$			
Surgery,	Musculoskeletal	System $1,221,009 $2,749,163 0.097$			
Orthotics $298,594 $672,300 0.024$			
Radiology $213,312 $480,282 0.017$			
Surgery,	Nervous	System $82,818 $186,469 0.007$			
Physical	Medicine	&	Rehabilitation $76,949 $173,254 0.006$			
Consultations $33,225 $74,807 0.003$			
Medical	&	Surgical	Supplies $24,132 $54,335 0.002$			
Drugs	Other	Than	Chemotherapy $23,549 $53,022 0.002$			
Hospital	Inpatient	Services $11,746 $26,448 0.001$			
Pathology	&	Laboratory $10,640 $23,956 0.001$			
Other	Services	&	Procedures $8,977 $20,213 0.001$			
Temporary	Codes	Assigned	by	CMS $5,553 $12,503 0.000$			
Temporary	Procedures	&	Professional	Services $5,103 $11,490 0.000$			
Temporary	National	Codes	Est.	by	Private	Payers $4,808 $10,826 0.000$			
Hydration,	Therapeutic,	Prophylactic,	Diagnostic	Injections	&	
Infusions,	and	Chemotherapy	&	Other	Highly	Complex	Drug	or	
Highly	Complex	Biologic	Agent	Administration $1,811 $4,078 0.000$			
Durable	Medical	Equipment $1,499 $3,376 0.000$			
Nursing	Facil ity	Services $1,474 $3,318 0.000$			
Prosthetics $1,223 $2,754 0.000$			
Home	Services $1,131 $2,548 0.000$			
Surgery,	Digestive	System $882 $1,986 0.000$			
Noninvasive	Vascular	Diagnostic	Studies $521 $1,174 0.000$			
Critical	Care	Services $334 $753 0.000$			
Domicil iary,	Rest	Home	(boarding	home)	or	Custodial	Care	
Services $326 $735 0.000$			
Preventive	Medicine	Services $307 $691 0.000$			
Transport	Services	Including	Ambulance $263 $592 0.000$			
Prolonged	Services $225 $507 0.000$			
Vaccines,	Toxoids $208 $468 0.000$			
Surgery,	Cardiovascular	System $96 $216 0.000$			
Immunization	Administration	for	Vaccines/Toxoids $83 $187 0.000$			
Chemotherapy	Drugs $82 $186 0.000$			
Emergency	Department	Services $75 $169 0.000$			
Special	Services,	Procedures,	and	Reports $56 $126 0.000$			
Neurology	&	Neuromuscular	Procedures $39 $89 0.000$			
Administrative,	Miscellaneous	&	Investigational $33 $73 0.000$			
Special	Otorhinolaryngologic	Services $12 $26 0.000$			
Unclassified	Services -$3,473 -$7,820 (0.000)$	
All	Services $7,276,347 $16,383,060 0.58$					
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Appendix	E:	List	of	Study	Acronyms	AAFP	 American	Academy	of	Family	Physicians	AAP	 American	Academy	of	Pediatrics	ABA	 Applied	Behavior	Analysis	ACA	 Patient	Protection	and	Affordable	Care	Act	ACIP	 Advisory	Committee	on	Immunization	Practices	ACOG	 American	College	of	Obstetrics	and	Gynecology	ACOG	 American	Congress	of	Obstetricians	and	Gynecologists	ACP	 American	College	of	Physicians	ACR	 American	College	of	Radiology	ACS	 American	Cancer	Society	ADDM	 Autism	and	Developmental	Disabilities	Monitoring	AHFS-DI	 American	Hospital	Formulary	Service-Drug	Information	AHRQ	 The	National	Guideline	Clearing	House	under	the	federal	Agency	for	Healthcare	Research	and	Quality	AMA	 American	Medical	Association	AMA-DE	 American	Medical	Association	Drug	Evaluations	APA	 American	Psychiatric	Association	APN	 Advanced	Practice	Nurse	APRN	 Advanced	Practice	Registered	Nurse	ART	 Assisted	Reproduction	Techniques	ASD	 Autism	Spectrum	Disorder	ASCP	 American	Society	for	Clinical	Pathology	ASCCP	 American	Society	for	Colposcopy	and	Cervical	Pathology	BDC	 Base	Direct	Cost	BLL	 Blood	Lead	Level	BMT	 Bone	Marrow	Transplant	C-Section	 Caesarean	Section	CAM	 Complementary	and	Alternative	Medicine	CDC	 Centers	for	Disease	Control	and	Prevention	CHIA	 Center	for	Health	Information	and	Analysis	CHT	 Combined	Hormone	Therapy	
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CIA	 Chemotherapy-Induced	Alopecia	CMS	 Centers	for	Medicare	and	Medicaid	Services	CNM	 Certified	Nurse-Midwife	COH	 Controlled	Ovarian	Hyperstimulation	CR	 Collaborative	Reanalysis	CR	 Cardiac	Rehabilitation	CRNA	 Certified	Registered	Nurse	Anesthetist	CVD	 Cardiovascular	Disease	DIR	 Developmental,	Individual	Differences,	Relationship-Based	Approach	DMEPOS	 Durable	Medical	Equipment,	Prosthetics,	Orthotics,	and	Supplies	DPA	 Diagnostic	Pharmaceutical	Agents	DPM	 Doctor	of	Podiatric	Medicine	DSM	 Diagnostic	and	Statistical	Manual	of	Mental	Disorders	DSM-IV	 Diagnostic	and	Statistical	Manual	of	Mental	Disorders,	4th	Edition	DSM-V	 Diagnostic	and	Statistical	Manual	of	Mental	Disorders,	5th	edition	DTT	 Discrete	Trial	Training	DVT	 Deep	Vein	Thrombosis	EHB	 Essential	Health	Benefit	EHDI	 Early	Hearing	Detection	and	Intervention	EIBI	 Early	Intensive	Behavioral	Intervention	EN	 Enteral	Nutrition	EPC	 Evidence-based	Practice	Center	EPSDT	 Early	and	Periodic	Screening,	Diagnosis	and	Treatment	ET	 Estrogen	Therapy	FDA	 Food	&	Drug	Administration	FEDVIP	 Federal	Vision	Insurance	Program	HDC-ABMT	 High-dose	Chemotherapy	plus	Autologous	Bone	Marrow	Transplant	HEN	 Home	Enteral	Nutrition	HHA	 Home	Health	Agency	HLA	 Human	Leukocyte	Antigen	HMO	 Health	Maintenance	Organization	HPV	 Human	Papillomavirus	
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HRSA	 Health	Resources	and	Services	Administration	HRT	 Hormone	Replacement	Therapy	HSC	 Health	Service	Corporation	HSCT	 Hematopoietic	(blood)	Stem	Cell	Transplants	ICSI	 Intracytoplasmic	Sperm	Injection	IDEA	 Public	Law	108-77:	Individuals	with	Disabilities	Education	Improvement	Act	(2004)	IVF	 In-Vitro	Fertilization	JCIH	 Joint	Committee	on	Infant	Hearing	Kuvan	 Sapropterin	Dihydrochloride	LPF	 Low	Protein	Food	MD	 Medical	Doctor	MDC	 Marginal	Direct	Cost	MDD	 Major	Depressive	Disorder	MEPS	 Medical	Expenditure	Panel	Survey	MSC	 Medical	Service	Corporation	MWS	 Million	Women	Study	NBEO	 National	Board	of	Examiners	in	Optometry	NCSBN	 National	Council	of	State	Boards	of	Nursing	NIDA	 National	Institute	for	Drug	Abuse	NMDP	 The	National	Marrow	Donor	Program	NP	 Nurse	Practitioner	NPA	 Non-Physician	Anesthetists	NPDC-ASD	 The	National	Professional	Development	Center	on	Autism	Spectrum	Disorder	PA	 Physician	Assistants	PAM	 Patient	Assessment	and	Management	PCHL	 Permanent	Congenital	Hearing	Loss	PECS	 Picture	Exchange	Communication	System	Phe	 Phenylalanine	PKU	 Phenylketonuria	PRT	 Pivotal	Response	Training	RDC	 Required	Direct	Cost	RN	 Registered	Nurse	
Comprehensive	Mandated	Benefit	Review		
compass Health Analytics 159 December 2016 
SNF	 Skilled	Nursing	Facility	SNRI	 Selective	Serotonin/Norepinephrine	Reuptake	Inhibitors	SSRI	 Selective	Serotonin	Reuptake	Inhibitors	TEACCH	 Treatment	and	Education	of	Autistic	and	Related	Communication	Handicapped	Children	TMOD	 Treatment	and	Management	of	Ocular	Disease	TPA	 Therapeutic	Pharmaceutical	Agents	USP-DI	 United	States	Pharmacopoeia-Drug	Information	USPSTF	 U.S.	Preventive	Services	Task	Force	VBI	 Verbal	Behavior	Intervention	WHI	 Women’s	Health	Initiative		 	
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The	U.S.	Preventive	Services	Task	Force	(USPSTF)	has	decided	not	to	review	the	evidence	and	update	its	
recommendations	for	this	topic.	The	previous	evidence	review	and	recommendation	may	contain	information	
that	is	outdated.		
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they	are	no	longer	relevant	to	clinical	practice.	This	may	be	the	result	of	changes	in	technology,	a	new	
understanding	of	the	etiology	or	natural	history	of	the	disease,	or	the	evolving	natural	history	of	the	disease.	
Topics	may	also	be	inactivated	because	they	involve	services	that	cannot	be	implemented	in	a	primary	care	
setting	or	are	not	referable	by	a	primary	care	clinician.	In	addition,	topics	that	have	a	low	public	health	burden	
or	that	otherwise	fall	outside	the	scope	of	the	USPSTF	may	be	inactivated.	
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